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FOREWORD
This toxicological profile is prepared in accordance with guidelines developed by the Agency for 
Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The 
original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews 
the key literature that describes a substance's toxicologic properties. Other pertinent literature is also 
presented, but is described in less detail than the key studies. The profile is not intended to be an 
exhaustive document; more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information. Each toxicological profile begins 
with a public health statement that describes, in nontechnical language, a substance's relevant toxicological 
properties. Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. The adequacy of information to determine a 
substance's health effects is described in a health effects summary. Data needs that are of significance to 
protection of public health are identified by ATSDR and EPA.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain die levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance is 
available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of 
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, 
and local levels; interested private sector organizations and groups; and members of the public. We plan to 
revise these documents in response to public comments and as additional data become available.
Therefore, we encourage comments that will make the toxicological profile series of the greatest use.
Comments should be sent to:
Agency for Toxic Substances and Disease Registry 
Division of Toxicology and Environmental Medicine 
1600 Clifton Road, N.E.
Mail Stop F-62 
Atlanta, Georgia 30333
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 
104(i)(l) directs the Administrator of ATSDR to . .effectuate and implement the health related 
authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances 
most commonly found at facilities on the CERCLA National Priorities List and that pose the most 
significant potential threat to human health, as determined by ATSDR and the EPA. Section 1 Q4(i)(3) of 
CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each 
substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances 
not found at sites on the National Priorities List, in an effort to . .establish and maintain inventory of 
literature, research, and studies on the health effects of toxic substances” under CERCLA Section 
104{i)( 1XB), to respond to requests for consultation under section 104(iX4), and as otherwise necessaiy to 
support the site-specific response actions conducted by ATSDR.
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that 
has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal 
scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a 
nongovernmental panel and is being made available for public review. Final responsibility for the contents 
and views expressed in this toxicological profile resides with ATSDR.
Howard Frumkin, M.D., Dr. P.H. 
Director, National Center for Environmental 
Health/Agency for Toxic Substances and Disease 
Registry
Thomas R. Frieden, M.D., M.P.H. 
Administrator, Agency for Toxic Substances and 
Disease Registry
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Q U IC K  R E F E R E N C E  F O R  H E A L T H  C A R E  P R O V ID E R S
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance. Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance. It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure.
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health.
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are 
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure.
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: I-8OO-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an
exposure history and how to conduct one are described, and an example of a thorough exposure 
history is provided. Other case studies of interest include Reproductive and Developmental 
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies.
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Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials. Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998
• Phone: 800-35-NIOSH.
The National Institute o f Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues. Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk 
Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.
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P E E R  R E V IE W
A peer review panel was assembled for carbon monoxide. The panel consisted of the following members:
1. Laurence Fechter, Ph.D., Senior Career Research Scientist, Jerry Pettis Memorial Veterans 
Medical Center, Loma Linda, California
2. Jerrold Leikin, M.D., Director of Medical Toxicology, NorthShore University Health System -  
OMEGA, Glenbrook Hospital, Glenview, Illinois
3. Stephen Thom, M.D., Ph.D., Professor, Emergency Medicine, University of Pennsylvania, 
Institute for Environmental Medicine, Philadelphia, Pennsylvania
These experts collectively have knowledge of carbon monoxide's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile. A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR.
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1. P U B L IC  H EA LTH  S T A T E M E N T
This public health statement tells you about carbon monoxide and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Carbon monoxide has been found in at least 12 of the 1,699 current or former 
NPL sites. Although the total number of NPL sites evaluated for this substance is not known, the 
possibility exists that the number of sites at which carbon monoxide is found may increase in the future as 
more sites are evaluated. This information is important because these sites may be sources of exposure 
and exposure to this substance may be harmful.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment. Such a release does not always lead to exposure. You 
can be exposed to a substance only when you come in contact with it. You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to carbon monoxide, many factors will determine whether you will be harmed. These 
factors include the dose (how much), the duration (how long), and how you come in contact with it. You 
must also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, 
pregnancy status, and state of health.
1.1 WHAT IS CARBON MONOXIDE?
Carbon monoxide is a gas Carbon monoxide is a colorless, nonirritating, 
odorless, and tasteless gas. It is found in both 
outdoor and indoor air.
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Sources of carbon monoxide in the 
atmosphere
Carbon monoxide is made when carbon in fuel 
is not burned completely. Carbon monoxide is 
produced from both human-made and natural 
sources. The most important human-made 
source of carbon monoxide arises from the 
exhaust of automobiles.
Inside homes, improperly adjusted gas 
appliances, furnaces, wood burning stoves, and 
fireplaces are a potential source of carbon 
monoxide (see Section 1.3).
Industrial uses Carbon monoxide can be used in industry to 
synthesize many compounds such as acetic 
anhydride, polycarbonates, acetic acid, and 
polyketone.
1.2 WHAT H APPEN S TO CARBON MONOXIDE WHEN IT EN TER S THE ENVIRONMENT?
Converts to carbon dioxide When carbon monoxide is released to the 
environment, it enters the air and remains in the 
atmosphere for an average of about 2 months.
Eventually, carbon monoxide reacts with other 
compounds in the atmosphere and is converted 
to carbon dioxide.
Microorganisms found in soil and water can 
also convert carbon monoxide to carbon 
dioxide.
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1.3 HOW MIGHT I B E  EXPO SED  TO CARBON MONOXIDE?
All people are exposed to carbon monoxide at 
varying levels through inhalation of air. Places 
and times of the day that have a lot of vehicular 
traffic generally have higher levels of carbon 
monoxide as compared to areas of low traffic.
You can be exposed to carbon monoxide from 
cigarette smoke whether as a smoker or from 
second-hand smoke.
You can be exposed to carbon monoxide by 
using gas appliances or wood burning stoves 
and fireplaces.
People are exposed to carbon monoxide inside 
of vehicles.
1.4 HOW CAN CARBON MONOXIDE EN TER AND LEA V E  MY BODY?
Carbon monoxide in the air rapidly enters all 
parts of the body, including blood, brain, heart, 
and muscles when you breathe.
The carbon monoxide in your body leaves the 
body through your lungs, when you breathe out 
(exhale), but there is a delay in eliminating 
carbon monoxide.
It takes about a full day for carbon monoxide to 
leave your body.
1.5 HOW CAN CARBON MONOXIDE A F F E C T  MY HEALTH ?
This section looks at studies concerning potential health effects in animal and human studies.
Carbon monoxide can harm the heart, brain, 
and lungs
Breathing lower levels of carbon monoxide can 
permanently harm your heart and brain.
Carbon monoxide can be more harmful to you if 
you have heart or lung disease.
3
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1.6 HOW CAN CARBON MONOXIDE AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from 
conception to maturity at 18 years of age.
Breathing carbon monoxide during 
pregnancy can harm your unborn child
Breathing high levels of carbon monoxide can 
lead to miscarriage.
Breathing lower levels of carbon monoxide 
during pregnancy may harm the mental 
development of your child.
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO CARBON MONOXIDE?
Reduce indoor air levels of carbon 
monoxide
The most dangerous levels of carbon monoxide 
usually occur in indoor air. High levels occur as 
a result of improperly installed or unvented 
appliances that burn natural gasoline, kerosene, 
or other fuels. These include stoves, furnaces, 
heaters, and generators. Make sure that all of 
your appliances are installed properly and have 
periodic maintenance performed by 
professional installers. Always follow the 
manufacturer’s recommendations on installing 
and using these devices.
Make certain wood burning heaters and 
fireplaces are properly vented.
Never use a gas-powered generator or burn 
charcoal indoors, as this can quickly lead to 
dangerous levels of carbon monoxide in your 
home.
Do not use older portable propane heaters in 
enclosed indoor settings, including campers 
and tents, as dangerous levels of carbon 
monoxide can build up. Look for portable 
heaters that contain an oxygen depletion sensor 
(ODS) and are safer to use when camping. If 
oxygen levels start to fall, the sensor 
automatically shuts down the heater before it 
can produce dangerous levels of carbon 
monoxide. Older generation heaters without an 
ODS are intended for outdoor use only and 
should not be used indoors.
Do not let your car idle for long periods of time 
in your garage.
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Avoid tobacco smoke You can reduce your exposure to carbon 
monoxide by avoiding smoke from cigarettes 
and cigars since the sidestream smoke contains 
carbon monoxide.
Install carbon monoxide detectors in your 
home
Carbon monoxide detectors can be purchased 
at home remodeling or hardware stores. It is 
important to understand that most smoke 
detectors do not detect carbon monoxide, so 
you should install carbon monoxide detectors in 
your home as well as smoke detectors.
1.8 IS TH ERE A M EDICAL T E S T  TO DETERM INE W HETHER I HAVE BEEN EX PO SED  TO 
CARBON MONOXIDE?
Carbon monoxide exposure can be 
measured with a blood test
Medical devices called carbon monoxide­
oximeters that are found in clinical laboratories 
or hospitals can estimate the level of carbon 
monoxide in blood by a simple test.
1.9 WHAT RECOM MENDATIONS HAS THE FE D E R A L GOVERNM ENT MADE TO 
P R O TEC T HUMAN HEALTH ?
The federal government develops regulations and recommendations to protect public health. Regulations 
can be enforced by law. The EPA, the Occupational Safety and Health Administration (OSHA), and the 
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic 
substances. Recommendations provide valuable guidelines to protect public health, but cannot be 
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National 
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop 
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels. These are levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value. This critical value is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans. Sometimes 
these not-to-exceed levels differ among federal organizations because they used different exposure times 
(an 8-hour workday or a 24-hour day), different animal studies, or other factors.
Recommendations and regulations are also updated periodically as more information becomes available. 
For the most current information, check with the federal agency or organization that provides it.
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Some regulations and recommendations for carbon monoxide include the following:
Levels in air set by EPA EPA established an environmental limit of 
10 mg/m3 (9 ppmv) of carbon monoxide in air 
averaged over 8 hours and not to be exceeded 
more than once per year.
Levels in workplace air set by OSHA OSHA set a legal limit of 55 mg/m3 (50 ppmv) 
for carbon monoxide in air averaged over an 
8-hour work day.
1.10 W HERE CAN I G ET  MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous 
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You may 
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical 
assistance number at I-8OO-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing 
to:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine
1600 Clifton Road NE
Mailstop F-62
Atlanta, GA 30333
Fax: 1-770-488-4178
Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS) 
5285 Port Royal Road 
Springfield, VA 22161 
Phone: 1-800-553-6847 or 1-703-605-6000 
Web site: http://www.ntis.gov/
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2 . R E L E V A N C E  T O  P U B L IC  H E A L T H
2.1 BACKGRO UND AND ENVIRONM ENTAL EX P O SU R ES TO CARBON MONOXIDE IN 
THE UNITED ST A T E S
Carbon monoxide is a colorless, odorless, non-irritating, and tasteless gas that is ubiquitous in the 
atmosphere. It arises from both natural and anthropogenic sources. It is produced as a primary pollutant 
during the incomplete combustion of fossil fuels and biomass. Carbon monoxide is also produced 
indirectly from the photochemical oxidation of methane and other volatile organic compounds (VOCs) in 
the atmosphere. Vegetation can emit carbon monoxide directly into the atmosphere as a metabolic 
byproduct, and the photooxidation of organic matter in surface waters (lakes, streams, rivers, oceans) and 
soil surfaces also results in the formation of carbon monoxide. Volcanic activity is an additional natural 
source of carbon monoxide in the atmosphere. Carbon monoxide is also produced endogenously in 
humans during the normal catabolism of hemoglobin (Hb). The vast majority of anthropogenic carbon 
monoxide emissions arise from gasoline-powered automobile usage, although the total amount of carbon 
monoxide emitted to the environment from this source has declined significantly over the past several 
decades due to the use of catalytic converters and other emission control devices that are standard 
equipment on modern passenger vehicles. However, there are numerous additional sources of carbon 
monoxide generation that while minor in terms of total tonnage released to the atmosphere, may have 
significance with regard to generation of carboxyhemoglobin (COHb) in exposed individuals.
The annual average outdoor carbon monoxide concentrations are roughly 0.12 parts per million by 
volume (ppmv) in the Northern Hemisphere and about 0.04 ppmv in the Southern Hemisphere. These 
levels are variable throughout the course of the year, with seasonal maximum levels occurring during late 
winter in both hemispheres and minimum levels being observed during late summer. Carbon monoxide 
concentrations are reported to range from a minimum of about 0.03 ppmv during summer in the Southern 
Hemisphere to about 0.20 ppmv at high latitudes in the Northern Hemisphere during winter. Urban 
locations with high automobile usage or a high volume of stationary emission sources such as refineries 
or power plants typically have greater atmospheric levels of carbon monoxide as compared to rural or 
remote sites. Carbon monoxide levels in indoor air are strongly influenced by the presence of various 
appliances and whether or not the occupants of the residence smoke tobacco products. Unvented 
kerosene and gas space heaters; leaking chimneys and furnaces; back-drafting from furnaces, gas water 
heaters, wood stoves, and fireplaces; gas stoves, generators and other gasoline-powered equipment; 
automobile exhaust from attached garages; and tobacco smoke all contribute to indoor air levels of carbon
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monoxide. Average levels in homes without gas stoves vary from 0.5 to 5 ppmv. Levels near properly 
adjusted gas stoves are often 5-15 ppmv and those near poorly adjusted stoves may be >30 ppmv.
Exposure of the general population to carbon monoxide occurs through inhalation of outdoor and indoor 
air. Populations living in urban areas with heavy vehicular traffic or stationary sources such as petroleum 
refineries, gas and coal burning power plants, petrochemical plants, and coke oven plants are more likely 
to be exposed to higher levels of carbon monoxide from ambient outdoor air. Occupational exposure for 
employees who work in these industries and other occupations that are subject to high levels of vehicular 
exhaust (such as taxi cab drivers and toll booth workers) are also likely to be exposed to higher levels. 
Industrial or in-home use of methylene chloride paint strippers in poorly ventilated areas can lead to high 
levels of carbon monoxide in blood since carbon monoxide is a metabolic byproduct of methylene 
chloride. Members of the public who smoke or work in smoke-filled environments such as restaurants, 
bars, and casinos where smoking is allowed are also exposed to higher levels of carbon monoxide than 
members of the population who do not smoke and are not frequently exposed to second-hand tobacco 
smoke. Section 6.5 discusses exposures to the general population and occupational exposures in greater 
detail.
2.2 SUMMARY OF HEALTH E F F E C T S
Health effects associated with acute carbon monoxide poisoning have been extensively documented. In 
the last decade, growing evidence has revealed endogenous carbon monoxide (produced from catabolism 
of heme and other endogenous precursors) to be a cell signaling agent that contributes to the regulation of 
numerous physiological systems, including brain and muscle oxygen storage and utilization (myoglobin, 
neuroglobin), relaxation of vascular and extra-vascular smooth muscle, modulation of synaptic 
neurotransmission, anti-inflammation, anti-apoptosis, anti-proliferation, and anti-thrombosis (see 
Section 3.5.2, Mechanisms of Toxicity). Current toxicological and epidemiological research has focused 
on examining health effects of low-level carbon monoxide exposures that do not result in overt carbon 
monoxide poisoning and attempting to understand the connections between carbon monoxide toxicity and 
carbon monoxide physiology. This research has revealed that the heart and cardiovascular system, and 
brain and developing nervous system are particularly sensitive to carbon monoxide. These studies have 
also shown that people with ongoing cardiovascular and/or respiratory disease may be particularly 
vulnerable to carbon monoxide.
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Modes of Action of Carbon Monoxide. Carbon monoxide exerts effects on cell metabolism through 
hypoxic and non-hypoxic modes of action. Both modes of action are thought to be largely (if not 
entirely) the result of the ability of carbon monoxide to bind to heme and alter function and/or metabolism 
of heme proteins. Formation of COHb decreases the O2 carrying capacity of blood and impairs release of
O2 from Hb for its utilization in tissues. Through similar mechanisms, carbon monoxide decreases O2 
storage in muscle cells by binding to and displacing O2 from myoglobin. Although all tissues are 
vulnerable to carbon monoxide-induced hypoxic injury, those having the highest O2 demand are 
particularly vulnerable, including the brain and heart.
Most of the non-hypoxic mechanisms of action of carbon monoxide have been attributed to binding of 
carbon monoxide to heme in proteins other than Hb. Notable targets of carbon monoxide include 
components of several important physiological regulatory systems, including brain and muscle oxygen 
storage and utilization (myoglobin, neuroglobin); nitric oxide cell signaling pathway (e.g., nitric oxide 
synthase, guanylyl cyclase); prostaglandin cell signaling pathway (cyclooxygenase, prostaglandin H 
synthase); energy metabolism and mitochondrial respiration (cytochrome c oxidase, cytochrome c, 
NADPH oxidase); steroid and drug metabolism (cytochrome P450); cellular redox balance and reactive 
oxygen species (catalase, peroxidases); and various transcription factors (e.g., neuronal PAS domain 
protein, NPAS2).
Endogenous Carbon Monoxide. In addition to inhalation exposure to carbon monoxide in air, internal 
exposures to carbon monoxide occur as a result of production of carbon monoxide from endogenous 
precursors (e.g., heme degradation, auto-oxidation of phenols, photo-oxidation of organic compounds, 
and lipid peroxidation of cell membrane lipids) and production of carbon monoxide from oxidative 
metabolism of exogenous precursors (e.g., carbon tetrachloride, dichloromethane and other 
dihalomethanes). The latter two metabolic sources of carbon monoxide result in a carbon monoxide body 
burden in the absence of exposure to exogenous carbon monoxide in air. Endogenous carbon monoxide 
production rate has been estimated to be approximately 0.42 mL carbon monoxide STPD/hour, 0.006 mL 
carbon monoxide/hour-kg body weight. However, numerous physiological and disease factors affect the 
rate of endogenous production of carbon monoxide, including the menstrual cycle, pregnancy, diseases, 
and stimuli that increase catabolism of Hb or other heme proteins, including hemolysis, hematomas, 
hemolytic anemias, thalassemia, and Gilbert’s syndrome.
Growing evidence has revealed endogenous carbon monoxide to be a cell signaling agent that contributes 
to the regulation of numerous physiological systems, including brain and muscle oxygen storage and
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utilization (myoglobin, neuroglobin), relaxation of vascular and extra-vascular smooth muscle, 
modulation of synaptic neurotransmission, anti-inflammation, anti-apoptosis, anti-proliferation, and anti­
thrombosis. This has potentially important implications for the understanding of carbon monoxide 
toxicology and dose-response relationships for the following reasons: (1) carbon monoxide modulation 
of physiological processes may underlie some aspects of the toxicity of exogenous carbon monoxide;
(2) exogenous carbon monoxide may disrupt physiological regulation of those systems that are responsive 
to endogenous carbon monoxide (e.g., vascular resistance); and (3) exposures to exogenous carbon 
monoxide may affect carbon monoxide-mediated physiological responses at levels that approach those 
resulting from endogenous production. One implication of this is that the dose threshold for effects of 
exogenous carbon monoxide on carbon monoxide-modulated physiological systems may lie near or below 
ambient air carbon monoxide concentrations.
Toxicokinetics. Inhaled carbon monoxide is rapidly and extensively absorbed into blood and distributes 
throughout the body. The distribution of carbon monoxide in the body largely reflects the binding of 
carbon monoxide to heme proteins (e.g., Hb, myoglobin). Measurements of total carbon monoxide 
concentrations in tissues obtained from human autopsies showed the highest concentrations in blood, 
spleen, lung, kidney, and skeletal muscle, with detectable levels also in brain and adipose tissue (Vreman 
et al. 2006). Higher concentrations of carbon monoxide in blood, heart, skeletal muscle, and spleen 
reflect the abundance of the major carbon monoxide binding proteins in these tissues. In blood, carbon 
monoxide rapidly distributes into erythrocytes where is exists primarily as a complex with Hb (COHb). 
Carbon monoxide in muscle exists primarily as a complex with myoglobin (COMb). Carbon monoxide 
in the maternal system distributes to fetal tissues where it binds to fetal Hb and other heme proteins. 
Steady-state fetal blood COHb concentrations are approximately 10-15% higher than maternal blood 
(fetal/maternal ratio=1.1-1.25) and fetal blood COHb elimination kinetics are slower than maternal (Hill 
et al. 1977; Longo 1977). Carbon monoxide binding to fetal Hb is analogously similar to maternal Hb.
Absorbed carbon monoxide is eliminated from the body by exhalation and oxidative metabolism. 
Oxidative metabolism of carbon monoxide has been estimated to be a relatively small fraction (<10%) of 
endogenous carbon monoxide elimination. Under most conditions, the dominant route of elimination of 
absorbed carbon monoxide is exhalation. The decline in blood %COHb following cessation of an 
inhalation exposure to carbon monoxide exhibits at least two kinetic phases. The fast phase is thought to 
reflect a combination of exhalation of carbon monoxide along with slower distribution of blood carbon 
monoxide to tissues that continues after cessation of exposure. The elimination half-time for the slow 
phase is approximately 100-300 minutes. The carbon monoxide elimination half-time increases with age,
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with the most pronounced increase occurring from age 2 to 20 years and is marginally longer in males 
compared to females. Exercise decreases carbon monoxide elimination half-time, although exercise and 
the increase in respiration would lead to increased CO exposure, if CO is still present in inspired air.
The importance of COHb as a potential biomarker of carbon monoxide exposure and hypoxia, 
particularly at low levels of exposure, has led to the development of a physiologically-based mechanistic 
model of carbon monoxide kinetics for predicting relationships between exposure and blood COHb 
levels. The model that has received the greatest attention and use in risk assessment and in clinical 
medicine is the Coburn-Forster-Kane (CFK) model. This model can be used to predict steady-state blood 
COHb levels that correspond to a given continuous inhalation exposure to carbon monoxide in a typical 
adult. The CFK model has been used to support discussions of the health effects of carbon monoxide in 
this Toxicological Profile, by providing a means for interconverting carbon monoxide exposure levels 
expressed in units of ppm or mg/m3 and corresponding equivalent steady-state COHb% values (i.e., the 
COHb% that would be achieved with continuous exposure to the reported air carbon monoxide 
concentration). Predicted steady-state blood COHb levels corresponding to a range of carbon monoxide 
exposure concentrations are presented in the introduction to Section 3.2 (Table 3-1). Several other 
toxicokinetics models are described in Section 3.4.5.
Acute Carbon Monoxide Poisoning. Carbon monoxide poisoning is one of leading causes of morbidity 
and mortality due to poisoning in the United States. The principal mechanism of many adverse effects of 
carbon monoxide exposure is COHb-induced tissue hypoxia; thus, tissues with high oxygen requirements 
(e.g., brain, heart) are the most sensitive to carbon monoxide-induced hypoxia. However, other non- 
hypoxic mechanisms (e.g., binding of carbon monoxide to other heme proteins, such as myoglobin and 
cytochrome c oxidase) and alterations in biological and physiological functions of endogenous carbon 
monoxide, likely contribute to the adverse effects of acute carbon monoxide poisoning.
The extent of injury from acute carbon monoxide exposure depends upon the concentration and duration 
of exposure and the underlying health status of the exposed individual. The most commonly reported 
signs and symptoms associated with acute carbon monoxide poisoning are due to effects on the central 
nervous system and the cardiovascular system; however, because carbon monoxide exposure has the 
potential to affect nearly all tissues, the clinical presentation of acute carbon monoxide poisoning includes 
a wide range of symptoms. The severity of carbon monoxide poisoning is typically categorized as mild, 
moderate, or severe, based on clinical presentation. Signs and symptoms of mild carbon monoxide 
poisoning include headache, nausea, vomiting, dizziness, and blurred vision; headache and dizziness are
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the most commonly reported symptoms. Because these symptoms mimic flu-like viral illnesses, mild 
carbon monoxide poisoning can easily be misdiagnosed. Symptoms associated with moderate carbon 
monoxide poisoning may include confusion, syncope, chest pain, dyspnea, weakness, tachycardia, 
tachypnea, and rhabdomyolysis. Effects of severe poisoning may be life-threatening, including cardiac 
arrhythmias, myocardial ischemia, cardiac arrest, hypotension, respiratory arrest, noncardiogenic 
pulmonary edema, seizures, and coma. In addition to the immediate-onset effects of exposure, delayed- 
onset development of neuropsychiatric impairment typically occurs from several days to approximately 
3-4 weeks of exposure, with symptoms including inappropriate euphoria, impaired judgment, poor 
concentration, memory loss, cognitive and personality changes, psychosis, and Parkinsonism. Acute 
carbon monoxide poisoning during pregnancy has been associated with spontaneous abortion and fetal 
death; pregnancy outcome is likely to be dependent upon the severity of maternal poisoning and fetal age.
The relationship between the severity of clinical signs and symptoms of acute carbon monoxide poisoning 
and COHb levels is not well correlated. The poor correlation may be due to the length of time elapsed 
between cessation of exposure and measurement of COHb levels or to effects of supplemental oxygen 
treatment prior to COHb measurement. Generally, in healthy individuals, mild carbon monoxide 
poisoning that requires medical intervention are associated with COHb levels >20%. Fatalities due to 
carbon monoxide poisoning have been reported for a wide range of COHb levels (3-70%). Levels of 
COHb >50% are frequently fatal.
Primary Targets of Low-level Carbon Monoxide Exposure. The primary targets of low-level exposures 
to carbon monoxide (i.e., those that result in blood COHb levels <20%) appear to include the heart and 
cardiovascular system, central nervous system, and the fetus and neonate. Adverse effects in the 
respiratory tract have also been observed in human clinical studies and in animal studies at higher 
exposures than those associated with effects on the cardiovascular system, central nervous system, and on 
development. A large body of epidemiologic studies also has provided evidence that ambient levels of 
carbon monoxide in air may contribute to respiratory morbidity and aggravation of ongoing respiratory 
disease (e.g., asthma; see Table 3-3). Epidemiologic studies have also examined possible associations 
between ambient air carbon monoxide concentrations and hematologic biomarkers of coagulation and 
inflammation. Although some studies have found significant associations, collectively, findings from 
these studies are inconclusive.
Cardiovascular System. Cardiovascular effects of inhalation exposures to carbon monoxide have 
been evaluated in controlled human clinical studies, epidemiology studies, and in various animal models
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(monkeys, dogs, rats, and rabbits). In general, these studies provide convincing evidence for adverse 
cardiovascular effects in association with carbon monoxide exposures that result in blood COHb levels of 
>2.4%, with effects occurring at the lowest levels in subjects who have compromised cardiovascular 
function (e.g., coronary artery disease).
Results of controlled clinical studies in patients with coronary artery disease show that acute-duration 
exposure to carbon monoxide at levels producing blood COHb levels between 2.4 and 5.9% exacerbates 
underlying cardiovascular disease, including enhanced myocardial ischemia and increased cardiac 
arrhythmias. In patients with exertional angina, carbon monoxide exposure exacerbated exercise-induced 
myocardial ischemia, including decreased time-to-onset of angina symptoms, increased duration of 
angina symptoms, decreased time-to-onset of ST-segment depression (EKG change indicative of 
myocardial ischemia), and decreased left ventricular ejection fraction. At the lowest blood COHb level 
evaluated in patients (i.e., COHb 2.4%), time-to-onset of angina symptoms and of ST-segment depression 
were significantly decreased by 4.2 and 5.1%, respectively.
Epidemiological studies of exposure to carbon monoxide and cardiovascular outcomes have yielded 
mixed results. In general, the weight of evidence suggests that risks of certain specific outcomes 
(hospitalizations and emergency room visits related to congestive heart failure, ischemic heart disease, 
myocardial infarction, and stroke) are associated with increasing ambient carbon monoxide 
concentrations. The interpretation of these associations is complicated by the possibility that ambient air 
carbon monoxide levels may be a surrogate measure for air pollution in general. However, the 
corroborated observations of associations between carbon monoxide exposure and outcomes related to 
ischemic heart disease is particularly provocative in the context of results of human clinical studies in 
which carbon monoxide-induced hypoxia exacerbated ischemia symptoms in patients with coronary 
artery disease. Mean ambient air carbon monoxide concentrations reported in studies that have found 
carbon monoxide-associated adverse cardiovascular outcomes have ranged from 0.5 to 10 ppm, with 
maximum values ranging from 2 to 50 ppm. These values correspond to approximate steady-state blood 
COHb levels of <2% for the mean, and <10% for the maximum.
Studies in animals have investigated adverse cardiovascular effects of carbon monoxide exposure over a 
much wider range of exposure conditions (e.g., exposure concentration and duration) and have evaluated 
additional outcome measures that are not possible to assess in humans. These studies provide further 
evidence of adverse cardiovascular effects of carbon monoxide exposure, including compensatory 
alterations in hemodynamics, cardiac hypertrophy, cardiac arrhythmias, and possibly atherosclerosis.
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Based on studies described above, a blood COHb concentration of 2.4% is identified as lowest-observed- 
adverse-effect level (LOAEL) for adverse cardiovascular outcomes in coronary artery disease patients. A 
no-observed-adverse-effect level (NOAEL) for this effect was not identified. The LOAEL for COHb can 
be converted to an equivalent human exposure concentration (for continuous exposure) that would yield 
the same steady-state blood COHb concentration (2.4%) by implementing the CFK model. The human 
equivalent exposure concentration is approximately 14 ppm.
Developmental Effects. Epidemiological studies have examined possible associations between 
exposure to ambient air carbon monoxide concentrations and various developmental outcomes, including 
pre-term birth, birth weight, congenital anomalies, and neonatal and infant death. Results of these studies 
have been mixed and, collectively do not provide strong evidence for developmental effects in association 
with exposures to ambient levels of carbon monoxide. In general, these studies have examined relatively 
low air carbon monoxide concentrations, typical of ambient levels (e.g., mean concentrations ranging 
from 0.5 to 3 ppm, with highest reported values <10 ppm). The air carbon monoxide measurements do 
not necessarily represent exposures that occurred during gestation or during any particular period of 
gestation.
Numerous studies on developmental effects of gestational and early postnatal exposure to carbon 
monoxide have been conducted in animals. In general, most studies evaluated effects of relatively low 
carbon monoxide concentrations (i.e., <300 ppm), with exposure concentrations selected to produce 
maternal COHb levels typically associated with smoking (5-10%); however, studies did not consistently 
report maternal or fetal COHb levels. Studies in animals have examined effects of carbon monoxide 
exposure on numerous developmental outcomes, including several outcomes that have not been assessed 
in epidemiological studies (e.g., auditory and immune system development). Results of animal studies 
show adverse developmental effects of gestational and early postnatal carbon monoxide exposure, 
including decreased fetal weight, adverse central nervous system development, altered peripheral nervous 
system development, cardiac effects, altered sexual behavior, immunological effects, and hematological 
effects. In addition, some studies showed that developmental effects persisted beyond the postnatal 
period, although persistence of effects was not examined in all studies. The lowest LOAEL values for 
developmental effects were obtained in studies evaluating effects of carbon monoxide on the developing 
auditory system (i.e., LOAEL 12-25 ppm carbon monoxide); however, since other developmental 
outcomes were not assessed at this range of low carbon monoxide concentrations, it is not possible to 
determine if the developing auditory system is more sensitive to carbon monoxide exposure than other
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systems. Gestational and/or early postnatal exposure of rats to 25 ppm carbon monoxide produced 
morphological changes in the developing auditory system, including swelling, cytoplasmic vacuolization 
and atrophy of nerve terminals innervating inner hair cells, “distorted myelin” with vacuolization in the 
8th cranial nerve at the level of the internal auditory canal, decreased immunoreactivity of the enzymes 
cytochrome oxidase, NADH-TR, and calcium-mediated myosin ATPase, and decreased immunostaining 
of neurofilament and myelin basic protein in the organ of corti. Exposure of rat pups during the early 
postnatal period decreased action potential amplitude of the 8th cranial nerve at >12 ppm carbon 
monoxide and decreased in otoacoustic emissions at >50 ppm carbon monoxide, with effects on action 
potential amplitude of the 8th nerve persisting through age 73 days.
Based on studies described above, a maternal exposure concentration of 12 ppm is identified as a LOAEL 
for adverse neurodevelopmental outcomes in rats. This LOAEL can be converted to an equivalent blood 
COHb level in the rat by implementation of the CFK model, as adapted for the rat. The time-averaged 
blood COHb level predicted for the 16-day exposure (22 hours/day) is 1.8%. The equivalent human 
exposure concentration (for continuous exposure) that would yield the same steady-state blood COHb 
concentration (1.82%) is approximately 10 ppm
Central Nervous System. As previously noted, acute exposure to high levels of carbon monoxide 
produces symptoms of central nervous system toxicity, including headache, dizziness, drowsiness, 
weakness, nausea, vomiting, confusion, disorientation, irritability, visual disturbances, convulsions, and 
coma. Lesions of the basal ganglia (primarily of the globus pallidus) and white matter have also been 
observed in magnetic resonance imaging (MRI) and computed tomography (CT) scans in association with 
acute carbon monoxide poisoning. Motor impairments consistent with damage to basal ganglia have been 
observed following carbon monoxide poisoning. Following acute-onset effects, delayed development of 
neuropsychiatric impairment may occur from several days to 3-4 weeks of exposure, with symptoms 
including inappropriate euphoria, impaired judgment, poor concentration, memory loss, cognitive and 
personality changes, psychosis, and Parkinsonism. Delayed neuropsychiatric impairment has been 
estimated to occur in up to 68% of patients with acute carbon monoxide poisoning. There is a poor 
correlation between initial symptom severity and the likelihood of developing of delayed neuropsychiatric 
impairment has not been established.
Based on an extensive database of acute carbon monoxide poisoning, it is generally accepted that central 
nervous system symptoms are associated with acute exposures that result in blood COHb levels >20%. 
However, despite extensive clinical experience, general consensus on the dose-response relationship for
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carbon monoxide-induced nervous system effects at blood COHb levels between 5 and 20% has not been 
achieved.
Based on studies described above, a blood COHb concentration of 20% is identified as a LOAEL for 
adverse neurological outcomes, although the LOAEL range may extend below this level to 5%. These 
levels, 5 and 20%, can be converted to equivalent human exposure concentrations (for continuous 
exposure) that would yield the same steady-state blood COHb concentration by implementing the CFK 
model. The human equivalent exposure concentrations are approximately 32 ppm (COHb=5%) and 
160 ppm (COHb=20%).
Respiratory Effects. Although cardiopulmonary arrest is an end point of fatal carbon monoxide 
poisoning, results of controlled clinical studies in healthy subjects indicate that the respiratory tract does 
not appear to be a primary target organ for carbon monoxide toxicity. Brief exposure to carbon monoxide 
at levels >1,000 ppm may decrease ventilatory performance, although conflicting results have been 
reported. Epidemiological studies have examined possible associations between ambient air carbon 
monoxide concentrations and mortality. These studies have examined relatively low carbon monoxide 
concentrations (from a toxicological perspective) that are typical of ambient conditions of study period 
(mean concentrations ranging from 0.3 to 10 ppm with the highest values <30 ppm). Collectively, these 
studies have yielded mixed results, with some studies finding significant associations between increasing 
ambient air carbon monoxide concentrations and respiratory outcomes (e.g., exacerbation of asthma 
symptoms, hospitalizations and emergency room visits related to asthma), and few studies finding 
associations that persist after accounting for exposures to other air pollutants that also have been shown to 
contribute to respiratory disease risk (e.g., NO2, O3, particulate matter, and SO2). The lack of strong 
evidence for associations between ambient air carbon monoxide concentrations at <30 ppm and 
pulmonary function is also consistent with the results of human clinical studies. Studies conducted in 
animals provide supporting evidence that the respiratory tract does not appear to be a primary target organ 
for carbon monoxide. Most of these studies evaluated carbon monoxide exposures that produced much 
higher COHb concentrations (i.e., COHb >50%) than those evaluated in controlled clinical studies in 
humans.
Hematological Effects. Hematological effects of carbon monoxide include compensatory responses 
to tissue hypoxia resulting from binding of carbon monoxide to Hb (e.g., increased blood volume, Hb, 
hematocrit, and erythrocyte count and volume). Possible associations between ambient air carbon 
monoxide concentrations and biomarkers of coagulation and inflammation have been examined in
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epidemiological studies. Biomarkers examined have included inflammation markers, CRP, serum 
amyloid A (SAA), and white blood cell count (WBC); cell adhesion markers, E-selectin, von Willebrand 
factor, antigen (vWF), ICAM-1; and coagulation markers, fibrinogen, factor VII (FVII), prothrombin 
fragment 1+2, prothrombin time (PT), and activated partial thromboplastin time (APTT). Although some 
studies have found significant associations between environmental carbon monoxide exposures and 
alteration in plasma proteins, these studies do not distinguish between possible direct effects of carbon 
monoxide and/or other air pollutants directly on coagulation and immune systems from indirect effects 
that result in changes in blood biomarkers. Furthermore, findings across studies are inconsistent. 
Environmental carbon monoxide exposures were shown to correlate with elevated C reactive protein in 
one trial, but not another by the same group. Plasma fibrinogen was increased in one study, decreased in 
one study, and unchanged in two studies. Other studies have reported an elevation in soluble intercellular 
adhesion molecule-1, along with decreases in factor VII, serum albumin, and prothrombin time. 
Therefore, no conclusions can be drawn at this time on whether low-level environmental exposures may 
alter plasma inflammatory or coagulation markers. Nevertheless, direct effects are plausible, given 
mechanistic studies that have revealed evidence that endogenous carbon monoxide may participate in the 
regulation of thrombosis and immune function (see Section 3.5.2, Mechanisms of Toxicity).
2.3 CARBON MONOXIDE D O SE-R ESPO N SE RELATIO N SH IPS
Epidemiological and clinical studies provide evidence for a progression of some of the adverse health 
effects of carbon monoxide in humans with increasing blood levels of COHb (Figure 2-1). The 
relationship shown in Figure 2-1 does not necessarily mean that these effects result directly from 
formation of COHb at the expense of decreasing O2Hb levels in blood (i.e., hypoxic mechanisms). Other 
important mechanisms, previously mentioned and described in greater detail in Section 3.5.2, 
(Mechanisms of Toxicity), may also contribute to these effects. COHb may serve as a biomarker for 
carbon monoxide body burden or carbon monoxide burdens in specific target tissues where nonhypoxic 
modes of actions of carbon monoxide exert effects.
An alternative presentation of the relationship between blood COHb levels and adverse health effects is 
provided in Table 2-1. This table shows the predicted relationship between blood COHb levels that
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Figure 2-1. Blood Carboxyhemoglogin Levels Corresponding to Adverse Health
Effects of Carbon Monoxide in Humans
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Table 2-1. Blood Carboxyhemoglobin Levels Corresponding to Adverse Health
Effects of Carbon Monoxide
Effect
COHba Exposureb 
(Percent) (ppm)
Endogenous production <0.5 0
Typical level in nonsmoker 0.5-1.5 1-8
Increased risk of arrhythmias in coronary artery disease patients and 
exacerbation of asthma (epidemiological studies)
0.3-2b 0.5-10b
Neurodevelopmental effects on the auditory system in rats 2-4b 12-25b
Enhanced myocardial ischemia and increased cardiac arrhythmias in coronary 
artery disease patients
2.4-6 14-40
Decreased exercise stamina in healthy adults 5-8 30-50
Neurobehavioral/cognitive changes, including visual and auditory sensory effects 
(decreased visual tracking, visual and auditory vigilance, visual perception), fine 
and sensorimotor performance, cognitive effects (altered time discrimination, 
learning, attention level, driving performance), and brain electrical activity
5-20 30-160
Acute and delayed onset of neurological impairment (headache, dizziness, 
drowsiness, weakness, nausea, vomiting, confusion, disorientation, irritability, 
visual disturbances, convulsions, and coma), and pathology (basal ganglia 
legions)
20-60 160-1000
High risk of death >50 >600
a R e p o r t e d  v a l u e ,  u n l e s s  o t h e r w i s e  d e n o t e d  a s  p r e d i c t e d .
b P r e d i c t e d  f r o m  t h e  C o b u r n - F o r s t e r - K a n e  ( C F K )  m o d e l  ( u n l e s s  o t h e r w i s e  d e n o t e d  a s  r e p o r t e d ) ,  w i t h  a  r a t e  o f  
e n d o g e n o u s  c a r b o n  m o n o x i d e  p r o d u c t i o n  a s s i g n e d  a  v a l u e  o f  0 . 0 0 6  m L  C O / k g  b o d y  w e i g h t  a n d  a l l  o t h e r  p a r a m e t e r  
v a l u e s  a s  n o t e d  i n  T a b l e  3 - 1 3 .
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roughly correspond to adverse health effects and their corresponding equivalent human exposure 
concentrations (HEC) that would result in the same-steady state blood COHb level. For example, in 
Table 2-1, a continuous exposure to approximately 14 ppm for a period exceeding 16 hours (i.e., 
sufficient to achieve steady state) would be expected to result in a blood COHb level of approximately 
2.4%, the lower end of the range for cardiac effects in coronary artery disease patients. All predictions 
shown in Table 2-1 are based on the CKF model, described in Section 3.4.5 (Physiologically Based 
Pharmacokinetic/Pharmacodynamic Models).
2.4 MINIMAL R IS K  L E V E L S  (MRLs)
Given the above considerations, MRLs for carbon monoxide are not proposed at this time. The rationale 
for this determination is as follows:
(1) Growing evidence suggests that endogenous carbon monoxide production is physiologically 
regulated and plays a role in regulating various important physiological processes, including 
processes that may underlie adverse effects on the cardiovascular system, immune system, blood 
coagulation system, and nervous system that have been observed in human clinical studies, 
epidemiological studies, and animal studies.
(2) Given the physiological role of endogenous carbon monoxide, it is likely that an exposure 
threshold for carbon monoxide actions, if one exists at all, would be at or near the endogenous 
production rate. Therefore, any exogenous source of carbon monoxide exposure would have the 
potential for exceeding the threshold and producing potentially adverse effects.
(3) Although there may be an exposure level that can be tolerated with minimal risk of adverse 
effects, the currently available toxicological and epidemiological data do not identify such 
minimal risk levels. Experimental clinical studies and animal toxicology studies that identify the 
lowest LOAELs do not identify NOAELs. These LOAELs are relatively low: COHb 2.4% for 
cardiovascular effects in humans, exposure concentrations of >12 ppm in rats for developmental 
effects. Converting these to human equivalent exposure concentrations (i.e., levels of continuous 
exposure that would result in steady-state COHb concentration in blood estimated from the CFK 
model) yield corresponding LOAELs of 14 and 10 ppm, respectively. Application of appropriate 
uncertainty factors to these LOAELs (e.g., for extrapolation from a LOAEL, for extrapolation 
from animals to humans, and for extrapolation to sensitive subpopulations), would result in 
MRLs that are 30-100 times lower than the corresponding LOAELs (e.g., approximately 0.1­
0.5 ppm). These values are within the range of ambient carbon monoxide concentrations in the 
United States and would result, even for acute (e.g., 14-day) exposures, in internal doses that 
would be similar to endogenous production of carbon monoxide.
(4) Any exposure level determined to be of minimal risk at sea level would not necessarily be of 
minimal risk at higher altitudes (i.e., at lower O2 partial pressures). This would apply, in 
particular, to modes of actions of carbon monoxide that involve competition between carbon 
monoxide and O2 for heme binding sites. The latter would include hypoxic mechanisms of 
actions that appear to underlie adverse cardiovascular effects of carbon monoxide (e.g., 
exacerbation of exercise induced arrhythmias in patients who have coronary artery disease).
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE 21
3 . H E A L T H  E F F E C T S
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of carbon monoxide. 
It contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
Focus of the Health Effects Review. The literature on the toxicology of carbon monoxide is immense. 
Relatively recent reviews of the literature have been prepared by various organizations, including WHO 
(1999). EPA (2000, 2009g) and numerous reviews have been compiled on the clinical toxicology and 
management of acute carbon monoxide poisoning. The review of the literature provided in this section is 
not intended to be comprehensive; rather, it is focused on the more important, recent developments in the 
toxicological and epidemiological assessment of carbon monoxide. Studies that have potential relevance 
to understanding the lower end of the dose-response relationship for carbon monoxide are emphasized. 
Typically, dose-response information is presented in Toxicological Profiles in Levels of Significant 
Exposure (LSE) tables and figures. However, this information on carbon monoxide has been represented 
in various types of units (e.g., exposure concentration, blood COHb), and end points are not easily 
assigned into categories of no-observed-adverse-effect-level (NOAEL) or lowest-observed-adverse- 
effect-level (LOAEL) (e.g., odds ratio from epidemiological studies). Therefore, in place of an LSE 
table, Table 3-1 provides an overview of exposures (ppm) and blood COHb levels (%) that have been 
associated with specific categories of health effects. Table 3-2 can be used to convert the reported 
ambient air carbon monoxide concentrations into equivalent predicted blood COHb levels. However, 
considerable uncertainty attends to these dose interconversions as well as their relevance to a particular 
outcome. Predicted COHb levels and corresponding exposure concentrations may have greater relevance 
to outcomes mediated through hypoxic mechanisms than to those mediated through nonhypoxic 
mechanisms. Furthermore, steady-state requires exposure durations of approximately 16-24 hours. 
Exposures to lower levels of carbon monoxide for longer durations and exposures to higher levels for 
shorter durations that achieve similar blood COHb levels may not yield equivalent responses.
The discussion of health effects has been limited to the inhalation exposure pathway. Carbon monoxide 
exists in the environment as a gas (Henry’s law constant >50,000 atm/mol fraction, 25 °C). As a result,
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Table 3-1. Carbon Monoxide Exposures and Carboxyhemoglobin Levels Associated with Health Effects from Selected
Studies Representing the Lowest Adverse Effect Levels
Study type Subjects
Exposure
(ppm)
COHb
(%) Effect Comments Reference
Respiratory
Epidemiological Asthmatic children
Cardiovascular
Clinical (acute 
exposure)
Coronary artery 
disease patients 
(63 male adult 
nonsmokers)
0 .3 -2 N R  Asthma
117 
(1 hour)
2 .4%  Myocardial ischemia
Exacerbation of asthma. Associations 
confounded by co-exposure to other 
air pollutants (N O 2 , O 3 , P M 10, P M 2 5 , 
SO 2).
Park et al. 2005a; 
Rabinovitch et al. 2004; 
Rodriguez et al. 2007; 
Schildcrout et al. 2006; 
Silkoff et al. 2005; 
Slaughter et al. 2003; 
von Klot et al. 2002; Yu 
et al. 2000
Decreased time-to-onset of angina and Allred et al. 1989, 1991 
arrhythmia (ST-segm ent changes) 
during exercise.
Clinical (acute 
exposure)
Healthy adults 
(15 male adult 
nonsmokers)
NR
Epidemiological General public
Animal study, Rats 
chronic exposure
0 .3 -2
5.1%  Performance
N R  Cardiovascular disease
200
(20 hour/ 
day, 72
N R Cardiomegaly
Decreased maximal exercise duration 
and effort. No effect on heart rate or 
rhythm, cardiac perfusion, or blood 
pressure.
Increased risk of congestive heart 
failure, ischemic heart disease, 
myocardial infarction, and stroke. 
Effect size more pronounced in elderly 
and people with ongoing respiratory or 
cardiovascular disease. Associations 
confounded by co-exposure to other 
air pollutants (N O 2, O 3, P M 10, P M 25, 
S O 2).
Left and right ventricle weights 
increased by 20%  (p<0.001) and 14%  
(p<0.001).
Adir et al. 1999
Berger et al. 2006; 
D ’Ippoliti et al. 2003; 
Hosseinpoor et al. 2005; 
Lanki et al. 2006; Lee et 
al. 2003b; Mann et al. 
2002; Szyszkowicz 2007; 
von Klot et al. 2005
S0rhaug et al. 2006
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Table 3-1. Carbon Monoxide Exposures and Carboxyhemoglobin Levels Associated with Health Effects from Selected
Studies Representing the Lowest Adverse Effect Levels
Study type Subjects
Exposure COHb 
(ppm) (%) Effect Comments Reference
Neurological
Clinical, acute 
exposure
Clinical, acute 
exposure
Animal study, 
acute exposure
Healthy adults
week)
NR 5 -2 0  Neurobehavioral/cognitive 
changes.
Carbon monoxide- 
poisoning
NR 4 0 -6 0  Neurological impairment 
and pathology
Rat 5 0 0 -1 ,5 0 0 Neurosensory impairment
Visual and auditory sensory effects 
(decreased visual tracking, visual and 
auditory vigilance, visual perception), 
fine and sensorimotor performance, 
cognitive effects (altered time 
discrimination, learning, attention level, 
driving performance), and brain 
electrical activity.
Acute and delayed onset neurological 
impairment (headache, dizziness, 
drowsiness, weakness, nausea, 
vomiting, confusion, disorientation, 
irritability, visual disturbances, 
convulsions, and coma) and pathology 
(basal ganglia legions).
Potentiates noise-induced hearing 
loss, including noise-induced elevation 
of compound action potential threshold 
and auditory threshold shifts
Beningnus et al. 1994
Cham bers et al. 2008; 
Dolan 1985; Ernst and 
Zibrak 1998; Hopkins et 
al. 2006; Kao and 
Nanagas 2006; Lo et al. 
2007; Parkinson et al. 
2002; Raub and 
Benignus 2002
Chen and Fechter 1999; 
Fechter et al. 1988; 
Young et al. 1987
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Table 3-1. Carbon Monoxide Exposures and Carboxyhemoglobin Levels Associated with Health Effects from Selected
Studies Representing the Lowest Adverse Effect Levels
Study type Subjects
Exposure
(ppm)
COHb
(%) Effect Comments Reference
Developmental
Animal study, 
acute exposure
Neonatal rat 
(exposed post 
utero)
1 2 -2 5 NR Neurosensory
development
Morphological changes in the 
developing auditory system, decreased  
8th cranial nerve action potentials and 
otoacoustic emissions in pups, which 
persisted to age 73 days
Lopez et al. 2003, 2008; 
Stockard-Sullivan et 
al.2003; W ebber et al. 
2003
Animal study, 
acute exposure
Neonatal rats or 
mice (exposed in  
utero)
6 0 -1 5 0 Neurosensory/
neurobehavioral
development
Decreased motor activity and response 
to stimulation, impaired righting 
reflexes, and impaired homing and 
memory acquisition behaviors.
De Salvia et al. 1995; 
Fechter and Annau 1977, 
1980; Giustino et al.
1999; Mactutus and 
Fechter 1985; Singh 
1986
C O H b  =  b l o o d  c a r b o x y h e m o g l o b i n ;  N R  =  n o t  r e p o r t e d
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Table 3-2. Predicted Steady-State Blood Carboxyhemoglobin (COHb) Levels3
Carbon monoxide exposure concentration (ppm) Steady-state blood COHb (percent)
0.1 0.25
0.5 0.32
1 0.39
2 0.50
5 1.0
10 1.8
15 2.5
20 3.2
40 6.1
60 8.7
80 11
100 14
200 24
400 38
600 48
800 56
1,000 61
a B l o o d  C O H b  l e v e l s  a r e  p r e d i c t e d  f r o m  t h e  C o b u r n - F o r s t e r - K a n e  ( C F K )  m o d e l  ( s e e  S e c t i o n  3 . 5 . 4  f o r  a  d i s c u s s i o n  o f  
m o d e l  a n d  p a r a m e t e r  v a l u e s ) .
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humans can be exposed to carbon monoxide from breathing and/or contact with carbon monoxide in air. 
No information is available on the dermal absorption or toxicity of carbon monoxide resulting from 
exposures to gaseous carbon monoxide. However, as is the case for other gases that are avidly absorbed 
from the lung (e.g., O2), during exposure to carbon monoxide in air, dermal absorption of carbon 
monoxide through intact skin would be expected to make a minor contribution to absorbed carbon 
monoxide, relative to inhalation. No information is available on the absorption or toxicity of carbon 
monoxide resulting from oral exposures to gaseous carbon monoxide. Although carbon monoxide can 
dissolve in water (23 mL carbon monoxide/L water, 20 °C), appreciable concentrations in drinking water 
would occur only at very high partial pressures of carbon monoxide in air, conditions in which inhalation 
would be the dominant absorption pathway. Therefore, the only relevant pathway of exposure to humans 
is the inhalation pathway, and oral and dermal exposures are not considered further.
3.2 D ISCUSSION OF HEALTH E F F E C T S
This section of the Toxicological Profile summarizes results obtained from clinical cases of carbon 
monoxide poisoning, studies of controlled exposures conducted in humans, epidemiological studies of 
health outcomes associated with ambient air carbon monoxide concentrations, and experimental studies 
conducted in various animal models. Reported clinical studies are limited to exposures of acute duration. 
Animal studies have examined longer-duration exposures. Epidemiological studies have examined 
outcomes in the context of chronic exposures, or acute variations in exposure concentrations that occur 
during chronic exposures. Some studies (e.g., clinical studies) have reported carbon monoxide doses in 
terms of blood COHb levels, while most epidemiological studies and some animal studies have reported 
exposures concentrations (e.g., ppm, mg/m3). For comparability to human clinical studies, reported air 
carbon monoxide concentrations can be converted to corresponding equivalent steady-state COHb% 
values (i.e., the COHb% that would be achieved with continuous exposure to the reported air carbon 
monoxide concentration) model. This conversion has been made by application of the CFK model (see 
Section 3.4.5). Predicted steady-state blood COHb levels corresponding to a range of carbon monoxide 
exposure concentrations are presented in Table 3-2. This table can be used to convert the reported 
ambient air carbon monoxide concentrations into equivalent predicted blood COHb levels. Exposure 
concentrations are typically reported in units of ppm or mg/m3; in the Toxicological Profile, exposure 
units are presented in units of ppm. At standard temperature and pressure (e.g., 25 °C, 760 Torr), the 
conversion factor is approximately 1 (i.e., 1 mg/m3 ~ 0.87 ppm).
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Overview of Acute Carbon Monoxide Toxicity and Modes of Action. Carbon monoxide exerts effects on 
cell metabolism through both hypoxic and non-hypoxic mechanisms. Both types of effects are thought to 
be largely (but not entirely) the result of the ability of carbon monoxide to bind to heme and alter function 
and/or metabolism of heme proteins. Formation of COHb decreases the O2 carrying capacity of blood 
and impairs release of O2 from Hb for its utilization in tissues. Through similar mechanisms, carbon 
monoxide decreases O2 storage in muscle cells by binding to and displacing O2 from myoglobin.
Although all tissues are vulnerable to carbon monoxide-induced hypoxic injury, those having the highest
O2 demand are particularly vulnerable, including the brain and heart. The developing fetus may also be a 
sensitive target of carbon monoxide, through hypoxic and/or non-hypoxic mechanisms (Carratu et al. 
1993, 2000a, 2000b; De Salvia et al. 1995; Lopez et al. 2003, 2008; Stockard-Sullivan et al. 2003;
Webber et al. 2003). Acute carbon monoxide poisoning is largely the result of tissue hypoxia. Signs and 
symptoms of carbon monoxide toxicity, in order of increasing severity include: (1) headache, nausea, 
dilation of cutaneous vasculature, vomiting, dizziness, and blurred vision; (2) confusion, syncope, chest 
pain, dyspnea, weakness, tachycardia, and tachynea rhabdomyolysis; and (3) palpitations, cardiac 
dysrhythmias, hypotension, myocardial ischemia, cardiac arrest, respiratory arrest, pulmonary edema, 
seizures, and coma (Kao and Nanagas 2006). Although binding of carbon monoxide to blood Hb is a 
primary component of the hypoxic mode of action of carbon monoxide, blood COHb levels have not been 
shown to be a reliable predictor of severity of acute toxicity, in part, due to time elapsed from removal 
from carbon monoxide exposure to COHb measurement and to the effects of emergency medical 
intervention (i.e., treatment with oxygen) on COHb levels prior to COHb measurement (Hampson and 
Hauff 2008). In general, typical levels of COHb in nonsmokers are <2% (Adams et al. 1988; Allred et al. 
1991; Anderson et al. 1973; Hinderliter et al. 1989; Kleinman et al. 1989, 1998; Sheps et al. 1987, 1990). 
Of this, approximately 0.2-1.0% is derived from endogenous production of carbon monoxide (Coburn et 
al. 1963; Delivoria-Papadopoulos et al. 1974; Longo 1977). Levels ranging from 2 to 6% have been 
shown to exacerbate underlying cardiovascular disease, including enhanced myocardial ischemia and 
increased cardiac arrhythmias (Adams et al. 1988; Allred et al. 1989, 1991; Anderson et al. 1973; 
Kleinman et al. 1989, 1998; Leaf and Kleinman 1996b). In general, signs and symptoms of acute carbon 
monoxide poisoning can present at COHb levels ranging from 3 to 24% (Hampson and Hauff 2008; Kao 
and Nanagas 2006). This level overlaps with levels found immediately following cigarette smoking, up 
to approximately 10% (Kao and Nanagas 2006). More severe signs of carbon monoxide poisoning are 
poorly correlated with blood COHb, with loss of consciousness occurring at mean levels of 24.3% (range: 
2-70; Hampson and Hauff 2008) and fatality at mean levels of 32.1% (range: 3.0-60; Hampson and 
Hauff 2008). Exposures that result in COHb levels >60-70% are usually fatal (Kao and Nanagas 2006). 
Persistent neurologic sequelae, which can be delayed in onset, can also occur, including memory loss,
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
3. HEALTH EFFECTS
28
impairments of concentration and language, affective disorders (e.g., depression), and Parkinsonism (Choi 
2002; Klawans et al. 1982; Ringel and Klawans 1972), some of which may be related to pathologic 
changes in the brain (Lo et al. 2007; Gorman et al. 2003).
Most of the non-hypoxic mechanisms of action of carbon monoxide have been attributed to binding of 
carbon monoxide to heme in proteins other than Hb. Notable targets of carbon monoxide include 
components of several important physiological regulatory systems, such as brain and muscle oxygen 
storage and utilization (myoglobin, neuroglobin); nitric oxide cell signaling pathway (e.g., nitric oxide 
synthase, guanylyl cyclase); prostaglandin cell signaling pathway (cyclooxygenase, prostaglandin H 
synthase); energy metabolism and mitochondrial respiration (cytochrome c oxidase, cytochrome c, 
NADPH oxidase); steroid and drug metabolism (cytochrome P450), cellular redox balance, and reactive 
oxygen species (catalase, peroxidases); and various transcription factors (e.g., neuronal PAS domain 
protein, NPAS2). Endogenously produced carbon monoxide may participate in the physiological 
regulation of some, if not all, of these systems. This has potentially important implications for the 
understanding of carbon monoxide toxicology and dose-response relationships for the following reasons:
(1) carbon monoxide modulation of physiological processes may underlie some aspects of the toxicity of 
exogenous carbon monoxide; (2) exogenous carbon monoxide may disrupt physiological regulation of 
those systems that are responsive to endogenous carbon monoxide (e.g., vascular resistance); and
(3) exposures to exogenous carbon monoxide may affect carbon monoxide-mediated physiological 
responses at levels that approach those resulting from endogenous production. One implication of this is 
that the dose threshold for effects of exogenous carbon monoxide on carbon monoxide -modulated 
physiological systems may lie near or below ambient air carbon monoxide concentrations.
Epidemiological Studies. Epidemiological studies of health outcomes associated with exposure to carbon 
monoxide fall into two major categories. Some studies have examined relationships between long-term 
average ambient air carbon monoxide concentrations and health outcomes, where the air carbon 
monoxide concentrations represent averages over years or decades. Other studies have examined 
associations between outcomes and air concentrations measured over relatively narrow time slices (e.g., 
1-24-hour average or maxima). These short-term studies are particularly suited to outcomes that might 
be related to short-term elevations in carbon monoxide exposure in close temporal proximity to the 
outcome of interest, which might otherwise be lost in longer-term average carbon monoxide 
concentrations (e.g., change in heart rate, heart rate variability, arrhythmia). End points that have been 
assessed in epidemiological studies include mortality, morbidly, and rates of medical assistance.
Examples of the latter category include rates of hospital admissions or emergency room visits recorded to
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have been prompted by a given morbidity outcome, rates of activation of recorded activation of 
implantable cardioverter defibrillator (ICD) devices, and rates of rescue medication use by asthmatics. 
These studies are typically conducted using time-series analysis and Poisson regression models for 
estimated associations between carbon monoxide concentrations and outcome rates. Case-crossover 
designs have also been widely applied in air pollution epidemiology. This design offers many of the 
advantages of the case-control design (e.g., matching of individual cases and controls for potential co­
variables and confounders), with the additional feature of each case serving as its own control, with each 
case assigned a case exposure period, usually within a few days of the outcome measurement, and a 
control exposure period, usually some time before or after the case exposure period. Another widely 
reported design in assessment of morbidity is the panel study in which members of the study cohort, 
usually a relatively small sample, are followed individually with respect to exposures and outcomes. Also 
reported are case-control studies, retrospective and cross-sectional cohort studies, and a few prospective 
studies of mortality.
Several important features of the epidemiological studies of ambient air carbon monoxide are of generic 
relevance to public health assessments. In particular, their utility for establishing dose-response 
relationships is limited by several factors:
(1) Nearly all studies have relied on area monitoring for estimating exposure levels; this has the 
potential to produce errors in assigning exposure levels to individuals.
(2) The temporal correspondence between monitored exposure levels and outcomes is highly 
uncertain. Outcomes that might be related to carbon monoxide exposure might occur in response 
to short-term elevations in carbon monoxide concentrations not captured in air monitoring data 
that are averaged over longer time periods (e.g., 24-hour average). Also, outcomes associated 
with a given exposure may have a latency period (e.g., myocardial infarction may occur days 
after the exposure that initiated the event). One approach to this problem has been to apply time- 
series techniques to quantify air concentration trends and to explore lag times between exposure 
concentration trends and the time of outcome.
(3) Ambient air carbon monoxide concentrations tend to be strongly correlated with other air quality 
variables that can affect cardiovascular function, either directly or indirectly (e.g., through effects 
on the respiratory tract). Typical variables that correlate with air carbon monoxide concentrations 
include particulate matter (e.g., total suspended particulates, PM10, PM2 5), NO2, O3, and SO2. 
Ignoring co-variables that contribute to risk in regression models (e.g., single-pollutant models) 
can introduce upward bias in observed associations between air carbon monoxide concentrations 
and outcomes (e.g., inflate relative risk). On the other hand, assuming strongly correlated co­
variables are independent in multi-pollutant models can introduce downward bias in the carbon 
monoxide association. Although the strength of the carbon monoxide association may be 
underestimated in multi-pollutant models, for the reasons noted above, persistence of significant 
associations between the measured outcome and air carbon monoxide concentrations, when co­
pollutants are accounted for in multivariate models, provides stronger support for a contribution
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of carbon monoxide to the outcome. Not all studies have explored multi-pollutant models; 
however, such models lend supporting evidence to the results of clinical studies that have shown 
carbon monoxide to exacerbate coronary vascular disease.
(4) Outcomes investigated have tended to be serious, life-threatening events (e.g., cardiac arrhythmia, 
myocardial infarction, stroke, heart failure); these outcomes reflect the “late-stage” consequences 
of contributing pathophysiology that might be associated with exposures to lower levels of carbon 
monoxide for longer durations than indicated in the epidemiological studies.
(5) Mean values of carbon monoxide exposure concentrations have ranged from 0.3 to 5 ppm with 
the highest values <30 ppm. These values correspond to predicted steady-state COHb levels of 
<1% for the mean and <5% for the highest values (predicted from the CFK model). At these 
COHb levels, it is possible that only highly susceptible individuals exhibit the serious hypoxia- 
related outcomes. For these and other reasons, epidemiologic studies have typically focused on 
highly susceptible populations. A typical design has been to examine associations between 
temporal trends in ambient air carbon monoxide concentrations and hospital admissions or 
emergency department visits for which the reported diagnosis was some form of cardiovascular 
and/or respiratory disease of impairment.
3.2.1 Death
The Centers of Disease Control and Prevention (CDC) estimated that during the period 1999-2004, 
carbon monoxide was listed as a contributing cause of death on 16,447 death certificates in the United 
States, of which 2,631 deaths were categorized as unintentional and unrelated to fires (CDC 2007). 
Typically, fatal exposures to carbon monoxide produce coma, convulsions, and cardiorespiratory arrest 
(Raub et al. 2000; Wolf et al. 2008). Symptoms preceding death can include headache, dizziness, 
weakness, nausea, vomiting, mental confusion and visual disturbances, and loss of consciousness (Choi 
2001; Raub et al. 2000). Clinical signs of life-threatening toxicity can include cardiac arrhythmia and 
myocardial ischemia, hypotension, pulmonary edema, and seizures (Kao and Nanagas 2006). Patients 
who have been resuscitated following carbon monoxide-induced cardiac arrest have a very low prognosis 
for survival (Hampson and Zmaeff 2001).
Although severe carbon monoxide toxicity is thought to primarily derive from hypoxia resulting from 
binding to and displacement of O2 from heme proteins, including blood Hb, the relationship between 
blood COHb levels and signs indicative of life-threatening toxicity is highly uncertain (e.g., loss of 
consciousness, convulsions, coma, cardiopulmonary depression). In a survey of 1,407 cases of acute 
carbon monoxide poisoning patients (i.e., record of history of carbon monoxide exposure, signs and 
symptoms, blood COHb >2%, treatment with hyperbaric O2), the mean blood COHb concentration was 
22.3% (95% confidence interval [CI]: 22.7-23.9, range: 2.1-72.3; Hampson and Hauff 2008). The 
group mean was only marginally lower than in patients who lost consciousness (24.3%, 95% CI: 23.3-
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25.1, range: 2.1-73.3) or died (32.1%, 95% CI: 27.9-36.4, range: 3.0-60.0). Although survivors had 
lower mean COHb levels (23.1, 95% CI: 22.5-23.6) than that of fatalities, the upper end of the range 
exceeded that of fatalities (2.1-72.3%). The lower end of the range for COHb levels (2.1%) in this study 
reflects, at least in part, time delays between termination of exposure and measurement of blood COHb 
levels. However, that notwithstanding, this study suggests that blood COHb levels do not provide a 
reliable predictor of lethality. COHb levels can be converted to estimates of corresponding continuous air 
exposure levels by application of the CFK model. The mean for fatalities (32.1%) corresponds to a 
steady-state exposure (e.g., >500 minutes) to 300 ppm, or exposure to 1,000 ppm for approximately 80­
90 minutes.
Epidemiological Studies. Epidemiological studies have examined possible associations between ambient 
air carbon monoxide concentrations and mortality. These studies have examined relatively low carbon 
monoxide concentrations (from a toxicological perspective) that are typical of ambient conditions of 
study period. Mean air carbon monoxide concentrations in most of the studies were <2 ppm, with 
maximum values <10 ppm. Epidemiologic studies of ambient carbon monoxide and mortality can be 
grouped into two categories: (1) studies that have examined the relationship between exposures to carbon 
monoxide estimated from short-term (e.g., daily or monthly average) ambient air carbon monoxide 
concentrations; and (2) studies that have based exposure estimates on long-term average air carbon 
monoxide concentrations. Although both types of studies have yielded mixed results, the larger, multi­
city studies of long-term exposure have yielded estimates of carbon monoxide-associated mortality risk 
that are zero or less than zero (Jerrett et al. 2003; Lipfert et al. 2006b; Miller et al. 2007; Pope et al. 2002). 
Results from short-term exposures studies have been more varied, with some studies showing increased 
mortality risk when carbon monoxide is considered in single-pollutant models (percent increase in 
mortality: 0.2-0.6), which did not persist when the models are adjusted for co-pollutants (Burnett et al. 
2004; Dominici et al. 2003a, 2003b; Samoli et al. 2007). This conclusion is supported by at least one 
meta-analysis of time-series published between 1985 and 2001 (Stieb et al. 2002), which estimated excess 
mortality risk (pooled meta estimate) for a 1.1 ppm increment in air carbon monoxide concentration to be
1.6 (95% CI: 1.1-2.1) based on a single-pollutant model and 0.7% (95% CI: -0.1-1.5), based on a multi­
pollutant model that included NO2, O3, PM10, and SO2 (both estimates from generalized additive model 
regression models). A study of survival among 1,073 carbon monoxide poisoning patients (followed 
from 1978 to 2005) found that survivors of carbon monoxide poisoning had an increased mortality 
(standardized mortality ratios [SMR]=1.9) (95% CI: 1.6-2.2; NIOSH Life Table analysis as reference; 
Hampson et al. 2009; Leikin and Wills 2009).
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While these studies provide some evidence in support of a mortality risk associated with inhalation 
exposures to carbon monoxide, as previously discussed in the introduction to Section 3.2, their utility for 
establishing dose-response relationships for these effects are limited by several factors: (1) reliance on 
area monitoring for estimating exposure levels; and (2) relatively strong correlations between ambient air 
carbon monoxide concentrations and other air quality variables that may contribute to mortality risk. The 
discussion presented below focuses on outcomes of the most recent follow-ups of larger (e.g., multi-city) 
studies. Numerous single-city studies have also been reported; however, results of these studies are, in 
general, consistent with findings of multi-city studies.
Three multi-city prospective mortality studies have examined possible associations between long-term 
average ambient air carbon monoxide concentrations and mortality. A prospective study examined 
mortality in a cohort of 552,138 adults in 151 U.S. metropolitan areas, enrolled in the study in 1982 and 
followed through 1998 (Pope et al. 1995, 2002), A reanalysis of the study was reported in Jerrett et al.
(2003). Based on estimated average ambient air carbon monoxide concentration during the period 1982­
1998, increasing air carbon monoxide concentration was significantly associated with decreasing 
mortality from all-causes, cardiopulmonary, and lung cancer. The relative risk for cardiopulmonary death 
was estimated to be approximately 0.95 (95% CI: 0.9-0.99) per 1 ppm increase in carbon monoxide 
concentration (estimated from Figure 5 of Pope et al. 2002). A smaller prospective study focused on 
cardiovascular deaths among postmenopausal women between the ages of 50 and 79 years (Miller et al. 
2007). Women (n=65,893) without previous history of cardiovascular disease were enrolled in the study 
from 36 U.S. metropolitan areas during the period 1994-1998 and deaths recorded up to mid-2003. 
Among the subset of the cohort that had complete data on ambient air pollutant levels from local 
monitoring stations (n=28,402), the hazard ratio for cardiovascular mortality was 0.92 (95% CI: 0.71­
1.21) per 1 ppm increase in ambient air carbon monoxide concentration based on a single-pollutant model 
and 0.93 (95% CI: 0.67-1.30) based on a multi-pollutant model that adjusted for air concentrations of 
NO2, O3, PM2 5, PM10, and SO2. A prospective study of U.S. military veterans examined mortality 
outcomes in approximately 70,000 males who had been diagnosed with hypertension (Lipfert et al. 2000, 
2006a, 2006b). Subjects were enrolled in the study in 1976 at the average age of 51 years and were 
followed through 2001 (Lipfert et al. 2006a). Mortality risk (all causes of death) was not significantly 
associated with ambient air carbon monoxide concentration. The relative risk was estimated to be 
1.032 (95% CI: 0.954-1.117) per 1 ppm increase in air carbon monoxide concentration based on a single­
pollutant model and 1.023 (95% CI: 0.939-1.115) after adjustment for NO2 and O3.
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A multi-city, cross-sectional study examined mortality in all U.S. counties (excluding those of Alaska) for 
the period 1969-1997 (Lipfert and Morris 2002). Risk estimates were made for various exposure periods 
ranging from 2 to 9 years and for age categories. Estimates of mortality risk (all causes) attributable to 
average ambient air carbon monoxide concentrations for the exposure periods were mostly either not 
significant or significantly negative. Elevated risk was observed in some exposure periods for the age 
group 15-44 years; however, this outcome was not consistently observed across time periods.
Several multi-city studies have found significant associations between increasing short-term average 
ambient air carbon monoxide concentration and increasing mortality risk when carbon monoxide is 
considered in single-pollutant models, with the associations attenuated when models are adjusted for other 
co-pollutants. A time-series study examined mortality in 82 U.S. cities during the period 1987-1994 
(Dominici et al. 2003b; HEI 2005; Samet et al. 2000). In the Dominici et al. (2003b) analysis of these 
data, a 1 ppm increase in ambient air carbon monoxide concentration (lag 1 day) was associated with 
increased mortality (from all causes) of 0.46% (95% CI: 0.18-0.73). Mortality risk was not significant 
after adjustment for air concentration of PM10, alone, or PMJ0 and NO2. A time-series study examined 
morality in 12 Canadian cities during the period 1987-1994 (Burnett et al. 2004). Mortality risk (all non­
accidental causes) was significantly associated with ambient air carbon monoxide concentration (lag
1 day) in single-pollutant models, with an increase of 0.68% (t=3.12) per 1.02 ppm increases in air carbon 
monoxide concentration. However, the association did not persist when adjusted for NO2 (0.07%, 
t=0.30). A time-series analysis examined mortality in 19 European cities during the period 1990-1997 
(Samoli et al. 2007). This study found a significant association between carbon monoxide and total non­
accidental and cardiovascular mortality in single-pollutant models. The estimated effect size varied 
depending on the model applied. The effect size for total mortality based on a single-pollutant model 
ranged from 0.59% increase (95% CI: 0.41-1.79) to 1.20% (95% CI: 0.63-1.77) per 1 mg/m3 increase in 
carbon monoxide concentration (0-1-day lag). The effect on cardiovascular mortality ranged from 0.8% 
increase (95% CI: 0.53-1.07) to 1.25 (95% CI: 0.30-2.21). Inclusion of black smoke or NO2 in the 
models substantially decreased the estimated risk attributable to carbon monoxide, with the effect sizes no 
longer significant in some models.
3.2.2 System ic Effects
Respiratory Effects. Although cardiopulmonary arrest is an end point of fatal carbon monoxide 
poisoning, results of controlled clinical studies in healthy subjects indicate that the respiratory tract does 
not appear to be a primary target organ for carbon monoxide toxicity. Brief exposure to carbon monoxide
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at levels >1,000 ppm may decrease ventilatory performance, although conflicting results have been 
reported (Chevalier et al. 1966; Fisher et al. 1969; Koike et al. 1991; Ren et al. 2001; Vesely et al. 2004). 
Epidemiological studies have examined possible associations between ambient air carbon monoxide 
concentrations and mortality. These studies have examined relatively low carbon monoxide 
concentrations (from a toxicological perspective) that are typical of ambient conditions of study period 
(mean concentrations ranging from 0.3 to 10 ppm with the highest values <30 ppm). Collectively, these 
studies have yielded mixed results, with some studies finding significant associations between increasing 
ambient air carbon monoxide concentrations and respiratory outcomes (e.g., exacerbation of asthma 
symptoms, hospitalizations and emergency room visits related to asthma), and few studies finding 
associations that persist after accounting for exposures to other air pollutants that also have been shown to 
contribute to respiratory disease risk (e.g., NO2, O3, particulate matter, and SO). The lack of strong 
evidence for associations between ambient air carbon monoxide concentrations at <30 ppm and 
pulmonary function is also consistent with the results of human clinical and animal studies. Studies 
conducted in animals provide supporting evidence that the respiratory tract does not appear to be a 
primary target organ for carbon monoxide (EPA 1991, 2000; S0rhaug et al. 2006).
Clinical Studies. Few controlled clinical studies have evaluated adverse respiratory effects of carbon 
monoxide exposure. Available clinical studies have been conducted in small numbers (i.e., 4-12) of 
healthy subjects under acute exposure conditions (Chevalier et al. 1966; Fisher et al. 1969; Koike et al. 
1991; Ren et al. 2001; Vesely et al. 2004). No controlled clinical studies evaluating respiratory effects of 
intermediate- or chronic-duration exposure in healthy subjects or of any duration exposure in patients 
with underlying respiratory diseases were identified.
Results of controlled clinical studies in healthy subjects indicate that brief exposure to carbon monoxide 
may decrease ventilatory performance, although conflicting results have been reported; however, based 
on results of available clinical studies, the respiratory tract does not appear to be a major target organ for 
carbon monoxide. Exposure of 10 healthy subjects to 5,000 ppm carbon monoxide for 2-4 minutes 
(COHb 4%) decreased inspiratory capacity by 7.5% (p<0.05), total lung capacity decreased by 2.1% 
(p<0.02), and mean resting diffusing capacity of lungs decreased by 7.6% (p<0.05) (Chevalier et al.
1966). However, other studies have found no effects of acute carbon monoxide exposure on ventilatory 
function. No changes in ventilatory mechanics (vital capacity, functional residual capacity, airway 
conductance, lung volume, pulmonary resistance, dynamic lung compliance, diffusing capacity) were 
observed in four healthy subjects exposed to carbon monoxide producing blood COHb levels of 11-20% 
(Fisher et al. 1969). Exposure to 1,000 ppm carbon monoxide for 10-30 minutes (COHb ~10%;
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10 subjects) (Ren et al. 2001) or 1,200 ppm carbon monoxide for 30-45 minutes (COHb 10.2%;
10 subjects) (Vesely et al. 2004) did not affect resting ventilation. During submaximal exercise 
challenge, acute exposure of 10 subjects to carbon monoxide producing blood COHb levels of 11-20% 
did not alter ventilation mechanics (Koike et al. 1991). The reason for these conflicting results is not 
apparent, although the small number of subjects evaluated in each study may have been a contributing 
factor.
Epidemiological Studies. Epidemiological studies of exposure to carbon monoxide and respiratory 
outcomes fall into two major categories: (1) studies that have assessed respiratory morbidity in 
association with ambient air carbon monoxide concentrations; and (2) studies that have evaluated 
associations between ambient air carbon monoxide concentrations and the incidence of hospital 
admissions and/or emergency room visits related to respiratory disease (e.g., time-series studies, case- 
crossover). Collectively, these studies have yielded mixed results. Although some studies have found 
significant associations between increasing ambient air carbon monoxide concentrations and respiratory 
outcomes (e.g., exacerbation of asthma symptoms, hospitalizations and emergency room visits related to 
asthma), few studies have examined the robustness of the association in models that adjust for exposures 
to other air pollutants that also have been shown to contribute to respiratory disease risk (e.g., NO2, O3, 
particulate matter, and SO2). While these studies provide some evidence in support of adverse respiratory 
effects of inhalation exposures to carbon monoxide, as previously discussed in the introduction to 
Section 3.2, their utility for establishing dose-response relationships for these effects are limited by 
several factors: (1) reliance on area monitoring for estimating exposure levels; (2) uncertainty in 
knowledge of temporal correspondence between monitored exposure levels and outcomes; (3) relatively 
strong correlations between ambient air carbon monoxide concentrations and other air quality variables 
that can affect respiratory function; and (4) relatively low carbon monoxide exposures studied. Mean 
values of carbon monoxide exposure concentrations have ranged from 0.3 to 10 ppm with the highest 
values <30 ppm. These concentrations are well below those explored in experimental studies that found 
minimal or no effects of carbon monoxide on pulmonary function in association with acute exposures to 
carbon monoxide (i.e., >1,000 ppm). The relatively low carbon monoxide concentrations studied in 
epidemiological studies, together with concurrent exposures to other air pollutants that may have more 
pronounced effects on respiratory function, may have contributed to the mixed results of these studies and 
relatively weak associations with carbon monoxide that have been observed (e.g., odds ratios and relative 
risks very close to 1). The lack of strong evidence for associations between ambient air carbon monoxide 
concentrations at <30 ppm and pulmonary function is also consistent with the results of human clinical 
and animal studies.
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
3. HEALTH EFFECTS
36
The presentation of epidemiology is organized by major categories of respiratory outcomes for which the 
studies were designed to evaluate, which include pulmonary function, asthma and exacerbation of asthma 
symptoms, and hospital admissions and emergency room visits related to respiratory disease. Study 
conclusions are presented in the text, with selected supporting details presented in tabular form 
(Table 3-3). Although most studies explored various time lags between monitored air carbon monoxide 
concentrations and outcomes, as well as various sample strata, for the sake of brevity, only selected 
representative time lags (usually, those indicative of the strongest associations to carbon monoxide) are 
presented in the tables. Where co-pollutant models have been explored, these results are also presented.
Studies of Pulmonary Function. Studies of possible associations between inhalation exposures to carbon 
monoxide and effects on pulmonary function have yielded mixed results (Chen et al. 1999; Fischer et al. 
2002; Lagorio et al. 2006; Penttinen et al. 2001; Rabinovitch et al. 2004; Silkoff et al. 2005; Timonen et 
al. 2002). Several of these studies examined subjects who had ongoing lung disease (e.g., asthma, chronic 
obstructive lung disease) and who might be more sensitive to agents that affect pulmonary function 
(Rabinovitch et al. 2004; Silkoff et al. 2005; Timonen et al. 2002). Mean ambient air carbon monoxide 
concentrations studied ranged from 0.5 to 10 ppm, with the highest values <30 ppm (Lagorio et al. 2006). 
Only one of these studies explored multi-pollutant models and found that the association with carbon 
monoxide was substantially weakened when adjustments were made for air particle matter (Penttinen et 
al. 2001). Therefore, is it difficult to sort out the effects of carbon monoxide from those of other urban air 
pollutants that have strong correlations with air carbon monoxide concentrations and that also could have 
affected pulmonary function.
Studies of children have yielded mixed results that are further complicated by lack of assessment of 
models in which correlated concentrations of other air pollutants were included (Chen et al. 1999; Fischer 
et al. 2002; Rabinovitch et al. 2004; Timonen et al. 2002). A study conducted in the San Joaquin Valley, 
California, examined lung function in a cohort of 232 asthmatic children (age 6-11 years) found that 
long-term average exposures to carbon monoxide in infancy and childhood (age 0-6 years) was 
associated with significant decreasing forced expiratory volume in 1 second (FEVi)/forced vital capacity 
(FVC) and forced midexpiratory flow rate (FEF25-75)/FVC (Mortimer et al. 2008). Mean air carbon 
monoxide concentrations during the study period ranged from approximately 1-1.5 ppm, with the highest 
value <6 ppm. The effect sizes (per 1 ppm increase in air carbon monoxide concentration) were of 
approximately 2.5% decrease in FEVi/FVC and 4.8% decrease in FEF25-75/FVC, A panel study 
conducted in Denver, Colorado (1999-2002) examined lung function in asthmatic children (n=41-63, age
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Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study Design features CO exposure Effect size
Lung function
Chen et al. (1999)
Period: 1 9 9 5 -1 9 9 6  
Location: Taiwan, China
Fischer et al. (2002)
Period: NR
Location: Utrecht, Netherlands
Lagorio et al. (2006) 
Period: 1999  
Location: Rome, Italy
Park et al. (2005a)
Period: 2002  
Location: Incheon, Korea
Penttinen et al. (2001) 
Period: 1 9 9 6 -1 9 9 7  
Location: Helsinki, Finland
Mortimer et al. (2008)
Period: 1 9 8 9 -2 0 0 0  
Location: San Joaquin Valley, 
California
Outcome: Lung function (FVC, 
F E V 1 , F E V 1/FV C , FE F 2 5 -7 5 % , PEF) 
Design: Cross-sectional 
Sample: n=941, age 8 -1 3  years 
Outcome: Lung function (FVC, 
F E V 1, PEF, M M EF)
Design: Panel study 
Sample: n=68, age 10 -11  years
Outcome: Lung function (FVC, 
F E V 1)
Design: Tim e-series panel study 
Sample: Patients (age 5 0 -8 0  
years) diagnosed with C O P D  n=11; 
asthma, n=11; IHD, n=7 
Outcome: Lung function (PEF  
variability (>20% ), mean PEF); 
Design: Panel 
Sample: n=64 bronchial 
asthmatics, age 1 6 -7 5  years 
Outcome: Lung function (PEF) 
Design: Panel
Sample: n=57 adults asthmatics
Outcome: Lung function (FVC, 
F E V 1, PEF, FE F 2 5-75 , F E V 1/FV C ,
F E F 25-75/FV C , FE F 25, FE F 75)
Design: Cohort
Sample: n=232 asthmatic children 
(age 6 - 1 1  years
Avg time: 1 hour m ax  
Range: 0 .4 -3 .6  ppm
Avg time: 24 hours 
Mean: 0 .80 ppm 
Range: 0 .2 8 -1 ,3 4  ppm
Avg time: 24 hours 
Mean: 6 .5  ppm 
Range: 1 .4 -2 5 .2  ppm
Avg time: 24 hours 
Mean: 0.6 ppm 
SD range: 0 .0 9 -0 .1 5  ppm
Avg time: 24 hours 
Median: 0 .35  ppm 
Range: 0 .0 9 -0 .9 6  ppm
Avg time: 8 hour m ax  
Mean: 1 -1 .5  ppm 
Range: m ax ~6 ppm
Increment: NR
p Coefficient (SE), lag 2 days for 24  hours avg CO: 
FVC (mL) -147.71 (64.48)
FEV-i (mL) -82 .42  (60.95)
Increment: 100 pg/m3 
N O %  increase (95%  CI):
28 .2  (6 .9 -5 3 .9 )
No significant associations with lung function 
endpoints
Increment: 1 m g/m3
No significant associations with lung function 
endpoints
Increment: NR  
p Coefficient (SE): 
M ean PEF (L/min): -10.103 (2.7146)
Increment: 0.2 mg/m 3 
p Coefficient (SE); lag 1 day: 
P EF Deviations (L/minute)
CO: -1 .08  (0.36)
C O +P N C : -0 .67  (0.64); 1 
Increment: ~1 ppm 
p Coefficient (SE);
F E V 1/FVC : -0 .0073  (0 .0016) 
F E F 2 5 -7 5 /FVC : -0 .2179  (0 .0446) 
% Decrease:
F E V 1/FVC : 2.5%
F E F 2 5 -7 5 /FVC : 4.8%
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Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study Design features CO exposure Effect size
Rabinovitch et al. (2004) 
Period: 1 9 9 9 -2 0 0 2  
Location: Denver, Colorado
Silkoff et al. (2005)
Period: 1999-2001  
Location: Denver, Colorado
Timonen et al. (2002) 
Period: 1994  
Location: Kuopio, Finland
Asthma and exacerbation of asthma 
Hwang et al. (2005)
Period: 2001 
Location: Taiwan, China
Park et al. (2005a)
Period: 2002  
Location: Incheon, Korea
Rabinovitch et al. (2004) 
Period: 1 9 9 9 -2 0 0 2  
Location: Denver, Colorado
Outcome: Lung function (F E V 1, 
PEF)
Design: Panel study
Sample: n = 4 1 -6 3  asthmatics, age
6 -12  years
Outcome: Lung function (F E V 1, 
PEF)
Design: Panel
Sample: n = 1 6 -1 8 , form er smokers, 
age >40 years
Outcome: Lung function (FVC, 
F E V 1 , M M EF, A EFV)
Design: Panel
Sample: n=33 with respiratory 
symptoms, age 7 -1 2  
symptoms 
Outcome: Asthma 
Design: Cross-sectional 
Sample: n=32,672, 
age 6 -1 5  years
Outcome: Asthma symptoms 
Design: Panel 
Sample: n=64 bronchial 
asthmatics, age 1 6 -7 5  years 
Outcome: Asthma symptoms, 
rescue inhaler use 
Design: Panel study 
Sample: n = 4 1 -6 3  asthmatics, age 
6 -12  years
Avg time: 24 hours 
Mean 1.0 ppm 
Range: 0.3, 3.5 ppm
Pollutant: CO  
Avg Time: 24 hours 
Mean: 1 ppm 
Range: 0 .3 -3 .8  ppm
Avg time: 24 hours 
Mean: 0.5 ppm 
Range: 0 .0 9 -2 .4  ppm
Avg time: year.
Mean: 0 .66 ppm 
Range: 0 .4 2 -0 .9 6  ppm
Avg time: 24 hours 
Mean: 0.6 ppm 
SD range: 0 .0 9 -0 .1 5  ppm
Avg time: 24 hours 
Mean 1.0 ppm 
Range: 0.3, 3.5 ppm
Increment: 0.4 ppm
No significant associations with lung function 
endpoints
Increment: 1 ppm
Significant association with decreasing F E V 1 in 
second winter season of study, but not in first 
(p coefficients reported graphically)
Increment: 0.32 mg/m 3 
p Coefficient (SE), lag 2 days:
Baseline F E V 1 (mL): 11.7 (SE: 5 .77, p<0.05) 
Exercise A F E V 1 (%): 0 .087 (0.26)
Increment: 0.1 ppm  
Adjusted O R  (95%  CI)
CO: 1.045 (1 .0 1 7 -1 .0 7 4 )
C O +SO 2: 1.066 (1 .0 3 4 -1 .0 9 9 )
C O +P M 10: 1.079 (1 .0 4 7 -1 .1 1 2 )
C O +O 3: 1.063 (1 .1 -1 .4 7 4 )
C O +S O 2+O 3: 1.111 (1 .0 7 4 -1 .1 5 )
C O +P M 10+  O3: 1.119 (1 .0 8 4 -1 .1 5 5 )
Increment: NR
No significant association with asthma symptoms
Increment: 0.4 ppm  
p Coefficient (SE), 3-day moving avg: 
Asthma exacerbation: 1.012 (0 .9 1 3 -1 .1 2 3 )  
Rescue inhaler: 1.065 (1 .0 0 1 -1 .1 3 3 )
CARBON MONOXIDE 
38
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC 
COMMENT***
Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study Design features CO exposure Effect size
Rodriguez et al. (2007) 
Period: 1 9 9 6 -2 0 0 3  
Location: Perth, Australia
Schildcrout et al. (2006) 
Period: 1 9 9 3 -1 9 9 5  
Location: 8 North American  
cities
Silkoff et al. (2005)
Period: 1999-2001  
Location: Denver, Colorado
Slaughter et al. (2003)
Period: 1 9 9 3 -1 9 9 5  
Location: Seattle, Washington
von Klot et al. (2002) 
Period 1 9 9 6 -1 9 9 7  
Location: Erfurt, Germ any
Yu et al. (2000)
Period: 1 9 9 3 -1 9 9 5  
Location: Seattle, Washington
Outcome: Respiratory symptoms 
Design: Panel
Population: n=263, age 0 -5  years
Outcome: Asthma symptoms; 
rescue inhaler use 
Design: Panel
Sample: 990 asthmatics, age 5­
12  years
Outcome: Asthma symptoms, 
rescue inhaler use 
Design: Panel
Sample: n = 1 6 -1 8 , form er smokers, 
age >40 years 
Outcome: Asthma severity; 
medication use 
Design: Panel
Sample: n=133 asthmatics, age 5­
13 years
Outcome: Asthma symptoms; 
medication use 
Design: Panel
Sample: 53 asthmatics, age 37­
77 years
Outcome: Asthma symptoms 
Design: Panel
Sample: n=133 asthmatics, age 5­
13 years
Avg time: 8 hours 
Mean 1.4 ppm 
Range: 0 .0 1 -8 .0  ppm
Avg time: 24 hours 
10th-90th% : 0 .4 -2 .4  ppm
Avg time: 24 hours 
Mean: 1 ppm 
Range: 0 .3 -3 .8  ppm
Increment: NR
O R  (95% C I), w heeze/chest rattle, lag 5-days: 
lag 0 days: 1.089 (0 .9 6 8 -1 .2 2 6 )  
lag 5 days: 1.136 (1 .0 1 6 -1 .2 6 ) 
lag 0 -5  days: 1.035 (1 .0 0 5 -1 .0 6 6 )
Increment: 1.0 ppm
O R  (95%  CI), asthma symptoms, lag 0 days:
CO: 1.08 (1 .0 1 -1 .1 4 )
C O +N O 2 1.07 (1 -1 .1 4 )
C O +P M 10: 1.08 (1 .0 1 -1 .1 5 )
C O +S O 2 1.07 (0 .9 9 -1 .1 6 )
Increment: 1 ppm
No significant associations with asthma symptoms 
or rescue medications
Avg time: 24 hours 
Median: 1.47 ppm
25th-7 5 th%:
Increment: 0.67 ppm 
O R  (95%  CI), asthma severity, lag 1 day: 
0 .2 3 -1 .8 7  ppm Asthma severity: 1.21 (1 .0 8 -1 .3 5 )
Rescue inhaler use: 1.09 (1 .0 3 -1 .1 6 )
Avg time: 24 hours 
Mean: 0.8 ppm 
Range: 0 .3 -2 .3  ppm
Avg time: 24 hours 
Mean 1.6 ppm 
Range: 0 .6 5 -4 .1 8  ppm
Increment: 0.6 mg/m
O R  (95%  CI); wheezing prevalence, 5-day avg: 
CO: 0 1.13 (1 .0 5 -1 .2 2 )
C O + M C 0 0 1 - 2 5 : 1.15 (1 .0 4 -1 .2 7 )
C O +N C 0 .0 1 -0 .1 : 1.09 (0 .9 8 -1 .2 2 )
Increment: 1.0 ppm  
O R  (95%  CI), lag=2 days:
1.26 (1 .0 9 -1 .4 6 )
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Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study Design features CO exposure Effect size
Hospital admissions and em ergency room visits related to respiratory disease
Burnett et al. (2001)
Period: 1 9 8 0 -1 9 9 4  
Location: Toronto, Canada
Cakm ak et al. (2006)
Period: 1 9 9 3 -2 0 0 0  
Location: 10 Canadian cities
Karr et al. (2006)
Period: 1 9 9 5 -2 0 0 0  
Location: Southern California
Linn et al. (2000)
Period 1 9 9 2 -1 9 9 5  
Location: Los Angeles, 
California 
Lin et al. (2003)
Period: 1 9 8 1 -1 9 9 3  
Location: Toronto, Canada
Lin et al. (2005)
Period: 1998-2001  
Location: Toronto, Canada
Avg time: 1 hour 
Mean: 1.18 ppm 
25th-7 5 th%: 1 .3 -2 .3  ppm
Outcome: Asthma, acute 
bronchitis/bronchiolitis; croup; 
pneumonia HAs 
Design: Tim e series 
Sample: <2 years
Outcome: Respiratory disease HAs Avg time: 24 hours 
Design: Tim e-series Mean: 0.8 ppm
Sample: All ages Range: 0 .0 -6 .5  ppm
Outcome: Acute bronchiolitis HAs Avg time: 24 hours
Design: Case-crossover 
Sample: age <1 year
Outcome: Asthma, C O PD, 
pulmonary HAs 
Design: Tim e-series  
Sample: age 0 -2 9 , >30 years 
Outcome: Asthma HAs 
Design: Case-crossover 
Sample: age 6 -1 2  years
Outcome: Respiratory infection 
HAs
Design: Case-crossover 
Sample: age <15 years
Mean: 17 ppm 
Range: 0 .0 0 4 -9 .6  ppm
Avg time: 24 hours 
Mean: 1 .0 -2 .1  ppm  
Range: 0 .3 -5 .3  ppm
Avg time: 24 hours 
Mean: 1.18 ppm 
Range: 0 -6 .1  ppm
Avg time: 24 hours 
Mean: 1.16 ppm 
Range: 0 .3 8 -2 .4 5  ppm
Increment: 1.9 ppm  
% Increase (t value), lag 0 -1  day:
CO: 19.20%  (3.48)
C O +O 3: 14.30%  (2.6)
Increment: 0.8 ppm  
% Increase(95%  CI), lag 2 .8  days:
CO: 0 .60%  (0.20, 1)
C O +S O 2+N O 2+O 3: -0 .20%  (-0 .7 0 -0 .3 0 ) 
Increment: 1.36 ppm 
O R  (95%  CI), lag 1 day:
All: 0 .99 (0 .9 6 -1 .0 2 )
Age 2 5 -2 9  weeks: 0 .86 (0 .6 8 -1 .1 )
Increment: 1.0 ppm
ß (SE): Asthma, <30 years: 0 .036 (0 .016, p<0.05) 
Asthma >30 years: 0.028 (0.010, p<0.05)
C O P D , >30 years: 0 .019 (0.007, p<0.05) 
Increment: 0.5 ppm  
O R  (95%  CI), lag 1 day:
Males CO: 1.05 (1 -1 .1 1 )
Males C O +PM : 1.05 (0 .9 9 -1 .1 1 )
Fem ales CO: 1.00 (0 .9 3 -1 .0 6 )
Fem ales C O +PM : 1.00 (0 .9 3 -1 .0 7 )
Increment: 0.44 ppm 
O R  (95%  CI), lag 0 -5  days:
Males, CO: 1.13 (1 .0 2 -1 .2 5 )
Males, C O +PM : 1.08 (0 .9 7 -1 .2 0 )
Fem ales, CO: 1.05 (0 .9 3 -1 .1 8 )
Fem ales, C O +P M : 1.02 (0 .9 0 -1 .1 5 )
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Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study Design features CO exposure Effect size
Peel et al. (2005)
Period: 1 9 9 3 -2 0 0 0  
Location: Atlanta, Georgia
Outcome: Asthma; C O PD, 
pneumonia EDVs  
Design: Tim e-series  
Sample: ages all, 2 -1 8  years
Slaughter et al. (2005) 
Period: 1995-2001
Outcome: Respiratory, asthma; 
C O P D , respiratory infection HAs
Location: Spokane, Washington and EDVs
Design: Tim e-series  
Sample: All ages, adults
Tolbert et al. (2007)
Period: 1 9 9 3 -2 0 0 4  
Location: Atlanta, Georgia
Yang et al. (2003)
Period: 1 9 8 6 -1 9 9 8  
Location: Vancouver, Canada
Avg time: 1 hour maximum  
Mean: 1.8 ppm 
10th-9 0 th%: 0 .5 -3 .4  ppm
Avg time: 24 hours 
5th-9 5 th%: 1 .2 5 -3 .0 5  ppm
Outcome: Asthma; CO PD; URI, 
pneumonia; bronchiolitis EDVs  
Design: Tim e-series  
Sample: All ages
Outcome: Respiratory disease HA) 
Design: Case-crossover 
Sample: ages <3; >65 years
Avg time: 1 hour maximum  
Mean: 1.6 ppm 
Range: 0 .1 -7 .7  ppm
Avg time: 24 hours 
Mean: 0 .98 ppm 
25th-7 5 th%: 0 .6 2 -1 .1 6  pm
Increment: 1.0 ppm  
RR (95% CI); lag 0 -1 3  days:
All respiratory: 1.066 (1 .0 4 5 -1 .0 8 7 )
Asthma: 1.076 (1 .0 4 7 -1 .1 0 5 )
Pneumonia: 1.045 (1 .0 1 1 -1 .0 8 0 )
C O PD: 1.032 (0 .9 7 5 -1 .0 9 2 ), 1.026 (1 .0 0 4 -1 .0 4 8 ;  
lag=0-2 days)
No significant associations after adjustment for 
P M 10, N O 2, O 3 
Increment: 1.0 ppm  
R R (95%  CI); lag 3 days:
Respiratory E D V:1.03 (1 .0 0 -1 .0 6 )
Asthma EDV: 1.06 (1 .0 0 -1 .1 1 )
C O P D  EDV, Adults: 1.01 (0 .9 3 -1 .1 0 )
Respiratory HA: 0.99 (0 .9 6 -1 .0 3 )
Asthma HA: 1.00 (0 .9 1 -1 .1 1 )
C O P D  HA.: Adults: 0 .97 (0 .8 8 -1 .0 6 )
Increment: 1.22 ppm 
R R (95%  C I), lag 3 days:
Respiratory diseases: 1.016 (1 .0 0 9 -1 .0 2 2 )
Not significant after adjustment for O 3, N O 2, or
P M 10.
Increment: 0.54 ppm
O R  (95%  CI), lag 1 day: <3 years, CO: 1.04  
(1 .0 1 -1 .0 7 )
<3 years, C O +O 3: 1.04 (1 .0 1 -1 .0 7 )
<3 years, C O +O 3+N O 2+  SO2: 1.02 (0 .9 6 -1 .0 8 ) 
>65 years, CO: 1.02 (1 .0 0 -1 .0 4 )
>65 years, C O +O 3: 1.02 (1 .0 0 -1 .0 4 )
>65 years, CO, O3, N O 2, SO2: 0 .96 (0 .9 3 -1 .0 0 )
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Table 3-3. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Respiratory Disease
Study________________________Design features_______________CO exposure__________ Effect size___________________________
Zanobetti and Schwartz (2006) Outcome: Pneumonia HAs Avg time: 24 hours Increment: 0 .475 ppm
Period: 1 9 9 5 -1 9 9 9  Design: Case-crossover 25t - 7 5 th%: 0 .3 9 -0 .6 0  ppm % Increase (95%  CI): 5 .45 (1.10, 9.51; lag=0
Location: Boston, Sample: All ages days)
Massachusetts___________________________________________________________________________________ 5.12 (0.83, 9.16; lag=0-1 days)______________
A E F V  =  a r e a  u n d e r  t h e  e x p i r a t o r y  f l o w - v o l u m e  c u r v e ;  A v g  =  a v e r a g e ;  C I  =  c o n f i d e n c e  i n t e r v a l ;  C O  =  c a r b o n  m o n o x i d e ;  C O P D  =  c h r o n i c  o b s t r u c t i v e  p u l m o n a r y  d i s e a s e ;  
E D V  =  e m e r g e n c y  d e p a r t m e n t  v i s i t ;  F E F  =  f o r c e d  e x p i r a t o r y  f l o w ;  F E F 2 5 - 7 5  =  f o r c e d  e x p i r a t o r y  f l o w  a t  2 5 - 7 5 %  o f  v i t a l  c a p a c i t y ;  F E V 1  =  f o r c e d  e x p i r a t o r y  v o l u m e  a t
1  s e c o n d ;  F V C  =  f o r c e d  v i t a l  c a p a c i t y ;  H A  =  h o s p i t a l  a d m i s s i o n ,  I H D  =  i s c h e m i c  h e a r t  d i s e a s e ;  M C  =  p a r t i c l e  m a s s  c o n c e n t r a t i o n ;  N C  =  p a r t i c l e  n u m b e r  c o n c e n t r a t i o n ;
N R  =  n o t  r e p o r t e d ;  P E F  =  p e a k  e x p i r a t o r y  f l o w ;  P N C  =  p a r t i c l e  n u m b e r  c o n c e n t r a t i o n / c o u n t ;  R R  =  r e l a t i v e  r i s k ;  S D  =  s t a n d a r d  d e v i a t i o n ;  S E  =  s t a n d a r d  e r r o r ;  U R I  =  u p p e r  
r e s p i r a t o r y  i n f e c t i o n
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6-12 years) and did not find a significant association between air carbon monoxide concentration and 
pulmonary function end points, FEVj, and peak expiratory flow (PEF) (Rabinovitch et al. 2004). The 
mean air carbon monoxide concentration in the study was 1.0 ppm (range: 0.3-3.5 ppm). A similar panel 
study conducted in Kuopio, Finland examined lung function in children (n=33, age 7-12 years) who were 
diagnosed with chronic respiratory disease symptoms (Timonen et al. 2002). Increasing air carbon 
monoxide concentration was associated with decreasing FVC and FEVi, when measured at rest, but not 
during exercise. Other air pollutants were also associated with decrements in baseline pulmonary 
function (particulate matter, NO2); however, multi-pollutant models were not explored. The air carbon 
monoxide concentrations in this study were similar to that in the Rabinovitch et al. (2004) study (mean 
0.6 mg/m3, range: 0.1-2.8 mg/m3). A cross-sectional cohort study conducted in Taiwan, China (1995­
1996) included asthmatic children (n=941, age 8-13 years; Chen et al. 1999). A significant association 
was found between increasing air carbon monoxide concentration and decreasing FVC; however, multi­
pollutant models were not explored. Peak daily air carbon monoxide concentrations ranged from 0.4 to
3.6 ppm. Fischer et al. (2002) examined possible associations between carbon monoxide and pulmonary 
function in a panel of children (n=68, age 10-11 years) in The Netherlands. Increasing air carbon 
monoxide concentration was not associated with FVC, FEVi, PEF, or maximal midexpiratory flow 
(MMEF); however, it was associated with increasing levels of expired endogenous nitric oxide radical 
(NO )^. Here again, multi-pollutant models were not explored. The mean air carbon monoxide 
concentration in this study was 0.9 mg/m3 (range: 0.3-1.5 mg/m3).
Results of studies of pulmonary function in adults have also been mixed and conflicting (Lagorio et al. 
2006; Penttinen et al. 2001; Silkoff et al. 2005). A panel study of adult nonsmoking asthmatics (n=57, 
mean age 53 years) conducted in Helsinki, Finland (1996-1997) found that increasing air carbon 
monoxide concentration was associated with decreasing PEF; however, the association was not 
significant when adjusted for particulate matter (Penttinen et al. 2001). The mean air carbon monoxide 
concentration was 0.4 mg/m3 (range: 0.1-1.1 mg/m3). A panel study of adult former smokers, diagnosed 
with chronic obstructive pulmonary disease (COPD), conducted in Denver, Colorado (1999-2001, n=16- 
18, age >40 years) found somewhat conflicting results. A significant association between increasing air 
carbon monoxide concentration and decreasing FEV1 was found in the second winter season of the study, 
but not in the first winter season of the study (Silkoff et al. 2005). Air carbon monoxide concentrations 
(ppm) were not significantly different in the two seasons (mean: 1.1-1.2; ranges: 0.3-3.8 and 0.4-2.8), 
although concentrations of other air pollutants (e.g., PM10, PM25, and NO2) were higher in the second 
winter season, suggesting that other air pollutants may have contributed to the associations attributed to 
carbon monoxide in single-pollutant models. The study conducted by Lagorio et al. (2006) is notable
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because it included relatively high air carbon monoxide concentrations (mean range: 1.8 [spring]-
10.6 [winter] ppm; range: 1.5-25.1 ppm). This panel study examined adults (n=29, age 18-80 years) in 
Rome, Italy (1999) who were diagnosed with asthma, COPD, or ischemic heart disease. Increasing air 
carbon monoxide concentration was not significantly associated with lung function parameters, and multi­
pollutant models were not explored. A panel study conducted in Incheon, Korea examined lung function 
in asthmatics (n=57, ages 16-75 years) found a significant association between air carbon monoxide 
concentrations and decreasing PEF; however, multi-pollutant models were not explored (Park et al. 
2005a). The mean air carbon monoxide concentration was 0.6 ppm.
Studies of Asthma Incidence (or Prevalence) and Exacerbation of Asthma Symptoms. A cross­
sectional study examined asthma diagnoses among school-age children (n=32,672, age 6-15 years) in 
Taiwan, China (Hwang et al. 2005). The odds ratio for 0.1 ppm increases in air carbon monoxide 
concentration (annual average) was estimated to be 1.045 (95% CI: 1.017-1.074) and persisted after 
adjustment for O3, PM10, and/or SO2 in multi-pollutant models. The mean air carbon monoxide 
concentration was 0.6 ppm (range: 0.4-0.9 ppm). Several studies have examined possible associations 
between ambient air carbon monoxide concentrations and asthma symptoms (e.g., coughing, wheezing, 
chest tightness, shortness of breath, inhaler use). Results of these studies have been mixed; however, 
collectively, these studies provide evidence for associations between increasing air carbon monoxide 
concentration and increasing severity of asthma (Park et al. 2005a; Rabinovitch et al. 2004; Rodriguez et 
al. 2007; Schildcrout et al. 2006; Silkoff et al. 2005; Slaughter et al. 2003; von Klot et al. 2002; Yu et al. 
2000). One of the larger studies examined asthma symptoms in a panel of 990 children (ages 5-12 years) 
in eight North American cities (1993-1995, Schildcrout et al. 2006). A 1 ppm increase in air carbon 
monoxide concentration (lag=0 days) was associated with an odds ratio of 1.08 (95% CI: 1.01-1.14) for 
asthma symptoms. The association remained significant after adjusting for NO2, PM10, or SO2 in two- 
pollutant models. Air carbon monoxide concentrations ranged from approximately 0.4 to 2.4 ppm (10th-  
90th percentile range). Significant associations with increasing carbon monoxide concentration were also 
found when rescue medication use was evaluated as the asthma symptom end point.
The above results are consistent with those of several smaller panel studies. A study conducted in Seattle, 
Washington examined asthma symptoms (Yu et al. 2000) and asthma severity (Slaughter et al. 2003) in a 
panel of 133 asthmatic children (age 5-13 years). The mean air carbon monoxide concentration was
1.6 ppm (range: 0.6-4.8 ppm; Yu et al. 2000). Both studies found significant associations between 
ambient air carbon monoxide and asthma symptoms. In the Yu et al. (2000) study, a 1 ppm increase in air 
carbon monoxide (lag=2 days) was associated with an odds ratio of 1.26 (95% CI: 1.09-1.46) for asthma
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symptoms. In the Slaughter et al. (2003), a 0.67 ppm increase in air carbon monoxide concentration was 
associated with an odds ratio of 1.21 (95% CI: 1.08-1.35) for an increase in severity of asthma attack. A 
significant association with increasing carbon monoxide concentration was also found when rescue 
medication use was evaluated as the asthma severity end point (Slaughter et al. 2003). Rabinovitch et al.
(2004) also found a significant association between increasing air carbon monoxide concentrations and 
increasing rescue medication use in a study of children in Denver, Colorado (1999-2002, n=41-63, age 
6-12 years). A panel study of 263 children (age 0-5 years) in Perth, Australia, who were not diagnosed 
with asthma, also found a significant association between air carbon monoxide concentration and 
wheezing/chest rattle (Rodriguez et al. 2007).
Results of studies conducted in older asthmatic subjects have been mixed (Park et al. 2005a; Silkoff et al. 
2005; von Klot et al. 2002). In a panel of 53 asthmatic adults (age 37-77 years) in Erfurt, Germany 
(1996-1997), a 0.6 mg/m3 increase in air carbon monoxide concentration (5-day average) was associated 
with an odds ratio of 1.13 (95% CI: 1.05-1.22) for prevalence of wheezing; however, the association was 
attenuated when adjusted for ultrafine particle number concentration in air. In two other panel studies of 
asthmatics, one conducted in Incheon, Korea (2002, n=54, age 16-76 years; Park et al. 2005a) and one in 
Denver, Colorado (n=16 or 18, age >40 years, Silkoff et al. 2005) did not find significant associations 
between air carbon monoxide concentrations and asthma symptoms.
Studies of Hospital Admissions and Emergency Room Visits Related to Respiratory Symptoms. A large 
number of studies have examined associations between ambient carbon monoxide concentrations and 
rates of hospital admissions (e.g., Burnett et al. 2001; Cakmak et al. 2006; Karr et al. 2006; Lin et al. 
2003, 2005; Linn et al. 2000; Slaughter et al. 2005; Yang et al. 2003; Zanobetti and Schwartz 2006) or 
emergency room visits related to respiratory disease (e.g., Peel et al. 2005; Slaughter et al. 2005; Tolbert 
et al. 2007). Collectively, these studies provide evidence for associations between increasing carbon 
monoxide concentrations and increasing risk of respiratory symptoms that trigger the need for medical 
assistance. However, only a few studies have examined associations in multi-pollution models; therefore, 
relative contributions of other air pollutants to the reported outcomes are highly uncertain.
In studies that did evaluate multi-pollutant models, the associations between carbon monoxide 
concentrations and outcomes persisted is some studies (Burnett et al. 2001; Lin et al. 2003, Yang et al. 
2003), but not in others (Lin et al. 2005; Peel et al. 2005; Tolbert et al. 2007). In a time-series analysis 
conducted in Toronto, Canada (1980-1994), Burnett et al. (2001) found a significant association between 
increasing air carbon monoxide concentrations and hospital admissions for asthma, acute bronchitis/
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bronchiolitis, croup, and pneumonia in children (age <2 years). A 1.9 ppm increase in air carbon 
monoxide concentration (lag: 0-1 day) was associated with a 19.2% increase in hospital admissions, 
which remained elevated when adjusted for air O3 concentration. A case-crossover study of hospital 
admissions of children (ages 6-12 years) for asthma in Toronto, Canada (1981-1993) found that a 
0.5 ppm increase in air carbon monoxide concentration was associated with an odds ratio (lag: 1 day) of 
1.05 (95% CI: 1.00-1.11) in males but not in females (odds ratio: 1.00, 95% CI: 0.93-1.06), and 
persisted in males after adjustment for particulate matter (Lin et al. 2003). Another case-crossover study 
directed at respiratory infections in children (age <15 years, males), also conducted in Toronto, Canada 
(1988-2001) estimated the odds ratio for a 0.44 ppm increase in air carbon monoxide concentration (lag: 
0-5 days) to be 1.13 (95% CI: 1.01-1.25) and 1.08 (95% CI: 0.97-1.20) after adjustment for PM10 and 
PM10-2.5 (Lin et al. 2005). Odds ratios for females were not significant. Yang et al. (2003) conducted a 
case-crossover study of hospital admissions for various respiratory disease categories in Vancouver, 
Canada (1986-1998) and found that an increase in carbon monoxide concentration of 0.5 ppm was 
associated with odds ratios of 1.04 (95% CI: 1.01-1.07) for children (age <3 years) and 1.02 (95% CI:
1.00-1.04) for elderly adults (age >65 years). The associations persisted when adjusted for air O3 
concentration. In a time-series analysis of >400,000 emergency room visits for respiratory disease in 
Atlanta, Georgia (1993-2000), the estimated risk ratio for a 1 ppm increase in air carbon monoxide 
concentration (lag: 0-13 days) was 1.076 (95% CI: 1,047-1.105) for all ages and 1.019 (1.004-1.035) 
for asthma visits in children aged 2-18 years (Peel et al. 2005). The associations were not significant 
when adjusted for other air pollutants in two-pollutant models (e.g., PM10, NO2, or O3). This study also 
found a significant risk ratio for emergency room visits related to pneumonia (risk ratio: 1.045, 95% CI: 
1.011-1.080; lag: 0-13 days). A revisit to the Atlanta, Georgia study, with the study period expended to 
1993-2004 (Tolbert et al. 2007), found essentially similar results as reported in Peel et al. (2005). The 
risk ratio for all emergency room visits for all respiratory disease categories was 1.016 (95% CI: 1.009­
1.022) per 1.22 ppm increase in 1-hour max carbon monoxide concentration (lag: 3 days); however, the 
association was attenuated in models that adjusted for O3, NO2, or PM10.
Studies that examined COPD admissions and emergency room visits yielded mixed results (Peel et al. 
2005; Slaughter et al. 2005; Yang et al. 2003). In the Yang et al. (2003) time-series study, conducted in 
Vancouver, Canada (1994-1998), the risk ratio for a 0.5 ppm increase in air carbon monoxide 
concentration (lag: 0-6 days) was 1.14 (95% CI: 1.03-1.23) for COPD hospital admissions. On the 
other hand, significant associations between air carbon monoxide concentration and COPD hospital 
admissions or emergency room visits were not found in a time-series study conducted in Spokane, 
Washington (1995-2001; Slaughter et al. 2005). In the Peel et al. (2005) time-series study conducted in
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Atlanta, Georgia (1993-2000), relative risk for emergency room visits for COPD was 1.03 (95% CI:
1.00-1.05) per 1 ppm increase in carbon monoxide concentration days, and 1.03 (95% CI: 0.98-1.09) for 
lag: 0-2 days, and 1.03 (95% CI: 0.98-1.09) for lag: 0-13 days. The air carbon monoxide 
concentrations in these studies were similar (10th-90th percentile range: approximately 1.25-4.3 ppm)
Animal Studies. Most studies evaluating adverse respiratory effects of carbon monoxide in animals were 
conducted using carbon monoxide exposures that produced much higher COHb concentrations (i.e., 
COHb >50%) than those evaluated in controlled clinical studies in humans. Even at these high 
exposures, results of animal studies support those of controlled clinical studies indicating that the 
respiratory tract is not a major target organ for carbon monoxide. Animal studies published prior to 2000 
have been reviewed in detail by the EPA (1991, 2000); therefore, these reviews largely form the basis of 
the following discussions for animals studies published prior to 2000.
Studies investigating adverse respiratory effects of carbon monoxide have evaluated the lung function and 
morphology, with most studies evaluating effects of brief exposure (i.e., a few minutes to <1 hour). In 
acute-duration studies, alterations in lung function (decreased compliance and increased airway 
resistance) were observed in rabbits and cats exposed to 8,000-28,400 ppm carbon monoxide for <1 hour 
(COHb >60%); however no changes in lung function were observed in dogs exposed to 8,000­
14,000 ppm carbon monoxide for 10-20 minutes (COHb 18-59%) (EPA 1991). In an intermediate- 
duration study, continuous exposure of rats to 50 ppm carbon monoxide for 21 days (COHb not reported) 
did not alter the pulmonary pressure-flow relationship (Carraway et al. 2002). Results of these studies 
suggest that carbon monoxide-induced changes in pulmonary function occur only following exposure to 
high carbon monoxide concentrations.
Studies evaluating effects of acute-duration carbon monoxide exposure on lung morphology have 
reported conflicting results (EPA 1991). Minimal changes in type 2 epithelial cells (fragmentation of 
lamellar bodies) and in nonciliated bronchiolar cells (dilation of smooth endoplasmic reticulum and 
increased mitochondrial cristae) were reported in mice exposed to 50-90 ppm carbon monoxide for 1­
5 days (COHb <10%) (Niden 1971); however, study results were not presented in detail and the 
toxicological significance of these finding is not known. In rabbits exposed to 8,000 ppm for 30 minutes 
(COHb 63%), examination of lung tissue by electron microscopy showed alveolar epithelial edema with 
detachment of the endothelium from the basement membrane (Fein et al. 1980). However, no 
morphological changes in lung tissue were observed following acute exposure (30 minute to 5 hours) of 
dogs and rabbits at carbon monoxide exposure producing blood COHb levels of 18-39% or following
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intermediate-duration exposure (6 weeks) of rabbits to 200 ppm carbon monoxide (COHb 11.9-19%) 
(Fisher et al. 1969; Hugod 1980). Results of a recent study in rats exposed chronically to 200 ppm carbon 
monoxide (COHb 14.7%) for 20 hours/day for 72 weeks showed no histopathological changes to lung 
tissue (S0rhaug et al. 2006).
Cardiovascular Effects. Cardiovascular effects of inhalation exposures to carbon monoxide have 
been evaluated in controlled human clinical studies, epidemiology studies, and in various animal models 
(monkeys, dogs, rats, and rabbits). In general, these studies provide convincing evidence for adverse 
cardiovascular effects in association with carbon monoxide exposures that result in blood COHb levels of 
2.4% and higher, with effects occurring at the lowest levels in subjects who have compromised 
cardiovascular function (e.g., coronary artery disease). Results of controlled clinical studies in patients 
with coronary artery disease show that acute-duration exposure to carbon monoxide at levels producing 
blood COHb levels between 2.4 and 5.9% exacerbates underlying cardiovascular disease, including 
enhanced myocardial ischemia and increased cardiac arrhythmias.
In healthy subjects, acute exposure to carbon monoxide at concentrations producing blood COHb levels 
of 3.35 and 20.5% resulted in compensatory cardiovascular responses and decreased exercise 
performance consistent with COHb-induced decreased O2 carrying capacity of the blood; however, 
subjects did not exhibit exercise-induced adverse cardiovascular effects (e.g., evidence of myocardial 
ischemia or cardiac arrhythmias). Continuous exposure of healthy subjects, which included smokers, to 
carbon monoxide resulting in blood COHb levels of 2.4 and 5.1% produced P-wave deviations under 
resting conditions, although similar findings have not been reported in other studies.
Epidemiological studies of exposure to carbon monoxide and cardiovascular outcomes have yielded 
mixed results; although, in general, the weight of evidence suggests that risks of certain specific outcomes 
are associated with increasing ambient carbon monoxide concentrations (hospitalizations and emergency 
room visits related to congestive heart failure, ischemic heart disease, myocardial infarction, and stroke). 
The corroborated observations of associations between carbon monoxide exposure and outcomes related 
to ischemic heart disease is particularly provocative in the context of results of human clinical studies in 
which carbon monoxide-induced hypoxia exacerbated ischemia symptoms in patients with coronary 
artery disease. Mean ambient air carbon monoxide concentrations reported in studies that have found 
carbon monoxide-associated cardiovascular outcomes have ranged from 0.5 to 10 ppm, with maximum 
values ranging from 2 to 50 ppm. These values correspond to approximate steady-state blood COHb 
levels of <2% for the mean and <10% for the maximum. Studies conducted in animals provide additional
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evidence for adverse cardiovascular effects of carbon monoxide exposure, including compensatory 
alterations in hemodynamics, cardiac hypertrophy, cardiac arrhythmias, and possibly atherosclerosis.
Studies in animals have investigated adverse cardiovascular effects of carbon monoxide exposure over a 
much wider range of exposure conditions (e.g., exposure concentration and duration) and have evaluated 
additional outcome measures that are not possible to assess in humans. These studies provide further 
evidence of adverse cardiovascular effects of carbon monoxide exposure, including compensatory 
alterations in hemodynamics, cardiac hypertrophy, cardiac arrhythmias, and possibly atherosclerosis.
Human Clinical Studies
Studies of Patients with Cardiovascular Disease. The effects of acute-duration carbon monoxide 
exposure on cardiovascular function have been evaluated in several controlled clinical studies in patients 
with underlying cardiovascular disease (Adams et al. 1988; Allred et al. 1989, 1991; Anderson et al.
1973; Dahms et al. 1993; Hinderliter et al. 1989; Kleinman et al. 1989, 1998; Leaf and Kleinman 1996b; 
Sheps et al. 1987, 1990) and in healthy subjects (Adir et al. 1999; Davies and Smith 1980; Hausberg and 
Somers 1997; Horvath et al. 1975; Kizakevich et al. 2000; Morse et al. 2008; Resch et al. 2005; Vogel 
and Gleser 1972; Zevin et al. 2001). In general, similar effects of acute-duration carbon monoxide 
exposure were not observed in studies on healthy study subjects, due to functional cardiovascular 
compensatory mechanisms (e.g., vasodilation and increased cardiovascular output) that protect against 
COHb-induced tissue hypoxia. Mechanisms contributing to cardiac effects of carbon monoxide in 
patients with coronary artery disease have not been conclusively established. Under conditions of cardiac 
ischemia, tissue hypoxia secondary to elevated COHb levels is thought to be a contributing factor. 
However, other direct cellular effects of carbon monoxide on cardiac muscle may also be important. 
These include modulation of coronary arteriole calcium-activated potassium channels. These channels 
are required for membrane hyperpolarization and flow-induced dilation, and are reversibly activated by 
carbon monoxide under normoxic conditions, but they are inhibited when hypoxic/ischemic conditions 
prevail (Wang and Wu 1997; Wang et al. 1997a, 1997b).
Controlled clinical studies conducted in small numbers of patients with underlying coronary artery 
disease have evaluated effects of carbon monoxide exposure on myocardial ischemia. Patients evaluated 
had a diagnosis of coronary artery disease with exertional angina (i.e., exercise-induced angina or stable 
angina) and/or ventricular arrhythmia. Most studies were conducted using a randomized, double-blind, 
crossover design, with cardiovascular function assessments conducted during exercise challenge, either
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during or immediately following carbon monoxide exposure. Carbon monoxide exposures (concentration 
and duration) were designed to reach target blood COHb levels between 2 and 6%; exposure durations 
ranged from 1 to 4 hours via an environmental chamber with carbon monoxide concentrations ranging 
from 42 to 357 ppm. Effects of carbon monoxide exposure were evaluated by comparison to assessments 
conducted during room air exposure and at corresponding COHb concentrations (<1%). Additional 
experimental details for each study are summarized in Table 3-4.
Results of controlled clinical studies in patients with coronary artery disease show that acute-duration 
exposure to carbon monoxide at levels producing blood COHb levels between 2.4 and 5.9% exacerbates 
underlying cardiovascular disease, including enhanced myocardial ischemia and increased cardiac 
arrhythmias. In patients with exertional angina, carbon monoxide exposure exacerbated exercise-induced 
myocardial ischemia, including decreased time-to-onset of angina symptoms (Adams et al. 1988; Allred 
et al. 1989, 1991; Anderson et al. 1973; Kleinman et al. 1989, 1998; Leaf and Kleinman 1996b), 
increased duration of angina symptoms (Anderson et al. 1973; Kleinman et al. 1989), decreased time-to- 
onset of ST-segment depression (EKG change indicative of myocardial ischemia) (Allred et al. 1989, 
1991; Kleinman et al. 1989), and decreased left ventricular ejection fraction (Adams et al. 1988). At the 
lowest blood COHb level evaluated in patients (i.e., COHb 2.4%), time-to-onset of angina symptoms and 
of ST-segment depression were significantly decreased by 4.2 and 5.1%, respectively (Allred et al. 1989, 
1991). In contrast, no carbon monoxide-induced exacerbation of exertional angina, based on time-to- 
onset of angina symptoms and ST-segment depression and duration of angina symptoms, were observed 
at a blood COHb level of 4.1% (Sheps et al. 1987). Clinical evaluations in angina patients with 
ventricular arrhythmias have yielded mixed results on the effects of carbon monoxide-induced ventricular 
arrhythmias (Dahms et al. 1993; Hinderliter et al. 1989; Sheps et al. 1990). At a blood COHb level of 
5.9%, but not 4.0%, single and complex premature ventricular depolarizations were significantly 
increased by 36 and 6.3%, respectively (Sheps et al. 1990). However, at this same blood COHb level, 
carbon monoxide exposure did not increase ventricular arrhythmias in other studies (Dahms et al. 1993; 
Hinderliter et al. 1989). Reasons for conflicting results in these studies are not readily apparent, although 
numbers of patients evaluated were small and severity of underlying coronary artery disease may have 
varied in each study.
Studies o f Healthy Subjects. Several controlled clinical studies in small numbers of healthy subjects have 
evaluated effects of acute-duration exposure to carbon monoxide on exercise performance, including 
cardiovascular function. In general, study protocols were similar to those used in clinical studies on 
patients with coronary artery disease, although typical carbon monoxide exposures were for shorter
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Adam s et al. 
1988
30 nonsmokers 
(22 men, 8 women; 
mean age:
58 years; age range 
3 6 -7 5  years) 
diagnosed with 
coronary artery 
disease with 
exertional angina 
pectoris
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
2 test days: 1 -hour exposure 
to room air (m easured C O H b  
prior to exercise challenge: 
1.6±0 .1% a) or C O  (m easured  
C O H b prior to exercise 
challenge: 5 .9±0 .1% a; mean 
C O  concentration: 100­
200 ppm). C O H b measured 
by C O -O x.
Duration of exercise, 
tim e-to-onset of exercise- 
induced angina 
symptoms and ischemic 
ST-segm ent changes 
(EKG), radionuclide 
ventriculograph 
(ventricular ejection 
fraction), systolic blood 
pressure. Results for CO  
exposure compared to 
room air exposure.
Mean duration of exercise: Decreased  
by 6 .5%  (p<0.05) following CO  
exposure, compared to air exposure. 
Tim e-to-onset of angina sym ptom s: 
Using actuarial analysis, subjects more 
likely to experience angina symptoms 
earlier in exercise following C O  vs. air 
exposure (p<0.05).
Tim e-to-onset of ischemic ST-segm ent 
changes: No effect of exposure. 
Systolic blood pressure: No effect of 
exposure.
Ventricular ejection fraction: Left 
ventricular ejection fraction at 
submaximal exercise was decreased  
following C O  exposure, compared to air 
exposure (p<0.05).
NOAEL: Not established 
LOAEL: C O H b 5.9%
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Allred et al. 
1989, 1991
63 male
nonsmokers (4 1 -7 5  
years) diagnosed  
with coronary artery 
disease with 
exertional angina 
pectoris and 
ischemic 
ST-segm ent 
changes on EKG
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(treadmill)
administered
prior to and
immediately
following each
exposure.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
3 test days: 1-hour exposure 
to room air (m easured C O H b  
prior to exercise challenge: 
0 .70±0 .02% a), low CO  
(measured C O H b prior to 
exercise challenge: 
2 .38±0 .05% a; mean CO  
concentration: 117 ppm, 
range 4 2 -2 0 2  ppm), or high 
C O  (m easured COHb: 
4 .66±0 .09% a; mean CO  
concentration: 253 ppm, 
range 1 4 3 -3 5 7  ppm). C O Hb  
measured by GC.
Tim e-to-onset of 
exercise-induced angina 
symptoms and ischemic 
ST-segm ent changes 
(EKG), total exercise 
duration, heart rate- 
systolic blood pressure 
double product. Effects 
determined based 
comparison (percent 
change) for pre- and post­
exposure exercise 
challenge outcomes on 
each test day. Results for 
each C O  exposure 
compared to room air 
exposure.
Tim e-to-onset of angina sym ptom s: 
Decreased by 4 .2%  (p=0.027) for low 
C O  exposure and 7.1%  (p=0.002) for 
high C O  exposure, compared to room 
air exposure.
Tim e-to-onset of ischemic ST-segm ent 
changes: Decreased by 5.1%  (p=0.01) 
for low C O  exposure and 12.1%  
(p<0.0001) for high C O  exposure, 
compared to room air exposure.
Mean duration of exercise: Decreased  
by 1.7%  (p=0.29) for low C O  exposure 
and 6.2%  (p<0.0001) for high CO  
exposure, compared to room air 
exposure.
Heart rate-systolic blood pressure 
double product: No effect of CO  
exposure.
NOAEL: Not established 
LOAEL: C O H b 2 .38%
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Anderson et al. 
1973
Dahm s et al. 
1993
10 men (5 smokers, Randomized,
5 nonsmokers; cross-over, 
mean age double-blind;
49.9  years) with following C O H b  
diagnosed coronary elevation to 
artery disease with target levels, 
exertional angina patients were  
pectoris administered
exercise 
challenge test 
(treadmill) under 
maintenance 
C O  exposure.
33 nonsmokers 
(28 men, 5 women; 
mean age:
58 years; age range 
3 6 -7 5  years) 
diagnosed with 
coronary artery 
disease with 
chronic ventricular 
arrhythmias
Patients ad ministered one of Tim e-to-onset and 
the following treatments (via duration of angina 
environmental chamber) on symptoms.
3 test days: 4-hour exposure 
to room air (measured  
COHb, prior to exercise 
challenge: 1.3% ), low C O  
(measured COHb: 2.9% ; CO  
concentration: 50 ppm), or 
high C O  (m easured COHb:
4.5% ; C O  concentration:
100 ppm). C O H b measured 
by spectrometry.
Randomized, 
cross-over, 
double-blind; 
following C O H b  
elevation to 
target levels, 
patients were  
administered 
exercise 
challenge test 
(treadmill) under 
maintenance 
C O  exposure.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
3 test days: 1-hour exposure 
to room air (m easured C O H b  
by C O -O x, prior to exercise 
challenge: 0.7), low C O  
(measured COHb: 3.2% ; 
mean C O  concentration:
159 ppm), or high CO  
(measured COHb: 5.1% ; 
mean C O  concentration:
292 ppm). Maintenance  
exposure on the CO  
exposure days was to 19 and 
31 ppm for the low and high 
C O H b exposures, 
respectively. C O H b  
measured by C O -O x.
Frequency of ventricular 
arrhythmias evaluated  
during exposure, during 
exercise (under 
m aintenance exposure), 
1 -6  hours after cessation 
of exposure, 7 -1 6  hours 
after cessation of 
exposure. Primary 
outcome was frequency 
of exercise-induced 
ventricular arrhythmias. 
Results for C O  exposure 
compared to room air 
exposure.
Tim e-to-onset of angina sym ptom s: 
Decreased by 4 .2%  (p=0.027) for low 
C O  exposure and 7.1%  (p=0.002) for 
high C O  exposure, compared to room 
air exposure.
Duration of angina sym ptom s: No 
effect for low C O  exposure; duration 
increased (p<0.01) for high CO  
exposure, compared to room air 
exposure.
NOAEL: Not established 
LOAEL: C O H b 2.9%
No effect of CO, compared to room air, 
on frequency of ventricular arrhythmia 
under any conditions assessed.
NOAEL: C O H b 5.9%
LOAEL: Not established
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
oA73
03o
Reference Study subjects Design Exposure Outcomes Assessed Results 01 DHinderliter et al. 
1989
0 XJ p c
031o
Co
10  nonsmokers 
(7 males,
3 females; mean 
age 61 years) 
diagnosed with 
coronary artery 
disease with angina 
and low basesline 
ventricular ectopy
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure
Patients administered one of 
the following treatments (via 
environmental chamber) on 
3 test days: 1 -hour exposure 
to room air (m easured C O H b  
following exposure: 
1 .4±0 .5% b), low CO  
(measured C O H b following 
exposure: 4 .0±0 .4% b; CO  
concentration: 100  ppm), or 
high C O  (m easured CO Hb  
following exposure: 
5 .8±0 .4% b; CO  
concentration: 200 ppm). 
C O H b measured by C O -O x.
Ventricular arrhythmia. 
Results for C O  exposure 
compared to room air 
exposure.
No effect of CO, compared to room air, 
on frequency of ventricular arrhythmia.
NOAEL: C O H b 5.9%
LOAEL: Not established
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Kleinman et al, 
1989
24 male
nonsmokers (mean  
age: 59 years; age 
range: 49 ­
66 years) 
diagnosed with 
coronary artery 
disease with stable 
angina pectoris
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure
Patients administered one of 
the following treatments (via 
environmental chamber) on 
2 test days: 1 -hour exposure 
to room air (m easured C O H b  
following exposure: 
1.4±0 .1% c) or C O  (measured  
C O H b following exposure: 
3 .0±0 .1% c; mean CO  
concentration: 100ppm). 
C O H b measured by C O -O x.
Tim e-to-onset and 
duration of angina 
symptoms, time-to-onset 
of ischemic ST-segm ent 
changes (EKG), heart 
rate, systolic blood 
pressure, oxygen update 
at angina. Results for CO  
exposure compared to 
room air exposure.
Tim e-to-onset of angina: Decreased by 
5.89%  (p<0.046) following CO  
exposure, compared to room air 
exposure.
Duration of angina sym ptom s:
Increased by 8 .33%  (not statistically 
significant) following C O  exposure, 
compared to room air exposure. 
Tim e-to-onset of ischemic ST-segm ent 
changes: Decreased by 19.05%  
(p<0.044) following C O  exposure, 
compared to room air exposure.
Oxygen uptake at angina: Decreased  
by 2 .15%  (p<0.04) following CO  
exposure, compared to room air 
exposure.
Systolic blood pressure: No effect of 
exposure
Heart rate: No effect of exposure.
NOAEL: Not established 
LOAEL: C O H b 3.0%
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Kleinman et al. 
1998; Leaf and 
Kleinman 1996b
17 male
nonsmokers (mean 
age: 66 years; age 
range: 58­
83 years) living at 
or near sea level, 
diagnosed with 
coronary artery 
disease with 
exertional angina 
pectoris
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure at sea
levels and under
conditions
simulating high
altitude.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
4 test days: 2-hour exposure 
to room air at sea level 
(measured C O H b following 
exposure: 0 .6±0 .3% b), room 
air at artificial high elevation 
(measured C O H b following 
exposure: 0 .6±0 .3% b), C O  at 
sea level (m easured COHb: 
3 .9±0 .5% b; mean CO  
concentration: 100  ppm), or 
C O  at artificial high elevation 
(measured COHb:
4 .0±0 .6% b; mean CO  
concentration: 100  ppm), 
C O H b measured by C O -O x.
Tim e-to-onset and 
duration of angina 
symptoms, ST-segm ent 
depression and 
preventricular 
contractions (EKG), peak 
(end-exercise) heart rate, 
blood pressure, oxygen 
update, and carbon 
dioxide output. Results 
for C O  exposure 
compared to room air 
exposure.
Tim e-to-onset of angina: Decreased by 
9.1%  (p<0.05) following C O  exposure at 
sea level and by 7.6%  (p<0.05) 
following C O  exposure at high altitude, 
compared to matched room air 
exposure.
Duration of angina sym ptom s: No 
effect of C O  exposure.
ST-segm ent changes: No effect of CO  
exposure.
Preventricular contractions: No effect 
of C O  exposure
Peak heart rate: Increased (p<0.05) for 
C O  at high altitude compared to C O  at 
sea level and to room air at high 
altitude.
Peak blood pressure: Increased  
(p<0.05) for C O  at high altitude 
compared to room at C O  at sea level. 
Oxygen uptake and carbon dioxide 
output: Decreased (p<0.05) by CO  
exposure at sea level and high altitude.
NOAEL: Not established 
LOAEL: C O H b 3 .9 -4 .0 %
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
oA73
03o
Reference Study subjects Design Exposure Outcomes Assessed Results 01 DSheps et al. 
1987
o
73A
0 
73 p c
031o
Co
30 nonsmokers 
(age range 38­
75 years) with 
diagnosed coronary 
artery disease with 
exertional angina 
pectoris
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
2 test days: 1 -hour exposure 
to room air (m easured C O H b  
following exposure: 
1 .5±0 .05% b) or CO  
(measured C O H b following 
exposure: 4 .1±0 .05% b; CO  
concentration: 100  ppm). 
C O H b measured by C O -O x.
Tim e-to-onset and 
duration of angina 
symptoms, ST-segm ent 
depression, 
cardiovascular function 
(heart rate, blood 
pressure, rate x  pressure 
product, peak exercise 
workload, left ventricular 
ejection fraction), 
exercise duration.
Results for C O  exposure 
compared to room air 
exposure.
No statistically significant CO-induced  
changes for any outcomes, except for a 
small (0.5%  decrease; p=0.049) in 
maximal ejection fraction. Study authors 
did not consider this change to be 
clinically significant.
NOAEL: C O H b 4.1%
LOAEL: Not established
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Table 3-4. Effects of Acute-duration Exposure to Carbon Monoxide on Cardiovascular Function in Patients with
Coronary Artery Disease
Reference Study subjects Design Exposure Outcomes Assessed Results
Sheps et al. 
1990
41 nonsmokers 
(36 men, 5 women; 
mean age:
62.8  years; age 
range: 47 ­
77 years) with 
diagnosed coronary 
artery disease
Randomized,
cross-over,
double-blind;
exercise
challenge tests
(bicycle)
administered
immediately
following each
exposure.
Patients administered one of 
the following treatments (via 
environmental chamber) on 
3 test days: 1-hour exposure 
to room air (m easured C O H b  
following exposure: 
1 .46±0 .07% a), low CO  
(measured C O H b following 
exposure: 4 .01±0 .06% a; CO  
concentration: 100  ppm), or 
high C O  (m easured CO Hb  
following exposure: 
5 .91±0 .08% a; CO  
concentration: 200 ppm). 
C O H b measured by C O -O x.
Ventricular arrhythmia 
(EKG) and ventricular 
ejection fraction 
(radionuclide 
ventriculography), blood 
pressure, heart rate, 
exercise duration. 
Results for C O  exposure 
compared to room air 
exposure.
For C O H b 4.01% : No effects on any 
param eter evaluated.
For C O H b 5.91% : During exercise, 
statistically significant changes in single 
premature ventricular depolarizations 
(36%  increase; p=0.03), complex 
premature ventricular depolarizations 
(6.3%  increase; p=0.02), heart rate 
(3.2%  increase; p=0.01),
NOAEL: C O H b 4 .01%
LOAEL: C O H b 5.91%
a m e a n ± s t a n d a r d  e r r o r  ( S E )  
b m e a n ± s t a n d a r d  d e v i a t i o n  ( S D )  
c m e a n s ;  r e p o r t  d o e s  n o t  i n d i c a t e  i f  S D  o r  S E
C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  C O - O x  =  C O  o x i m e t r y ;  E K G  =  e l e c t r o c a r d i o g r a m ;  G C  =  g a s  c h r o m a t o g r a p h y ;  L O A E L  =  l o w e s t - o b s e r v e d - a d v e r s e -  
e f f e c t  l e v e l ;  N O A E L  =  n o - o b s e r v e d - a d v e r s e - e f f e c t  l e v e l
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durations (a few minutes to <1 hour) to higher carbon monoxide concentrations (50-3,000 ppm), and 
produced slightly higher blood COHb levels (2.4-20.5%). However, one study exposed subjects 
continuously for 7 days (Davies and Smith 1980). Additional experimental details for each study are 
summarized in Table 3-5.
Results of several controlled clinical studies in healthy subjects show that carbon monoxide exposures 
that resulted in blood COHb levels between 3.35 and 20.5% decreased exercise performance, including 
decreased exercise duration (Adir et al. 1999); decreased maximal exercise effort or maximal aerobic 
capacity (Adir et al. 1999; Horvath et al. 1975; Vogel and Gleser 1972); decreased resistance to muscle 
fatigue (Morse et al. 2008); and induced compensatory increases in heart rate and cardiac output 
(Kizakevich et al. 2000; Vogel and Gleser 1972). The above effects on exercise performance are 
consistent with COHb-induced decreased O2 carrying capacity of the blood and normal physiological 
compensatory mechanisms. Evaluations on the potential for carbon monoxide exposure to produce 
exercise-induced cardiac arrhythmias similar to those observed in patients with coronary artery disease 
(i.e., ST-segment depression and premature ventricular contractions) have yielded negative results at 
blood COHb levels up to 5.1% (Adir et al. 1999; Horvath et al. 1975; Kizakevich et al. 2000), although 
the potential for carbon monoxide-induced cardiac arrhythmias during exercise challenge was not 
evaluated at higher blood COHb levels. In subjects (including smokers and nonsmokers) exposed 
continuously for 7 days and evaluated at rest, EKG showed P-wave deviations in 3/15 subjects exposed to 
15 ppm carbon monoxide (COHb 2.4%) and in 6/15 subjects exposed to 50 ppm carbon monoxide 
(COHb 5.1%), compared to 0/14 in subjects exposed to room air (Davies and Smith 1980). In one 
subject, a heavy smoker, marked ST-depression also was observed. However, interpretation of these 
findings is limited due to lack of statistical analyses and of evaluation for potential confounding factors 
(e.g., smoking, medication use). Other studies evaluating effects of a single 1-hour exposure to carbon 
monoxide (Hausberg and Somers 1997) or repeated brief exposures to carbon monoxide (approximately 
once every 45 minutes to simulate smoking; Zevin et al. 2001) on cardiovascular function (blood 
pressure, heart rate, forearm blood flow) under resting conditions show no effects at blood COHb levels 
up to 8.3%.
In conclusion, results of controlled clinical studies in patients with cardiovascular disease provide 
compelling evidence that acute-duration exposure to carbon monoxide resulting in COHb levels of 2.4­
5.8% exacerbates cardiovascular morbidity (myocardial ischemia and cardiac arrythmias). Effects at 
lower blood COHb levels have not been evaluated. However, it should be noted that patients with more 
severe cardiovascular disease may be more sensitive than patients evaluated in these clinical studies. In
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Table 3-5. Effects of Acute-Duration Carbon Monoxide Exposure on Cardiovascular Function in Healthy Subjects
Reference Study subjects Design Exposure Outcomes assessed Results
Adir et al. 1999 15 healthy 
nonsmoking men 
(mean age:
26 years; age 
range: 18­
35 years)
Randomized, 
cross-over, 
double-blind; 
exercise challenge 
tests (bicycle) 
administered 
immediately 
following each 
exposure.
Subjects administered 
one of the following 
treatments (via closed 
breathing circuit) on 
2 test days: 3­
4 minute exposure to 
room air (COHb: 
0 .59±0 .08% a) or CO  
(m easured COHb: 
5 .1±0 .65% a; CO  
concentration not 
reported). C O Hb  
measured by C O -O x.
Level of anaerobic 
respiration (plasma 
lactate/pyruvate ratio), 
cardiac arrhythmia (EKG), 
heart rate and blood 
pressure (resting and 
peak), cardiac perfusion 
(thallium heart 
scintigraphy), exercise 
duration, maximal effort 
(metabolic equivalent 
units).
Anaerobic respiration: No effect of CO  
exposure.
Cardiac arrhythm ia: No effect of CO  
exposure.
Cardiac perfusion: No effect of CO  
exposure.
Heart rate and blood pressure: No effect of 
C O  exposure.
Exercise duration: Decreased by 10.4%  
(p=0.0012) for C O  exposure compared to air 
exposure.
Maximal effort: Decreased by 12.4%  
(p=0.001) for C O  exposure compared to air 
exposure.
Davies and 
Smith 1980
Groups (14­
15/group) of 
matched healthy 
(no information on 
sex reported; age 
range 17­
27 years)
Randomized, 
parallel group
Continuous exposure 
to room air (CO Hb  
0.5% ), low C O  (15 ppm 
CO; C O H b 2 .4% ) or 
high C O  (50 ppm CO; 
C O H b 7.2% ) for 7 days
EKG; no statistical 
analysis conducted.
NOAEL: Not established 
LOAEL: C O H b 5.1%
P-wave changes: P-wave deviations of >0.1 
m V observed in 3 /15 subjects at low C O  and 
6/15 at high CO , compared to 0 /14 for room 
air.
Marked ST-segm ent depression:
1/15 subject (a heavy smoker) at low CO  
exposure.
NOAEL: Not established 
LOAEL: C O H b 2.4%
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Table 3-5. Effects of Acute-Duration Carbon Monoxide Exposure on Cardiovascular Function in Healthy Subjects
Reference Study subjects Design Exposure Outcomes assessed Results
Hausberg and 
Som ers 1997
10 healthy 
subjects (8 men, 
2 women; mean 
age: 27 years); 
9/10 were  
nonsmokers
Randomized, 
double-blind, 
vehicle (air) 
controlled
Subjects were Forearm blood flow
assessed under vehicle (plethysmography), blood 
control (room air), then pressure, heart rate, 
administered C O  minute ventilation, muscle 
(1,000 ppm for sympathetic nerve activity
30 minutes, followed by (microneurography)
100 ppm for 
30 minutes); CO Hb  
increased from 
0.2±0.1 % b for room air 
exposure to 8 .3±0 .5% b 
during the first 30 
minutes of exposure;
C O H b levels were  
maintained during the 
second 30 minutes of 
C O  exposure. C O H b  
measured by C O -O x.
No effects of C O  treatm ent on any 
param eter evaluated.
NOAEL:
LOAEL:
C O H b 8.3%  
Not established
CARBON MONOXIDE 
61
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC 
COMMENT***
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Reference Study subjects Design Exposure Outcomes assessed Results
Horvath et al. 
1975
4 healthy men 
(mean age:
24.6 years; age 
range: 23 ­
33 years);
3 /4  were  
nonsmokers
Randomized, 
single-blind, cross­
over; exercise 
challenge tests 
(treadmill) to 
exhaustion 
administered 
immediately 
following each 
exposure.
Subjects administered 
one of the following 
treatments (via 
environmental 
chamber) on 3 test 
days exposure duration 
not reported): Vehicle 
exposure to room air 
(measured CO Hb  
following exposure: 
0 .33±0 .06% b), low CO  
(m easured CO Hb  
following exposure: 
3.35±0 .14% b; CO  
concentration:
75 ppm), or high CO  
(m easured CO Hb  
following exposure: 
4 .3 0 ±0 .3 0 % b; CO  
concentration: 100 
ppm). Method for 
measuring C O H b not 
reported.
EKG, maximal aerobic 
capacity (maximal oxygen 
consumption), work time, 
ventilatory volume
EKG: No effect of C O  exposure. 
Maximal aerobic capacity: Decreased at 
high C O  exposure (p<0.05).
Ventilatory volume and work times: 
Decreased at low and high C O  exposure 
(p<0.05).
NOAEL: Not established 
LOAEL: C O H b 3.35%
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Reference Study subjects Design Exposure Outcomes assessed Results
Kizakevich et al. 
2000
16 healthy 
nonsmoking men 
(age range: 18­
29 years)
Randomized, 
cross-over (no 
details on blinding 
reported); upper 
(handcrank) and 
lower body
Subjects exposed to 
C O  (concentrations 
1 ,0 0 0 -3 ,0 0 0  ppm) for 
4 -6  minutes, followed 
by maintenance CO  
exposure (2 7 -1 0 0
(treadmill) exercise ppm) on separate test
challenges at 
submaximal effort 
administered 
following 
exposure.
Cardiac rhythm, output, 
stoke volume, heart rate, 
and contractility, time-to- 
peak ejection time, blood 
pressure.
days: Room air 
(COHb: 1.8% ); CO-1 
(COHb: 5.0% ); C O -2  
(COHb: 9.8% ); C O -3  
(COHb: 14.8% ); C O -4  
(COHb: 19.2% ). 
C O H b measured by 
CO -O x.
Cardiac rhythm: No effects of C O  exposure, 
compared to room air exposure; no 
arrhythmias or ST-segm ent depression. 
Com pensatory changes associated with 
reduced oxygen carrying capacity: 
Significant increases in heart rate at all CO  
exposures and cardiac contractility at C O H b  
9.8% .
NOAEL: Not established 
LOAEL: C O H b 5.0%
Morse et al. 
2008
12  healthy 
nonsmoking men 
(mean age:
25 years)
Cross-over; 
skeletal muscle 
fatigue challenge 
administered 
following exposure
Room air or 3 ,000 ppm 
for 6 minutes (C O H b  
6 .2%)
Leg strength, muscle 
fatigue assessed during 
voluntary and electrically 
evoked muscle 
contractions
Resistance to muscle fatigue decreased  
under voluntary (13%  decrease; p<0.05) 
and electrically evoked stimulation (12.5%  
decrease; p<0.05). No effect on leg 
strength.
Resch et al. 
2005
6 healthy 
nonsmoking men 
(mean age:
26 years)
Randomized,
cross-over,
double-blind
Subjects administered 
the following 
treatments: Room air 
(C O H b 1.2% ), 500 ppm 
for 30 minutes (CO Hb  
8.5% ; 500 ppm for 30 
minutes (C O H b 9.4% ).
Retinal and subm acular 
choroidal blood flow
NOAEL: Not established 
LOAEL: C O H b 6.2%
Significant increases in retinal and choroidal 
blood flow and retinal vessel d iam eter at 
C O H b >8.5% . Study authors state that 
relationship of this finding to tissue hypoxia 
is unknown.
NOAEL: Not established 
LOAEL: C O H b 8.5%
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Reference Study subjects Design Exposure Outcomes assessed Results
Vogel and 
Gleser 1972
8 men, including 
3 smokers (age 
range: 20­
23 years)
Randomized, 1-hour exposure to air
cross-over (no (C O H b 1 .0 -1 .7 % ) or
details on blinding 225 ppm C O  (C O H b
reported); exercise 18 .6 -2 0 .5 % )
challenges
administered
during exposure.
Maximal oxygen uptake 
assessed at rest and at 
submaximal and maximal 
exercise
At rest, no effect of C O  exposure. At 
submaximal exercise, no change in oxygen 
uptake due to compensatory increase in 
cardiac output. At maximal exercise, 
oxygen uptake decreased by 23%  (p<0.001)
NOAEL: Not established 
LOAEL: C O H b 1 8 .6 -2 0 .5 %
Zevin et al. 2001 12  healthy men 
(smokers; age 
range: 2 7 -4 7 )
Single-blind, cross­
over;
Subjects exposed to 
3 treatments for 
durations of 7 days 
each: Room air (CO Hb  
0.4% ), 1,200 ppm CO  
inhalation 20 times/day  
(~every 45 minutes,
20 tim es/day to 
simulate smoking 
(C O H b 6%), or 
20 cigarettes/day  
(C O H b 5% ).
Heart rate, blood pressure, 
catecholamine release, 
platelet activation, white 
blood cell count,
C-reactive protein 
(inflammation marker)
C O  exposure: No effect on serum levels of 
C R P  or platelet factor 4, heart rate, blood 
pressure, or catecholamine release, 
compared to room air.
Sm oking: Significant elevation in serum  
levels of C R P  and platelet factor 4, 
increased heart rate, or catecholamine 
release, compared to room air. No effect on 
blood pressure.
N O A EL (CO): C O H b 6%
LOAEL (CO): Not established
a m e a n ±  s t a n d a r d  d e v i a t i o n  ( S D )
b m e a n ±  s t a n d a r d  e r r o r  ( S E )
c m e a n s ;  r e p o r t  d o e s  n o t  i n d i c a t e  i f  S D  o r  S E
C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  C O - O x  =  C O  o x i m e t r y ;  E K G  =  e l e c t r o c a r d i o g r a m ;  G C  =  g a s  c h r o m a t o g r a p h y ;  L O A E L  =  l o w e s t - o b s e r v e d - a d v e r s e -  
e f f e c t  l e v e l ;  N O A E L  =  n o - o b s e r v e d - a d v e r s e - e f f e c t  l e v e l
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healthy subjects, acute exposure to carbon monoxide at concentrations producing blood COHb levels of 
3.35 and 20.5% resulted in compensatory cardiovascular responses and decreased exercise performance 
consistent with COHb-induced decreased O2 carrying capacity of the blood; however, subjects did not 
exhibit exercise-induced adverse cardiovascular effects (e.g., evidence of myocardial ischemia or cardiac 
arrhythmias). Continuous exposure of healthy subjects, which included smokers, to carbon monoxide 
resulting in blood COHb levels of 2.4 and 5.1% produced P-wave deviations under resting conditions, 
although similar findings have not been reported in other studies.
Epidemiological Studies. Epidemiological studies of exposure to carbon monoxide and cardiovascular 
outcomes fall into two major categories: (1) studies that have assessed cardiovascular morbidity in 
cohorts or individuals (e.g., case-crossover, case-control) in association with ambient air carbon 
monoxide concentrations; and (2) studies that have evaluated associations between air carbon monoxide 
concentrations and the incidence of hospital admissions and/or emergency room visits related to 
cardiovascular disease (e.g., time-series studies, case-crossover). Collectively, these studies have yielded 
mixed results; although, in general, the weight of evidence suggests that risks of certain specific outcomes 
are associated with increasing ambient carbon monoxide concentrations (hospitalizations and emergency 
room visits related to congestive heart failure, ischemic heart disease, myocardial infarction, and stroke). 
Corroborated observations of association between carbon monoxide exposure and outcomes related to 
ischemic heart disease are consistent with results of human clinical studies that have shown that carbon 
monoxide-induced hypoxia exacerbates symptoms of coronary artery disease. Therefore, it is plausible 
that in certain susceptible populations, such as individuals who have ongoing cardiac impairment that 
would make them vulnerable to ischemia, exposure to carbon monoxide could contribute to triggering 
ischemic episodes and cardiac sequelae. While these studies provide some evidence in support of adverse 
cardiovascular effects of inhalation exposures to carbon monoxide, their utility for establishing dose- 
response relationships for these effects are limited by several factors: (1) reliance on area monitoring for 
estimating exposure levels; 2) uncertainty in knowledge of temporal correspondence between monitored 
exposure levels and outcomes; (3) relatively strong correlations between ambient air carbon monoxide 
concentrations and other air quality variables that can affect respiratory function; (4) outcomes 
investigated have tended to be serious, life-threatening events (e.g., cardiac arrhythmia, myocardial, 
infarction, stroke, heart failure) and reflect the “late-stage” consequences of contributing pathophysiology 
that might be associated with exposures to lower levels of carbon monoxide for longer durations than 
indicated in the epidemiological studies; and (5) relatively low carbon monoxide exposures studied.
Mean values of carbon monoxide exposure concentrations have ranged from 0.3 to 4.6 ppm with the 
highest values <30 ppm. These values correspond to predicted steady-state COHb levels of <1% for the
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mean and <5% for the highest values (predicted from the CFK model). The latter range is consistent with 
COHb levels observed in a study of emergency department admissions for cardiopulmonary complaints 
(Leikin and Vogel 1986). At these COHb levels, it is possible that only highly susceptible individuals 
exhibit the serious cardiovascular outcomes that have been studied. Clinical studies described previously 
in this section of the Toxicological Profile have found that exposures to carbon monoxide that produce 
COHb levels 2.4-5% can exacerbate underlying cardiovascular disease, including exercise-induced 
angina and cardiac arrhythmia; however, higher levels (3-20%) can be tolerated without producing such 
effects, even under exertion, in health individuals. For these and other reasons, epidemiologic studies 
have typically focused on highly susceptible populations. A typical design has been to examine 
associations between temporal trends in ambient air carbon monoxide concentrations and hospital 
admissions or emergency department visits for which the reported diagnosis was some form of 
cardiovascular disease of impairment.
The presentation of the epidemiology is organized by major categories of cardiovascular outcomes for 
which the studies were designed to evaluate, which include studies of heart rate and heart rate variability, 
cardiac arrhythmia, ischemic heart disease and related subcategories (e.g., myocardial infarction), heart 
failure, stroke, and blood pressure. Study conclusions are presented in the text, with selected supporting 
details presented in tabular form. Although most of the studies explored various time lags between 
monitored air carbon monoxide concentrations and outcomes, as well as various sample strata, for the 
sake of brevity, only those indicative of the strongest associations to carbon monoxide are presented in 
the tables. Where co-pollutant models have been explored, these results are also presented.
Studies of Heart Rate (HR) and Heart Rate Variability (HRV). Studies of associations between exposure 
to carbon monoxide and various measures of HR and HRV have yielded mixed results (Table 3-6). 
Carbon monoxide exposure concentrations in these studies represent relatively narrow time periods (e.g., 
averages over 1-5 days prior to the end point assessment). Mean values of carbon monoxide exposure 
concentrations ranged from 0.3 to 4.6 ppm, with the highest values <30 ppm (predicted steady-state 
COHb%: <5). Significant associations between increasing carbon monoxide exposure and increasing 
HR were found in some studies (Liao et al. 2004; Peters et al. 1999) and not in others (Gold et al. 2000). 
Assessments of HRV found significant associations with increasing carbon monoxide exposure in some 
studies (Dales 2004; Riojas-Rodriguez et al. 2006; Schwartz et al. 2005; Tarkiainen et al. 2003; Timonen 
et al. 2006) and no associations with HRV in other studies (Chan et al. 2005; Gold et al. 2000; Holguin et 
al. 2003; Liao et al. 2004; Park et al. 2005b). In general, associations for HRV end points were not robust 
for various measures of HRV across studies. For example, assessments of standard deviation of the
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Cardiovascular Disease
Study Design features CO exposure Effect size
Heart rate and heart rate variability
Chan et al. (2005)
Period: 2 0 0 1 -2 0 0 2  
Location: Taipei, Taiwan
Dales (2004)
Period: NR
Location: Toronto, Canada
Gold et al. (2000)
Period: 1997 
Location: Boston, 
Massachusetts
Holguin et al. (2003)
Period: 2000
Location: Mexico City, Mexico
Liao et al. (2004)
Period: 1 9 9 6 -1 9 9 8  
Location: Various U.S. cities
Park et al. (2005b) 
Period: 2 0 0 0 -2 0 0 3  
Location: Boston, 
Massachusetts
Outcome: H R V  
Design: Panel
Sample: 83 patients, age 43 ­
75 years
Outcome: H R V  
Design: Panel 
Sample: 36 subjects with 
preexisting CAD, age 51­
88 years
Outcome: H R  and H R V  
Design: Panel/Cohort 
Sample: n=21, age 5 3 -8 7
Outcome: H R V  
Design: Panel
Sample: n=34 age 6 0 -9 0  years
Outcome: H R  HRV. 
Design: Cohort 
Sample: n=6784, age 45­
64 years
Outcome: H R V  
Design: Panel/Cohort 
Sam ple Description: n=497  
males, age 2 1 -8 1  years
Avg time: 1 hour 
Mean 1.1 ppm 
Range: 0 .1 -7 .7  ppm
Avg time: 24 hours 
Mean 95th%: 2 .40 ppm 
Range: 0 .4 -1 6 .5  ppm
Avg time: 24 hours 
Mean: 0 .47 ppm 
Range: 0 .1 2 -0 .8 2  ppm
Avg time: 24 hours 
Mean: 3.3 ppm 
Range: 1.8, 4 .8  ppm
Avg time: 24 hours 
M ean 0 .65 ppm 
SD: 0.44 ppm
Avg time: 24 hours 
Mean: 0 .50 ppm 
Range: 0 .1 3 -1 .8  ppm
No statistically significant effect on SD N N , 
rM SSD, LFV, H FV
Increment: NR
Regression coefficient (95%  CI):
SD N N  (not taking P-blockers): 0.0111 (0 .002­
0.020, p=0.02)
No statistically significant effect on H R V  among 
those taking p-blockers
Increment: 0.6 ppm  
% Change (lag 2 day):
No significant effect of C O  on HR or H R V
Increment: 10 ppm
Regression coefficients (95%  C I), lag 0 day: 
HFV: 0 .003 (-0 .0 0 4 -0 .0 0 1 )
LFV: 0.001 (-0 .0 0 6 -0 .0 0 8 )
LFV/HFV: 0.001 (-0 .0 0 5 -0 .0 0 2 )
Increment: 0 .44 ppm 
Regression coefficient, lag 1 day:
H R  (bpm): 0.404 (p<0.05)
H FV  (log transformed): -0 .033  
LFV (log transformed): 0.006  
SDN N: -0 .274
Increment: 0.24 ppm
% Change in H R V  (95%  C I), 4-hour moving avg: 
SD N N  (log10): 2.0 (-2 .9 -7 .3 )
H FV  (log10): 8.8 (-4 .6 -2 4 .1 )
LFV(log10): 3.2 (-7 .0 -1 4 .6 )
LFV:HFV(log10): -5.1 (-1 3 .5 -4 .1 )
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Cardiovascular Disease
Study Design features CO exposure Effect size
Peters et al. (1999)
Study: 1 9 8 4 -1 9 8 5  
Location: Augsburg, Germ any
Riojas-Rodriguez et al. (2006) 
Period: 2 0 0 1 -2 0 0 2
Outcome: HR  
Design: Cohort 
Age Groups Analyzed: 25­
64 years
Sample: n=2,681, age 25­
64 years
Outcome: H R V  
Design: Panel
Avg time: 24 hours 
Mean: 3.9 ppm 
Range: 0 .8 -1 0 .0  ppm
Avg time: 24 hours 
Mean: 2 .9  ppm
Location: Mexico City, Mexico Sample: n=30, age 2 5 -7 6  years Range: 0 .1 -1 8 .0  ppm
Schwartz et al. (2005) 
Period: 1999 
Location: Boston, 
Massachusetts
Tarkiainen et al. (2003) 
Period: 1997-1998  
Location: Kuopio, Finland
Timonen et al. (2006)
Period: 1 9 9 8 -1 9 9 9  
Location: Amsterdam, 
Netherlands; Erfert, Germany; 
Helsinki, Finland
Outcome: H R V  
Design: Panel
Sample: n=28, age 6 1 -8 9  years
Outcome: H R V  
Design: Panel
Sample: n=6 males, age 5 5 -6 8  
years
Avg time: 24 hours 
Median: 0 .45 ppm
0 .3 8 -0 .5 4  ppm25th-7 5 th%:
Avg time: 24 hours 
Mean: 4 .6  ppm 
Range: 0 .5 -2 7 .4  ppm
Outcome: H R V  
Design: Panel 
Sample: n=131, age 64 ­
72 years
Avg time: 24 hour 
Mean: 0 .3 -0 .5  ppm 
Range: 0 .1 -2 .2  ppm
Increment: 6.6 mg/m
M ean change in HR, bpm (95%  CI), lag 0 day:
All: 0 .97 (0 .0 2 -1 .9 1 )
Male: 0 .95 (-0 .3 7 -2 .2 7 )
Female: 0 .98 (-0 .3 7 -2 .3 4 )
Increment: 1 ppm
Regression coefficients (95%  CI, lag 5 minutes: 
HFV: -0 .006  (-0 .023 to 0 .010)
LFV: -0 .024  (-0.041 to -0 .007)
VLFV: -0 .034  (-0.061 to -0 .007)
Increment: 0 .16 ppm 
% Change in H R V  (95%  C I), lag 1 day):
SDNN: -4 .2  (-0 .6  to -7.7) 
rM SSD: -10 .2  (-2 .4  to -17.4)
PNN50: -14 .8  (-3 .0  to -25.2)
LFV/HFV: 6 .2  (-0 .6  to 13.4)
Increment: NR
RR (95%  CI, lag 5 minutes)
C O >2.7  ppm: Significant increase in rM SSD  
(2.4 ms, p=0.034).
C O  <27 ppm: No significant association between 
C O  and NN, SD N N , or rM SSD
Increment: 1 m g/m3 
P coefficient (95%  CI), lag 2 days 
SDN N: -5 .96  (-10.7, -0 .72) l 
HF: -30 .7  (-59.8, -1.5)
LH/HF: -10.1 (-36.9, 16.7)
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Study Design features CO exposure Effect size
Cardiac arrhythmia
Berger et al. (2006)
Period: 2 000 -2001  
Location: Erfurt, Germ any
Dockery et al. (2005)
Period: 1 9 9 5 -2 0 0 2  
Location: Boston, 
Massachusetts
Gold et al. (2005)
Period: 1999  
Location: Boston, 
Massachusetts
M etzger et al. (2007)
Period: 1 9 9 3 -2 0 0 2  
Location: Atlanta, Georgia
Peters et al. (2000b)
Period: 1 9 9 5 -1 9 9 7  
Location: Eastern 
Massachusetts
Rich et al. (2004)
Period: 2000
Location: Vancouver, Canada
Rich et al. (2005)
Period: 1 9 9 5 -1 9 9 9  
Location: Boston, 
Massachusetts
Outcome: S V T  and V T  24 hour 
ECG )
Design: Panel
Sample: 57 males with C HD , 
age 5 2 -7 6  years
Outcome: Tachycardia 
Design: Panel
Sample: n=203 with ICDs, age 
1 9 -9 0  years
Outcome: ST-segm ent 
Design: Panel
Sample: n=24, age 6 1 -6 8  years
Outcome: CAR, VT  
Design: Panel
Sample: n=518 with ICDs, with 
>1 V T  event, age 1 5 -8 8  years
Outcome: V T  or fibrillation 
Design: Panel
Sample: n=100 with ICDs, mean 
age 62 years
Outcome: CAR  
Design: Case-crossover 
Sample: n=34 with >1 ICD  
discharge, age 1 5 -8 5  years
Outcome: VAR  
Design: Panel/Case-crossover 
Sample: n=203 with implanted 
ICDs
Avg time: 24 hours 
Mean: 0 .45 ppm 
Range: 0 .1 0 -1 .6 8  ppm
Avg time: 24 hours 
Median: 0.8 ppm 
25th-7 5 th%: 0 .5 3 -1 .0 2  ppm
Avg time: 5 hours 
Median: 0 .52 ppm 
10th-9 0 th%: 0 .2 0 -1 .0 8  ppm
Avg time: 1 hour 
Mean 1.7 ppm 
Range: 0 .1 -7 .7  ppm
Avg time: 24 hours 
Mean 0 .58 ppm 
25th-7 5 th%: 0.66 ppm
Avg time: 24 hours 
Mean: 0 .553 ppm 
Interquartile range: 0 .162 ppm
Avg time: 24 hours 
Median: 0 .78 ppm 
25th-7 5 th%: 0 .5 2 -1 .0 3
Increment: 0 .22 mg/m
R R  for S VT  (95%  CI), 5-day avg:
1.18 (1 .0 4 -1 .3 5 )
Increment: 0 .48 ppm
O R  for V T  (95%  CI), lag 2-day:
All: 1.14 (0 .9 5 -1 .2 9 )
A R  <3 days prior: 1.65 (1 .1 7 -2 .3 3 )
Significant association between C O  and 
ST-segm ent depression did not persist in multiple 
pollutant models
Increment: 1 ppm
O R  for V T  (95%  CI), lag 0 day:
All: 0 .999 (0 .9 7 0 -1 .0 2 8 )
Increment: 0.65 ppm
O R  for >10 defibrillated discharges (95%  CI):
Lag 3: 1.98 (1 .0 5 -3 .7 2 )
Lag 5-day avg: 1.94 (1 .0 1 -0 .7 5 )
No significant effect of C O  (quantitative results 
not reported)
Increment: 0.5 ppm
OR: (95%  C I), lag 0 -2  day): 1.11 (0 .8 8 -1 .4 0 ) 
(also not significant at other lags)
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Cardiovascular Disease
Study Design features CO exposure Effect size
Rich et al. (2006b)
Period: 2001 and 2002  
Location: St. Louis, Missouri
Rich et al. (2006a)
Period: 1 9 9 5 -1 9 9 9  
Location: Boston, 
Massachusetts
Sarnat et al. (2006)
Period: 2000
Location: Steubenville, Ohio
Vedal et al. (2004)
Period: 1 9 9 7 -2 0 0 0  
Location: Vancouver, Canada
Cardiac arrest
Levy et al. (2001) 
Period: 1 9 8 8 -1 9 9 4
Outcome: VAR  
Design: Case-crossover 
Sam ple description: n=60 with 
>1 ICD C AR  recorded
Outcome: AF
Design: Panel/ case-crossover 
Sample: n=203 with ICDs
Outcome: CAR  
Design: Panel
Sam ple 32 nonsmoking, age 53­
90 years
Outcome: CAR  
Design: Panel
Sample: n=50 with ICDs and 
>1 CAR event/4 years, age 12­
77 years
Outcome: Cardiac arrest 
Design: Case-crossover
Location: Seattle, Washington Sample: 362 cases, age 25 ­
75 years
Sullivan et al. (2003)
Period: 1 9 8 5 -1 9 9 4  
Location: Washington State
Outcome: Cardiac arrest 
Design: Case-crossover 
Sample: 1,542 cases, median 
age 69 years
Avg time: 24 hours 
Median: 0.5 ppm 
25th-7 5 th%: 0.6 ppm
Avg time: 24 hours 
Median: 0 .78 ppm 
25th-7 5 th%: 0 .5 2 -1 .0 3  ppm
Avg time: 24 hours 
Mean: 0 .02 ppm 
Range 0 -1 .5  ppm
Avg time: 24 hours 
Mean: 0.6 ppm 
Range: 0 .3 -1 .6  ppm
Avg time: 24 hours 
Mean: 1.79 ppm 
Range: 0 .5 2 -5 .9 2  ppm
Avg time: 24 hours 
Mean: 1.92 ppm 
Range: 0 .5 2 -7 .2 1  ppm
Increment: 0.2 ppm
O R  for VAR  (95%  CI), lag 0 -1  day: 0 .99 (0 .80­
1 .2 1 )
Increment: 0: 0 .58 ppm 
O R  for AF (95%  CI):
Lag 0: 0 .87 (0 .5 6 -1 .3 7 )
Lag 0 -2 3  hours: 0.71 (0 .3 9 -1 .2 8 )
Increment: 0.2 ppm
R R (95%  CI), 5-day moving avg:
SVE: 0.99 (0 .7 6 -1 .2 9 )
VE: 1.05 (0 .7 5 -1 .4 6 )
Increment: 0.2 ppm
No significant effect for C O  (results shown in 
plots)
RR (95%  CI), lag 1 day: 
0.99 (0 .8 3 -1 .1 8 )
Increment: 1.02 ppm 
O R  (95%  CI):
Lag 0 
Lag 1 
Lag 2
0.95 (0 .8 5 -1 .0 5 ) 
0.97 (0 .8 7 -1 .0 8 ) 
0.99 (0 .8 9 -1 .1 1 )
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Table 3-6. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Cardiovascular Disease
Study Design features CO exposure Effect size
Myocardial infarction
Peters et al. (2001) Outcome: Onset of MI Avg time: 24 hours Increment: 1 or 0.6 ppm
Period: 1 9 9 5 -1 9 9 6 Design: Case-crossover Mean: 1.09 ppm O R  (95%  CI):
Location: Boston, 
Massachusetts
Sample: 772 cases 5th-9 5 th%: 0 .4 9 -1 .7 8  ppm 2 hours: 1.22 (0 .8 9 -1 .6 7 ) per 1 ppm  
24 hours: 0 .98 (0 .7 0 -1 .3 6 ) per 0.6 ppm
Rosenlund et al. (2006) Outcome: MI Avg time: 30 years Increment: 300 pg/m3
Period: 1 9 9 2 -1 9 9 4 Design: Case-control Mean: 0 .058 ppm OR: (95%  CI):
Location: Stockholm, Sweden Sample: 1,397 cases, 1,870  
controls, age range 4 5 -7 0  years
5th-9 5 th%: 0 .0 1 2 -0 .2 5 8  ppm All cases: 1.04 (0 .8 9 -1 .2 1 )
Nonfatal: 0 .98 (0 .8 2 -1 .1 6 )
Fatal: 1.22 (0 .9 8 -1 .5 2 )
Fatal, in-hospital: 1.16 (0 .8 9 -1 .5 1 )  
Fatal, out-hospital: 1.36 (1 .0 1 -1 .8 4 )
Blood pressure
Ibald-Mulli et al. (2001) Outcome: SBP Avg time: 24 hours Increment: 5.6 mg/m3
Period: 1 9 8 4 -1 9 8 5 Design: Cohort Mean: 3.6 ppm Mean change in SBP, mmHg (95%  CI):
Location: Augsburg, Germ any Sample: n=2,607 men and 
women age 2 5 -6 4  years
Range: 1 .5 -7 .2  ppm All: 0 .53 (-0 .6 6 -1 .7 2 )  
Males: 0 .68 (-0 .9 4 -2 .3 1 )  
Females: 0.51 (-1 .3 1 -2 .1 9 )
Zanobetti et al. (2004b) Outcome: BP Avg time: 120 hours Increment: NR
Period: 1999-2001 Design: Cohort/Panel Mean: 0 .66 ppm RR: No significant effect of C O  on BP
Location: Boston, 
Massachusetts
Sam ple description: n=62, age 
3 9 -9 0  years
10th-9 0 th%: 0 .4 8 -0 .8 6  ppm
A F  =  a t r i a l  f i b r i l l a t i o n ;  A P  =  a n g i n a  p e c t o r i s ;  A R  =  a r r h y t h m i a ;  A v g  =  a v e r a g e ;  B P  =  b l o o d  p r e s s u r e ;  B P M  =  b e a t s  p e r  m i n u t e ;  C A D  =  c o r o n a r y  a r t e r y  d i s e a s e ;
C A R  =  c a r d i a c  a r r h y t h m i a ;  C I  =  c o n f i d e n c e  i n t e r v a l ;  C H D  =  c o r o n a r y  h e a r t  d i s e a s e ;  C O  =  c a r b o n  m o n o x i d e ;  E C G  =  e l e c t r o c a r d i o g r a m ;  H F V  =  h i g h  f r e q u e n c y  ( H R )  
v a r i a b i l i t y  p a r a m e t e r ;  H R  =  h e a r t  r a t e ;  H R V  =  h e a r t  r a t e  v a r i a b i l i t y ;  I C D  =  i m p l a n t a b l e  c a r d i o v e r t e r  d e f i b r i l l a t o r ;  L F V  =  l o w  f r e q u e n c y  ( H R )  v a r i a b i l i t y  p a r a m e t e r ;
M a x  =  m a x i m u m ;  M I  =  m y o c a r d i a l  i n f a r c t i o n ;  N R  =  n o t  r e p o r t e d ;  O R  =  o d d s  r a t i o ;  P N N 5 0  =  p r o p o r t i o n  o f  i n t e r v a l  d i f f e r e n c e s  o f  s u c c e s s i v e  n o r m a l - b e a t  i n t e r v a l s  g r e a t e r  
t h a n  5 0  m s  i n  E K G ;  r M S S D  =  r o o t  m e a n  s q u a r e d  d i f f e r e n c e s  b e t w e e n  a d j a c e n t  R R  i n t e r v a l s ;  R R  =  r e l a t i v e  r i s k ;  S B P  =  s y s t o l i c  b l o o d  p r e s s u r e ;  S D N N  =  s t a n d a r d  d e v i a t i o n  
n o r m a l - t o - n o r m a l  ( N N  o r  R R )  t i m e  i n t e r v a l  b e t w e e n  e a c h  Q R S  c o m p l e x  i n  t h e  E K G ;  S V E  =  s u p r a v e n t r i c u l a r  e c t o p y ;  S V T  =  s u p r a v e n t r i c u l a r  t a c h y c a r d i a ;  V A R  =  v e n t r i c u l a r  
a r r h y t h m i a ;  V L F V  =  v e r y  l o w  f r e q u e n c y  ( H R )  v a r i a b i l i t y  p a r a m e t e r  ; V E  =  v e n t r i c u l a r  e c t o p y ;  V T  =  v e n t r i c u l a r  t a c h y c a r d i a
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normal-to-normal interval (SDNN) yielded significant associations in some studies (Dales 2004;
Schwartz et al. 2005; Timonen et al. 2006) and not in others (Chan et al. 2005; Gold et al. 2000; Liao et 
al. 2004; Park et al. 2005b; Tarkiainen et al. 2003).
Three studies are particularly notable for their relatively large size. Park et al. (2005b) assessed HRV in 
497 male subjects (age range: 21-82 years) of the Boston Normative Aging Study and linked these data 
to local measurements of air pollutant concentrations (carbon monoxide, PM2.5, O3, NO2, SO2). The mean 
carbon monoxide exposure concentration was 0.50 ppm (24-hour average, range: 0.13-18 ppm). The 
study did not find significance between carbon monoxide exposure levels and HRV end points assessed 
(SDNN, low frequency [LF], high frequency [HF], LF/HF). A study conducted in Augsburg, Germany 
evaluated possible associations between exposures to total suspended particles (TSP), SO2, and carbon 
monoxide (mean: 4.5 mg/m3, range: 2.4-6.8 mg/m3) and HR in 2,681 adults (age range: 25-64 years; 
Peters et al. 1999). A 6.6 mg/m3 (5.8 ppm) increase in 24-hour average carbon monoxide concentration 
was associated with a small but significant increase in HR of approximately 1 beat per minute 
(0.97 beats/minute, 95% CI: 0.02-1.91); however, carbon monoxide exposure was not significantly 
associated with HR when based on a 5-day average exposure concentration (0.7 per 3.3 mg/m3, 95% CI: 
-0.09-1.58). A subsample of 6,232 adults (age range: 45-64 years) from the Atherosclerosis Risk in 
Communities (ARIC) study (Washington County, Maryland; Forsyth County, North Carolina; and 
selected suburbs of Minneapolis, Minnesota and Jackson, Mississippi) examined possible associations 
between exposure to carbon monoxide (mean: 0.65 ppm, standard deviation [SD]: 0.44) and HR and 
HRV, as well as to other air pollutants (PM10, O3, NO2, SO2; Liao et al. 2004). An increase in carbon 
monoxide exposure concentration of 0.44 ppm was associated with a small but significant, increase in HR 
of 0.4 beats per minute (standard error [SE]: 0.16, 95% CI: 0.09-0.7 [calculated from SE]). Carbon 
monoxide exposure was not significantly associated with HRV.
Studies of Arrhythmia. Studies of associations between exposure to carbon monoxide and cardiac 
arrhythmia (e.g., fibrillation, tachycardia) have yielded mixed results. Mean values of carbon monoxide 
exposure concentrations (i.e., averages over 1-5 days prior to the end point assessment) ranged from 
0.2 to 1.7 ppm, with the highest values <8 ppm. Significant associations between increasing carbon 
monoxide exposure and arrhythmia episode incidence were found in some studies, particularly when the 
analysis was restricted to subjects with prior recent arrhythmia (Berger et al. 2006; Dockery et al. 2005; 
Peters et al. 2000a), but not in other studies (Metzger et al. 2007; Rich et al. 2004, 2005; Sarnat et al. 
2006; Vedal et al. 2004). One of the larger studies examined associations between exposures to carbon 
monoxide (median: 0.8 ppm; 95th percentile: 1.37 ppm) and other air pollutants (e.g., PMJ0, PM25, O3,
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NO2, SO2) and ventricular arrhythmia episodes in 203 patients who were monitored with implanted 
defibrillators (ICDs) and who had prior episodes of ventricular tachycardia (Dockery et al. 2005; Rich et 
al. 2005). In the total sample, exposure to carbon monoxide was not significantly associated with 
ventricular arrhythmia; however, when restricted to patients who had experienced arrhythmias within the 
3 days of the exposure assessment, increasing carbon monoxide exposure of 0.48 ppm was significantly 
associated ventricular arrhythmia (odds ratio: 1.65; 96% CI: 1.17-2.33). A larger study examined 
512 patients (age range: 15-88 years) exposed to a mean carbon monoxide concentration of 1.7 ppm 
(range: 0.1-7.7 ppm) and did not find a significant association with defibrillator discharges and carbon 
monoxide exposure concentration (Metzger et al. 2007).
Studies that have assessed arrhythmias from electrocardiogram (ECG) measurements have also yielded 
mixed results (Berger et al. 2006; Sarnat et al. 2006). A study of 57 coronary heart disease patients (age 
range: 52-76 years) found a significant association between increasing carbon monoxide exposure and 
risk of supraventricular tachycardia (Berger et al. 2006). Mean carbon monoxide exposure concentration 
was 0.52 mg/m3 (0.45 ppm; range: 0.11-1.93 mg/m3). The relative risk for a 0.27 mg/m3 (0.24 ppm) 
increase in carbon monoxide was 1.18 (95% CI: 1.04-1.35). A significant association between carbon 
monoxide exposure and ventricular tachycardia was not evident. Sarnat et al. (2006) did not find a 
significant association between carbon monoxide exposure concentrations (mean: 0.2 ppm, range: 0.1­
1.5) and arrhythmia in a sample of 32 adults (age range: 53-90 years). The study did find significant 
associations between increased blood pressure and other air pollutants (e.g., PM25, SO2, O3, back carbon).
Studies of Ischemic Heart Disease. Numerous studies have examined possible associations between 
carbon monoxide exposure and ischemic heart disease (Tables 3-6 and 3-7). Although results have been 
mixed, most studies, in particular those that have examined hospital admissions or emergency room visits 
as the health outcome, have found increased risk association with increased ambient air carbon monoxide 
concentrations. A case-control study of myocardial infarction (1,397 cases, 1,870 controls) conducted in 
Sweden, did not find a significant association with carbon monoxide exposure (Rosenlund et al. 2006). 
Exposure concentrations were estimated from emissions data and air dispersion modeling; the mean was 
61.8 ^g/m3 (0.067 ppm; 5th-95th percentile range: 14-296 ^g/m3; predicted steady-state COHb%: <0.3). 
Odds ratio for myocardial infarct for a 300 ^g/m3 (0.3 ppm) increase in 30-year average carbon monoxide 
concentration was 1.04 (95% CI: 0.89-1.21). When restricted to out-of-hospital deaths, the odds ratio 
was 1.36 (95% CI: 1.01-1.84). A smaller case-crossover study (772 cases) conducted in Boston, 
Massachusetts did not find a significant association between carbon monoxide exposure and myocardial 
infarction (Peters et al. 2001). The odds ratio for 1 ppm increment in carbon monoxide exposure
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Table 3-7. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Hospital Admissions and Emergency Department Visits Related to Cardiovascular Disease
Study Design features CO exposure Effect size
Ischemic heart disease
D ’Ippoliti et al. (2003) 
Period: 1 9 9 5 -1 9 9 7  
Location: Rom e, Italy
Hosseinpoor et al. (2005) 
Period: 1996 -2001  
Location: Tehran, Iran
Lanki et al. (2006)
Period: 1 9 9 4 -2 0 0 0  
Location: Helsinki, Rome, 
Stockholm
Lee et al. (2003b)
Period: 1 9 9 7 -1 9 9 9  
Location: Seoul, Korea
Maheswaran et al. (2005b) 
Period: 1 9 9 4 -1 9 9 8  
Location: Sheffield, United 
Kingdom
Mann et al. (2002)
Period: 1 9 8 8 -1 9 9 5  
Location: California
Outcome: MI HAs 
Design: Case-crossover 
Sample: n =6 ,531 , ages >18 years
Outcome: AP HAs 
Design: Tim e series 
Sample: n=1,826
Outcome: MI HAs 
Design: Tim e series 
Sample: 26 ,854  admissions, 
age >35 years
Outcome: IHD, MI, AP HAs 
Design: Tim e series 
Sample: ~10 ,000  HAs
Avg time: 24 hours 
Mean: 3.8 ppm 
25th- 7 5 th%: 2 .4 -3 .8  ppm
Avg time: 24 hours 
Mean: 9.4 ppm 
Range: 1 .4 -5 0 .5  ppm
Avg time: 24 hours 
Median: 0 .4 -2 .3  ppm  
75th% Range: 0 .5 -2 .9  ppm
Avg time: Daily maximum  
Mean: 1.8 ppm 
25th- 7 5 th%: 1 .2 -2 .2  ppm
Outcome: IHD HAs 
Design: Ecological 
Subjects: 11,407 admissions, age 
> 45 years
Outcome: IHD, MI HAs 
Design: Tim e series 
Sample: 54 ,863  HAs
Avg time: NR
20th- 8 0 th% : 0 .3 4 -0 .4 0  ppm
Avg time: 8 hours 
Mean: 2 .07  ppm  
Range: 0 .3 0 -1 1 .8  ppm
Increment: 1 mg/m  
O R  (95%  CI), lag 0 -2  days:
C O  alone: 1.044 (1 .0 0 0 -0 .0 8 9 )
C O  with TSP: not significant
Increment: 1 mg/m (0.87 ppm)
RR (95%  C I), lag 1 day:
C O  alone: 1.0096 (1 .0 0 6 0 -1 .0 1 3 2 )
C O  with N O 2, O 3, and P M 10: 1.0093 (1 .0036­
1.0151)
Increment: 0.2 mg/m3 
RR (95%  C I), lag 0 day:
All: 1.007 (1 .0 0 1 -1 .0 1 2 )
Fatal (<75 years): 1.027 (1 .0 0 6 -1 .0 4 8 )
Increment: 1 ppm 
RR (95%  C I), lag 5 days:
All year, all ages: 0 .94 (0 .9 1 -0 .9 8 )
All year, >64 years: 1.07 (1.01 -1 .1 3 )
Sum mer, all ages: 1.19 (1 .0 2 -1 .3 8 )
Sum mer, >64 years: 1.60 ( 1 .2 7 -2 .0 3 )
All year, >64 years (with P M 10): 1.04 (0 .9 8 -1 .1 1 )
Increment: 5th vs. 1st quintile
RR, adjusted for sex, age, deprivation, smoking
(95%  CI):
0.88 (0 .7 9 -0 .9 8 )
Increment: 1 ppm
% Change (95%  C I), lag 0 day:
with arrhythmia: 2 .99  (1 .8 0 -4 .9 9 )
with CHF: 3 .60 (1 .6 2 0 -5 .6 3 )
without secondary diagnosis: 1.62 (0 .6 5 -2 .5 9 )
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Table 3-7. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Hospital Admissions and Emergency Department Visits Related to Cardiovascular Disease
Study Design features CO exposure Effect size
Szyszkowicz (2007) 
Period: 1 9 9 7 -2 0 0 3  
Location: Montreal
von Klot et al. (2005) 
Period: 1992-2001  
Location: 5 European cities
Stroke
Chan et al. (2006) 
Period: 1 9 9 7 -2 0 0 2  
Location: Taipei, Taiwan
Henrotin et al. (2007) 
Period: 1 9 9 4 -2 0 0 4  
Location: Dijon, France
Maheswaran et al. (2005b) 
Period: 1 9 9 4 -1 9 9 8  
Location: Sheffield, United 
Kingdom
Outcome: IHD EDVs  
Design: Tim e series 
Sample: 4 ,979  EDVs
Avg time: 24 hours 
Mean: 0.5 ppm 
Range: 0 .1 -3 .1  ppm
Outcome: MI, AP, CAR, HF, HAs Avg time: 24 hours
Design: Prospective cohort 
Sample: 22 ,006  survivors of first 
MI
Outcome: Stroke EDVs  
Design: Tim e series 
Sample: 7,341 EDVs, age 50­
100 years
Outcome: Stroke HAs 
Design: Case-crossover 
Sample: 1,707 cases, age: 
>40 years
Outcome Stroke HAs 
Design: Ecological 
Sample: 11 ,407 HAs, age 
>45 years
Mean: 0 .3 7 -0 .8 7  ppm
Avg time: 8 hours 
Mean: 1.7 ppm 
Range: 0 .6 -4 .4  ppm
Avg time: 24 hours 
Mean: 0 .60 ppm  
Range: 0 -3 .5  ppm
Avg time: NR
20th- 8 0 th% : 0 .3 4 -0 .4 0  ppm
Increment: 0.2 ppm  
% Change (95%  C I), lag 0 day:
All: 5 .4 (2 .3 -8 .5 )
Males: 7.5 (3 .6 -1 1 .6 )
Females: 2.7 ( -2 .0 -  7.6)
All: >64 years: 4.9 (1 .3 -8 .7 )
Males: >64 years: 7.5 (2 .6 -1 2 .6 )
Females: >64 years: 0: 2.4 (-3 .0  to 0.0)
3
Increment: 0.2 mg/m  
RR (95%  C I), lag 0 day:
MI: 1.022 (0 .9 9 8 -0 .0 4 7 )
AP: 1.009 (0 .9 9 2 -0 .0 2 )
Any cardiac: 1.014 (1 .0 0 1 -0 .0 2 6 )
Increment: 0.8 ppm  
O R  (95%  CI), lag 2 days:
All: 1.03 (1.01, 1.06)
Stroke: 1.03 (1.01, 1.05)
Significant after adjustment for O 3, PM 2.5, P M 10 
3
Increment: 10 ^g/m  
O R  (95%  CI), lag 0 day:
Ischemic: 0.999 (0 .9 9 7 -1 .0 0 1 )
Hemorrhagic: 1.000 (0 .9 9 6 -1 .0 0 4 )
Other lags not significant
Increment: 5th vs. 1st quintile
RR (95%  CI) adjusted for sex, age, deprivation,
smoking: 1.11 (0 .9 9 -1 .2 5 )
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Table 3-7. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Hospital Admissions and Emergency Department Visits Related to Cardiovascular Disease
Study Design features CO exposure Effect size
Tsai et al. (2003)
Period: 1 9 9 7 -2 0 0 0  
Location: Kaohsiung, Taiwan
Villeneuve et al. (2006a) 
Period: 1 9 9 2 -2 0 0 2  
Location: Edmonton, Canada
Wellenius et al. (2005a) 
Period: NR  
Location: 9 U.S. cities
Heart failure
Lee et al. (2007a)
Period: 1 9 9 6 -2 0 0 4  
Location: Kaohsiung City, 
Taiwan
Symons et al. (2006)
Period: 2002
Location: Baltimore, Maryland
Wellenius et al. (2005b) 
Period: 1 9 8 7 -1 9 9 9  
Location: Pennsylvania
Outcome: Stroke HAs 
Design: Case-crossover 
Statistical analyses: NR  
Sample: 23 ,192  HAs
Outcome: Stroke EDVs)
Design: Case-crossover 
Sample: 12 ,422 EDVs, age 
>65 years
Outcome: Stroke EDVs  
Design: Tim e series 
Sample: 155,503 EDVs, age 
>65 years
Outcome: C H F HAs 
Design: Case-crossover 
Sample Description: 13 ,475 HAs
Outcome: C H F HAs, symptom  
exacerbation 
Design: Case-crossover 
Sample: 125 cases, median age 
70 years
Outcome: C H F HAs 
Design: Case-crossover 
Sample: 54 ,019  HAs, age 
>65 years
Avg time: 24 hours 
M ean 0 .79 ppm 
Range: 0 .2 4 -1 .7 2  ppm
Avg time: 24 hours 
Mean: 0.8 ppm 
25th- 7 5 th%: 0 .5 -1 .0  ppm
Avg time: NR  
Median: 1.02 ppm 
25th- 7 5 th%: 0 .7 3 -1 .4 4  ppm
Avg time: 24 hours 
Mean: 0 .76 ppm  
Range: 0 .1 4 -1 .7 2  ppm
Avg time: 24 hours 
Mean: 0.4 ppm 
Range: 0 .1 -1 .0  ppm
Avg time: 24 hours 
Mean: 1.03 ppm  
25th- 7 5 th%: 0 .6 8 -1 .2 3  ppm
Increment: 0.8 ppm  
O R  (95%  CI), lag 0 -2  days:
>20°C: 1.21 (1 .1 4 -1 .2 8 )
<20°C: 1.77 (1 .3 1 -2 .3 9 )
Significant O R  when adjusted for P M 1 0 , S O 2 , or 
O 3
Increment: 0.5 ppm 
O R  (95%  CI), lag 0 -2  days:
April— September: 1.32 (1.09, 1.60) (not 
significant for all seasons)
Increment: 0.71 ppm 
% Change (95%  CI) lag 0 days:
Ischemic: 2 .83 (1 .2 3 -4 .4 6 )
Hemorrhagic: -1.61 (-4 .7 9 -1 .6 8 )
Increment: 0.31 ppm 
O R  (lag 0 -2  days):
>25 °C: 1.19 (1 .0 9 -1 .3 1 )
<25 °C: 1.39 ( 1 .2 4 -1 .5 4 )
Significant when adjusted for P M 10 , N O 2 , S O 2 , or 
O 3
Increment: 0.2 ppm 
O R  (95%  CI), lag 1 day:
Avg: 0 .90 (0 .7 0 -1 .1 7 )
Cumulative: 0.82 (0 .6 0 -1 .1 3 )
Other lags not significant 
Increment: 0 .55 ppm 
% Change (85%  C I), lag 0 day:
4 .55 (3 .3 3 -5 .7 9 )
Significant when adjusted for N O 2 P M 10, N O 2 , 
S O 2 , or O 3
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Table 3-7. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Hospital Admissions and Emergency Department Visits Related to Cardiovascular Disease
Study Design features CO exposure Effect size
Miscellaneous cardiovascular disease
Ballester et al. (2001)
Period: 1 9 9 4 -1 9 9 6  
Location: Valencia, Spain
Ballester et al. (2006) 
Period: 1 9 9 5 -1 9 9 9  
Location: 14 Cities in Spain
Barnett et al. (2006)
Period: 1998 -2001  
Location: Australia, 
Auckland, New  Zealand
Chang et al. (2005) 
Period: 1997 -2001  
Location: Taipei, Taiwan
Fung et al. (2005)
Period: 1 9 9 5 -2 0 0 0  
Location: Windsor, Ontario, 
Canada
Jalaludin et al. (2006) 
Period: 1997-2001  
Location: Sydney, Australia
Outcome: HD, C BVD  EDVs  
Design: Tim e series 
Sample: >9 ,000  EDVs
Outcome: HD, C VD  HAs 
Design: Tim e series 
Sample: >250 ,000  HAs
Outcome: C VD  HAs 
Design: Case-crossover 
Sample: age >15 years
Outcome: C VD  HAs 
Design: Case-crossover 
Sample 74,509 HAs
Outcome: C VD  HAs 
Design: Tim e series 
Sample: 11 ,632 HAs
Outcome: C VD  EDVs  
Design: Tim e series 
Sample: >100 ,000  EDVs, age 
>65 years
Avg time: 1 hour 
Mean: 5.4 ppm 
Range: 0 .5 -1 5 .5  ppm
Avg time: 8 hours 
Mean: 1 .2 -2 .4  ppm 
10th% Range: 0 .3 -1 .5  ppm 
90th% Range: 1 .7 -3 .4  ppm
Avg time: 8 hours 
Mean: 0 .5 -2 .1  ppm 
Range: 0 .0 -7 .9  ppm
Avg time: 24 hours 
Mean: 1.37 ppm  
Range: 0 .3 7 -3 .6 6  ppm
Avg time: 24 hours 
Mean: 1.3 ppm 
Range: 0 .0 -1 1 .8  ppm
Avg time: 8 hours 
Mean 0 .82 ppm 
Range: 0 .0 2 -4 .6 3  ppm
Increment: 1 mg/m  
RR (95%  CI):
All, lag 2: 1 .0077 (0 .9 9 1 2 -1 .0 1 3 8 )
HD, lag 1: 1 .0092 (0 .9 9 4 5 -1 .0 2 4 2 )
CBV, lag 1: 0 .9874 (0 .9 6 4 6 -1 .0 1 0 7 )
Increment: 1 mg/m  
% Change (95%  C I), lag 0 -1  day:
CVD: 2 .06 (0 .6 5 -3 .4 8 )
HD: 4 .15  (1 .3 1 -7 .0 8 )
Increment: 0.9 ppm  
% Change (95%  CI) lag 0 -1  day:
Lags examined (days): 0 -1  
1 5 -6 4  years
CVD , <65 years: 1.2 (0 .3 -2 .1 )
CVD , >65 years: 2 .2  (0 .9 -3 .4 )
Significant when adjusted for N O 2 or P M 10
Increment: 0 .49 ppm 
O R  (95%  CI) lag 0 -2  day:
>20°C: 1.090 (1 .0 6 4 -1 .1 1 8 )
<20°C: 0 .984 (0 .9 2 7 -1 .0 4 4 )
Significant when adjusted for P M 10 , N O 2 , S O 2 , or 
O 3
Increment: 1.2 ppm 
% Change (95%  C I), lag 0 -2  day:
<65 years: -0 .5  (-6 .7 -6 .0 )
>65 years: 2 .8  (-1 .1 -7 .0 )
Increment: 0 .69 ppm 
% Change (95%  C I), lag 0 -1  day:
2 .35 (1 .3 9 -3 .3 2 )
Significant when adjusted for P M 10 , N O 2 , S O 2 , or 
O 3
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Table 3-7. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Hospital Admissions and Emergency Department Visits Related to Cardiovascular Disease
Study Design features CO exposure Effect size
Koken et al. (2003)
Period: 1 9 9 3 -1 9 9 7  
Location: Denver, Colorado
Linn et al. (2000)
Period: 1 9 9 2 -1 9 9 5  
Location: Los Angeles, 
California
M etzger et al. (2004) 
Study: 1 9 9 3 -2 0 0 0  
Location: Atlanta, Georgia
Peel et al. (2007)
Period: 1 9 9 3 -2 0 0 0  
Location: Atlanta, Georgia
Yang et al. (2004a) 
Period: 1 9 9 7 -2 0 0 0  
Location: Kaohsiung City, 
Taiwan
Outcome: C VD  HAs Avg time: 24 hours
Design: Tim e series Mean: 0.9 ppm
Sample: >4000 HAs, age 65 years Range: 0.3, 1 .6 ppm
Outcome: C VD , C BVD HAs 
Design: Tim e series 
Sample: >500 ,000  HAs, age 
>30 years
Outcome: Cardiovascular: CVD  
EDVs
Design: Tim e series 
Sample: 4 ,407 ,535  EDVs
Outcome: C VD  EDVs  
Design: Case-crossover 
Sample: 4 ,407 ,535  EDVs
Outcome: C VD  HAs 
Design: Case-crossover 
Sample: 29,661 HAs
Avg time: 24 hours 
Mean 1 .0 -2 .0  ppm 
Range: 0 .2 -5 .3  ppm
Avg time: 1 hour 
Median: 1.5 ppm 
10th- 9 0 th% : 0 .5 -3 .4  ppm
Avg time: 1 hour 
Mean: 1.8 ppm 
SD: 1.2 ppm
Avg time: 24 hours 
Mean: 0 .79 ppm  
Range 0 .2 4 -1 .7 2  ppm
Increment: 0.3 ppm  
% Change (95%  CI) lag 3 day:
CHF: 10.5 (0 .1 -2 2 .0 )
C O  not significantly associated with other C VD  
categories.
Increment: 1 ppm
Poisson regression coefficient (SE), lag 0 day: 
CVD , all: 0 .032  (0 .003) (p<0.05)
Significant for AR, C BVD, C HF, MI, stroke p<0.05
Increment: 1 ppm 
RR (95%  C I), lag 0 -2  day:
All CVD: 1.017 (1 .0 0 8 -1 .0 2 7 )
PVD /C B VD : 1.031 (1 .0 1 0 -1 .0 5 2 )
Not significant for AR. C H F, IHD categories
Increment: 1.2 ppm  
O R  (95%  CI), lag 0 -2  day:
1.020 (1 .0 1 0 -1 0 .0 3 0 )
ORs for specific C VD  categories tended to 
increase with co-diagnoses of HT, AR, CHF, 
C O PD
Increment: 0 .28 ppm 
O R  (95%  CI), lag 0 -2  day:
>25 °C: 1.264 (1 .2 0 5 -1 .3 2 6 )
<25 °C: 1.448 (1 .3 5 7 -1 .5 4 5 )
Significant when adjusted for P M 10 , N O 2 , S O 2 , or 
O 3
A P  =  a n g i n a  p e c t o r i s ;  A R  =  a r r h y t h m i a ;  A v g  =  a v e r a g e ;  C A R  =  c a r d i a c  a r r h y t h m i a ;  C B C D  =  c e r e b r o v a s c u l a r  d i s e a s e ;  C H F  =  c o n g e s t i v e  h e a r t  f a i l u r e ;  C I  =  c o n f i d e n c e  
i n t e r v a l ;  C O  =  c a r b o n  m o n o x i d e ;  C O P D  =  c h r o n i c  o b s t r u c t i v e  p u l m o n a r y  d i s e a s e ;  C V D  =  c a r d i o v a s c u l a r  d i s e a s e ;  E D V  =  e m e r g e n c y  d e p a r t m e n t  v i s i t ;  H A  =  h o s p i t a l  
a d m i s s i o n ;  H F  =  h e a r t  f a i l u r e ;  H T  =  h y p e r t e n s i o n ;  I H D  =  i s c h e m i c  h e a r t  d i s e a s e ;  M I  =  m y o c a r d i a l  i n f a r c t i o n ;  N R  =  n o t  r e p o r t e d ;  O R  =  o d d s  r a t i o ;  P V D  =  p e r i p h e r a l  v a s c u l a r  
d i s e a s e ;  R R  =  r e l a t i v e  r i s k ;  S D  =  s t a n d a r d  d e v i a t i o n ;  S E  =  s t a n d a r d  e r r o r
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concentration, for 2-hour period prior to infarct, was 1.22 (95% CI: 0.89-1.67); the mean carbon 
monoxide exposure concentration was 1.09 (5th-95th percentile range: 0.49-1.78 ppm, predicted steady- 
state COHb%: <0.55).
Possible associations between carbon monoxide exposure (and other air pollutants; e.g., PM, NO2, O3) 
and ischemic heart disease have also been explored in studies of hospital admissions and/or hospital 
emergency department visits (D’Ippoliti et al. 2003; Hosseinpoor et al. 2005; Lanki et al. 2006; Lee et al. 
2003b; Maheswaran et al. 2005b; Mann et al. 2002; Szyszkowicz 2007; von Klot et al. 2005). Although 
results have been mixed, most studies have found significant associations between increasing carbon 
monoxide exposure concentration and ischemic heart disease-related admissions or emergency room 
visits (Table 3-7). These included increased odds (or relative risk) for hospital admissions for angina 
pectoris, myocardial infarction, and aggregated ischemic heart disease categories (D’Ippoliti et al. 2003; 
Hosseinpoor et al. 2005; Lanki et al. 2006; Lee et al. 2003b; Mann et al. 2002; Szyszkowicz 2007; von 
Klot et al. 2005). Mean air carbon monoxide concentrations in these studies ranged from approximately 
0.4-2 ppm, with the upper percentiles (i.e. >75th) ranged from approximately 1 to 5 ppm, although one 
study reported a mean of 10.8 mg/m3 and maximum of 57.9 mg/m3 (approximately 50 ppm; Hosseinpoor 
et al. 2005). Associations with carbon monoxide tended to be stronger for more elderly males than for 
females or other age strata (e.g., Lee et al. 2003b; Szyszkowicz 2007). Risks were higher when ischemic 
heart disease was accompanied by a diagnosis of arrhythmia or congestive heart failure (Mann et al. 2002; 
see further discussion of carbon monoxide associations with congestive heart failure, below). Lee et al. 
(2003b) found a significant association (1997-1999) between ischemic heart disease-related hospital 
admissions in Seoul, Korea, and carbon monoxide exposure concentrations among males >64 years of 
age, but not for females or other age strata. A 1 ppm increase in carbon monoxide concentration was 
associated with a relative risk of 1.07 (95% CI: 1.01-1.1) for hospital admission. The mean daily 1-hour 
maximum carbon monoxide concentration was 1.8 ppm (25th-75th percentile range: 1.2-2.2 ppm). The 
association with carbon monoxide exposure was not significant after adjustment for exposure to PM10 in a 
two-pollutant model (1.04. 95% CI: 0.98-1.11). Two-pollutant models with carbon monoxide and other 
gaseous pollutants were not reported, although significant associations were found when NO2, O3, or SO2 
were considered alone. Szyszkowicz (2007) examined records of 4,979 emergency room visits in 
Montreal, Canada for the period 1997-2002. The percent increase in visits related to ischemic heart 
disease for a 0.2 ppm increase in carbon monoxide concentration was 5.4% (95% CI: 2.3-8.5) for all 
patients, 7.5% (2.6-12.6) for males >64 years, and 2.4 (-3.0-0.0) for females >64 years. The mean 
carbon monoxide exposure concentration was 0.5 ppm (range: 0.1-3.1 ppm). Two other studies 
examined ischemic heart disease end points in multiple-pollutant models. Hosseinpoor et al. (2005)
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found that the relative risk for hospital admissions in related for angina pectoris (1,826 cases; Tehran,
Iran; 1996-2001) was 1.044 (95% CI: 1.000-0.089) when air carbon monoxide concentrations were 
considered in a carbon monoxide model, and 1.0093 (95% CI: 1.0036-1.0151) when the model was 
adjusted for PM10, O3, and NO2. Air carbon monoxide concentrations examined in this study were 
relatively high, compared to other studies (mean 10.8 ppm; range: 1.6-58 ppm). A study conducted in 
Rome, Italy examined records of 6,351 hospital admissions (1995-1997) for myocardial infarction and 
found a significant association between increasing air carbon monoxide concentration and increasing odds 
of hospital admission (odds ratio: 1.004, 95% CI: 1.000-0.089), which did not persist when adjusted for 
total suspended solids (D’Ippoliti et al. 2003). The mean air carbon monoxide concentration was 3.8 ppm 
(25th-75th percentile range: 2.4-3.7 ppm).
Studies of Stroke. Possible associations between ambient air carbon monoxide concentrations and stroke 
have been examined in studies of hospital admissions and emergency room visits (Chan et al. 2006; 
Henrotin et al. 2007; Maheswaran et al. 2005b; Tsai et al. 2003b; Villeneuve et al. 2006a; Wellenius et al. 
2005a; Table 3-7). Although results of these studies have been mixed, several studies have found 
significant associations between stroke admissions and/or emergency room visits, and increasing air 
carbon monoxide concentrations (Chan et al. 2006; Tsai et al. 2003b; Villeneuve et al. 2006a; Wellenius 
et al. 2005a). Studies that explored two-pollutant models found that the associations persisted after 
adjustment for PM10, SO2, or O3 (Chan et al. 2006; Tsai et al. 2003b). Mean air carbon monoxide 
concentrations in these studies ranged from 0.4 to 1.7 ppm and the highest reported value was <5 ppm. 
The largest study was a time-series analysis of ambient air carbon monoxide concentrations and 
155,503 records of stroke-related emergency room visits in nine U.S. cities (Wellenius et al. 2005a). The 
study found that a 0.71 ppm increase in ambient air carbon monoxide concentration was associated with a 
2.83% (95% CI: 1.23-4.46) increase in daily rate of emergency room visits for ischemic stroke. Chan et 
al. (2006) conducted a time-series analysis of ambient air carbon monoxide concentrations in Taipei, 
China (1997-2002) and emergency room visits related to cerebrovascular disease, including stroke 
(n=7,341), and found a significant odds ratio for a 0.8 ppm increase in air carbon monoxide 
concentration, for all cerebrovascular disease (1.03, 95% CI: 1.01-1.06) and stroke (1.03, 95% CI: 1.01­
1.05), which remained significant after adjusting for O3, PM25 and PM10 or PM25 (1.034, 95% CI: 1.001­
1.067). A larger study conducted in Kaohsiung, China (1997-2000) examined records of 23,192 hospital 
visits for stroke in a case-crossover design and found significant odds ratios for a 0.8 ppm increase in 
carbon monoxide concentration (1.77, 95% CI: 1.31-2.39), which also persisted after adjustment for SO2, 
O3, or PMio (Tsai et al. 2003b).
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Studies of Other Cardiovascular Outcomes. Two case-control (i.e., case crossover) studies conducted in 
Seattle, Washington have examined possible associations between ambient carbon monoxide 
concentrations and cardiac arrest did not find significant associations (Levy et al. 2001; Sullivan et al. 
2003; Table 3-6). The mean carbon monoxide exposure concentration (both studies) was 1.7 ppm, with 
the highest value reported as 5.9 ppm. The study reported by Levy et al. (2001) included 362 cases out- 
of-hospital cardiac arrests (1988-1994); the relative risk for a 1-day lag between exposure estimate and 
outcome was 0.88 (95% CI: 0.83-1.18). The Sullivan et al. (2003) study examined 1,542 cases of out- 
of-hospital cardiac arrest cases (1985-1994); the odds ratio for a 1.02 ppm increase in carbon monoxide 
concentration (1 day lag) was 0.97 (95% CI: 0.87-1.08).
Possible associations between air carbon monoxide concentrations and cardiac failure (primarily, 
congestive heart failure) have also been examined in studies of hospital admissions (Lee et al. 2007a; 
Symons et al. 2006; Wellenius et al. 2005b; Table 3-6). The larger of the these studies examined 
13,475 hospital admissions for congestive heart failure in Kaohsiung, China (1996-2004) and found a 
significant odds ratios for hospital admission associated with a 0.31 ppm increase in air carbon monoxide 
concentration (odds ratio: 1.39, 95% CI: 1.24-1.54). The odds ratio remained significant in two- 
pollutant models that adjusted for PM10, NO2, SO2, or O3.
Studies of possible associations between carbon monoxide exposure and abnormal blood pressure have 
not found significant associations (Ibald-Mulli et al. 2001; Zanobetti et al. 2004b; Table 3-6). The Ibald- 
Mulli et al. (2001) study included 2,607 men and women (age range 25-64 years) in the Augsburg, 
Germany area; the mean carbon monoxide exposure concentration was approximately 3.6 ppm and the 
upper end of the range was 7.2 ppm. The estimated increment in systolic blood pressure for 4.9 ppm 
increase in carbon monoxide concentration was a 1.06 (95% CI: -0.17-2.29). The Zanobetti et al. 
(2004b) study measured blood pressure in repeated examinations of 62 subjects, and found no association 
between blood pressure and carbon monoxide exposure concentrations (90th percentile concentration 
<1.2 ppm).
Several studies have evaluated more generic cardiovascular disease outcomes, for example, hospital 
admissions or emergency room visits for any cardiovascular disease (Ballester et al. 2001, 2006; Barnett 
et al. 2006; Chang et al. 2005; Fung et al. 2005; Jalaludin et al. 2006; Koken et al. 2003; Linn et al. 2000; 
Metzger et al. 2004; Peel et al. 2007; Yang et al. 2004a; Table 3-7). Here again, although results have 
been mixed, most studies have found significant associations between increased rate of hospital 
admissions or emergency room visits and increased air carbon monoxide concentrations. The association
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was stronger for older subjects (e.g., >64 years, Barnett et al. 2006) and in several studies that examined 
multi-pollutant models, the association persisted after adjustment for PM10, NO2, SO2, or O3 (Chang et al. 
2005; Jalaludin et al. 2006; Yang et al. 2004a). Mean air carbon monoxide concentrations in these studies 
ranged from 0.8 to 6 ppm, with the highest value <18 ppm.
Animal Studies. Although clinical studies in patients with coronary artery disease provide compelling 
evidence of adverse cardiovascular effects of acute-duration exposure to carbon monoxide, these studies 
are limited with respect to exposure conditions and outcomes assessed. Studies in animals, however, have 
investigated adverse cardiovascular effects of carbon monoxide exposure over a much wider range of 
exposure conditions (e.g., exposure concentration and duration) and have evaluated additional outcome 
measures that are not possible to assess in humans. In general, animal studies evaluated carbon monoxide 
exposures resulting in higher COHb levels than those evaluated in clinical studies in patients and healthy 
volunteers. Results of animal studies provide evidence of adverse cardiovascular effects of carbon 
monoxide exposure, including compensatory alterations in hemodynamics, cardiac hypertrophy, cardiac 
arrhythmias, and possibly atherosclerosis. For most outcomes evaluated in animal studies, conflicting 
evidence has been reported. Although the reasons for different results have not been established, 
differences in species sensitivity, exposure regimens, and experimental protocols are possible factors. 
Animal studies published prior to 2000 have been reviewed in detail by EPA (1991, 2000); therefore, 
these reviews largely form the basis of the following discussions for animals studies published prior to 
2000.
Studies investigating the effects of acute-duration carbon monoxide exposure on hemodynamics have 
been conducted in several animal species, including monkeys, dogs, rats, and rabbits, under exposure 
conditions producing blood COHb levels ranging from 6.2 to 70% (EPA 1991, 2000). Results show that 
brief exposure (from a few minutes to approximately 3 hours) to carbon monoxide at concentrations of 
80-20,000 ppm produces alterations in hemodynamics that are consistent with COHb-induced hypoxia 
and responsive compensatory mechanisms (e.g., vasodilation and increased cardiovascular output), 
including increased coronary blood flow, decreased myocardial O2 consumption, increased heart rate, and 
alterations in blood flow to various vascular beds (e.g., cerebral, limb muscular). Generally, carbon 
monoxide-induced effects on hemodynamics were observed at blood COHb levels >7.5%. With longer 
exposure durations, COHb-induced tissue hypoxia and subsequent compensatory increases in heart rate 
and cardiac workload lead to the development of cardiomyopathy. Several studies confirm carbon 
monoxide-induced cardiomegaly in rats and rabbits exposed to 160-11,000 ppm carbon monoxide 
(COHb 12-58%) for intermediate durations (14 days to ~6 months) (EPA 1991, 2000). In rats exposed
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chronically to 200 ppm carbon monoxide (COHb 14.7%) for 20 hours/day for 72 weeks, left and right 
ventricle weights increased by 20% (p<0.001) and 14% (p<0.001), respectively (S0rhaug et al. 2006). 
Studies evaluating developmental cardiovascular effects are reviewed in Section 3.2.6 (Developmental 
Effects).
Alterations in cardiac rhythm, possibly due to disturbances in cardiac conduction, have been observed in 
animals exposed to carbon monoxide for acute to intermediate durations (EPA 1991, 2000). Under 
conditions of simulated myocardial ischemia (i.e. coronary artery ligation), acute exposure (up to 
15 minutes) of dogs to up to 5,000 ppm carbon monoxide (COHb 4.9-15%) enhanced myocardial 
ischemia, as indicated by ST-segment alterations, and severity of myocardial injury. Results of a recent 
study in rats exposed to 50 ppm carbon monoxide (COHb not reported) for 1 week indicate that rats with 
pulmonary hypertension may be more sensitive to carbon monoxide-induced myocardial ischemia 
(Gautier et al. 2007). However, in other studies simulating myocardial injury in dogs exposed to 100­
500 ppm carbon monoxide for 6-120 minutes (COHb 5.1-20%), cardiac arrhythmias or alterations in 
cardiac conduction speed were not observed. In studies evaluating intermediate-duration (6-24 weeks) 
exposure of dogs and monkeys, 100 ppm carbon monoxide (COHb 2.6-12%) induced cardiac 
arrhythmias, including R-wave depression, ST-segment elevation, increased T-wave, preventricular 
contractions, and reduced threshold for stimulus-induced ventricular fibrillation. In contrast, no evidence 
of cardiac arrhythmias was observed in dogs exposed continuously to 50 ppm carbon monoxide (COHb 
7.3%) for 3 months or in monkeys exposed intermittently to 500 ppm (COHb 21.6%) for 14 months.
Conflicting evidence has been reported regarding the potential for carbon monoxide exposure to induce or 
enhance atherosclerosis (EPA 1991, 2000). Results of most studies in animals (monkeys, baboons, 
rabbits, and pigs) fed normal diets were negative for inducing or enhancing atherosclerosis at carbon 
monoxide concentrations of 50-400 ppm (COHb ~20%) for exposure durations up to 14 months. 
However, atherosclerosis was increased in monkeys continuously exposed to 200 ppm carbon monoxide 
(COHb 20.6%) for 2 weeks (Thomsen 1974) and in rabbits and monkeys fed high cholesterol diets 
exposed to 100-300 ppm carbon monoxide (COHb 9-33%) for 2-7 months. Based on the weight-of- 
evidence, EPA (1991, 2000) concluded that the available data do not strongly support a relationship 
between atherogenic effects and carbon monoxide exposure.
Gastrointestinal Effects. Studies evaluating gastrointestinal effects of exposure to low levels of 
carbon monoxide (i.e., producing blood COHb levels <20%) were not identified. Although the 
gastrointestinal tract has not been identified as a specific target organ for carbon monoxide-induced
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toxicity, exposure to carbon monoxide at levels producing hypoxia would be expected to affect any tissue, 
in particular those tissues with high O2 utilization requirements (e.g., brain, liver, kidney, heart, small 
intestine).
Hematological Effects. Hematological effects of carbon monoxide include compensatory responses 
to tissue hypoxia resulting from binding of carbon monoxide to Hb (e.g., increased blood volume, Hb, 
hematocrit, and erythrocyte count and volume). Possible associations between ambient air carbon 
monoxide concentrations and hematologic biomarkers of coagulation and inflammation have been 
examined in epidemiological studies. Collectively, these studies provide some evidence for associations 
that may reflect effects of carbon monoxide in modulating these systems.
Hypoxia and Related Compensatory Responses. Inhalation exposure to carbon monoxide results in the 
formation of COHb, a stable complex between carbon monoxide and Hb. Because carbon monoxide has 
a much higher affinity for Hb than O2 (equilibrium constant for carbon monoxide is >200 times that of
O2), O2 is displaced from Hb by relatively low partial pressures of carbon monoxide. Binding of carbon 
monoxide to Hb has two effects that contribute to impaired O2 delivery to tissues: (1) in the presence to 
carbon monoxide, the amount of O2 that can be stored on Hb for delivery to tissues decreases; and 
(2) binding of carbon monoxide to Hb impairs release of O2 from Hb for its diffusion into tissues (see 
Section 3.4.3 for further discussion of effects of carbon monoxide on O2 dissociation from Hb). At 
sufficient levels of COHb, the combined effects of impaired O2 storage and transport results in tissue 
hypoxia, the principal mechanism of many adverse effects of carbon monoxide exposure.
To maintain O2 delivery to tissues under conditions of hypoxia, compensatory hematological responses 
(e.g., increased erythrocyte count, hematocrit, and Hb) occur. The dose-response relationship for carbon 
monoxide-induced compensatory hematological responses in humans has not been established. Studies in 
animals show that compensatory hematological effects occur in response to the COHb-induced reduction 
in O2 delivery to tissues. Compensatory hematological effects, including increased blood volume, Hb, 
hematocrit, and erythrocyte count and volume, have been observed following acute- and intermediate- 
duration carbon monoxide exposure (Davidson and Penney 1988; Penney 1988; Penney et al. 1974a, 
1974b; WHO 1999). Continuous exposure of rats to 500 ppm carbon monoxide (COHb 40%) for 5­
42 days produced duration-dependent increases in hematocrit, blood Hb, erythrocyte count, and mean cell 
Hb concentration; mean cell volume was increased after 42 days of exposure (Davidson and Penney 
1988). The largest increases (approximately 45-55%) were observed for hematocrit, blood Hb, and 
erythrocyte count, with increases reaching maximum levels after 30 and 42 days of exposure. Similarly,
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blood Hb concentration increased by 70% in rats exposed continuously to 500 ppm carbon monoxide 
(COHb approximately 12% after 42 days) for up to 42 days, with the most rapid increase occurring within 
the first 21 days of exposure (Penney et al. 1974b). A small, but statistically significant increase in Hb 
concentration (6.0%; p<0.001) was observed in rats exposed to 100 ppm carbon monoxide (COHb 
9.25%) for 30 days (Penney et al. 1974b). In rats exposed to 200-1,300 ppm carbon monoxide (COHb 
not reported) for 10-17 days, dose-related increases in hematocrit and blood volume were observed 
(Penney et al. 1988).
Epidemiological Studies of Blood Markers Related to Coagulation. Studies of carbon monoxide 
mechanisms of action have provided evidence that carbon monoxide may participate in the regulation of 
vascular thrombi formation and inflammation (see Section 3.5.2, Mechanisms of Toxicity). Possible 
associations between ambient air carbon monoxide concentrations and biomarkers of coagulation and 
inflammation have been examined in epidemiological studies (Baccarelli et al. 2007; Liao et al. 2005; 
Pekkanen et al. 2000; Ruckerl et al. 2006, 2007; Steinvil et al. 2008). Biomarkers that have been 
examined include inflammation markers, C-reactive protein (CRP), serum amyloid A (SAA), and WBC 
count; cell adhesion markers, E-selectin, von Willebrand factor, antigen (vWF), ICAM-1; and 
coagulation markers, fibrinogen, factor VII (FVII), prothrombin fragment 1+2, prothrombin time (PT), 
and activated partial thromboplastin time (APTT). Collectively, these studies provide some evidence for 
associations between ambient air carbon monoxide concentration and changes in hematological 
indicators of inflammation and coagulation. However, interpretation of the results of these studies, in 
particular, quantitative estimates of the effect magnitudes on outcomes, is limited by several factors: (1) 
reliance on area monitoring for estimating exposure levels; (2) uncertainty in knowledge of temporal 
correspondence between monitored exposure levels and outcomes; (3) relatively strong correlations 
between ambient air carbon monoxide concentrations and other air quality variables that can affect 
respiratory function; and (4) relatively low carbon monoxide exposures studied. Mean values of carbon 
monoxide exposure concentrations have ranged from 0.3 to 3 ppm with the highest values <12 ppm.
Major findings from the body of reported epidemiological studies hematological outcomes are 
summarized below. Although most of the studies explored various time lags between monitored air 
carbon monoxide concentrations and outcomes, as well as various sample strata, for the sake of brevity, 
only those indicative of the strongest associations to carbon monoxide are presented. Where co-pollutant 
models have been explored, these results are also presented.
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A cohort study conducted in London, United Kingdom (1991-1993) examined plasma fibrinogen 
concentrations in adult office workers (n=7,205) and found a significant association between increasing 
air carbon monoxide concentrations (mean 1.4 mg/m3, maximum: 9 mg/m3) and increasing plasma 
fibrinogen concentrations (Pekkanen et al. 2000). For a 3-day lag between measured carbon monoxide 
concentration and fibrinogen assessment, the odds ratio for a plasma fibrinogen exceeding 3.19 g/L was 
1.22 (p<0.02) per 1.6 mg/m3 increase in air carbon monoxide concentration. Increasing air concentration 
of NO2 was also associated with increasing plasma fibrinogen concentration (odds ratio: 1.22, p<0.01), 
and when both were considered in two-pollutant models, the associations were no longer significant, 
reflecting the relative high correlation between air carbon monoxide and NO2 concentrations (r=0.81). 
When stratified by gender, the carbon monoxide association for a 1-day lag (3-day lag data not reported) 
was significant in males, but not in females (Steinvil et al. 2008). A smaller cohort study conducted in 
Tel-Aviv, Israel (2003-2006, n=3,659, mean age: 46 years) also found a significant association between 
increases in air carbon monoxide concentration and decreasing plasma fibrinogen concentration among 
males, but not among females. The largest effect was estimated for the 1-week air carbon monoxide 
average (mean: 0.8 ppm, 75th percentile: 1 ppm), for which a 0.3 ppm increase in air carbon monoxide 
concentration was associated with a 7.7 mg/dL (95% CI: -12.1, -3.3) decrease in plasma fibrinogen in 
males, with no association among females (-1.6 mg/dL, 95% CI: -7.3, 4.1). Increasing air carbon 
monoxide concentration was also associated with a significant decrease in WBCs among males 
(-158 cell/^L, 95% CI: -298, -18), but not females (-182 cell/^L, 95% CI: -281, 61). However, as in the 
Pekkanen et al. (2000) study, the association between air NO2 and fibrinogen was stronger than that of 
carbon monoxide and when included in two-pollutant models, the association with carbon monoxide was 
no longer significant. Significant associations with air carbon monoxide concentrations were not found 
for CRP.
A cohort study conducted in three U.S. locations (1996-1998) examined various blood biomarkers of 
coagulation and inflammation (i.e., fibrinogen, factor VIII-C, von Willebrand factor, serum albumin, 
WBC) in subjects enrolled in an Atherosclerosis Risk in Communities Study (n=10,208) and found a 
significant association between increasing air carbon monoxide concentrations (mean 1.4 ppm, SD: 0.6) 
and decreasing serum albumin concentrations (Liao et al. 2005). A 0.6 ppm increase in air carbon 
monoxide concentration corresponded to a 0.018 g/dL (SE: 0.003, p<0.01) decrease in serum albumin 
concentration. Other blood biomarkers evaluated were not significantly associated with air carbon 
monoxide concentration; results of multi-pollutant models were not reported.
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A panel study conducted in Efert, German (2000-2001) examined air carbon monoxide concentrations 
(mean: 0.52 mg/m3, range: 0.11-1.93) and several blood biomarkers of coagulation and inflammation in 
57 nonsmoking male coronary heart disease patients (age range: 51-7 years; Ruckerl et al. 2006). 
Biomarkers evaluated included inflammation markers, CRP and SAA; cell adhesion markers, E-selectin, 
vWF, ICAM-1; and coagulation markers, fibrinogen, FVII, and prothrombin fragment 1+2. Odds ratios 
for increase in air carbon monoxide concentration of 0.27 mg/m3 (2-day lag) were: increasing CRP,
1.5 (95% CI: 1.1-2.1); increasing ICAM-1, 1.7 (95% CI: 1.3-2.3); decreasing FVII, 2.8 (95% CI: 5.1­
0.4). Significant associations were not found for other blood biomarkers, including fibrinogen. A larger 
cohort study did not find significant associations between ambient air carbon monoxide concentrations 
(mean range: 0.3-1.48 mg/m3) and plasma interleukin-6 (IL-6), CRP, or fibrinogen among myocardial 
infarction survivors (n=1,003, age range: 31-87 years) in six European cities (2003-2004, Ruckerl et al. 
2007).
A panel study conducted in Milan, Italy (1995-2005) evaluated associations (mean range: 1.14­
3.11 ppm; highest value: 11.4 ppm) between air carbon monoxide concentrations and several blood 
coagulation, using prothrombin time (PT) and activated partial thromboplastin time (APTT) as outcome 
measures in 1,218 healthy adolescents and adults (age 11-84 years; Baccarelli et al. 2007). Increasing 
ambient air carbon monoxide concentration was associated with a decrease in PT (P coefficient: -0.11; 
95% CI: -0.18, -0.05). Associations were also significant for PM10 and NO2; however, results from 
multi-pollutant models were not reported. Significant associations with carbon monoxide were not found 
for other blood biomarkers evaluated in the study, including: carbon monoxide had no effect on 
fibrinogen, functional antithrombin, functional protein C, protein C antigen, functional protein S, or free 
protein S.
Musculoskeletal Effects. Studies evaluating effects of exposure to low levels of carbon monoxide 
(i.e., producing blood COHb levels <20%) on bone in humans or animals were not identified. In mice 
continuously exposed to 2,400 ppm for 180 days, increased bone mass was observed in parietal bone, 
sternum, lumbar vertebrae, and ribs (but not femur), and the marrow cavities of ribs, parietal bone, and 
femurs were expanded (Zebro et al. 1983).
Studies evaluating effects of exposure to low levels of carbon monoxide (i.e., producing blood COHb 
levels <20%) on muscle tissue in humans or animals were not identified. Rhabodomyolysis and 
myonecrosis have been reported in cases of carbon monoxide poisoning (Florkowski et al. 1992; Herman 
et al. 1988; Kuska et al. 1980; Wolff 1994). Damage to muscle tissue is consistent with hypoxia due to
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binding of carbon monoxide to Hb and myoglobin and with inhibition of cellular aerobic metabolism due 
to binding of carbon monoxide to intracellular cytochrome oxidases (Wolff 1994).
Hepatic Effects. Studies evaluating hepatic effects of exposure to low levels of carbon monoxide 
(i.e., producing blood COHb levels <20%) were not identified. Although the liver has not been identified 
as a specific target organ for carbon monoxide-induced toxicity, exposure to carbon monoxide at levels 
producing hypoxia would be expected to affect any tissue, in particular those tissues with high O2 
utilization requirements (e.g., brain, liver, kidney, heart, small intestine).
Renal Effects. Studies evaluating renal effects of exposure to low levels of carbon monoxide (i.e., 
producing blood COHb levels <20%) were not identified. Although the kidney has not been identified as 
a specific target organ for carbon monoxide-induced toxicity, exposure to carbon monoxide at levels 
producing hypoxia would be expected to affect any tissue, in particular those tissues with high O2 
utilization requirements (e.g., brain, liver, kidney, heart, small intestine). Acute renal failure secondary to 
rhabdomyolysis has been observed in cases of acute carbon monoxide poisoning (Florkowski et al. 1992; 
Kuska et al. 1980; WHO 1999; Wolff 1994).
Endocrine Effects. Studies evaluating endocrine effects of exposure to low levels of carbon 
monoxide (i.e., producing blood COHb levels <20%) were not identified. Although the endocrine system 
has not been identified as a specific target for carbon monoxide-induced toxicity, exposure to carbon 
monoxide at levels producing hypoxia would be expected to affect any tissue.
Dermal Effects. Studies evaluating dermal effects of exposure to low levels of carbon monoxide (i.e., 
producing blood COHb levels <20%) were not identified. Skin lesions have been observed in patients 
with severe carbon monoxide poisoning (Myers et al. 1985; Torne et al. 1991). Lesions are primarily 
observed in pressure areas and are characterized by blisters, subepidermal vesicles, and sweat gland 
necrosis.
Ocular Effects. No information was identified to indicate that carbon monoxide is an ocular irritant in 
humans or animals. Visual field deficits, temporary or permanent blindness, retinal venous congestion, 
retinal hemorrhage, papilledema, and optic atrophy have been associated with severe carbon monoxide 
poisoning in humans (Choi 2001).
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3.2.3 Immunological and Lymphoreticular Effects
Little information is available regarding the potential of carbon monoxide exposure to produce adverse 
immunological effects. Epidemiological studies blood biomarkers of immunological status are 
summarized in the section on Hematologic Effects. Immunological biomarkers examined in these studies 
have included CRP, serum amyloid A (SAA), and WBC; however, other markers that can be influenced 
by the immune system have also been evaluated, including cell adhesion markers such as E-selectin, 
vWF, ICAM-1; and coagulation markers such as fibrinogen, FVII, prothrombin fragment 1+2, PT, and 
APTT. Although results of these studies have been mixed, collectively, they provide some evidence for 
associations between ambient air carbon monoxide concentration and changes in hematological indicators 
of inflammation and coagulation. However, these studies do not distinguish between possible effects of 
carbon monoxide and/or other air pollutants on the immune system from indirect effects of carbon 
monoxide on blood biomarkers. Mechanistic studies have revealed evidence that carbon monoxide may 
participate in the regulation of immune function (see Section 3.5.2, Mechanisms of Toxicity).
Results of a study in guinea pigs investigating the effects of repeated brief bursts of carbon monoxide on 
systemic immune function were equivocal (Snella and Rylander 1979). Exposure of guinea pigs to 
3 minute bursts of 10,000 ppm carbon monoxide 12 times/day for 4 weeks resulted in an 88% reduction 
in the number of splenic plaque-forming cells, compared to unexposed controls; however, the reduction 
did not reach statistical significance. Studies evaluating effects of gestational exposure on the developing 
immune system function are reviewed in Section 3.2.6 (Developmental Effects) (Giustino et al. 1993, 
1994).
3.2.4 Neurological Effects
The literature reporting adverse nervous system effects, specifically central nervous system effects, of 
acute exposure of humans to carbon monoxide is extensive. This literature includes case studies of 
carbon monoxide poisoning, clinical studies of neurobehavioral effects of controlled exposures in 
humans, and experimental studies in a variety of animal models (e.g., dogs, rodents, nonhuman primates). 
Much of this literature has been summarized and analyzed in recent reviews and meta-analyses (Benignus 
et al. 1990; EPA 1991, 2000; Kao and Nanagas 2006; Raub et al. 2000; Raub and Benignus 2002; WHO 
1999). This section summarizes the major findings from these analyses. Although the literature on 
central nervous system effects of acute experimental and accidental exposures of humans to carbon 
monoxide is extensive, reports of effects of longer duration exposure of humans are not available. Effects
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of gestational and perinatal exposure on the developing nervous system are discussed in Section 3.2.6 
(Developmental Effects).
Acute exposure to high levels of carbon monoxide produces symptoms of central nervous system toxicity 
(EPA 1991, 2000; Ernst and Zibrak 1998; Raub and Benignus 2002; WHO 1999). Symptoms of central 
nervous system toxicity include headache, dizziness, drowsiness, weakness, nausea, vomiting, confusion, 
disorientation, irritability, visual disturbances, convulsions, and coma. Symptoms vary depending upon 
the degree of exposure; headache and dizziness are the most commonly reported symptoms (Dolan 1985; 
Ernst and Zibrak 1998). Neuroimaging evaluations of patients with acute carbon monoxide poisoning 
show lesions of the basal ganglia (primarily of the globus pallidus) and white matter (Hopkins et al. 2006; 
Kao and Nanagas 2006; Lo et al. 2007; Parkinson et al. 2002). Following acute-onset effects, delayed 
development of neuropsychiatric impairment may occur within 1-4 weeks of exposure, with symptoms 
including inappropriate euphoria, impaired judgment, poor concentration, memory loss, cognitive and 
personality changes, and psychosis. Delayed neuropsychiatric impairment has been estimated to occur in 
up to 68% of patients with acute carbon monoxide poisoning (Ernst and Zibrak 1998; Kao and Nanagas 
2006; Raub and Benignus 2002; Raub et al. 2000; WHO 1999; Wolf et al. 2008). The relationship 
between initial symptom severity and the likelihood of developing of delayed neuropsychiatric 
impairment has not been established. A cohort analysis of 256 patients with carbon monoxide poisoning 
suggests that initial symptom severity does not correlate to delayed-onset effects (Chambers et al. 2008). 
However, based on a review of available data, Kao and Nanagas (2006) concluded that patients with more 
severe initial symptoms are more likely to develop delayed neuropsychiatric impairment.
Mechanisms of acute and delayed adverse nervous system effects produced by carbon monoxide have not 
been conclusively established. Tissue hypoxia secondary to COHb formation may be a contributing 
factor; particularly in association with high levels of blood COHb (>60%); however, direct cellular effects 
of carbon monoxide (e.g., ATP depletion, exitotoxicty, oxidative stress, immunological responses) and 
postischemic reperfusion injury may also contribute to neurotoxicity (see Section 3.5.2, Mechanisms of 
Toxicity) (Ernst and Zibrak 1998; Gorman et al. 2003; Kao and Nanagas 2006). Under conditions of 
hypoxia, including that induced by COHb formation, cerebrovascular vasodilation and increased cardiac 
output occur as compensatory mechanisms to maintain O2 delivery to the brain (Gorman et al. 2003; 
Helfaer and Traystman 1996; Raub and Benignus 2002; WHO 1999). In healthy individuals, 
cardiovascular compensation effectively maintains whole brain O2 delivery up to COHb levels of 
approximately 60% (EPA 2000). However, based on studies conducted in animals, the elevated cerebral 
blood flow during carbon monoxide exposure is heterogeneous among different brain regions and may
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not be sufficient to satisfy O2 demand in all brain regions (Okeda et al. 1987; Sinha et al. 1991).
However, despite these compensatory cardiovascular actions, cerebral O2 consumption declines as blood 
COHb levels increase, with statistically significant decreases at COHb levels of 30-50% (Raub and 
Benignus 2002). Results of an analysis conducted by EPA (2000) of data obtained in goats (Doblar et al. 
1977) and sheep (Langston et al. 1996) show that the cerebral metabolic rate for O2 (CMRO2) decreased 
10% at a blood COHb of approximately 23%. These results are consistent with data obtained from 
humans showing no statistically significant decline in CMRO2 at COHb levels up to 20% (Paulson et al. 
1973).
Based on an extensive database of acute carbon monoxide poisoning, it is generally accepted that central 
nervous system symptoms are associated with acute exposures that produce blood COHb levels >20% 
(EPA 1991, 2000; Raub and Benignus 2002; Raub et al. 2000; WHO 1999). However, results of clinical 
studies of associations between carbon monoxide exposure and carbon monoxide-induced nervous system 
effects at blood COHb levels between 5 and 20% are more difficult to interpret (EPA 1991, 2000; Raub 
and Benignus 2002; Raub et al. 2000; WHO 1999). Numerous clinical studies have investigated the 
potential for carbon monoxide to induce adverse nervous system effects at COHb levels <20%, including 
visual and auditory sensory effects (decreased visual tracking, visual and auditory vigilance, visual 
perception), fine and sensorimotor performance, cognitive effects (altered time discrimination, learning, 
attention level, driving performance), and brain electrical activity (Benignus et al. 1990; EPA 1991, 2000; 
Raub and Benignus 2002; Raub et al. 2000). Interpretation of results from most of these clinical studies 
is complicated by poor study design (single-blind or unblinded designs, small number of study subjects), 
inadequate reporting, inconsistent results, and inability to duplicate positive findings (Benignus et al.
1990; EPA 1991, 2000; Raub and Benignus 2002; Raub et al. 2000). Therefore, although evidence has 
been provided for central nervous system effects in humans in association with carbon monoxide 
exposures that result in COHb levels <20%, dose-response relationships for these effects have not been 
firmly established. Effects of exposure to ambient environmental levels of carbon monoxide on 
neurological function and behavior have not been investigated in epidemiological studies.
Benignus (1994) conducted a meta-analysis of the clinical literature on carbon monoxide-induced 
behavioral effects, (also see Benignus et al. 1990; EPA 2000; Raub and Benignus 2002). To minimize 
the introduction of bias from poorly designed studies, the Benignus analysis included only studies 
conducted using a double-blind design. The primary goal of these analyses was to compare the dose- 
response relationship of carbon monoxide-induced effects in humans to other extrapolated data; 
specifically, the dose-response functions for COHb-induced behavioral effects in rats and for hypoxic
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hypoxia (HH)-induced behavioral effects in humans. Rat COHb dose-response data were converted to 
human COHb equivalents using a modification of the CFK human model, adjusted to predict exposure- 
COHb relationships in rats (Benignus and Annau 1994). Data on behavioral effects were also adjusted to 
account for carbon monoxide-Hb-related hypothermia that occurs in rats (Gordon 1990), but not in 
humans, assuming response additively of hypothermia and hypoxia (Benignus 1994). Dose-response data 
for HH-induced behavioral effects were converted to COHb equivalents (COHb% that yields the 
equivalent arterial O2 content as a given level of HH) and were corrected for hyperventilation that occurs 
in HH, and resulting changes in alveolar ventilation rate, based on estimates of blood CO2 (i.e., 
hypocapnia-induced by HH). For all data sets (i.e., carbon monoxide human, carbon monoxide rat, HH 
human), behavioral responses were transformed to percent of baseline response. Dose-response curves 
were fit to the extrapolated carbon monoxide rat and HH human data; curve-fitting was not conducted for 
carbon monoxide human data, due to the small effect level and low COHb levels. Comparison of the 
extrapolated carbon monoxide rat and HH human data showed very close agreement, with nearly 
superimposable dose-response curves (Figure 3-1); comparison of dose-response data from carbon 
monoxide humans to extrapolated data from HH humans is shown in Figure 3-2. The dose-response 
relationship from this meta-analysis predicts a 10% decrement in behavioral outcomes in humans in 
association with COHb levels of approximately >20% (range: approximately 18-25%, based on 90% 
confidence limits) in healthy, sedentary individuals. As discussed by Benignus (1994) and others 
(Benignus et al. 1990; Raub and Benignus 2002; EPA 1991), the magnitude of behavioral effects that 
may occur at blood COHb levels <20% is expected to be small. Although most task performances are not 
likely to be affected, it is possible that even small effects (i.e., <10% decrement) could interfere with 
successful task performance for more difficult or demanding tasks. Therefore, potential minimal 
behavioral changes occurring at COHb levels <20% may be important under certain conditions or in 
sensitive individuals (e.g., individuals with compromised cardiovascular or central nervous system 
function).
Clinical studies evaluating exposure to low levels of carbon monoxide (i.e., producing blood COHb levels 
<20%) have focused on the potential for carbon monoxide to induce behavioral effects; however, very 
little information is available on the effects of carbon monoxide on sensory system function in humans. 
Results of clinical studies in evaluating the effects of low carbon monoxide exposures on alterations in 
sensory perception (i.e., visual and auditory) are equivocal (EPA 1991, 2000). Epidemiological studies 
have not assessed the potential for carbon monoxide to produce alterations in sensory system function. 
Studies conducted in mature rats provide evidence that acute exposure (<10 hours) to higher levels of 
carbon monoxide (500-1,500 ppm) potentiates noise-induced hearing loss, including noise-induced
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Figure 3-1. HH Human and Carbon Monoxide Rat Curves*
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Figure 3-2. HH Human and Carbon Monoxide Human*
* B e h a v i o r a l  d e c r e m e n t s  i n  h u m a n s  ( c i r c l e s )  w i t h  e l e v a t e d  C O H b  c o m p a r e d  t o  b e h a v i o r a l  e f f e c t s  i n  h y p o x i c  h u m a n s  
( s o l i d  a n d  d o t t e d  l i n e s )  i n  w h i c h  h y p o x i a  h a s  b e e n  e x p r e s s e d  i n  e q u i v a l e n c e  t o  C O H b .  C l o s e d  a n d  o p e n  c i r c l e s  w e r e  
t h e  m e a n  v a l u e s  f o r  s t u d i e s  r e p o r t i n g  s t a t i s t i c a l l y  a n d  n o n - s i g n i f i c a n t  r e s u l t s ,  r e s p e c t i v e l y .
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elevation of compound action potential threshold (Chen and Fechter 1999) and auditory threshold shifts 
(Fechter et al. 1988; Young et al. 1987). In these studies, exposure to carbon monoxide alone did not 
produce changes in auditory function. Noise-induced hearing loss was partially reversed within 4 weeks 
following exposure to noise alone, but not following exposure to noise and carbon monoxide (Chen and 
Fechter 1999). Results are consistent with carbon monoxide-induced impairment of mechanisms that 
repair noise-induced damage to outer hair cells. In marked contrast to results observed in adult rats, 
developmental studies in animals show that gestational and early postnatal exposure to low levels of 
carbon monoxide (i.e., 12-25 ppm carbon monoxide) may lead to altered development of the auditory 
system (Lopez et al. 2003, 2008; Stockard-Sullivan et al. 2003; Webber et al. 2003). These data are 
discussed in Section 3.2.6.
Additional evidence for effects of carbon monoxide on depressed auditory thresholds and increased 
cochlear blood flow have been provided from studies in which adult rats received parenteral doses of 
carbon monoxide (Fechter et al. 1987b). However, in these studies, auditory thresholds assessed by 
measurement of the compound action potential recorded at the round window remained stable up to 
COHb levels of at least 30%. Transient impairments of the compound action potential threshold were 
observed among subjects that attained COHb levels of approximately 50%. Cochlear blood flow 
measured using laser Doppler flowmetry also increased following carbon monoxide exposure, reaching a 
maximum of 140% of control values at approximately 50% COHb. In those instances of high COHb 
production that did produce impairment of auditory threshold, recovery of function was observed as 
COHb levels declined.
3.2.5 Reproductive Effects
Fetal death in humans has been reported in cases of maternal carbon monoxide poisoning during 
pregnancy. Epidemiological studies have examined possible relationships between exposures to ambient 
air concentrations of carbon monoxide and fetal mortality (see Section 3.2.6). Studies in animals provide 
further evidence that maternal exposure during pregnancy can result in fetal death.
Case Reports. Several case reports have evaluated pregnancy outcomes following acute carbon 
monoxide poisoning (Brown et al. 1992; Caravati et al. 1988; Cramer 1982; Elkharrat et al. 1991; Farrow 
et al. 1990; Greingor et al. 2001; Hollander et al. 1987; Margulies 1986; Norman and Halton 1990; 
Silverman and Montano 1997). In all cases, the severity of carbon monoxide poisoning required 
emergency room treatment or hospitalization, suggesting that maternal COHb levels exceeded 20%.
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Pregnancy outcomes varied widely, from delivery of healthy infants at term to fetal death within first few 
days of exposure. Pregnancy outcome is most likely related to fetal age at time of exposure and severity 
of maternal poisoning, although, maternal COHb levels are not a good indicator of fetal outcome 
(Greingor et al. 2001). Fetal death may be secondary to maternal hypoxia and/or fetal hypoxia. The 
available information from these cases is not adequate to define dose-response relationships for acute 
carbon monoxide exposure and pregnancy outcomes.
Animal Studies. Few animal studies have assessed the effects of carbon monoxide exposure on 
reproductive function. Continuous exposure of male mice to 50 ppm carbon monoxide for 2 weeks prior 
to mating with unexposed females or of male and female mice to 50 ppm carbon monoxide for 2 weeks 
prior to mating had no effect on pregnancy rate or live or dead fetuses/dam (Stupfel and Bouley 1970). 
Exposure of pregnant rats over the entire gestational period to up to 200 ppm carbon monoxide had no 
effect on number of liters, fetuses per litter, or number of live/dead pups per litter (Fechter and Annau 
1977; Penney et al. 1983). In contrast, increased fetal death during the first 24 hours of the postnatal 
period was observed in rabbits following maternal exposure to 90 and 180 ppm carbon monoxide during 
pregnancy (9.9 and 35% mortality) (Astrup et al. 1972).
3.2.6 Developmental Effects
Epidemiological studies have examined possible associations between exposure to ambient air carbon 
monoxide concentrations and various developmental outcomes, including pre-term birth, birth weight, 
congenital anomalies, and neonatal and infant death. Results of these studies have been mixed and, 
collectively, do not provide strong evidence for developmental effects in association with exposures to 
ambient levels of carbon monoxide. Studies conducted in animals provide evidence of adverse 
developmental effects of gestational and early postnatal carbon monoxide exposure, including decreased 
fetal weight, adverse central nervous system development, altered peripheral nervous system 
development, cardiac effects, altered sexual behavior, immunological effects, and hematological effects.
In addition, some studies showed that developmental effects persisted beyond the postnatal period.
Epidemiological Studies. Interpretation of the results of epidemiological studies of developmental effects 
of carbon monoxide, in particular, quantitative estimates of the effect magnitudes on outcomes, is limited 
by several factors: (1) reliance on area monitoring for estimating exposure level that may not represent 
exposures that occurred during any particular period of gestation; (2) uncertainty in knowledge of 
temporal correspondence between monitored exposure levels and outcomes; (3) relatively strong
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correlations between ambient air carbon monoxide concentrations and other air quality variables that may 
affect developmental outcomes; and (4) relatively low carbon monoxide exposures studied. In general, 
these studies have examined relatively low air carbon monoxide concentrations, typical of ambient levels 
(e.g., mean concentrations ranging from 0.5 to 3 ppm, with the highest reported values <10 ppm). The 
presentation of the epidemiological studies is organized by major categories of birth and neonatal 
outcomes. Study conclusions are presented in the text, with selected supporting details presented in 
tabular form (Table 3-8). Although most studies explored various time lags between monitored air carbon 
monoxide concentrations and outcomes, as well as various sample strata, for the sake of brevity, only 
selected representative time lags (usually those indicative of the strongest associations to carbon 
monoxide) are presented in the tables. Where co-pollutant models have been explored, these results are 
also presented.
Studies of Pre-term Birth. Several epidemiological studies have examined possible associations between 
ambient air carbon monoxide concentrations and risk of pre-term birth (Huynh et al. 2006; Jalaludin et al. 
2007; Leem et al. 2006; Liu et al. 2003; Ritz et al. 2000, 2007; Wilhelm and Ritz 2005). Results of these 
studies have been mixed and have included estimates of significantly elevated risk or lower risks of pre­
term birth (Jalaludin et al. 2007). Mean air carbon monoxide concentrations evaluated in these studies 
ranged from 0.8 to 2.7 ppm, with the highest values <10 ppm (Ritz et al. 2000).
A retrospective cohort study (n=97,158 births) conducted in southern California (1989-1993) found a 
significant association between increasing air carbon monoxide concentration (mean: 2.7 ppm, range: 
0.6-9.12) and pre-term birth (Ritz et al. 2000). After adjustment for other risk factors as well as ambient 
air concentrations of NO2, O3, and PMJ0, the relative risk of pre-term birth was estimated to be 1.12 (95% 
CI: 1.04-1.21) per 3 ppm increase in air carbon monoxide concentration during the last 6 weeks of 
pregnancy. Subjects were matched to ambient carbon monoxide measurements made at monitors that 
were <2 miles from the residence. In a follow-up study (1994-2000) that included 106,483 births, 
relative risk (adjusted for NO2 and O3) was estimated to be 1.10 (95% CI: 1.03-1.08) per 1 ppm 
increment in air carbon monoxide concentration during the last 6 weeks of pregnancy (Wilhelm and Ritz 
2005). The association was not significant when PM10 was included in the model along with NO2 and O3 
(relative risk: 0.98; 95% CI: 0.83-1.18). A subsequent analysis of Southern California data included a 
nested case-control study consisting of a subset of 2,543 cases of pre-term birth (<37 weeks of gestation) 
or low birth weight (<2,500 g) and an equal number of randomly selected controls for a larger cohort of 
58,316 births (Ritz et al. 2007). Detailed individual data on potential co-variables were obtained, 
including maternal age, race, education, marriage status, birth season, parity, active and passive smoking,
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Table 3-8. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Developmental Outcomes
Study Design features CO exposure Effect size
Bell et al. (2007)
Period: 1 9 9 9 -2 0 0 2  
Location: Connecticut and 
Massachusetts
Brauer et al. (2008)
Period: 1 9 9 9 -2 0 0 4  
Location: Vancouver, Canada
Chen et al. (2002) 
Period: 1 9 9 1 -1 9 9 9  
Location: Nevada
Gilboa et al. (2005) 
Period: 1 9 9 7 -2 0 0 0  
Location: Texas
Outcome: BW, LBW  
Design: Retrospective cohort 
Sample: n=358,504 live full term  
singleton births
Outcome: PTB, LBW, SGA  
Design: Retrospective cohort 
Sample: n=70,249 live singleton 
births
Outcome: BW, LBW  
Design: Retrospective cohort 
Sample: n=39,338 live singleton 
births
Outcome: CA (heart, orofacial) 
Design: Case-control 
Sample: n=4,594 cases
Avg time: 24 hours 
Mean: 0 .65 ppm 
SD: 0.2 ppm
Avg time: 24 hours 
Mean: 0 .55 ppm 
Range: 0 .1 1 -1 .2 3  ppm
Avg time: 8 hours 
Mean: 0 .86 ppm 
Range: 0 .4 2 -4 .2 5  ppm
Avg time: 24 hours 
Mean: NR
25th-7 5 th%: 0 .4 -0 .7  ppm
Increment: 0.30 ppm
P coefficient (95%  CI) B W  (g), total gestation:
CO: -16 .2  (-19.7, -12.6)
Significant negative P persisted after adjustment 
for N O 2, S O 2, PM 2.5, or P M 10 
O R  (90%  CI) LBW , total gestation:
CO: 1.028 (0 .9 8 3 -1 .0 7 4 )
Increment: 0.1 mg/m  
O R  (95%  C I), total gestation:
SGA: 1.06 (1 .0 3 -1 .0 8 )
LBW: 1.02 (0 .9 6 -1 .0 9 )
PTB: 1.16 (1 .0 1 -1 .3 3 )
Increment: 1ppm  
P coefficient (SE), B W  (g):
TM  1: -1 .02  (6 .68)
TM  2: -0 .07  (6.58)
TM  3: -3 .95  (6.76)
Not significant when adjusted for P M 10 or O3 
ORs not significant for LBW  
Increment: <0.4  ppm (reference), 0 .4 -0 .5  (L), 
0 .5 -0 .7  (M), >0.7  (H)
O R  (95%  C I), 3 -8  weeks of gestation:
Conotruncal defect: (L) 1.38 (0 .9 7 -1 .9 7 ); (M )1 .17  
(0 .8 1 -1 .7 0 ); (H) 1.46 (1 .0 3 -2 .0 8 )
Teratology of Fallot: (L) 0.92 (0 .5 2 -1 .6 2 ); (M)
1.17 (0 .7 5 -2 .1 4 ); (H) 2 .04  ( 1 .1 6 -3 .2 9 )
C O  not associated with other heart defects or 
orofacial defects
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Table 3-8. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Developmental Outcomes
Study Design features CO exposure Effect size
Gouveia et al. (2004) 
Period: 1997
Location: San Paulo, Brazil
Ha et al. (2001)
Period: 1 9 9 6 -1 9 9 7  
Location: Seoul, South Korea
Ha et al. (2003)
Period: 1 9 9 5 -1 9 9 9  
Location: Seoul, South Korea
Huynh et al. (2006)
Period: 1 9 9 9 -2 0 0 0  
Location: California
Outcome: BW, LBW  
Design: Retrospective cohort 
Sample: n=179,460 live full term  
singleton births
Avg time: 8 hours 
Mean: 3.7 ppm 
Range: 1 .1 -1 1 .4
Outcome: LBW  
Design: Retrospective cohort 
Sample: n=276,763 live full-term  
singleton births
Outcome: Post-neonatal mortality 
(1 - 1 2  months)
Design: Tim e series 
Sample: n=1,045 deaths 
Outcome: PTB  
Design: Case-control 
Sample: n=10,673 cases (24­
36 weeks), 32 ,119 controls (39­
44 weeks)
Avg time: 8 hours 
Median: 1.7 ppm 
25th-7 5 th%: 0 .99 -1 .41
Avg time: 24 hours 
Median: 1.2 ppm 
Range: 0 .3 9 -3 .3 8  ppm
Avg time: 24 hours 
Mean: 0.8 ppm 
SD: 0.2 ppm
Increment: 1 ppm 
P coefficient (95%  C I), B W  (g):
TM  1: -23.1 (-41 .3  to -4 .9)
TM  2: 3.2 (-18.2  to 24.5)
TM  3: 1.9 (-18.2  to 22.0)
Significant negative P did not persist after 
adjustment for SO 2 or P M 10 .
O R  (95%  C I), LBW: 4 th vs. 1st quartile exposure: 
TM  1: 1.02 (0 .8 2 -1 .2 7 );
TM  2: 1.07 (0 .8 8 -1 .3 0 )
TM  3: 0 .93 (0 .7 6 -1 .1 2 )
Increment: 0.42 ppm 
RR (95%  CI)
TM  1: 1.08 (1 .0 4 -1 .1 2 )
TM  3: 0.91 (0 .8 7 -0 .9 6 )
Increment: 0.57 ppm 
RR (95%  CI), lag 0 days:
All causes: 1.020 (0 .9 7 6 -1 .0 6 7 )
Respiratory: 1.388 (1 .0 0 9 -1 .9 1 1 )
Increment: 1 ppm 
O R  (95%  CI)
Month 1 (of gestation):
CO: 1.10 (0 .9 9 9 -1 .2 0 )
C O +P M 2 .5: 1.03 (0 .9 3 -1 .1 3 )
Last 2 weeks:
CO: 1.00 (0 .9 3 -1 .0 9 )
C O +P M 2 .5: 0 .97 (0 .9 0 -1 .0 6 )
Total gestation:
CO: 1.06 (0 .9 5 -1 .1 8 )
C O +P M 2 .4: 0 .98 (0 .8 7 -1 .1 0 )
No significant trend in O R  with exposure quartile
CARBON MONOXIDE 
99
3. HEALTH EFFECTS
***DRAFT FOR PUBLIC 
COMMENT***
Table 3-8. Selected Epidemiological Studies of Associations Between Ambient Carbon Monoxide Concentrations and
Developmental Outcomes
Study Design features CO exposure Effect size
Hwang and Jaakkola (2008) 
Period: 2 0 0 1 -2 0 0 3  
Location: Taiwan
Jalaludin et al. (2007) 
Period: 1 9 9 8 -2 0 0 0  
Location: Sydney, Australia
Lee et al. (2003a) 
Period: 1 9 9 6 -1 9 9 8  
Location: Seoul, Korea
Outcome: CA (oral cleft) 
Design: Case-control 
Sample: n=653 cases
Avg time: 8 hours 
Mean: 0 .69 ppm 
Range: 0 .2 5 -2 .7  ppm
Outcome: PTB (<37 or <42 weeks) Avg time: 8 hours
Design: Retrospective cohort 
Sample: n=721,289 full-term  
singleton births
Mean: 0.9 ppm 
SD: 0.68 ppm
Outcome: LBW  
Design: Retrospective cohort 
Sample: n=388,105 live full-term  
singleton births
Avg time: 24 hours 
Mean: 1.2 ppm 
Range: 0 .4 -3 .4  ppm
Increment: 0.1 ppm 
RR (95%  CI), oral cleft 
Cleft lip:
Month 1 
Month 2 
Month 3
1.00 (0 .9 6 -1 .0 4 )
1.00 (0 .9 6 -1 .0 S )
1.00 (0 .9 6 -1 .0 S )
O s, or
Cleft lip with or without cleft palate:
Month 1: 1.00 (0 .9 7 -1 .0 4 )
Month 2: 1.00 (0 .9 7 -1 .0 5 )
Month 3: 1.00 (0 .9 6 -1 .0 4 )
No significant ORs after adjustment for N O 2,
P M 10
Increment: 1 ppm
R R ( 95%  CI) <5 km of monitoring site or city-wide 
Month 1, <5 km: 1.03 (0 .6 8 -1 .5 4 )
Month 1, city-wide: 0 .89 (0 .8 4 -0 .9 5 )
TM  1, <5 km): 1.24 (0 .8 1 -1 .9 1 )
TM  1, city-wide:0.77 (0 .7 1 -0 .8 3 )
Last month, <5 km: 1.00 (0 .8 6 -1 .1 5 )
Last month, city-wide: 0.96 (0 .8 8 -1 .0 4 )
TM  3, <5 km: 1.11 (0 .9 4 -1 .3 1 )
TM  3, city-wide: 0 .99 (0 .9 0 -1 .0 9 )
Increment: 0.5 ppm 
O R  (95%  CI)
TM  1 
TM  2 
TM  3
1.04 (1 .0 1 -1 .0 7 )
1.05 (1 .0 0 -1 .0 6 ) 
0.96 (0 .9 S -0 .9 9 )
Total gestation: 1.05 (1 .0 1 -1 .0 9 )
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Leem et al. (2006)
Period: 2 0 0 1 -2 0 0 2  
Location: Incheon, Korea
Lin et al. (2004a)
Period: 1 9 9 8 -2 0 0 0  
Location: Sao Paulo, Brazil
Lin et al. (2004b)
Period: 1 9 9 5 -1 9 9 7  
Location: Taiwan
Outcome: PTB  
Design: Retrospective cohort 
Sample: n=52,113 live singleton 
births
Outcome: Neonatal mortality 
(<28 days)
Design: Tim e series 
Sample: n=6,700 deaths 
Outcome: LBW  
Design: Retrospective cohort 
Sample: n=92,288 live full-term  
singleton births
Liu et al. (2003)
Period: 1 9 8 5 -1 9 9 8  
Location: Vancouver, Canada
Avg time: 24 hours 
Mean: NR  
Range: 0 .3 -1 .4  ppm
Outcome: PTB LBW, IUGR  
Design: Retrospective cohort 
Sample: n=386,202 live singleton 
births
Avg time: 24 hours 
Median: 2 .83  ppm 
Range: 0 .5 4 -1 0 .2 5  ppm
Avg time: 24 hours 
Mean: Taipei, 0 .84 ­
1.31 ppm; Kaohsiun, 5 .56­
10.05 ppm 
Range: NR
Avg time: 24 hours 
Mean: 1.0 ppm 
25th-7 5 th%: 0 .7 -1 .2  ppm
Increment: quartiles (m g/m 3): 1st 0 .4 7 -0 .6 3 ; 2 nd 
0 .6 -0 .7 7 , 3 rd 0 .7 8 -0 .9 0 , 4 th 0 .9 1 -1 .2 7  
O R  (95%  CI)
TM  1: 2 nd, 0.92 (0 .81 -1 .05 ); 3 rd, 1.14 (1 .0 1 -1 .2 9 ); 
4th, 1.26 (1 .1 1 -1 .4 4 )
TM  3: 2 nd , 1.07 (0 .9 5 -1 .2 1 ); 3 rd, 1.07 (0 .9 4 -1 .2 2 ); 
4th, 1.16 (1 .0 1 -1 .3 4 )
Increment: 0.57 ppm
P coefficient (SE), deaths per day, lag 0 days 
0.0061 (0.0 1 10 )
Increment: <1.1 (re fe ren ce),1 .1 -14 .2  (L) vs. > 
14.2 (H) ppm 
O R  (95%  CI):
TM  1: (L) 1.01 (0 .8 9 -1 .1 6 ); (H) 0 .90 (0 .75 -1 .0 9 )
TM  2: (L) 1.02 (0 .9 0 -1 .1 6 ); (H) 1.00 (0 .8 2 -1 .2 2 )
TM  3: (L) 0 .88 (0 .7 7 -1 .0 0 ); (H) 0.86 (0 .7 1 -1 .0 3 )
Total gestation: (L) 0 .89 (0 .7 7 -1 .0 1 ); (H) 0.77  
(0 .6 3 -0 .9 4 )
Increment: 1 ppm 
O R  (95%  CI)
PTB, first month: 0 .95 (0 .8 9 -1 .0 1 )
PTB, last month: 1.08 (1 .0 1 -1 .1 5 )
LBW, first month: 1.01 (0 .9 3 -1 .0 9 )
LBW, last month: 0 .96 (0 .8 8 -1 .0 4 )
IUGR, first month:1.06 (1 .0 1 -1 .1 0 )
IUGR, last month: 0 .98 (0 .9 4 -1 .0 3 )
IUGR, TM  1 
IUGR, TM  2 
IUGR, TM  3
1.05 (1 .0 0 -1 .1 0 ) 
0.97 (0 .9 2 -1 .0 1 ) 
0.97 (0 .9 3 -1 .0 2 )
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Liu et al. (2007) 
Period: 1 9 9 5 -2 0 0 7  
Location: Canada
Maisonet et al. (2001) 
Period: 1 9 9 4 -1 9 9 6  
Location: Northeast United 
States
Mannes et al. (2005)
Period: 1 9 9 8 -2 0 0 0  
Location: Sydney, Australia
Outcome: IU G R  
Design: Retrospective cohort 
Sample: n=386,202 live singleton 
births
Outcome: BW
Design: Retrospective cohort 
Sample: n=89,557 live full term  
singleton births
Outcome: BW, SG A  
Design: Retrospective cohort 
Sample: n=136,056 live full term  
singleton births
Avg time: 24 hours 
Mean: 1.1 ppm 
25th-7 5 th%: 0 .6 -1 .3  ppm
Avg time: 24 hour 
Mean: 1.1 ppm 
25th-7 5 th%: 0 .9 -1 .5  ppm
Avg time: 8 hour 
Mean: 0.8 ppm 
25th-7 5 th%: 0 -4 .6  ppm
Increment: 1 ppm 
RR (95%  CI)
TM  1:
C O :1.18 ( 1 .1 4 -1 .2 3 ) 
C O +N O 2+O 3 : 1.18 (1 .1 2 -1 .2 4 ) 
TM  2:
CO :1.14 (1 .1 0 -1 .1 8 ) 
C O +N O 2+O 3 : 1.15 (1 .0 8 -1 .2 1 ) 
TM  3:
C 0 :1 .0 9  (1 .2 4 -1 .1 4 ) 
C O +N O 2+O 3 : 1.20 (1 .1 4 -1 .2 6 ) 
Increment: 1 ppm 
O R  (95%  CI):
TM  1 
TM  2 
TM  3
1.08 (0 .9 1 -1 .2 8 ) 
1.14 (0 .8 3 -1 .5 8 ) 
1.31 (1 .0 6 -1 .6 2 )
African-Americans:
TM  1: 1.43 (1 .1 8 -1 .7 4 )
TM  2: 1.27 (0 .8 7 -1 .8 6 )
TM  3: 1.75 (1 .5 0 -2 .0 4 )
C O  had no effect on strata for whites or Hispanics 
Increment: 1 ppm
P coefficient (95%  CI) B W  (g), TM  2, <5 km from 
monitoring site:
CO: -29 .87  (-50.98, -6 .76)
C O +N O 2: -20 .17  (-43.12, 2.78)
C O + P M 10: -27.31 (-55.30, 0.68)
O R  (95%  CI) SGAm  <5 km from monitoring site: 
TM  1 
TM  2 
TM  3
0.99 (0 .8 6 -1 .1 4 ) 
1.06 (0 .9 0 -1 .2 5 ) 
1.05 (0 .9 0 -1 .2 3 )
One month prior to birth: 1.10 (9 .9 6 -1 .2 7 )
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Medeiros and Gouveia (2005) 
Period: 1 9 9 8 -2 0 0 0  
Location: Sao Paulo, Brazil
Parker et al. (2005) 
Period: 2000  
Location: California
Ritz and Yu (1999) 
Period: 1 9 8 9 -1 9 9 3  
Location: California
Outcome: B W  and LBW  
Design: Retrospective cohort 
Sample: n=311,735 live full-term  
singleton births (37 -41  weeks)
Outcome: BW, SG A  
Design: Retrospective cohort 
Sample: n=18,247 live full-term  
singleton births
Outcome: LBW  
Design: Retrospective cohort 
Sample: n=125,275 live full-term  
singleton births
Avg time: 24 hours 
Mean: ~ 2 -3p p m  
Range: ~ 1 -1 2  ppm
Avg time: 24 hours 
Mean: 0 .78 ppm 
25th-9 5 th%: 0 .5 7 -0 .9 3  ppm
Avg time: 6 -9  AM  
Mean: 2 .59  ppm 
5.5 ppm95th%:
Increment: 1 ppm 
P coefficient (95%  CI) B W  
TM  1: -11 .9  (-15.5, -8.2)
TM  2 4 .9  (0 .5 -9 .3 )
TM  3: 12.1 (7 .6 -1 6 .6 )
O R  (85%  CI) LB W  (75 th % vs 25 th %):
TM  1: 0 .98 (0 .9 1 -1 .0 6 );
TM  2: 0 .97 (0 .9 0 -1 .0 5 )
TM  3: 1.03 (0 .96 -1 .11
Increment (ppm): <0 .57 (reference), 0 .5 7 -0 .7 6  
(L), 0 .7 6 -0 .9 3  (M ), >0 .93 (H)
O R  (95%  CI) for total gestation:
CO, L: 0 .93 (0 .8 0 -1 .0 9 )
CO, M: 0.91 (0 .7 8 -1 .0 6 )
CO, H: 0 .95 (0 .8 1 -1 .1 2 )
C O  (L) + PM 2 5 : 0 .90 (0 .7 7 -1 .0 6 )
C O  (M) + PM 2 5 : 0.91 (0 .7 7 -1 .0 7 )
C O  (H) + PM 2 .5 : 0 .82 (0 .6 8 -0 .9 9 )
Increment (ppm): <2.2 (reference), 2 .2 -<5 .5  (L), 
>5.5 (H)
O R  (95%  CI)
C O  (L): 1.04 (0 .9 6 -1 .1 3 )
CO, (H): 1.22 (1 .0 3 -1 .4 4 )
C O  (L)+ N O 2 +O a_ P M 10: 1.10 (0 .9 1 -1 .3 2 )
C O  (H )+ N O 2+O a_ P M 1Q: 1.38 (0 .8 6 -2 .2 2 )
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Rtiz et al. (2000) 
Period: 1 9 8 9 -1 9 9 3  
Location: California
Ritz et al. (2002) 
Period: 1 9 8 7 -1 9 9 3  
Location: California
Ritz et al. (2006) 
Period: 1 9 8 9 -2 0 0 0  
Location: California
Outcome: PTB  
Design: Retrospective cohort 
Sample: n=97,518 live singleton 
births
Outcome: CA (heart, orofacial) 
Design: Case-control 
Sample: n=3,549 cases
Avg time: 6 -9  AM  
Mean: 2 .70  ppm 
Range: 0 .3 6 -9 ,1 2  ppm
Avg time: 24 hour 
Mean: NR
25th-7 5 th%: 1 .4 -2 .4 6  ppm
Outcome: Post-neonatal mortality 
(28 days- 1  year)
Design: Case-control 
Sample: n=13,146 cases
Avg time: 24 hour 
Mean: 1.63 ppm 
Range: 0 .3 8 -3 .4 4  ppm
Increment: 3 ppm 
RR (95%  CI)
Adjusted for risk factors:
Last 6 weeks: 1.06 (1 .0 2 -1 .1 0 )
First month: 1.01 (0 .9 7 -1 .0 4 )
Adjusted for risk factors and season of birth and 
conception:
Last 6 weeks: 1.04 (0 .9 9 -1 .1 0 )
First month: 1.04 (0 .9 9 -1 .0 9 )
Adjusted for risk factors, N O 2 , O 3 , and P M 10:
Last 6 weeks: 1.05 (0 .9 7 -1 .1 2 )
First month: 1.03 (0 .9 6 -1 .1 0 )
Increment: <1.4  ppm (reference), 1 .1 4 -1 .5 7  (L), 
1 .5 7 -2 .3 9  (M ), >2 .39  (H)
O R  (95%  C I), month 2 of gestation:
Ventricular septal:
CO: (L) (L) 1.62 (1 .0 5 -2 .4 8 ); (M) 2 .09  (1 .19­
3.67); (H) 2 .95  ( 1 .4 4 -6 .0 5 )
C O +N O 2+O 3 + P M 10 : 1.63 (1 .0 0 -2 .6 6 ); (M ) 1.97  
(1 .0 -3 .9 1 ); (H) 2 .84  ( 1 .1 5 -6 .9 9 )
C O  not associated with conotruncal, aortic artery 
and valve, or pulmonary artery and valve defects 
Increment: 1 ppm
O R  (95%  C I), exposure period 2 months prior to 
death:
All causes: 1.11 (1 .0 6 -1 .1 6 )
SIDS: 1/19 (1 .1 0 -1 .2 8 )
O R  not significant after adjustment for N O 2 , O 3 ,
and P M 10
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Ritz et al. (2007) 
Period: 2003  
Location: California
Salam  et al. (2005) 
Period: 1 9 7 5 -1 9 8 7  
Location: California
Tsai et al. (2006a) 
Period: 1 9 9 4 -2 0 0 0  
Location: Taiwan
Outcome: PTB
Design: Nested case-control
Sample: n=2,543 cases,
2 ,543 controls from 58,316 births in 
registry
Outcome: BW, LBW, IU G R  
Design: Retrospective cohort 
Sample: n=3,901 births (37­
44 weeks)
Outcome: Post-neonatal mortality 
(27 days-1 year)
Design: Case-crossover 
Sample: n=206 cases
Avg time: 24 hours 
Mean: NR  
Range: NR
Avg time: 24 hours 
Mean: 1.8 ppm 
SD: 0.9 ppm
Avg time: 24 hours 
Mean: 0 .83 ppm 
Range: 0 .2 3 -1 .7 7  ppm
Increment (ppm): <0.58 (reference), 0 .5 9 -0 .9 1 (L ), 
0 .9 2 -1 .2 5  (M ), >1 .25  (H)
O R  (95%  C I), adjusted for risk factors:
TM  1: L, 1.17 (1 .0 8 -1 .2 6 ); M: 1.15 (1 .0 5 -1 .2 6 );
H: 1.25 (1 .1 2 -1 .3 8 )
Last 6 weeks: L, 1.00 (0 .9 3 -1 .0 8 ); M: 1.08 (0 .98­
120); H: 1.03 (0 .9 3 -1 .1 4 )
Total gestation: L, 0 .76 (0 .7 0 -0 .8 2 ); M: 0.84  
(0 .7 7 -0 .9 1 ); H: 1.03 (0 .9 1 -1 .1 7 )
Increment: 1.4 ppm 
O R  (95%  CI):
TM  1:
LBW, CO: 1.0 (0 .7 -1 .5 )
IUGR, CO: 1.2 (1 .0 -1 .4 )  
p coefficient (95%  CI) for IU G R  
TM  1:
CO: -21 .7  (-42,3, -1.1)
C O  + O 3: -28 .6  (-50.4, -6 .9)
Increment: 0.31 ppm 
O R  (95%  C I), lag 0 -2  days:
All causes: 1.051 (0 .3 0 4 -3 .6 3 0 )
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Wilhelm and Ritz (2005) Outcome: LBW, PTB Avg time: 24 hours Increment: 1 ppm (<1 mile from monitoring
Period: 1 9 9 4 -2 0 0 0 Design: Retrospective cohort Mean: 1 .2 -1 .4  ppm station)
Location: California Sample: n=106,483 births for PTB  
outcome, 136,134 births for LBW  
outcome
Range: 0 .2 -5 .9  ppm RR (95%  CI), adjusted for risk factors: 
PTB, TM  1:
CO: 1.06 (1 .0 0 -1 .1 2 )
C O +N O 3+O 3 : 1.10 (1 .0 1 -1 .2 0 )  
C O +N O 3+O 3 + P M 10: 0 .99 (0 .8 3 -1 .1 8 )  
PTB, Last 6 weeks:
CO: 1.04 (0 .9 8 -1 .0 9 )
C O +N O 3+O 3 : 1.10 (1 .0 3 -1 .1 8 )  
C O +N O 3+O 3 + P M 10: 0 .98 (0 .8 3 -1 .1 6 )  
LBW, TM  3:
CO: 1.10 (0 .9 8 -1 .2 3 )
C O +N O 3+O 3 : 1.15 (0 .9 8 -1 .3 5 )  
C O +N O 3+O 3+ P M 10: 1.21 (0 .8 5 -1 .7 4 )
W oodruff et al. (2008) Outcome: Post-neonatal mortality Avg time: 24 hours Increment: 0.39 ppm
Period: 1 9 9 9 -2 0 0 2 (28 days- 1  year) Mean: 0 .70 ppm O R  (95%  C I), exposure during age 0 -2  months:
Location: U.S. counties with Design: Retrospective cohort 25 -7 5  %: 0 .4 8 -0 .8 7  ppm All causes: 1.001 (0 .9 5 -1 .0 7 )
>250 ,000  residents Sample: n=6,639 deaths of 
3 ,583 ,495  births
Respiratory:
CO: 1.14 (0 .9 3 -1 .4 0 )  
C O + 0 3 + P M !o+S 02:.1 .02  (0 .8 9 -1 .1 5 )
SIDS: CO: 0 .88 (0 .7 6 -1 .0 3 )
S ID S, C 0 + O 3+ P M 10+ S 0 2:.0.96 (0 .8 7 -1 .0 6 )
Yang et al. (2006) Outcome: Post-neonatal mortality Avg time: 24 hours Increment: 0 .55 ppm
Period: 1 9 9 4 -2 0 0 0 (27 days-1 year) Mean: 1.158 ppm O R  (95%  CI),lag 0 -2  days:
Location: Taiwain Design: Case-crossover 
Sample: n=471 cases
Range: 0 .3 2 -4 .8 4  ppm All causes: 1.038 (0 .6 6 3 -1 .6 2 4 )
B W  =  b i r t h  w e i g h t ;  C A  =  c o n g e n i t a l  a n o m a l i e s ;  C O  =  c a r b o n  m o n o x i d e ;  I U G R  =  i n t r a u t e r i n e  g r o w t h  r a t e  ( B W < 1 0 t h  p e r c e n t i l e  o f  b i r t h  c o h o r t  w h e n  a d j u s t e d  f o r  g e s t a t i o n a l  
a g e ) ;  L B W  =  l o w  b i r t h  w e i g h t  ( < 2 , 5 0 0  g ) ;  P T B  =  p r e - t e r m  b i r t h  ( < 3 7  w e e k s ) ;  O R  =  o d d s  r a t i o ;  S D  =  s t a n d a r d  d e v i a t i o n ;  S E  =  s t a n d a r d  e r r o r ;  S G A  =  s m a l l  f o r  g e s t a t i o n a l  a g e  
( B W < 1 0 t h  p e r c e n t i l e  o f  b i r t h  c o h o r t  w h e n  a d j u s t e d  f o r  g e s t a t i o n a l  a g e ) ;  T M  =  t r i m e s t e r
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and alcohol use during pregnancy. The adjusted odds ratio in the case-control study for pre-term birth 
(exposure to >1.25 ppm in first trimester compared to <0.58 ppm) was 1.21 (95% CI: 0.88-1.65; adjusted 
for co-variables other than co-pollutants). The odds ratio in the larger cohort (n=58,316) was similar 
(odds ratio: 1.25, 95% CI: 1.12-1.38); adjusted for maternal age, race, education, birth season, and 
parity). Results of multi-pollutant models were not reported. A larger case-control study, also conducted 
in southern California (1999-2000), did not find a significant association between ambient air carbon 
monoxide concentration and pre-term birth (Huynh et al. 2006). This study examined 10,673 cases of 
pre-term births (<37 weeks of gestation) and 32,119 full-term controls (matched for last menstrual period 
date within 2 weeks of cases). The adjusted odds ratios for pre-term birth were not significant, when 
adjusted for maternal age, maternal race/ethnicity, maternal education, marital status, and parity (with or 
without inclusion of PM25 exposure). A 1 ppm increase in ambient carbon monoxide concentration 
during the first month of pregnancy was associated with an odds ratio of 1.10 (95% CI: 0.99-1.20) when 
CO was considered alone, and 1.03 (95% CI: 0.83-1.13) after adjustment for PM10. This study matched 
ambient carbon monoxide measurements to subjects whose residence was <5 miles of the monitoring 
station, whereas the Ritz et al. (2000, 2007) and Wilhelm and Ritz (2005) studies matched subjects to 
<2 miles from the monitoring station.
Other large retrospective cohort studies have examined pre-term births in association with ambient air 
carbon monoxide concentrations. Liu et al. (2003) examined a cohort of 229,085 births in Vancouver, 
Canada (1985-1998). The odds ratio for pre-term birth for a 1 ppm increase in ambient air carbon 
monoxide concentration measured during the first month of pregnancy was 1.08 (95% CI: 1.01-1.15; 
adjusted for maternal age, parity, infant sex, birth weight, and season of birth), and remained elevated 
after adjustment for NO2 and O3 (1.08, 95% CI: 1.00-1.20). The mean air carbon monoxide 
concentration in the study was 1 ppm and the highest value was 12.8 ppm. A cohort study of 
52,113 births in Incheon, Korea (2001-2002) also estimated elevated risks of pre-term birth in association 
with increasing ambient air carbon monoxide concentrations during the first trimester. The relative risk 
increased with increasing estimated exposure concentration and was 1.26 (95% CI: 1.11-1.44) for the 
strata 0.91-1.27 mg/m3 compared to the reference, >0.47-0.63 mg/m3 (adjusted for maternal age, parity, 
sex, season of birth, and education level of father and mother; Leem et al. 2006). Results of multi­
pollutant models were not reported. The ambient air carbon monoxide concentrations ranged from 
approximately 0.35 to 1.4 ppm and were matched to subjects by spatial kriging (a spatial statistical 
method for interpolating exposure levels between sampling locations) with spatial averaging on a scale of 
approximately 3.5 km2. A cohort study of 123,840 births in Sydney, Australia (1998-2000) did not find a 
significant association between ambient air carbon monoxide concentration and pre-term birth (Jalaludin
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et al. 2007). The highest odds ratio estimated was 1.24 (95% CI: 0.81-1.91) or a 1 ppm increase in 
8-hour maximum carbon monoxide concentration measured during first trimester, based on residence 
<5 km of the monitoring station. When exposure estimates were based on city-wide monitoring, the odds 
ratio was significantly less than one (0.89, 95% CI: 0.84-0.95), suggesting that risk of pre-term birth 
decreased with a 1 ppm increase in air carbon monoxide concentration. The city-wide mean 8-hour 
maximum air carbon monoxide concentration was 0.9 ppm (SD: 0.68).
Studies of Low Birth Weight. Results of studies of low birth weight (i.e., <2,500 g or <10th percentile 
weight for gestation age) have been mixed with most studies finding associations between increasing 
ambient air carbon monoxide concentrations and decreasing birth weight (Bell et al. 2007; Gouveia et al. 
2004; Ha et al. 2001; Lee et al. 2003a; Liu et al. 2003, 2007; Maisonet et al. 2001; Mannes et al. 2005; 
Medeiros and Gouveia 2005; Parker et al. 2005; Ritz and Yu 1999; Salam et al. 2005; Wilhelm and Ritz
2005). In some studies that found significant regression coefficients (i.e., P coefficients) relating air 
carbon monoxide concentration to birth weight (g), magnitudes of the changes in birth weight were not 
sufficient to produce elevated risk of low birth weight, where low birth weight is defined categorically as 
a birth weight <2,500 g. Furthermore, the relative contribution of co-exposures to other air pollutants has 
not been completely elucidated in epidemiology studies. In many, but not all, studies showing significant 
associations with birth weight, these associations were not significant after adjustments for exposures to 
other co-pollutants (e.g., NO2, O3, PMJ0). All of these studies described below estimated risks after 
adjustment for typical co-variables that are thought to affect birth weight (e.g., infant sex, maternal age, 
race/ethnicity, and education, interval since previous live birth, previous low birth weight or preterm 
infant, level of prenatal care, birth season, parity, and gestational age). Collectively, the reported studies 
of birth weight outcomes provide supportive evidence for an association between ambient air carbon 
monoxide concentrations and low birth weight.
A series of studies conducted in California found such associations that were stronger when carbon 
monoxide was the only pollutant considered in the model and attenuated when adjustments were made for 
co-pollutants (Parker et al. 2005; Ritz and Yu 1999; Salam et al. 2005; Wilhelm and Ritz 2005). Mean air 
carbon monoxide concentrations in these studies ranged from 0.75 to 2.4 ppm and the highest value 
reported was 6.70 ppm (Wilhelm and Ritz 2005). The Ritz and Yu (1999) study found elevated risk of 
low birth weight in a sample of 125,573 births (1989-1993). The odds ratio (>5.5 vs. <2.2 ppm during 
third trimester) was 1.22 (95% CI: 1.03-1.44) when carbon monoxide alone was the only air pollutant 
considered and 1.38 (95% CI: 0.86-2.22) when NO2, O3, and PMJ0 were included in the model. The 
odds ratios remained significant after adjustment for NO2, O3, and PMJ0, when the analysis was restricted
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to women <20 years of age (multi-pollutant model: 5.08, 95% CI: 1.77-16.63; carbon monoxide alone: 
1.54, 95% CI: 1.07-2.22). In a follow-up study (Wilhelm and Ritz 2005; 1994-2000) that included
136,134 births, the odds ratio (>1.84 vs. <0.96 ppm) was estimated to be 1.36 (95% CI: 1.04-1.76) for 
women who resided <1 mile from an air monitoring station; however, risk was no longer significant when 
NO2 and O3 (1.29, 95% CI: 0.92-1.81), or NO2, O3, and PMJ0 were included in the model (1.39, 95% CI: 
0.77-2.49). A smaller cohort study (1975-1987) of 3,901 births found significant associations between 
ambient air carbon monoxide concentrations and low birth weight and intrauterine growth retardation 
(IUGR, <15th percentile of weight at gestational age; Salam et al. 2005). The estimated odds ratio for 
IUGR was 1.2 (95% CI: 1.0-1.4) for a 1.4 ppm increase in air carbon monoxide concentration in the first 
trimester (carbon monoxide considered alone). Although the odds ratio for low birth weight was not 
significant (1.0, 95% CI: 0.7, 1.5), a significant association between increasing air carbon monoxide 
concentration and lower birth weight was observed when birth weight was treated as a continuous 
variable (P coefficient: -21.7 g, 95% CI: -42.3, -1.1), which persisted when O3 was included in the 
model (-28.6, 95% CI: -50.4, -6.9). A cohort study of 18,247 full-term births in California (2000) did not 
find a significant association between ambient air carbon monoxide concentration and risk of SGA (i.e., 
small for gestational age, <10th percentile of weight for gestational age; Parker et al. 2005). The SGA 
odds ratio (>0.97 vs. <0.57 ppm for entire pregnancy) was 0.95 (95% CI: 0.81-1.12) when carbon 
monoxide was considered alone and 0.82 (95% CI: 0.68-0.99) when adjusted for PM25. When treated as 
a continuous variable, a significant association between increasing air carbon monoxide concentration and 
lower birth weight was found when carbon monoxide was modeled alone (P coefficient: -20.5 g, 95% CI: 
-40.1, -0.8); however, the association was not significant when adjusted for PM25 (2.6, 95% CI: -20.6,
25.8).
Other studies of low birth weight conducted in the United States have yielded mixed results. A cohort 
study of 89,557 full tem births conducted in five northeastern cities (1994-1996) estimated the odds ratio 
for low birth weight to be 1.31 (95% CI: 1.06-1.62) for a 1 ppm increase in air carbon monoxide 
concentration during the third trimester (Maisonet et al. 2001). When stratified by race, the effect was 
only significant among African Americans for the first trimester (odds ratio: 1.43, 95% CI: 1.18-1.74) 
and third trimester (odds ratio: 1.75, 95% CI: 1.50-2.04). Results of multi-pollutant models were not 
reported. A cohort study of 358,504 births in Connecticut and Massachusetts found a significant 
association between increasing ambient air carbon monoxide concentration (for entire pregnancy) and 
reduced birth weight (P coefficient: -16.2, 95% CI: -19.7, -12.6), which persisted when adjusted for 
NO2, O3, PMi0, PM25, or SO2 (Bell et al. 2007). However, the magnitude of the change in birth weight
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did not result a significant odds ratio (odds ratio: 1.028, 95% CI: 0.983-1.074). Mean air carbon 
monoxide concentrations in the above studies ranged from 0.65 to 0.95 ppm.
Two studies examined low birth weight or IUGR in Canada (Liu et al. 2003, 2007). The Liu et al. (2003) 
study included 229,085 births in the Vancouver area (1985-1998), and found a significant association 
between ambient air carbon monoxide concentration (during fist month of pregnancy) and IUGR risk per 
1 ppm increase in carbon monoxide (odds ratio: 1.06, 95% CI: 1.01-1.10), which persisted when 
adjusted for NO2, O3, or SO2 (OR estimates not reported). In a larger area study (Liu et al. 2007) that 
included 386,202 births (1995-2000), odds ratios were significant for IUGR when ambient air carbon 
monoxide concentrations were considered during the first trimester (1.18, 95% CI: 1.14-1.22), second 
trimester(1.14, 95% CI: 1.10-1.18), or third trimester (1.19, 95% CI: 1.14-1.24). The odd ratios 
remained significant after adjustment for exposures to NO2, and PM25. The mean air carbon monoxide 
concentration in both studies was 1 ppm and the highest value reported was 5.6 ppm.
Two studies conducted in Seoul, South Korea (1996-1997, 1996-1998) found significantly increased risk 
of low birth weight in cohorts of 276,763 births (Ha et al. 2001) and 388,105 births (Lee et al. 2003a). In 
the Ha et al. (2001) study, the relative risk of low birth weight for a 0.42 ppm increase in ambient air 
carbon monoxide concentration during the first trimesters was 1.08 (95% CI: 1.04-1.12). In the Lee et 
al. (2003a) study, the odds ratios for a 0.5 ppm increase in carbon monoxide concentration were 
1.04 (95% CI: 1.01-1.07) for the first trimester, 1.03 (1.00-1.06) for the second trimester carbon 
monoxide, 0.96 (0.93-0.99) for the third trimester carbon monoxide, and 1.05 (1.01-1.09) for carbon 
monoxide concentration during the entire pregnancy. Results of multi-pollutant models were not 
reported. The mean air carbon monoxide concentration was 1.2 ppm (range: 0.4-3.4 ppm).
A cohort study conducted in Sydney, Australia (1998-2000) included 138,056 births and found a 
significant association between increased ambient air carbon monoxide concentration and decreasing 
birth weight (Mannes et al. 2005). For carbon monoxide exposure during the second trimester, an 
increase of 1 ppm was associated with a 28.7 g reduction birth weight (95% CI: 7.76-50.98). The 
association did not persist when the regression models were adjusted for exposure to NO2, or to PM10 in 
two-pollutant models. Furthermore, the magnitude of the effect did not result in a significant risk of SGA 
(<2 SD of mean weight for gestational age). The mean ambient carbon monoxide concentration of 
0.8 ppm (range: 0-4.6).
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Two cohort studies conducted in Sao Paulo, Brazil also found a significant association between increasing 
ambient air carbon monoxide concentration and decreasing birth weight (Gouveia et al. 2004; Medeiros 
and Gouveia 2005). In the Gouveia et al. (2004) study, in a cohort of 179,460 births (1997), a 1 ppm 
increase in ambient air carbon monoxide concentration during the first trimester was associated with a 
23.1 g reduction in birth weight (95% CI: 4.9.0-41.3); however, the effect was not of sufficient 
magnitude to result in elevated risk of low birth weight. The Medeiros and Gouveia (2005) included 
311,735 births (1998-2000) and estimated a reduction in birth weight of 11.9 g (95% CI: 8.2-15.5) per
1 ppm increase in first trimester carbon monoxide concentration. Here again, odds ratios for low birth 
weight were not significant. The ambient carbon monoxide concentrations in these studies ranged from 
approximately 1 to 11 ppm.
Studies of Congenital Anomalies. Possible associations between exposures to carbon monoxide and 
developmental anomalies have been evaluated in three case-control studies (Gilboa et al. 2005; Hwang 
and Jaakkola 2008; Ritz et al. 2002). Although two of the studies found significant associations between 
carbon monoxide and heart anomalies (i.e., ventricular septic defects (Ritz et al. 2002) and conotruncal 
defects (Gilboa et al. 2005), the two studies did not corroborate their findings. The Ritz et al. (2002) 
study did not find a significant association of conotrunal defects, and the Gilboa et al. (2005) study did 
not find a significant association with ventricular septal defects. The evaluation in the Hwang and 
Jaakkola (2008) study was limited to cleft lip and palate and found no association with carbon monoxide, 
consistent with the Ritz et al. (2002) study. Collectively, these studies do not provide convincing 
evidence for associations between exposure to carbon monoxide and congenital anomalies.
The Ritz et al. (2002) study included 3,549 cases and 10,649 controls born during the period 1987-1993 
in southern California. The study included various categories of anomalies including heart and 
pulmonary, conotruncal, cleft lip and palate, and chromosomal defects. Of these, significant odds ratios 
were found for ventricular septal defects with increasing ambient air carbon monoxide concentration 
during the second month of pregnancy. Odds ratios increased with increasing ambient air carbon 
monoxide concentration during the second month of pregnancy (<1.14 ppm reference): 1.14-1.60 ppm, 
odds ratio 1.62 (95% CI: 1.05-2.48), 1.60-<2.47 ppm, odds ratio 2.09 (95% CI: 1.19-3.67); >2.47 ppm, 
odds ratio 2.95 (95% CI: 1.44-6.05). Significant odds ratios for ventricular septal defects persisted in 
multi-pollutant models.
A case-control study conducted in Texas (1996-2000) included 4,594 cases and 3,667 controls (Gilboa et 
al. 2005). Anomalies considered in the study included heart and pulmonary, conotruncal, and cleft lip and
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palate. Of these, a significant dose trend was evident for Tetralogy of Fallot (a conotuncal anomaly of the 
heart), with a significant odds ratio (>0.7 vs. <0.4 ppm) for ambient air carbon monoxide concentration 
during the 3rd to 8th week of pregnancy (2.04 95% CI: 1.26-3.29). The odds ratio for any conotruncal 
anomaly was also significant at the highest exposure category (>0.7 vs. <0.4 ppm) (1.46 95% CI: 1.03­
2.08). Results of multi-pollutant models were not reported.
A case-control study conducted in Taiwan China (2001-2003) included 653 cases of cleft lip and/or 
palate and 6,530 controls and examined associations with ambient air carbon monoxide concentrations 
measured during the first trimester of pregnancy (Hwang and Jaakkola 2008). Air carbon monoxide 
concentration was not associated with odds ratio for either anomaly in single-pollutant or multiple- 
pollutant models (O3, PM10, or SO2).
Studies of Neonatal and Infant Mortality. Studies of possible associations between ambient air carbon 
monoxide concentrations and neonatal and infant mortality have yielded mixed results (Ha et al. 2003;
Lin et al. 2004a; Ritz et al. 2006; Tsai et al. 2006a; Woodruff et al. 2008;Yang et al. 2006). Although 
increased risk of infant mortality in association with increasing ambient air carbon monoxide 
concentrations has been reported (Ha et al. 2003; Ritz et al. 2006), these outcomes have not been 
rigorously examined for the possible confounding by birth weight and/or gestational age, two relatively 
influential variables in predicting infant mortality. In one study that did examine the effect of 
stratification by gestational age or birth weight, the association between air carbon monoxide 
concentration and mortality from all causes or sudden infant death syndrome (SIDS) persisted in single­
pollutant models, but not in models that adjusted for NO2, PM10, and O3 (Ritz et al. 2006). Collectively, 
these studies do not provide convincing evidence for an association between ambient air carbon monoxide 
concentrations and neonatal or infant mortality.
A time-series analysis conducted in Sao Paulo, Brazil (1998-2000) did not find a significant association 
between ambient air carbon monoxide concentrations and neonatal mortality (age 1-28 days; Lin et al. 
2004a). The mean air carbon monoxide concentration was 2.8 ppm (range: 0.5-10). A case-control 
study conducted in California (1989-2000) included 13,146 cases of infant death (age 28 days-1 year) 
and 151,015 controls (Ritz et al. 2006). Results varied depending on the temporal window for averaging 
air carbon monoxide concentration. The odds ratio for infant death for a 1 ppm increase in ambient air 
carbon monoxide concentration, averaged for 2 months prior to death, was 1.11 (95% CI: 1.06-1.16), 
with higher risk for deaths attributable to SIDS (odds ratio: 1.19; 95% CI: 1.10-1.28). However, risks 
were not significant after adjustment for co-pollutants (NO2, PMJ0, and O3). For an averaging period of
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2 weeks prior to death, risks were significant for all respiratory-related deaths that occurred between 
28 days and 1 year (odds ratio: 1.14, 95% CI: 1.03-1.25) or from age 28 days to 3 months (odds ratio: 
1.20, 95% CI: 1.02-1.40). Significant respiratory deaths persisted in multi-pollutant models. The 
association between air carbon monoxide concentration and SIDS mortality risk was persistent when the 
data were stratified by gestational age and birth weight; however, in these strata, the associations were not 
significant after adjustment for exposure to NO2, PM10, and O3. The mean air carbon monoxide 
concentration in the study was 1.6 ppm (range: 0.4-3.4).
A retrospective cohort study analyzed deaths that occurred between age 28 days and 1 year in a cohort of
3,590,134 births (6,939 deaths) across U.S. counties having a population >250,000 residents (1989-2000; 
Woodruff et al. 2008). Ambient air carbon monoxide concentration (median: ppm, 25th-75th percentile 
range: 0.7-0.9) during the first 2-months postpartum was not associated with infant death of any 
category, including all causes (odds ratio: 1.01, 95% CI: 0.95-1.07), respiratory (odds ratio: 1.14, 0.93­
1.40), or SIDS (odds ratio: 0.88, 0.76-1.03). The latter values were estimated from single-pollutant 
models; however, similar results were obtained in multi-pollutant models that adjusted for O3 and SO2.
A time-series study conducted in Seoul, South Korea (1995-1999) found a significant risk of respiratory- 
related mortality (age 1 month-1 year) in association with increasing ambient air carbon monoxide 
concentration measured on the day of death (odds ratio: 1.388, 95% CI: 1.009-1.911, per 0.57 ppm 
increase in carbon monoxide concentration), but not for deaths from all causes (Ha et al. 2003). Two 
case-crossover studies conducted in Taiwan, China (1994-2000) did not find a significant association 
between ambient air carbon monoxide concentration and infant mortality (Tsai et al. 2006a; Yang et al.
2006). The Tsai et al. (2006a) study included 206 cases (age 28 days-1 year) and the mean ambient air 
carbon monoxide concentration was 0.83 ppm (range: 0.23-1.77). The Yang et al. (2006) study included 
471 cases (age 27 days-1 year); the mean ambient air carbon monoxide concentration was 1.58 ppm 
(range: 0.3-4.8).
Animal Studies. Numerous studies on developmental effects of gestational and early postnatal exposure 
to carbon monoxide have been conducted in animals. Study details are summarized in Table 3-9. In 
general, most studies evaluated effects of relatively low carbon monoxide concentrations (i.e., <300 ppm), 
with exposure concentrations selected to produce maternal COHb levels typically associated with 
smoking; however, studies did not consistently report maternal or fetal COHb levels. Studies in animals 
have examined effects of carbon monoxide exposure on numerous developmental outcomes, including 
several outcomes that have not been assessed in epidemiological studies (e.g., auditory and immune
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Effects on birth weight 
Astrup et al. 1972 Rabbits
Carmines and Rat
Rajendran 2008
Fechter and Annau Rats 
1977
Fechter and Annau Rats 
1980
Fechter et al. 1987a Rats
Continuous exposure m C O H b: 8 -9 %  in 90 ppm 
to 0, 90, or 180 ppm C O  group; 1 6 -1 8 %  in 
C O  throughout 180 ppm C O  group 
gestation fC O H b : NR
2 hours/day to m C O H b: ~30%  (measured
600 ppm C O  on on G D  20)
GDs 6 -1 9  (nose-only fC O H b : NR  
exposure)
Continuous exposure m C O H b: 15%  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0-21
Continuous exposure 
to 0 or 150 ppm CO  
on G Ds 0 -2 0
Continuous exposure 
to 0, 75, 150, or 
300 ppm C O  from 
G D  0 through 
PND  10
m C O H b: NR  
fCOHb: NR
m C O H b: 11, 18, and 27%  
In the 75, 150, or 300 ppm 
CO, respectively 
fCOHb: NR
Birth weight: Fetal weight decreased by 11 and 20%  in the 90 
or 180 ppm C O  groups, respectively.
NO AEL (birth weight): Not established
LOAEL (birth weight): 90 ppm C O  (m CO Hb 8 -9 % )
Birth w eight: Significantly decreased by 11% , compare to 
control.
NO AEL (birth weight): Not established
LOAEL (birth weight): 600 ppm C O  (m C O H b ~30% )
Birth w eight: Decreased by 4.8% , compared to controls (not 
statistically significant)
Pre-weanling w eight: Pre-weanling weight significantly 
decreased, compared to control, on PNDs 4 -2 1  (decreased  
by 16 and 27%  on PND s 4 and 21, respectively).
NO AEL (pre-weanling weight): Not established 
LOAEL (pre-weanling weight): 60 ppm C O  (m C O H b 15%)
Birth weight: Decreased by 7.6% , compared to controls.
NO AEL (pre-weanling weight): Not established 
LOAEL (pre-weanling weight): 150 ppm CO
Birth weight: Fetal weight decreased by 8.9 and 13.8%  in 150 
and 300 ppm C O  groups, respectively compared to control; 
by PND  21, no effects of C O  treatm ent on pup weight.
NO AEL (birth weight): 75 ppm C O  (m CO Hb 11%)
LOAEL (birth weight): 150 ppm C O  (m C O H b 18%)
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Penney et al. 1983 Rats
Prigge and Hochrainer Rats 
1977
Storm and Fechter 
1985b
Rats
Continuous exposure 
to 0, 157, 166, or 
200 ppm C O  on 
GDs 5 -2 2
Continuous exposure 
to 0, 60, 125, 250, or 
500 ppm C O  on 
GDs 0 -21
m C O H b: 24 .9%  (in dams 
exposed to 200 CO, 
measured over period of 
PNDs 1 -6  days) 
fC O H b : 21.8, 24.9 , and 
3 .1 0 -3 3 .5 %  at 157, 166, or 
200 ppm CO, respectively 
(at birth)
m C O H b: NR  
fCOHb: NR
Continuous exposure m C O H b: 11.5, 18.5, and
Tolcos et al. 2000b  Guinea pigs
to 0, 75, 150, or 
300 ppm C O  for 
entire gestational 
period
10 hours/day 0 or 
200 ppm C O  from 
GDs 23 or 25 to 
G D  68
26.8%  in the 75, 150, or 
300 ppm C O  groups, 
respectively 
fC O H b : NR
m C O H b: 8.5%  
fCOHb: 13%
Effects on central nervous system (central control of respiratory function) 
M cGregor et al. 1998 Guinea pigs 10 hours/day 0 or m C O H b: 8.5%
200 ppm C O  from fC O H b : 13%
GDs 23 or 25 to GD  
68
Birth weight: Statistically significant decrease (~10% ) in all 
C O  groups, compared to control.
NO AEL (birth weight): Not established
LOAEL (birth weight): 157 ppm C O  (fCO Hb 21.8%  )
Birth weight: Dose-related, statistically significant decrease  
(7 .5 -3 6 .7 % ) in fetal weight at >125 ppm, compared to control.
NO AEL (birth weight): 60 ppm CO  
LOAEL (birth weight): 125 ppm CO
Birth weight: Fetal weight decreased by 12.5%  in 300 ppm 
C O  group, compared to control.
NO AEL (birth weight): 150 ppm C O  (m C O H b 18.5% )
LOAEL (birth weight): 300 ppm C O  (m C O H b 27% )
Birth w eight: Fetal weight decreased by 9.6%  in C O  group, 
compared to control.
NO AEL (birth weight): Not established
LOAEL (birth weight): 200 ppm C O  (m C O H b 8.5% )
C N S development (function): On PND  4, pups from C O ­
exposed dams exhibited abnormal respiratory responses to 
asphyxia and hypercapnia; responses consistent with 
developmental alterations in brain stem.
NO AEL (C N S function): Not established
LOAEL (C N S  function): 200  ppm C O  (m CO Hb 8.5% )
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Effects on central nervous system (behavioral)
De Salvia et al. 1995 Rats 0, 75, or 150 ppm 
C O  on G Ds 0 -2 0
m C O H b: ~15%  for 
150 ppm C O  (N R  for 
75 ppm CO) 
fCOHb: NR
C N S development (behavioral effects): Significant 
impairment of acquisition (at 3 and 18 months) and 
reacquisition (at 18 months) of conditioned avoidance 
behavior following gestational exposure of pups to 150 ppm 
CO.
Fechter and Annau 
1977
Rats Continuous exposure m C O H b: 15%  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -21
N O AEL (C N S  behavioral): 75 ppm CO  
LOAEL (C N S  behavioral): 150 ppm CO
C N S development (behavioral effects): During the 
preweaning period, C O  pups were less active and showed 
decreased response to L-DOPA-induced movement 
stimulation.
Fechter and Annau 
1980
Rats
Giustino et al. 1999 Rats
Continuous exposure m C O H b: NR  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -2 0
Continuous exposure m C O H b: 7.3 and 16.1%  in 
to 75 and 150 ppm 75 and 150 ppm CO
C O  on G Ds 0 -2 0  groups, respectively
fCOHb: NR
N O AEL (C N S  behavioral): Not established 
LOAEL (C N S  behavioral): 60 ppm C O  (m CO Hb 15%)
C N S development (behavioral effects): Pups of exposed 
dams showed impaired righting reflexes, impaired negative 
geotaxis, and delayed homing behavior.
N O AEL (C N S  behavioral): Not established 
LOAEL (C N S  behavioral): 150 ppm CO
C N S development (behavioral effects): Alterations in 
habituation and working memory in young adult male 
offspring at PND  40, including decreased time of exploration 
of novel objects (75 and 150 ppm CO) and lack of habituation 
after the second exposure to a previously viewed object (150  
ppm CO); decreased spontaneous motor activity in open field 
test (75 and 150 ppm CO).
N O AEL (C N S behavioral): Not established 
LOAEL (C N S  behavioral): 75 ppm CO
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Reference Species Exposure COHb Results
Mactutus and Fechter 
1985
Rats Continuous exposure m C O H b: 15.6%  
to 150 ppm C O  over fC O H b : NR  
entire gestational 
period
C N S development (behavioral effects): Prenatal CO  
exposure induced learning and memory deficits in male and 
fem ale offspring, as indicated by impairments in reacquisition 
performance, an index of retention, on PND  31 and 
decrements in two-way conditioned avoidance behavior 
(flashing light warnings followed by mild foot shock) on PND  
120 .
NO AEL (C N S behavioral): Not established
LOAEL (C N S  behavioral): 150 ppm C O  (m CO Hb 15.6% )
Singh 1986 Mice Continuous exposure m C O H b: NR  
to 0, 65, or 135 ppm fC O H b : NR  
C O  on G Ds 7 -1 8
C N S development (behavioral effects): On PNDs 1 -1 0 , pups 
of exposed dam s showed impaired righting reflexes (125 ppm 
CO), geotaxis (125 ppm CO ), and aerial righting reflex (65  
and 125 ppm CO)
Tattoli et al. 1999 Rats Continuous exposure C O H b in pups: 
to 0, 75, or 150 ppm 
C O  on PNDs 1 -1 0
NO AEL (C N S  behavioral): Not established 
LOAEL (C N S  behavioral): 65 ppm CO
NR C N S development (behavioral effects): Assessed at 3 and 18
months of age, no effects of early postnatal exposure on 
acquisition and reacquisition of an active avoidance task in 
both adult and aged rats.
NOAEL: 150 ppm CO  
LOAEL: Not established
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Reference Species Exposure COHb Results
Effects on central nervous system (neurotransmitter)
Cagiano et al. 1998 Rats Continuous exposure m C O H b: ~16%  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -2 0
C N S development (neurotransmitter changes): On PN D  80, 
no C O  effect on basal extracellular levels of dopamine in the 
nucleus accumbens; however, the amphetamine-induced  
dopamine release was decreased in pups of CO-exposed  
dams.
Fechter and Annau 
1977
Rats Continuous exposure m C O H b: 15%  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -21
N O AEL (C N S neurotransmitter): Not established
LOAEL (C N S  neurotransmitter): 150 ppm C O  (m CO Hb 16%)
C N S development (neurotransmitter changes): Brain 
dopamine content decreased by 45 and 25%  on PND s 1 and 
4, respectively.
Fechter and Annau 
1980
Rats
Fechter et al. 1987a Rats
Storm and Fechter 
1985a
Rats
Continuous exposure m C O H b: NR  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -2 0
Continuous exposure 
to 0, 75, 150, or 
300 ppm C O  from 
GD 0 through 
PND  10
m C O H b: 11, 18, and 27%  
In the 75, 150, or 300 ppm 
CO, respectively 
fCOHb: NR
Continuous exposure m C O H b: NR  
to 0 or 150 ppm for fC O H b : NR  
entire gestational 
period
NO AEL (C N S  neurotransmitter): Not established 
LOAEL (C N S  neurotransmitter): 60 ppm C O  (m CO Hb 15%)
C N S development (neurotransmitter changes): On PN D  1, no 
effect of C O  exposure on forebrain and hindbrain levels of 
dopamine or norepinephrine.
NO AEL (C N S  neurotransmitter): 150 ppm CO  
LOAEL (C N S  neurotransmitter): Not established
C N S development (neurotransmitter changes): On PND  21, 
pups of CO-exposed dams showed elevated dopamine levels 
in neostriatum (150 and 300 ppm CO).
N O AEL (C N S neurotransmitter): 75 ppm C O  (m CO Hb 11%) 
LOAEL (C N S  neurotransmitter): 150 ppm C O  (m CO Hb 18%)
C N S development (neurotransmitter changes):
Norepinephrine levels (amount and concentration) in 
cerebellum (but not cortex) elevated from PNDs 1 4 -4 2 , 
compared to controls.
N O AEL (C N S  neurotransmitter): Not established 
LOAEL (C N S  neurotransmitter): 150 ppm CO
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Storm and Fechter 
1985b
Rats Continuous exposure m C O H b: 11.5, 18.5, and
to 0, 75, 150, or 
300 ppm C O  for 
entire gestational 
period
26.8%  in the 75, 150, or 
300 ppm C O  groups, 
respectively 
fCOHb: NR
C N S development (neurotransmitter changes): On PN D  21, 
weight of cerebellum decreased by 8.5 and 11.4%  in 150 and 
300 ppm C O  groups, respectively; dose-related trend for 
decreased norepinephrine concentration in pons/medulla (but 
not neocortex, hippocampus or cerebellum; decreased  
serotonin concentration in pons/medulla in 150 and 300 ppm 
C O  groups. On PND  42, weight of cerebellum decreased by 
8.3%  in 300 ppm C O  group; dose-related trend for increased 
norepinephrine concentration neocortex and hippocampus 
(but not pons/medulla or cerebellum).
Tolcos et al. 2000b  Guinea pigs 10 hours/day 0 or 
200 ppm C O  from 
GDs 23 or 25 to 
GD 68
m C O H b: 8.5%  
fCOHb: 13%
N O AEL (C N S  neurotransmitter): 75 ppm C O  (m CO Hb  
11.5% )
LOAEL (C N S  neurotransmitter): 150 ppm C O  (m CO Hb  
18.5% )
C N S development (neurotransmitter changes): Effects on 
cholinergic and catecholaminergic pathways in the medulla, 
including significant decrease in tyrosine hydroxylase- 
immunoreactivity in the nucleus tractus solitarius, dorsal 
motor nucleus of the vagus, area postrema, intermediate 
reticular nucleus, and the ventrolateral medulla; significant 
increase in choline acetyltransferase-immunoreactivity in the 
dorsal motor nucleus of the vagus and hypoglossal nucleus, 
compared with controls.
N O AEL (C N S neurotransmitter): Not established
LOAEL (C N S  neurotransmitter): 200  ppm C O  (m CO Hb 8.5% )
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Effects on central nervous system (auditory system)
Lopez et al. 2003 Rats Continuous exposure m C O H b: NR
to 0, 12, or 25 ppm fC O H b : NR  
C O  on PNDs 8 -2 2
C N S development (auditory system ): Pups examined on 
PND  27, nerve terminals innervating inner hair cells were  
swollen, with cytoplasmic vacuolization and atrophy (25 ppm 
CO); in the 8th cranial nerve at the level of the internal 
auditory canal, fibers showed “distorted myelin” with 
vacuolization (25 ppm CO); in spiral ganglion neurons of the 
organ of corti, decreased immunoreactivity of enzymes  
cytochrome oxidase, N A D H -TR , and calcium-mediated  
myosin A TPase (25 ppm CO); in organ of corti, decreased  
immunostaining of neurofilament and myelin basic protein (25 
ppm CO).
Lopez et al. 2008 Rats 1 0 -1 8  hours/day to 
25 ppm C O  on GDs  
5 -2 0  or on GDs 5­
20 plus PNDs 5 -2 0
m C O H b: NR  
fCOHb: NR
NO AEL (C N S auditory): 12 ppm CO  
LOAEL (C N S  auditory): 25 ppm CO
C N S development (auditory system ): Similar effects in pups 
exposed during gestation only and during gestation and PNDs  
5 -2 0 . On PND  3, no morphological deterioration, or loss of 
inner or outer hair cells; on PND 20, vacuolization on the 
afferent terminals at the basal portion of the cochlea; type I 
spiral ganglia neurons and afferent nerve fibers showed 
decreased neurofilament-immunoreactivity.
NO AEL (C N S auditory): Not established 
LOAEL (C N S  auditory): 25 ppm CO
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Reference Species Exposure COHb Results
Stockard-Sullivan
2003
Rats
W ebber et al. 2003 Rats
22 hour/day to 1 2 , 
25, 50, or 100 ppm 
C O  on PNDs 6 -2 2
C O H b in pups: 5 -7 %  in 
100 ppm C O  group (not 
measured in other groups)
Continuous exposure m C O H b: NR  
to 0, 12.5, 25, or fC O H b : NR  
50 ppm C O  on GDs  
8 through 20-22
C N S development (auditory system ): Decreased in 
otoacoustic emissions at 50 and 100 ppm CO , measured at 
age 2 2 -2 4  days; attenuation of the amplitude of the 8th nerve 
action potential in all C O  groups, measured at age 2 2 -2 4  
days, with effects persisting though age 73 days in the 50 and 
100 ppm C O  group (not examined at later ages in other 
groups); no effect on auditory brain stem conduction times in 
any C O  group, measured at ages 22, 30, or 5 1 -5 2  days .
NO AEL (C N S auditory): Not established 
LOAEL (C N S  auditory): 12 ppm CO
C N S development (auditory system ): Examined effects of CO  
exposed on central inferior colliculus (an area of the mid-brain 
with auditory integrative functions) during period of 
synaptogenesis/auditory development. Immunostating of c­
Fos (m arker of neuronal activation in the nervous system) 
showed significant decrease in C-Fos immunoreactivity in the 
central inferior colliculus on PND 27 and PNDs 7 5 -7 7  in all 
C O  groups. Results indicate that gestational exposure to CO  
can produce changes in the auditory system of rats that 
persist into adulthood.
NO AEL (C N S  auditory): Not established 
LOAEL (C N S  auditory): 12.5 ppm CO
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Table 3-9. Effects of Gestational or Perinatal Exposure on Developmental Outcomes in Animals
Reference Species Exposure COHb Results
Effect on peripheral nervous system  
Carratu et al. 1993 Rats
Carratu et al. 2000a  Rats
Carratu et al. 2000b  Rats
Effects on cardiovascular system  
Penney et al. 1982 Rats
Continuous exposure m C O H b: ~15%  for 
to 0, 75, or 100 ppm 150 ppm C O  (N R  for 
C O  on G Ds 0 -2 0  75 ppm CO)
fCOHb: NR
Continuous exposure m C O H b: 16.02%  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -2 0
Continuous exposure m C O H b: 7 .34 and 16.08%  
to 0, 75, or 100 ppm in the 75 and 150 ppm CO  
C O  on G Ds 0 -2 0  groups, respectively 
fCOHb: NR
Continuous exposure C O H b in pups:38 -42%  
to 0 or 500 ppm C O  
on PND s 1 -3 2
PNS development (electrophysiological changes): In sciatic 
nerves isolated on PND  40, inactivation kinetics of inactive 
sodium channels were significantly slowed and negative shift 
in sodium equilibrium potential was observed in both C O  
groups; on PND  270, sciatic nerves showed negative shift in 
sodium equilibrium potential both C O  groups.
N O AEL (P N S  development): Not established 
LOAEL (P N S  development): 75 ppm CO
PNS development (neuronal developm ent): Altered 
sphingomyelin composition of sciatic nerve, but no effect on 
motor activity in pups at PND  90.
N O AEL (P N S  development): Not established 
LOAEL (P N S  development): 150 ppm CO
PNS development (neuronal developm ent): Exposure of 
dams produced decreased myelin sheath thickness of nerve 
fibers (75 and 100 ppm CO) but not axon diam eter or motor 
activity in pups at PNDs 40 and 90.
N O AEL (P N S  development): Not established 
LOAEL (P N S  development): 75 ppm CO
C VS (heart weight): Relative heart weight increased on PND  
14 and remained above normal through PND 104.
N O AEL (developmental heart weight): Not established 
LOAEL (developmental heart weight): 500 ppm C O  (CO Hb  
3 8 -4 2 % )
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Reference Species Exposure COHb Results
Penney et al. 1983 Rats Continuous exposure m C O H b: 24 .9%  (in dams
to 0, 157, 166, or 
200 ppm C O  on 
GDs 5 -2 2
exposed to 200 CO, 
measured over period of 
PNDs 1 -6  days) 
fC O H b : 21.8, 24.9 , and 
3 .1 0 -3 3 .5 %  at 157, 166, or 
200 ppm CO, respectively 
(at birth)
C VS  (heart weight): Dose-related, statistically significant 
increased in relative heart weight (1 0 -1 0 8 % ) in all CO  
groups, compared to control.
NO AEL (developmental heart weight): 
LOAEL (developmental heart weight): 
21.8%)
Not established 
157 ppm C O  (fCO Hb
Prigge and Hochrainer Rats 
1977
Sartiani et al. 2004 Rats
Continuous exposure m C O H b: NR  
to 0, 60, 125, 250, or fC O H b : NR  
500 ppm C O  on GDs  
0-21
Continuous exposure m C O H b: NR  
to 0 or 150 ppm C O  fC O H b : NR  
on G Ds 0 -2 0
C VS (heart w eight): Dose-related, statistically significant 
increase in relative heart weight (1 0 -5 2 % ) in all C O  groups, 
compared to control.
N O AEL (developmental heart weight): Not established 
LOAEL (developmental heart weight): 60 ppm CO
C VS (myocardial electrophysiological changes): In ventricular 
cardiocytes isolated from pups on PNDs 1 -6 0 , delayed 
development of age-related action potential duration 
shortening was observed. Delay was maximum at 4 weeks of 
age.
N O AEL (C V S  function): Not established 
LOAEL (C V S  function): 150 ppm CO
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Reference Species Exposure COHb Results
Effects on sexual behavior 
Cagiano et al. 1998 Rats
Effects on immunological system  
Giustino et al. 1993 Rats
Giustino et al. 1994 Rats
Effects on hematological system
Prigge and Hochrainer Rats 
1977
Continuous exposure m C O H b: ~7.5  and ~16%  in Developm ent of sexual behavior: On PND 80, in pups of
to O, 75, or 15O ppm 
C O  on G Ds O-2O
75 and 15O ppm CO  
groups, respectively 
fCOHb: NR
dams exposed to 150 ppm C O  (but not 75 ppm CO), 
alterations in sexual behavior, including increase in mount to 
intromission latency, decrease in mount to intromission 
frequency, and decrease in ejaculation frequency.
N O AEL (developmental sexual behavior): 75 ppm CO  
LOAEL (developmental sexual behavior): 150 ppm CO
Continuous exposure m C O H b: ~15%  in 150 ppm Immunological effects: On PNDs 15 and 21, decreased
to 75 and 15O ppm 
C O  on G Ds O-2O
C O  group (N R  in 75 ppm 
C O  group) 
fCOHb: NR
Continuous exposure m C O H b: ~15%  in 15O ppm
to 75 and 15O ppm 
C O  on G Ds O-2O
C O  group (N R  in 75 ppm 
C O  group) 
fCOHb: NR
Continuous exposure m C O H b: NR  
to 0, 60, 125, 250, or fC O H b : NR  
500 ppm C O  on GDs  
0-21
splenic macrophage phagocytosis of C andida a lb icans  
(150 ppm CO); on PND 15, decreased splenic macrophage 
killing (75 and 150 ppm CO); no effects observed on PND  60.
N O AEL (immunological): Not established 
LOAEL (immunological): 75 ppm CO
Immunological effects: On PND  21, significant decreased in 
number of leukocyte common antigen cells in 150 ppm CO  
group; no effects observed on PND  540.
N O AEL (immunological): 75 ppm C O
LOAEL (immunological): 150 ppm C O  (m CO Hb ~ 1 5% )
Hematological effects: Dose-related, statistically significant 
decrease in hematocrit (1 4 .8 -3 4 .2 % ) and hemoglobin (12.5­
28.4% ) at >250 ppm, compared to control.
N O AEL (hematological): 125 ppm CO  
LOAEL (hematological): 250 ppm CO
C N S  =  c e n t r a l  n e r v o u s  s y s t e m ;  C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  C V S  =  c a r d i o v a s c u l a r  s y s t e m ;  f C O H b  =  f e t a l  C O H b ;  G D  =  g e s t a t i o n  d a y ;  L O A E L  =  
l o w e s t - o b s e r v e d - a d v e r s e - e f f e c t  l e v e l ;  m C O H b  =  m a t e r n a l  C O H b ;  N O A E L  =  n o - o b s e r v e d - a d v e r s e - e f f e c t  l e v e l ;  N R  =  n o t  r e p o r t e d ;  P N D  =  p o s t n a t a l  d a y
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system development). Results of animal studies show adverse developmental effects of gestational and 
early postnatal carbon monoxide exposure, including decreased fetal weight, adverse central nervous 
system development, altered peripheral nervous system development, cardiac effects, altered sexual 
behavior, immunological effects, and hematological effects. In addition, some studies showed that 
developmental effects persisted beyond the postnatal period (Carratu et al. 1993, 2000a, 2000b; De Salvia 
et al. 1995; Mactutus and Fechter 1985; Stockard-Sullivan et al. 2003; Webber et al. 2003), although 
persistence of effects was not examined in all studies. The lowest LOAEL values for developmental 
effects were obtained in studies evaluating effects of carbon monoxide on the developing auditory system 
(i.e., LOAEL 12-25 ppm carbon monoxide); however, since other developmental outcomes were not 
assessed at this range of low carbon monoxide concentrations, it is not possible to determine if the 
developing auditory system is more sensitive to carbon monoxide exposure than other systems, or to 
identify a biological basis for such susceptibility.
Birth Weight. Several studies have evaluated effects of gestational exposure to carbon monoxide on birth 
weight in rats (Carmines and Rajendran 2008; Fechter and Annau 1977, 1980; Fechter et al. 1980, 1987a; 
Penney et al. 1983; Prigge and Hochrainer 1977; Storm and Fechter 1985b), rabbits (Astrup et al. 1972), 
and guinea pigs (Tolcos et al. 2000b). Results consistently show that gestational exposure to carbon 
monoxide significantly decreased birth weight and/or pre-weanling weight, with LOAEL values ranging 
from 60 ppm carbon monoxide (maternal COHb 15%) for continuous exposure during gestation (Fechter 
and Annau 1977) to 600 ppm (maternal COHb approximately 30%) for intermittent (2 hours/day) 
exposure (Carmines and Rajendran 2008). Decreases in birth weight exhibited exposure concentration- 
dependence (Astrup et al. 1972; Fechter et al. 1987a; Prigge and Hochrainer 1977).
Central Nervous System Development. Several studies have observed adverse effects on the developing 
central nervous system, including altered control of respiratory function, behavioral effects, changes in 
brain neurotransmitters levels, and auditory development. Gestational exposure of guinea pigs to 
200 ppm carbon monoxide produced abnormal respiratory responses to asphyxia and hypercapnia, 
indicative of altered brain stem development (McGregor et al. 1998). In rat or mouse pups exposed to 
60-150 ppm carbon monoxide during gestation, behavioral changes included decreased motor activity 
and response to stimulation (Fechter and Annau 1977, 1980), impaired righting reflexes (Fechter and 
Annau 1980; Singh 1986), and impaired homing and memory acquisition behaviors (Giustino et al. 1999; 
Mactutus and Fechter 1985). Effects on acquisition and reacquisition behavior persisted up to 18 months 
of age in rats exposed to 150 ppm carbon monoxide during gestation (De Salvia et al. 1995; Mactutus and 
Fechter 1985), although similar effects were not observed in pups exposed to 150 ppm carbon monoxide
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during the early postnatal period (Tattoli et al. 1999). Gestational exposure of rats or guinea pigs to 60­
300 ppm carbon monoxide produced altered levels of dopamine and norepinephrine in several regions of 
the brain (Cagiano et al. 1998; Fechter and Annau 1977; Fechter et al. 1987a; Storm and Fechter 1985a, 
1985b; Tolcos et al. 2000b). Gestational or postnatal exposure to low levels of carbon monoxide (i.e., 
12-25 ppm) has been shown to have effects on the developing auditory system. Gestational and/or early 
postnatal exposure of artificially-reared rat pups (i.e., reared in formula to allow exposure to the pups 
without exposure to the dams during nursing) to 25 ppm carbon monoxide produced morphological 
changes in the developing auditory system, including swelling, cytoplasmic vacuolization and atrophy of 
nerve terminals innervating inner hair cells, “distorted myelin” with vacuolization in the 8th cranial nerve 
at the level of the internal auditory canal, decreased immunoreactivity of the enzymes cytochrome 
oxidase, NADH-TR, and calcium-mediated myosin ATPase, and decreased immunostaining of 
neurofilament and myelin basic protein in the organ of corti, (Lopez et al. 2003, 2008). Limited 
physiological and acoustic testing of pups suggested potential functional impairment in the auditory 
system. Exposure of artificially-reared rat pups during the early postnatal period decreased action 
potential amplitude of the 8th cranial nerve at >12 ppm carbon monoxide, although the magnitude of the 
effect was not dose-dependent. Otoacoustic emissions showed a small reduction in amplitude (3 dB at 
two of three frequencies tested and one loudness level) at >50 ppm carbon monoxide, with effects on 
action potential amplitude of the 8th nerve persisting through age 73 days (Stockard-Sullivan et al. 2003). 
The reduction in amplitude of otoacustic emissions observed in this study was relatively small. Larger 
effects are more typically associated with hearing loss (e.g., 10-29 dB across five or more frequencies). 
Gestational exposure gestation days ([GDs] 8-20) of dam-reared rat pups to >12.5 ppm carbon monoxide 
significantly decreased neuronal activation of the central inferior colliculus (the area or the brain with 
auditory integrative function), with effects observed through postnatal days 75-77 (Webber et al. 2003). 
Results indicate that carbon monoxide-induced effects on brain auditory integrative neurons can persist 
into adulthood.
Peripheral Nervous System Development. Gestational exposure to carbon monoxide produced effects on 
peripheral nervous system development. In sciatic nerves of pups exposed during gestation, myelin 
sheath thickness was decreased and sphinogmyelin composition was altered at 75-150 ppm carbon 
monoxide, with changes persisting through age 90 days (Carratu et al. 2000a, 2000b). Altered nerve 
transmission, indicative of slowed inactivation kinetics of inactive sodium channels, was observed in 
sciatic nerves from pups exposed to 75 ppm carbon monoxide during gestation, with changes persisting to 
age 270 days (Carratu et al. 1993).
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Cardiac Effects. Dose-related increases in heart weight was observed in rat pups exposed to 60-157 ppm 
carbon monoxide during gestation (Penney et al. 1983; Prigge and Hochrainer 1977) or to 500 ppm 
carbon monoxide during the early postnatal period (Penney et al. 1982). The development of 
cardiomyopathy is consistent with a pathophysiological compensatory response to hypoxia. In ventricular 
cells isolated from pups exposed to 150 ppm carbon monoxide (but not 75 ppm carbon monoxide) during 
gestation, age-related decreases in action potential duration was delayed (Sartiani et al. 2004).
Sexual Behavior. In male pups exposed to 150 ppm carbon monoxide during gestation, altered 
development of sexual behavior was observed at age 80 days (Cagiano et al. 1998). Effects included 
increased mount to intromission latency, decreased mount to intromission frequency, and decreased 
ejaculation frequency.
Immune System Effects. In studies conducted by Giustino et al. (1993, 1994), gestational exposure 
produced reversible alterations in immune system function. Decreases in splenic macrophage 
phagocytosis of Candida albicans was observed in pups exposed to 150 ppm carbon monoxide and 
decreased splenic macrophage killing was observed in pups exposed to 75 and 150 ppm carbon monoxide 
(Giustino et al. 1993); effects did not persist at age 60 days. Rats exposed to 150 ppm carbon monoxide, 
but not 75 ppm carbon monoxide, showed an alteration in splenic immune cell populations, with a 
significant decreased in leukocyte common antigen cells; effects did not persist to age 540 days (Giustino 
et al. 1994).
Hematological Effects. Dose-related decreases in hematocrit and Hb were observed in pups exposed to 
250 and 500 ppm carbon monoxide during gestation (Prigge and Hochrainer 1977). Effects are consistent 
with physiological compensatory responses to COHb-induced hypoxia.
3.2.7 Cancer
Epidemiological studies have examined possible associations between exposure to ambient air 
concentration of carbon monoxide and cancer mortality (described in Section 3.2.1, Death). A 
prospective study examined mortality in a cohort of 552,138 adults in 151 U.S. metropolitan areas, 
enrolled in the study in 1982 and followed through 1998 (Jerrett et al. 2003; Pope et al. 1995, 2002).
Based on estimates of average ambient air carbon monoxide concentration during the period 1982-1998, 
increasing air carbon monoxide concentration was significantly associated with decreasing mortality from 
lung cancer. A time-series analysis conducted in New York City, New York (1985-1994) evaluated data
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on cancer deaths with or without contributing respiratory diseases (De Leon et al. 2003). Estimates of 
cancer mortality risk were significant only in the strata with contributing respiratory disease (risk ratio 
was approximately 1.18, the 95% lower confidence limit>1) and did not persist when estimates were 
adjusted for ambient concentrations of PM10 (risk ratio approximately 1.06, 95% CI: approximately 0.97­
1.17).
Carbon monoxide has not been assessed for carcinogenicity using animal models.
3.3 GENOTOXICITY
Few studies have evaluated the genotoxic effects of carbon monoxide exposure. Results of available 
studies are summarized in Table 3-10. An in vitro bacterial replication assay in Escherichia coli reported 
that exposure to carbon monoxide inhibited deoxyribonucleic acid (DNA) synthesis (Cairns and Denhardt 
1968); however, interpretation of study results is compromised by poor reporting of experimental and 
analytical methods (e.g., carbon monoxide concentration, exposure conditions, and statistical analyses). 
Exposure of pregnant mice to carbon monoxide during gestation produced dose-related increases in 
micronuclei and sister chromatid exchanges in maternal bone marrow and fetal blood (Kwak et al. 1986). 
Pregnant mice were exposed to 0, 1,500, 2,500, or 3,500 ppm carbon monoxide for 10 minutes on GDs 5,
11, or 15 or to 0 or 500 ppm carbon monoxide for 1 hour on gestation days 0-6, 7-13, or 14-20; maternal 
bone marrow and fetal blood were examined for micronuclei formation and sister chromatid exchanges on 
GD 21. Increases in micronuclei and sister chromatid exchanges in maternal bone marrow and fetal 
blood were observed under all carbon monoxide exposure conditions, compared to unexposed controls. 
The magnitude of effect was similar in dams and fetuses. Although blood COHb levels were not 
measured in this study, a 1-hour exposure to 500 ppm carbon monoxide would be expected to produce a 
maternal blood COHb concentration of approximately 20-25% (based on CFK model prediction for rats).
3.4 TOXICOKINETICS
Carbon monoxide exists in the environment as a gas (Henry’s law constant >50,000 atm/mol fraction,
25 °C, see Table 4-2). As a result, humans can be exposed to carbon monoxide from breathing and/or 
skin contact with carbon monoxide in air. No information is available on the dermal absorption of carbon 
monoxide resulting from exposures to gaseous carbon monoxide. However, as is the case for other gases 
that are avidly absorbed from the lung (e.g., O2) during exposures to carbon monoxide in air, dermal 
absorption of carbon monoxide through intact skin would be expected to make a minor contribution to 
absorbed carbon monoxide, relative to inhalation. Although carbon monoxide can dissolve in water
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Table 3-10. Genotoxicity of Carbon Monoxide
Species (test 
system) Exposure End point Results Reference
Prokaryotic organisms:
Escherichia coli, 
TAMT
Mammalian cells:
CO concentration 
not reported
DNA replication + Cairns and Denhardt 
1968
Mice (ICR strain, 
pregnant females, 
64/dose)
0, 1,500, 2,500, or 
3,500 ppm CO for 
10 minutes on GD 5, 
11, or 16.
Fetal blood and 
maternal bone 
marrow examined on 
GD 21
Sister chromatid 
exchange
Maternal bone 
marrow: + 
Fetal blood: +
Kwak et al. 1986
Mice (ICR strain, 
pregnant females, 
50/dose)
0 or 500 ppm CO for
1 hour on GDs 0-6, 
7-13, or 14-20.
Fetal blood and 
maternal bone 
marrow examined on 
GD 21
Sister chromatid 
exchange
Maternal bone 
marrow: + 
Fetal blood: +
Kwak et al. 1986
Mice (ICR strain, 
pregnant females, 
64/dose)
0, 1,500, 2,500, or 
3,500 ppm CO for 
10 minutes on GD 5, 
11, or 16.
Fetal blood and 
maternal bone 
marrow examined on 
GD 21
Chromosomal
aberrations,
micronucleus
assay
Maternal bone 
marrow: + 
Fetal blood: +
Kwak et al. 1986
Mice (ICR strain, 
pregnant females, 
50/dose)
0 or 500 ppm CO for
1 hour on GDs 0-6, 
7-13, or 14-20.
Fetal blood and 
maternal bone 
marrow examined on 
GD 21
Chromosomal
aberrations,
micronucleus
assay
Maternal bone 
marrow: + 
Fetal blood: +
Kwak et al. 1986
+  =  p o s i t i v e  r e s u l t ;  C O  =  c a r b o n  m o n o x i d e ;  G D  =  g e s t a t i o n  d a y
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(23 mL CO/L water, 20 °C), appreciable concentrations in drinking water would occur only at very high 
partial pressures of carbon monoxide in air, conditions in which inhalation would be the dominant 
absorption pathway. Since the only relevant pathway of exposure to humans is the inhalation pathway, 
oral and dermal exposures are not considered further in the discussion of the toxicokinetics of carbon 
monoxide,
3.4.1 Absorption
Inhaled carbon monoxide is rapidly and extensively absorbed into blood (Benignus et al. 1994; Burge and 
Skinner 1995; Peterson and Stewart 1970, 1975; Tikuisis et al. 1987b). Inhaled carbon monoxide is 
transported to lung alveoli as result of convective forces in the respiratory tract and diffusion. At the 
alveolar gas-blood interface, carbon monoxide dissolves into pulmonary capillary plasma and, from 
plasma, diffuses into erythrocytes and other tissues (Figure 3-3). Binding of carbon monoxide by 
erythrocyte Hb (to form COHb) contributes to maintaining relatively low concentrations of dissolved 
carbon monoxide in erythrocyte cytosol and a partial pressure gradient to drive carbon monoxide transfer 
from alveolar air to blood. Diffusion of carbon monoxide into erythrocytes and binding of carbon 
monoxide to Hb is sufficiently rapid that near equilibrium is achieved between carbon monoxide partial 
pressures in alveolar air and alveolar end capillary (arterial) blood (Chakraborty et al. 2004). Continued 
uptake of carbon monoxide results from systemic elimination processes that lower mixed venous blood 
carbon monoxide concentrations returned to alveolar capillaries (Benignus et al. 1994). The primary 
elimination processes include diffusive transfer of carbon monoxide to extravascular tissues and binding 
of carbon monoxide to intracellular heme proteins (e.g., muscle myoglobin), and oxidative metabolism of 
carbon monoxide to CO2. Seconds after initiating inhalation exposures to carbon monoxide, COHb is 
detected in arterial blood. During 2-6 minutes of exposure, arterial COHb concentrations were 
approximately twice venous COHb concentrations and approached unity within 3-5 minutes of cessation 
of exposure (Benignus et al. 1994). With continued exposure to a constant air carbon monoxide 
concentration, a steady-state would be achieved within 200-500 minutes (Figure 3-4; Bruce and Bruce 
2003; Peterson and Stewart 1970, 1975). At that point, net absorption diminishes to a value determined, 
primarily, by metabolic elimination of carbon monoxide (see Section 3.4.3, Metabolism).
Major factors that control absorption of carbon monoxide include those that affect delivery of inhaled air 
to the alveolar region of the lung and those that affect lung carbon monoxide diffusion capacity. Lung 
diffusion capacity refers to the driving force for diffusion of carbon monoxide across the alveolar air-
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Continuous Exposures to Air Carbon Monoxide at Concentrations of 25, 200,
or 1,000 ppm
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blood interface and is reflected in the carbon monoxide partial pressure difference between inspired and 
exhaled air. In general, factors that increase alveolar ventilation, cardiac output, and gas diffusing 
capacity of the lung, while maintaining alveolar ventilation perfusion matching (i.e., proportional 
increases in alveolar ventilation rate and cardiac output) tend to increase absorption of inhaled carbon 
monoxide. Factors that may increase net carbon monoxide absorption include exercise, supine position, 
age (increased in infancy and childhood and declines in adults with age), altitude, increasing blood Hb 
concentration, and decreasing partial pressure of O2 in inhaled air or blood (Castillo et al. 2006; Horvath 
et al. 1988; Joumard et al. 1991; McGrath et al. 1993; Peterson and Stewart 1975; Tikuisis et al. 1992).
3.4.2 Distribution
Inhaled carbon monoxide distributes to blood and extravascular tissues. In blood, carbon monoxide 
rapidly distributes into erythrocytes where is exists, primarily as a complex with Hb (COHb). The 
binding equilibrium constant for COHb is approximately 750 ^M"1 (Chakraborty et al. 2004; see further 
discussion in Section 3.4.3, Metabolism). At a blood Hb concentration of 150 g/L (approximately 
2.3 mM), the molar concentration ratio of COHb would be approximately 1.7x106 times greater than the 
molar concentration of dissolved carbon monoxide. The relative affinity of Hb for carbon monoxide and 
O2 greatly favors binding of carbon monoxide to Hb over O2. The CO/O2 affinity ratio (Haldane 
constant) is approximately 234 (Chakraborty et al. 2004). This means that a partial pressure of O2 (pO2) 
approximately 234 times that of pCO is needed to achieve an equilibrium in which equal amounts of O2 
and carbon monoxide are bound to Hb (i.e., %COHb = % oxyhemoglobin [O2Hb]; Engel et al. 1969; 
Rodkey et al. 1969; Roughton 1970). In general, typical levels of COHb in nonsmokers are <2% (Adams 
et al. 1988; Allred et al. 1991; Anderson et al. 1973; Hinderliter et al. 1989; Kleinman et al. 1989, 1998; 
Sheps et al. 1987, 1990). Of this, COHb levels of approximately 0.2-1.0% are thought to be derived from 
endogenous production of carbon monoxide (Coburn et al. 1963; Delivoria-Papadopoulos et al. 1974; 
Longo 1977). Levels of COHb can (rarely) achieve 10% immediately following cigarette smoking (Kao 
and Nanagas 2006; Landaw 1973).
Although bound extensively to Hb in blood, distribution of dissolved carbon monoxide out of the 
vasculature can occur in response to diffusion gradients for carbon monoxide created by binding of 
carbon monoxide to Hb, myoglobin and other heme proteins in extravascular tissues (e.g., muscle, 
spleen), as well as removal of carbon monoxide from extravascular tissues by oxidative metabolism 
(Bruce and Bruce 2006; Bruce et al. 2008; Luomanmaki and Coburn 1969). Myoglobin, the dominant 
binding protein for carbon monoxide in cardiac and skeletal muscle, has a lower affinity for carbon
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monoxide than Hb (COMb equilibrium constant «20 ^M-1, and Haldane constant of approximately 23) 
and a single binding site for carbon monoxide (Gibson et al. 1986); however, its abundance in muscle can 
result in transfer of substantial amounts of inhaled carbon monoxide into muscle tissue. At a skeletal 
muscle myoglobin concentration of 4.7 g/kg muscle (approximately 0.26 mmole/kg; Moller and Sylven 
1981), the molar concentration ratio of COMb would be approximately 7.4x103 times greater than the 
molar concentration of dissolved carbon monoxide. Binding of carbon monoxide to Hb in blood and 
myoglobin in muscle decreases the concentrations of dissolved carbon monoxide in both tissues and 
limits the concentration gradient for diffusion of carbon monoxide into muscle (Bruce and Bruce 2006; 
Bruce et al. 2008). Exercise can increase the rate of transfer of carbon monoxide from blood to skeletal 
muscle (Richardson et al. 2002; Werner and Lindahl 1980). The effect of exercise is thought to be 
related, in part, to increased O2 consumption and lower pO2 in muscle, which favors binding of carbon 
monoxide to myoglobin, and increased muscle blood flow. These effects a more pronounced at low 
COHb concentrations (<2%) than at higher concentrations (20% COHb; Richardson et al. 2002).
Hypoxia appears to increase transfer of carbon monoxide from blood to muscle (Coburn and Mayers 
1971; Richardson et al. 2002).
Binding of carbon monoxide to intracellular proteins, in particular, heme proteins, contributes to 
maintaining a favorable gradient for carbon monoxide diffusion from plasma into cells. Measurements of 
total carbon monoxide concentrations in tissues obtained from human autopsies showed the highest 
concentrations in blood, spleen, lung, kidney, and skeletal muscle, with detectable levels also in brain and 
adipose (Table 3-11, Vreman et al. 2006). Higher concentrations of carbon monoxide in blood, heart, 
skeletal muscle, and spleen observed in human autopsy studies reflect the abundance of the major carbon 
monoxide binding proteins in these tissue, Hb in erythrocytes and spleen (site of destruction and storage 
of erythrocytes), and myoglobin in cardiac and skeletal muscle. If the values presented in Table 3-11 are 
converted to tissue carbon monoxide mass (pmol), based on assumed tissue masses for a 70-kg adult 
(Davies and Morris 1993; ILSI 1994), carbon monoxide in blood and muscle accounted for approximately 
60-70 and 20-30% of total body carbon monoxide burden, respectively. Relatively large contributions of 
blood and skeletal muscle to total body carbon monoxide content is consistent with the contributions that 
these tissues make to total body Hb and muscle myoglobin (Bruce and Bruce 2003). In a typical adult, 
blood contains approximately 12 mmoles of Hb with a total binding capacity of approximately 48 mmole 
carbon monoxide when completely saturated, and muscle contains approximately 8 mmoles of myoglobin 
with a total binding capacity of 8 mmole carbon monoxide when completely saturated.
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Table 3-11. Post-Mortem Tissue Distribution of Carbon Monoxide in Humansa
Exposure Adipose Brain Muscle Heart Kidney Lung Spleen Blood
Concentration (pmol/100 g)
Background 2 3 15 31 23 57 79 165
Fire 5 7 24 54 27 131 95 286
Fire + carbon 
monoxide
18 17 168 128 721 1097 2,290 3,623
Carbon monoxide 
asphyxiation
Tissue/blood carbon
25 72 265 
monoxide concentration ratio
527 885 2694 3,455 5,196
Background 0.012 0.018 0.091 0.188 0.139 0.345 0.479 1.000
Fire 0.017 0.024 0.084 0.189 0.094 0.458 0.332 1.000
Fire + carbon 
monoxide
0.005 0.005 0.046 0.035 0.199 0.303 0.632 1.000
Carbon monoxide 
asphyxiation
0.005 0.014 0.051 0.101 0.170 0.518 0.665 1.000
Body weight (kg) 70 70 70 70 70 70 70 70
Tissue mass 200 
(percent)
Tissue carbon monoxide burden
2.0
(nmol)
40.0 0.5 0.4 1.4 0.3 7.4
Background 0.28 0.04 4.20 0.10 0.07 0.57 0.14 8.55
Fire 0.70 0.10 6.72 0.18 0.08 1.31 0.17 14.81
Fire + carbon 
monoxide
2.52 0.24 47.04 0.42 2.22 10.97 4.12 187.67
Carbon monoxide 3.50 
asphyxiation
Tissue carbon monoxide burden
1.01 74.20 
(percent of total)
1.73 2.73 26.95 6.22 269.15
Background 2.0 0.3 30.1 0.7 0.5 4.1 1.0 61.3
Fire 2.9 0.4 27.9 0.7 0.3 5.4 0.7 61.5
Fire + carbon 
monoxide
1.0 0.1 18.4 0.2 0.9 4.3 1.6 73.5
Carbon monoxide 
asphyxiation
0.9 0.3 19.2 0.4 0.7 7.0 1.6 69.8
a C a r b o n  m o n o x i d e  c o n c e n t r a t i o n s  b a s e d  o n  V r e m a n  e t  a l .  ( 2 0 0 6 ) .  T i s s u e  m a s s e s  b a s e d  o n  D a v i e s  a n d  M o r r i s  
( 1 9 9 3 )  a n d  I L S I  ( 1 9 9 4 ) .
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The distribution of carbon monoxide residues observed in human autopsy studies is similar to that 
observed in rodents. In mice and rats that had not been intentionally exposed to air carbon monoxide (i.e., 
sacrificed during steady-state conditions), blood and muscle accounted for most the total body carbon 
monoxide burden (Vreman et al. 2005). Following 30-minute exposures to carbon monoxide 
(5,000 ppm), blood made a much larger contribution (approximately 90%) to carbon monoxide body 
burden, reflecting the longer period needed for carbon monoxide to distribute from blood to extravascular 
tissues (Vreman et al. 2005).
Carbon monoxide in the maternal system distributes to fetal tissues. Measurements of steady-state fetal 
COHb concentrations in fetal and maternal blood of nonsmoking women have found fetal COHb 
concentrations to be approximately 10-15% higher than maternal blood (fetal/maternal ratio=1.1-1.15; 
Longo 1977). Carbon monoxide binding to fetal Hb is analogously similar to maternal Hb. Both Hbs 
have the same binding capacity of 4 moles CO/mole Hb and both exhibit cooperative binding of carbon 
monoxide, whereby binding affinity increases as carbon monoxide molecules are successively added to 
Hb (see Section 3.4.3, Metabolism). Binding affinity of fetal Hb is approximately twice that of maternal 
Hb (Di Cera et al. 1989). The Haldane coefficient, reflecting the relative affinities of carbon monoxide 
and O2 (CO/O2) for fetal Hb, appears to be approximately 20% lower than adult Hb (Di Cera et al. 1989; 
Engel et al. 1969; Hill et al. 1977). The higher binding affinity of fetal Hb as well as the relatively small 
diffusion gradients for carbon monoxide between maternal and fetal blood contribute to slower kinetics of 
COHb in fetal blood compared to maternal blood. This has been experimentally verified in studies 
conducted in pregnant sheep (Longo and Hill 1977). The half-time for approach to steady-state in the 
human fetus has been predicted (from modeling) to be approximately 7.5 hours in the fetus, compared to 
approximately 4 hours in maternal blood (Hill et al. 1977). As a result, with continuous exposure to a 
constant level of carbon monoxide in air, fetal blood COHb concentration would be expected to lag 
behind maternal levels, and reach a steady-state that is approximately 10-15% higher than maternal 
(Longo 1977). Similarly, following cessation of exposure, elimination kinetics of carbon monoxide from 
fetal blood would be expected to lag behind that of maternal blood (Hill et al. 1977).
3.4.3 Metabolism
Metabolism of carbon monoxide consists of three major processes: (1) metabolic production of carbon 
monoxide from endogenous and exogenous precursors; (2) binding of carbon monoxide to heme proteins 
(e.g., Hb, myoglobin, cytochromes); and (3) oxidative metabolism of carbon monoxide to CO2.
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Metabolic Production of Carbon Monoxide. Carbon monoxide is produced from the enzymatic 
degradation of endogenous and exogenous precursors. The major endogenous source of carbon monoxide 
production is the oxidative metabolism of heme by the enzyme heme oxygenase (HO). The net rate of 
endogenous production of carbon monoxide (i.e., total production minus metabolism) has been estimated 
in healthy adults to be approximately 0.42 mL CO/hour (16.4 ^mole/hour) or approximately 
400 ^mole/day (Coburn et al. 1963). Of this, approximately 75-80% is thought to be derived from Hb 
metabolism, and the remaining portion from metabolism of other heme proteins such as myoglobin, 
cytochromes, peroxidases, and catalase (Berk et al. 1976). Endogenous carbon monoxide production 
contributes to a blood COHb concentration of approximately 0.4-0.7% (Benignus 1995; Coburn et al. 
1965). Carbon monoxide is produced in all tissues that express HO; however, the major tissues 
contributing to carbon monoxide production are also major sites of heme metabolism, including liver, 
spleen, and reticuloendothelial system (Berk et al. 1974).
Numerous physiological and disease factors affect the rate of endogenous production of carbon 
monoxide. Carbon monoxide production increased by approximately 2-fold during the post-ovulatory 
(progesterone) phase of the menstrual cycle (Delivoria-Papadopoulos et al. 1974; Mercke and Lundh 
1976). Carbon monoxide production also increases during pregnancy, reaching values that are 2-5 times 
that of the estrogen phase of the menstrual cycle at partum and returning to pre-pregnancy levels within 
4 days following delivery (Longo 1977). Contributing factors to the increase in carbon monoxide 
production during pregnancy include the contribution of the growing fetus to carbon monoxide 
production, as well as the increase in maternal erythrocyte production and related changes in Hb 
metabolism (Longo 1977). The rate of production of carbon monoxide is accelerated in conditions that 
increase catabolism of Hb or other heme proteins, including hemolysis, hematomas, hemolytic anemias, 
thalassemia, and Gilbert’s syndrome (Berk et al. 1974; Coburn et al. 1964, 1965; Hampson 2007; Meyer 
et al. 1998; Solanki et al. 1988). Carbon monoxide production was estimated to be 2-3 times higher in 
patients with hemolytic anemia compared healthy individuals (Coburn et al. 1965).
HO is the rate limiting step in heme degradation and its expression and activity is modulated by numerous 
factors. The HO-1 isozyme (one of three isozymes) and expression of the enzyme is induced by heme 
and heme derivatives, oxidative stress, hypoxia (including altitude-induced hypoxia), various metals, 
various cytokines, and exogenous carbon monoxide (Wu and Wang 2005). These factors would tend to 
promote endogenous carbon monoxide production.
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In addition to endogenous carbon monoxide production from metabolism of heme, carbon monoxide is 
produced from oxidative metabolism of certain exogenous hydrocarbons, including dichloromethane and 
other dihalomethanes; and carbon tetrachloride (Agency for Toxic Substances and Disease Registry 2000, 
2005; Stevens et al. 1980). The oxidative metabolism of dichloromethane (DCM) by isoform CYP2E1 of 
cytochrome P450 results in the production of carbon monoxide and increased blood COHb concentrations 
in blood (Andersen et al. 1991). Elevated blood COHb levels has been observed following DCM 
poisoning (Leikin et al. 1990). Other sources of exogenous carbon monoxide production include the 
heme oxidase catalysis of products of auto-oxidation of phenols, photo-oxidation of organic compounds, 
and lipid peroxidation of cell membrane lipids (Rodgers et al. 1994).
Binding of Carbon Monoxide to Heme Proteins. Carbon monoxide binds to heme and competes for 
binding of O2. Binding of carbon monoxide to heme proteins (e.g., blood Hb, muscle myoglobin) has 
profound effects on the kinetics of distribution and elimination kinetics of both carbon monoxide and O2. 
Affinities of heme for carbon monoxide for Hb and myoglobin are sufficiently high to result in 
concentrations of dissolved carbon monoxide being 103-106 times lower than the concentrations of COHb 
or COMb. This substantially lowers the concentration of dissolved carbon monoxide in blood and tissues 
and decreases the diffusion gradients for carbon monoxide movement of carbon monoxide from tissues 
and blood to the lungs, and substantially prolongs the elimination time for carbon monoxide than would 
otherwise occur in the absence of binding. Furthermore, the rates of dissociation of carbon monoxide 
from Hb and myoglobin are substantially slower than that of O2 and sufficiently slow, relative to 
erythrocyte capillary transit times, to limit rates exchange of carbon monoxide between tissues and 
capillary blood. Binding of carbon monoxide to Hb also increases the affinity of Hb for O2, decreasing 
the availability of O2 to tissues.
Although carbon monoxide binds to many different heme proteins (see Section 3.5.2), the affinities and 
abundance of Hb and myoglobin in the body results in most of the body stores of carbon monoxide being 
associated with these two heme proteins. Estimated kinetics and equilibrium parameters for carbon 
monoxide and O2 binding to Hb and myoglobin are presented in Table 3-12. Each of the four heme 
moieties in Hb can bind O2 or carbon monoxide. The overall affinity (i.e., equilibrium constant, Keq) is 
substantially higher for carbon monoxide («750 (iM-1) compared to that of O2 («3.2 ^M-1). As a result, at 
similar partial pressures of the two gases (pCO=PO2), binding of carbon monoxide will occur at the 
expense of binding of O2 and O2 carrying capacity of blood will be compromised. The ratio of the 
Keq values (CO/O2) is referred to as the Haldane constant ( «234). This value gives the partial pressure 
ratio (pO2/pCO) needed to achieve equal amounts of bound COHb and O2Hb (i.e., %COHb = %O2Hb).
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Table 3-12. Hemoglobin and Myoglobin Binding Kinetics and Equilibrium 
Constants for Oxygen and Carbon Monoxide
Ligand
ka
GjM 'V )
kd
(s-1)
KEq
(j M-1) M
Hemoglobin3
Oxygen 66 20 3.2 1
Carbon monoxide 6 0.008 750 234
Myoglobinb
Oxygen 14 12 1.2 1
Carbon monoxide 0.51 0.019 26.8 23
a B a s e d  o n  C h a k r a b o r t y  e t  a l .  2 0 0 4  
b B a s e d  o n  G i b s o n  e t  a l .  1 9 8 6
k a =  a s s o c i a t i o n  r a t e  c o n s t a n t ;  k b =  d i s s o c i a t i o n  r a t e  c o n s t a n t ;  K Eq =  e q u i l i b r i u m  c o n s t a n t ;  M  =  H a l d a n e  c o n s t a n t  
( K Eq C O / K Eq O 2 )
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At an ambient air pO2 of approximately 160 Torr (21% O2), the equilibrium condition of equal %COHb = 
%O2Hb would be achieved at a carbon monoxide exposure concentration of approximately 900 ppm. The 
affinity of Hb for carbon monoxide results in an equilibrium condition in which nearly all carbon 
monoxide in blood is bound to Hb. For example, based on the value of Keq of 750 ^M-1, at a blood Hb 
concentration of 150 g/L («2.3 mM), the equilibrium ratio of bound carbon monoxide to dissolved carbon 
monoxide in blood would be approximately 1.7x106 (i.e., > 106 times as much carbon monoxide is bound 
to Hb than is circulating in blood as dissolved carbon monoxide). The carbon monoxide dissociation rate 
from Hb (kd«0.008 s-1; tJ/2«87 s) is slower than from O2 (ke«20 s-1, tJ/2«0.035 s). As a result exchange of
O2 bound to Hb in blood with alveolar air and tissues is much more efficient than carbon monoxide 
exchange (i.e., fast vs. slow dissociation relative to erythrocyte transit times in capillaries). These two 
characteristics (high affinity and slow dissociation) contribute to relatively long retention times of carbon 
monoxide in blood following exposures to carbon monoxide.
Binding of O2 to the four heme moieties of Hb is cooperative (Alcantara et al. 2007; Roughton 1970).
The associative reaction rate (ka) becomes faster with successive additions of O2, increasing the affinity 
(Keq) of Hb for O2 (values for ka shown in Table 3-12 are for the high affinity, R, state of fully loaded 
Hb). Cooperative binding of O2 to Hb serves an important physiological function. Under conditions of 
relatively high pO2 in arterial blood entering the lung (p02=100 mmHg), cooperative binding promotes 
the loading of Hb with O2; with successive binding of O2 molecules, the associative rate and affinity 
increases, promoting binding of a subsequent molecule of O2. Conversely, at lower pO2 in venous blood 
(p02«20 mmHg), cooperative binding promotes unloading of O2 for utilization; dissociation of a 
molecule of O2 decreases the affinity of Hb for O2, promoting the dissociation of a subsequent molecule 
of O2. Cooperative binding contributes to the sigmoid shape of the O2 dissociation curve for Hb 
(Figure 3-5).
Binding of carbon monoxide to Hb is also cooperative. Binding of carbon monoxide increases the 
associative rate of binding and affinity of both carbon monoxide and O2. As a result, the presence of 
carbon monoxide has several effects on the dissociation curve for O2 (Figure 3-5): (1) decreases the 
partial pressure of O2 in blood and tissues (i.e., by an amount equal to pCO), shifting the pO2 axis 
downscale at each point in the arterial-venous circuit; (2) displaces O2 from Hb, decreasing the maximum 
%COHb achieved in arterial blood; and (3) shifts the O2 dissociation curve downscale so that less O2 
dissociates O2 from Hb (more will remain bound, %O2Hb will be higher) at the lower pO2 values in 
venous blood. The combined result of these changes is that less O2 in blood is available for utilization in 
tissues.
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Figure 3-5. Oxyhemoglobin Dissociation Curve for Normal Human Blood 
Containing 50% Carboxyhemoglobin, and for Blood of Anemic Human
P 0 2 (m m Hg)
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The binding affinities of carbon monoxide and O2 to myoglobin are lower than that for Hb; however, the 
higher affinity for carbon monoxide (Haldane constant «23), results in preferential binding of carbon 
monoxide over O2 and displacement of O2 of myoglobin at similar partial pressures of both gasses 
(Table 3-12). In addition to displacing O2 from myoglobin, binding of carbon monoxide to myoglobin 
has a pronounced effect on the distribution of carbon monoxide in the body by limiting the dissolved 
carbon monoxide concentration in muscle and, thereby, the rates of diffusion of carbon monoxide from 
muscle to blood. The affinity of myoglobin (Keq«27) results in an equilibrium condition in which 
dissolved carbon monoxide concentrations in muscle are very low relative to COMb concentrations. For 
example, based on a value for Keq of 27 ^M'1, at a muscle myoglobin content of approximately 4.7 g/kg 
(«0.28 mM), the equilibrium ratio of bound carbon monoxide to dissolved carbon monoxide in muscle 
would be approximately 7.4x103 (approximately 104 times as much carbon monoxide is bound to 
myoglobin than is dissolved muscle tissue). Furthermore, the carbon monoxide dissociation rate from 
myoglobin (kd«0.019 s'1; t1/2«36 s) is slower than O2 (ke«12 s'1, t1/2«0.06 s). As a result exchange of 
carbon monoxide bound to myoglobin in muscle with blood is much less efficient than O2 exchange (i.e., 
slow vs. fast dissociation relative to erythrocyte transit times in capillaries). These two characteristics 
(high affinity and slow dissociation) contribute to relatively long retention times of carbon monoxide in 
muscle following exposures to carbon monoxide.
Oxidative Metabolism of Carbon Monoxide. Carbon monoxide can be oxidized to CO2. The rate of 
oxidation has been estimated in human subjects who inhaled 14CO to be approximately 0.015 mL 
CO/hour, which corresponds to approximately 0.6 ^mol/hour; 14 ^mol/day, and approximately 3% of 
endogenous carbon monoxide production (Luomanmaki and Coburn 1969). Similar measurements made 
in dogs yielded estimates for carbon monoxide metabolism that were approximately 8% of endogenous 
production (Luomanmaki and Coburn 1969). The major pathway for metabolism of carbon monoxide to 
CO2 is oxidation by mitochondrial cytochrome oxidase (Fenn 1970; Young and Caughey 1986).
3.4.4 Elimination and Excretion
Absorbed carbon monoxide is eliminated from the body by exhalation and oxidative metabolism. 
Oxidative metabolism of carbon monoxide has been estimated to be a relatively small fraction (<10%) of 
endogenous carbon monoxide production (Luomanmaki and Coburn 1969). Under most conditions, the 
dominant route of elimination of absorbed carbon monoxide is exhalation. Rates of elimination of carbon 
monoxide in humans who have been experienced inhalation exposures to carbon monoxide have been
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estimated from kinetic analyses of the time course of blood %COHb (Bruce and Bruce 2006; Joumard et 
al. 1991; Landaw 1973; Levasseur et al. 1996; Peterson and Stewart 1970; Shimazu et al. 2000; Weaver et 
al. 2000). The decline in blood %COHb following cessation of an inhalation exposure to carbon 
monoxide exhibits at least two kinetic phases (Bruce and Bruce 2006; Shimazu et al. 2000). The fast 
phase is thought to reflect a combination of exhalation of carbon monoxide along with slower distribution 
of blood carbon monoxide to tissues that continues after cessation of exposure (Bruce and Bruce 2006). 
The elimination half-times for both phases appears to increase with exposure intensity and/or duration; a 
contributing factor to this effect may be the amount of carbon monoxide accumulated in extravascular 
stores. In human subjects exposed to 2% carbon monoxide for 1-3 minutes (peak C0Hb%=30-40), 
values for elimination half-lives were 5.7±1.5 and 103±20.5 minutes for the fast and slow phases, 
respectively (Shimazu et al. 2000). The fast phase rate increased when subjects were exposed to 500 ppm 
for 5-10 hours (peak %COHb=34-37): 21.5±2.1 and 118±11.2 minutes, respectively (Shimazu et al. 
2000). Rates have been reported for the slow phase of elimination. In subjects whose peak %COHb 
ranged from 2 to 15, the half-life was 320 minutes (range: 128-409 minutes, Peterson and Stewart 1970). 
Bruce and Bruce (2006) measured the time to achieve one half of peak %COHb in subjects whose peak 
%COHb values ranged from 15 to 20 and estimated a half-life of 248 minutes (range: 206-328). Clinical 
studies conducted on healthy individuals exposed to ambient air carbon monoxide concentrations have 
found that elimination half-time increases with age, with the most pronounced increase occurring from 
age 2 to 20 years and is marginally longer in males compared to females (Joumard et al. 1991). The 
gender effect may be related to relative differences in body size and/or muscle mass. Exercise decreases 
carbon monoxide elimination half-time (Joumard et al. 1991).
The rate of elimination of absorbed carbon monoxide is accelerated by inhaling high concentrations of O2 
(Landaw 1973; Peterson and Stewart 1970; Weaver et al. 2000). Elimination half-lives of approximately 
20 minutes have been observed in subjects who inhaled 100% O2 following cessation of exposure to 
carbon monoxide. An analysis of elimination rates observed in 93 acute carbon monoxide poisoning 
patients who were treated with 100 O2 did not find significant associations between elimination half-lives 
and age, gender (<40 years, >40 years), smoke inhalation, history of loss of consciousness, concurrent 
tobacco smoking, degree of initial metabolic acidosis (base excess), or initial %COHb level (Weaver et al. 
2000).
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Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994). PBPK models are also called biologically based tissue dosimetry 
models. PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985). Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from 
route to route, between species, and between subpopulations within a species. The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994). In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993). PBPK models for a particular substance require estimates of the chemical substance- 
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes. Solving these differential and algebraic equations 
provides the predictions of tissue dose. Computers then provide process simulations based on these 
solutions.
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models
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many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994). 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species. 
Figure 3-6 shows a conceptualized representation of a PBPK model.
If PBPK models for carbon monoxide exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
The first physiologically-based mechanistic model of carbon monoxide kinetics was reported in Coburn et 
al. (1965). This model, which subsequently became known as the Coburn-Forster-Kane (CFK) model, 
was developed to predict relationships between inhalation exposures to carbon monoxide and blood 
COHb levels in humans. Numerous modifications and extensions of the original CFK model have been 
reported that more rigorously address nonlinearities resulting from interdependence of COHb and O2Hb 
levels in blood (Tikuisis et al. 1987b), simulation of arterial and venous blood compartments (Smith et al. 
1994), simulation of maternal-fetal transfer of carbon monoxide (Hill et al. 1977), extrapolation to 
nonhuman species (Benignus and Annau 1994; Hill et al. 1977; Longo and Hill 1977), linkage of the CFK 
model to more complex respiratory gas exchange models (Abram et al. 2007; Benignus 1995), and use in 
simulating the elimination kinetics of carbon monoxide produced from exogenous precursors (Andersen 
et al. 1991). A multi-compartment model was also developed that simulates carbon monoxide absorption 
and distribution kinetics in muscle (Bruce and Bruce 2003; Bruce et al. 2008).
Coburn-Forster-Kane Model
The CFK model, as originally described in Coburn et al. (1965), is a single-compartment model of 
instantaneous equilibrium between carbon monoxide, O2, and blood Hb, and assumes that blood O2Hb 
concentration is constant (i.e., independent of COHb concentration). This linear form of the CFK model
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Figure 3-6. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance
Inhaled c h e m ic a l-----  ^ |-----► Exhaled  chem ical
C hem icals  
con tacting  skin
N o t e :  T h i s  i s  a  c o n c e p t u a l  r e p r e s e n t a t i o n  o f  a  p h y s i o l o g i c a l l y  b a s e d  p h a r m a c o k i n e t i c  ( P B P K )  m o d e l  f o r  a  
h y p o t h e t i c a l  c h e m i c a l  s u b s t a n c e .  T h e  c h e m i c a l  s u b s t a n c e  i s  s h o w n  t o  b e  a b s o r b e d  v i a  t h e  s k i n ,  b y  i n h a l a t i o n ,  o r  b y  
i n g e s t i o n ,  m e t a b o l i z e d  i n  t h e  l i v e r ,  a n d  e x c r e t e d  i n  t h e  u r i n e  o r  b y  e x h a l a t i o n .
S o u r c e :  a d a p t e d  f r o m  K r i s h n a n  a n d  A n d e r s e n  1 9 9 4
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is expressed in the following differential equation which is integrated over time to solve for COHb 
concentration (Equation 1):
Eq. (1)
where t represents time at the end of the integration time step and t-1 represents the time at the beginning 
of the time step; Vb is blood volume in mL; [COHb] is the COHb concentration in mL carbon monoxide 
per mL blood (STPD); VCO is the endogenous carbon monoxide production rate in mL/minute (STPD); 
[O2Hb] is the oxyhemoglobin concentration in mL O2 per mL blood (STPD); PcO2 is the average partial 
pressure of O2 in lung capillaries in Torr; M  is the Haldane constant; VA is the alveolar ventilation in 
mL/minute (STPD); DLCO is the lung diffusing capacity of carbon monoxide in mL/minute-Torr (STPD); 
and PjCO is the carbon monoxide partial pressure in inhaled air in Torr.
The linear form of the CFK model is acceptable for simulating low COHb concentrations (<6%; Smith 
1990). However, at higher COHb levels, appreciable errors are introduced into the simulation by ignoring 
the interdependence of COHb and O2Hb levels that result from limited binding capacity of Hb. This 
interdependence can be introduced into the CFK model by replacing the constant term for [O2Hb] with 
the following expression relating COHb and O2Hb (Tikuisis et al. 1987b; Equation 2):
Eq. (2)
where 1.38-Hb represents the maximum binding capacity of Hb for O2 or carbon monoxide in mL O2/mL 
blood (STPD). The resulting nonlinear form of the CFK model is expressed in Equations 2, 3, and 4:
Eq. (3)
Eq. (4)
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where PB is the barometric pressure (Torr) and the value 47 represents the partial pressure of water in 
water saturated air (Torr). Typical parameters values used in the CFK model are presented in Table 3-13. 
Parameter values for application of the nonlinear CFK model for predicting COHb levels in rats were 
reported by Benignus and Annau (1994) and are also shown in Table 3-13.
Validation of the model. Numerous studies have examined the accuracy of exposure-blood COHb 
relationships predicted from the CFK model (Benignus et al. 1994; Coburn et al. 1965; Hauck and 
Neuberger 1984; Joumard et al. 1991; Peterson and Stewart 1970, 1975; Stewart et al. 1970, 1973; 
Tikuisis et al. 1987a, 1987b). In general, the model performs well for predicting near equilibrium 
conditions; however, it performs less well in predicting the early uptake phase of carbon monoxide 
kinetics, and COHb levels associated with rapidly changing exposures (Benignus et al. 1994; Tikuisis et 
al. 1987a, 1987b). The model also underestimates the arterial blood COHb level and overestimates the 
venous blood COHb level, an expected outcome of the simplistic assumption of a single well-mixed 
blood compartment. Nevertheless, the model predicts quasi-steady-state blood COHb levels that agree 
closely with observations (Benignus et al. 1994; Bruce and Bruce 2003; Tikuisis et al. 1987a, 1987b).
McCartney (1990) reported a sensitivity analysis of the CFK model and found that parameter value 
sensitivities varied considerably in magnitude at different points in the exposure simulation (Figure 3-7). 
At steady-state, the model is most sensitive to the values assigned to the parameters representing the input 
value, the inhaled carbon monoxide concentration (PjCO), as well as total Hb level (Hb), and the Haldane 
coefficient (M). Increases in values for any of these parameters results in higher predicted COHb levels. 
However, during the accumulation phase of the simulation, the predicted COHb level is also highly 
sensitive to alveolar ventilation rate (VA) and the lung carbon monoxide diffusing capacity (DLCO), with 
increases in these parameters resulting in higher COHb levels, and to the value assigned to the blood 
volume (Vb), with increases in the parameter value resulting in lower predicted COHb levels.
Risk assessm ent. The CFK model has been used in establishing the National Ambient Air Quality 
Standard for carbon monoxide (EPA 2000) and has been used in analyses that have supported 
development of Threshold Limit Values for occupational safety (Tikuisis et al. 1987b).
Target tissues. The CFK model predicts COHb levels in blood.
Species extrapolation. Although originally developed to simulate blood COHb levels in humans, 
the model can be used to predict COHb levels in other mammalian species if physiological and chemical-
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Table 3-13. Parameter Values for Coburn-Forster-Kane (CFK) Model
Parameter Definition Unit Humana
Value
Ratb
BW Body weight kg 70 0.250
COHb0 Blood COHb level at start of 
simulation
mL CO/mL blood 
(STPD)
0.00155 0.00155
Dl CO Lung CO diffusing capacity mL CO/minute-Torr 
(STPD)
30 0.027 0.563 BW
Hb Blood Hb concentration g/mL 0.144 0.158
M Haldane coefficient unitless 218 207
O2HbMAX Maximum blood O2Hb 
concentration
mL O2/mL blood 
(STPD)
1.38 1.38
Pc 0 2 Average partial pressure of O2 in 
alveolar air
Torr (STPD) 49 49
PICO Partial pressure of inhaled CO Torr (STPD) Input Input
Va Alveolar ventilation rate L/hourc (15BW0'74) (15BW0'74)
Vb Blood volume Ld 0.074 BW 0.074 BW
Vc o Endogenous CO production rate mL/minute (STPD) 0.007 0.000333 BW
a B a s e d  o n  T i k u i s i s  e t  a l .  ( 1 9 9 2 )
b B a s e d  o n  B e n i g n u s  a n d  A n n a u  ( 1 9 9 4 )
c M u s t  b e  c o n v e r t e d  t o  m L / m i n u t e  b y  m u l t i p l y i n g  1 , 0 0 0 / 6 0 .
d M u s t  b e  c o n v e r t e d  t o  m L  b y  m u l t i p l y i n g  b y  1 , 0 0 0 .
B W  =  b o d y  w e i g h t ;  C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  H b  =  h e m o g l o b i n ;  S T P D  =  s t a n d a r d  
t e m p e r a t u r e  a n d  p r e s s u r e ,  d r y  ( i . e . ,  a d j u s t e d  f o r  p a r t i a l  p r e s s u r e  o f  w a t e r  v a p o r  i n  s a t u r a t e d  a i r  [ 4 7  T o r r  S T P ]
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Figure 3-7. Plot of Standardized Sensitivity Coefficients for Carboxyhemoglobin 
(COHb) Levels Predicted from the Coburn-Forster-Kane (CFK) Model for a 
100 ppm Exposure to an Individual Engaged in Vigorous Exercise 
(Alveolar Ventilation Rate=30 L/Minute)*
* E a c h  c u r v e  r e p r e s e n t s  t h e  t i m e  t r e n d  o f  s e n s i t i v i t y  c o e f f i c i e n t s  f o r  a  g i v e n  p a r a m e t e r  d u r i n g  t h e  s i m u l a t i o n .  T i m e  
t r e n d s  f o r  s i x  m o d e l  p a r a m e t e r s  a r e  s h o w n :  D l C O ,  l u n g  c a r b o n  m o n o x i d e  d i f f u s i o n  c a p a c i t y ;  F i C O ,  f r a c t i o n a l  a i r  
c a r b o n  m o n o x i d e  c o n c e n t r a t i o n  ( p p m ) ;  M ,  H a l d a n e  c o e f f i c i e n t ;  T H b ,  b l o o d  h e m o g l o b i n  c o n c e n t r a t i o n ;  V a , a l v e o l a r  
v e n t i l a t i o n  r a t e ;  a n d  V b , b l o o d  v o l u m e .  S e n s i t i v i t y  c o e f f i c i e n t s  a n d  c e n t r a l  c o e f f i c i e n t s  a r e  f o r  1 %  u p w a r d  a n d  
d o w n w a r d  p e r t u r b a t i o n  o f  e a c h  p a r a m e t e r .  C o e f f i c i e n t s  > 0  i n d i c a t e  a n  i n c r e a s e  i n  p r e d i c t e d  C O H b  i n  a s s o c i a t i o n  w i t h  
a n  i n c r e a s e  i n  t h e  p a r a m e t e r  v a l u e ;  c o e f f i c i e n t s  t h a t  a r e  < 0  i n d i c a t e  t h a t  C O H b  d e c r e a s e d  i n  a s s o c i a t i o n  w i t h  a n  
i n c r e a s e  i n  t h e  p a r a m e t e r  v a l u e .
S ource : E P A  2009g  based  on M cC a rtn e y  (19 9 0 )
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specific parameter values are available for the species of interest. The latter include the Haldane 
coefficient (M), the binding capacity of Hb, and the lung carbon monoxide diffusing capacity (DLCO). 
Parameter values for the rat have been reported by Benignus and Annau (1994; Table 3-13).
Interroute extrapolation. The CFK model simulates inhalation exposures.
Smith et al. (1994) Multi-compartment Model
The nonlinear CFK model, described above, represents blood as a well-mixed compartment, an 
acceptable assumption for simulating near equilibrium conditions. However, during uptake and 
elimination phases of carbon monoxide kinetics, appreciable differences have been observed between 
arterial and venous blood (Benignus et al. 1994). Improved prediction of arterial COHb levels was 
achieved with an expansion of the CFK model to include slowly and rapidly perfused compartments, and 
an arm compartment (representing vascular sampling sites) that includes compartments representing the 
major arterial and venous vasculature (Smith et al. 1994, Figure 3-8; Table 3-14).
Validation of the model. The Smith et al. (1994) models was evaluated with data collected from 
15 healthy adults subjects who inhaled carbon monoxide under controlled conditions (Benignus et al. 
1994). Each subject (15 adult males) inhaled for approximately 5 minutes from a bag that had an initial 
carbon monoxide concentration of approximately 7,000 ppm. The exposures achieved end exposure 
blood COHb concentrations ranging from 10 to 15%. The Smith et al. (1994) model provided improved 
predictions of COHb levels in samples taken from radial artery and antecubital vein.
Risk assessm ent. Risk assessment applications of the Smith et al. (1994) were not identified in the 
available literature.
Target tissues. The Smith et al. (1994) model predicts COHb levels in arterial and venous blood.
Species extrapolation. Although originally developed to simulate blood COHb levels in humans, 
the model could be used to predict COHb levels in other mammalian species provided that physiological 
and chemical-specific parameter values are available for the species of interest
Interroute extrapolation. The Smith et al. (1994) model simulates inhalation exposures.
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Figure 3-8. Structure of the Smith et al. (1994) Model*
* D i f f u s i v e  e x c h a n g e  c a r b o n  m o n o x i d e  ( C O )  a n d  o x y g e n  ( O 2 )  o c c u r s  b e t w e e n  l u n g  a l v e o l a r  s p a c e  a l v e o l a r  c a p i l l a r y  
b l o o d .  I n s t a n t a n e o u s  e q u i l i b r i u m  i s  a s s u m e d  b e t w e e n  g a s e s  a n d  b l o o d  h e m o g l o b i n ,  g o v e r n e d  b y  t h e  H a l d a n e  
c o e f f i c i e n t .  B l o o d  c a r b o x y h e m o g l o b i n  ( C O H b )  i s  a p p o r t i o n e d  t o  v a r i o u s  b l o o d  s u b c o m p a r t m e n t s  a c c o r d i n g  t o  
s u b c o m p a r t m e n t  b l o o d  f l o w s  a n d  v o l u m e s .
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Table 3-14. Parameter Values for the Smith et al. (1994) Model
Parameter Definition Unit Value
Chemical parameters®
COHbQ Blood COHb level at start of simulation mL CO/mL blood 
(STPD)
Q.QQ155
D|_CO Lung CO diffusing capacity mL CO/minute-Torr 
(STPD)
SQ
Hb Blood Hb concentration g/mL Q.144
M Haldane coefficient unitless 218
O2HbMAX Maximum blood O2Hb concentration mL O2/mL blood 
(STPD)
1.38
Pc O2 Average partial pressure of O2 in alveolar 
air
Torr (STPD) 49
PICO Partial pressure of inhaled CO Torr (STPD) Input
V O O Endogenous CO production rate mL/minute (STPD) Q.QQ7
Compartment volumesb
BW Body weight kg 7Q
Vb Blood volume L Q.Q74BW
V1 Volumes of pulmonary capillaries and veins 
and % heart
L Q.1Vb
V2 Volume of rapidly perfused compartment L Q.11Vb
Vs volume of slowly perfused compartment L Q.652Vb
V4 Volume of major arteries in arms L Q.QQ69Vb
CD
>V5 Volume of small vessels in arms L Q.QQ76Vb
V7 Volume of intermediate veins in arms L Q.QQ25Vb
Va Volume of large veins in arms L Q.QS61Vb
V9 Volume of % heart and pulmonary arteries L Q.Q85Vb
Compartment flowsc
Va Alveolar ventilation rate L/hour (15BW° 74)
QC Cardiac output L/hour (15BW° 74)
Q12 Flow to rapidly perfused tissue L/hour Q.6QC
Q1S Flow to slowly perfused tissue L/hour Q.S5QC
Q14 Flow to arteries of arms L/hour Q.Q5QC
Q45 Flow to small vessels in arms L/hour Q.QQ5QC
a B a s e d  o n  T i k u i s i s  e t  a l .  ( 1 9 9 2 )
b M u s t  b e  c o n v e r t e d  t o  m L / m i n u t e  b y  m u l t i p l y i n g  1 , 0 0 0 / 6 0  
c M u s t  b e  c o n v e r t e d  t o  m L  b y  m u l t i p l y i n g  b y  1 , 0 0 0
B W  =  b o d y  w e i g h t ;  C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  H b  =  h e m o g l o b i n ;  S T P D  =  s t a n d a r d  
t e m p e r a t u r e  a n d  p r e s s u r e ,  d r y  ( i . e . ,  a d j u s t e d  f o r  p a r t i a l  p r e s s u r e  o f  w a t e r  v a p o r  i n  s a t u r a t e d  a i r  ( 4 7  T o r r  S T P )
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Hill et al. (1977) developed a multi-compartment model for simulating matemal-fetal transfer of carbon 
monoxide. This model includes simulations of maternal, placental, and fetal compartments, as well as 
maternal and fetal contributions to endogenous production of carbon monoxide (Figure 3-9; Table 3-15). 
The model assumes instantaneous equilibrium of O2 and carbon monoxide with Hb in maternal, placental, 
and fetal tissues, with delivery to placental and fetal tissues governed by blood flow rates.
Validation of the model. The Hill et al. (1977) model was evaluated with data collected in 
experiments conducted in pregnant sheep (Longo and Hill 1977; Longo 1977). Pregnant sheep were 
exposed to 30, 50, or 100 ppm carbon monoxide for 24 hours, or to 300 ppm for 4 hours and maternal and 
fetal arterial blood was sampled from indwelling catheters for measurement of COHb levels. These 
exposures achieved maternal blood COHb levels ranging from approximately 4 to 24% (300 ppm). 
Steady-state blood COHb levels in the fetus, achieved during the exposures to 30-100 ppm, were 
approximately 70% higher than maternal levels. The model predicted maternal and fetal arterial blood 
COHb levels that agreed with observations (e.g., were within ±1 SD of observations). The model predicts 
slower accumulation and elimination of COHb in the human fetus compared to the maternal system, with 
steady-state values in fetal blood that are approximately 10-12% higher in than maternal blood. The 
latter prediction agrees with observations made in cord blood (Longo 1977).
Risk assessm ent. Risk assessment applications of the Hill et al. (1977) model were not identified in 
the available literature. However, Hill et al. (1977) present and discuss predictions made with the model 
regarding effects of various factors on maternal and fetal blood COHb levels, including air carbon 
monoxide concentration, air O2 concentration, altitude, exercise, fetal O2 utilization, and fetal blood flow. 
Of particular relevance to risk assessment is the prediction of slower accumulation and elimination of 
COHb in the human fetus compared to the maternal system. Based on model predictions, the elimination 
half-times were approximately 4 hours for maternal and 7.5 hours for fetal. Furthermore, the model 
predicted a more pronounced effect of breathing 100% O2 on carbon monoxide elimination from the 
maternal system (5-fold decrease in half-time) compared to the effect on fetal half-time (2-fold decrease).
Target tissues. The Hill et al. (1977) model predicts COHb levels in maternal and fetal blood.
Species extrapolation. The Hill et al. (1977) model has been applied to predicting maternal and 
fetal blood COHb levels in humans and sheep (Hill et al. 1977; Longo 1977; Longo and Hill 1977).
Hill et al. (1977) Maternal-Fetal Model
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Figure 3-9. Structure of the Hill et al. (1977) Maternal-Fetal Model*
P |CO v COjM v COjF
* A v e r a g e  b l o o d  c a r b o x y h e m o g l o b i n  ( C O H b )  l e v e l s  i n  m a t e r n a l  a n d  f e t a l  t i s s u e s  a r e  c a l c u l a t e d  i n  t h e  B o d y  G a s  
E q u i l i b r a t i o n  M o d e l ,  b a s e d  o n  i n p u t s  o f  P O 2/ O 2H b  f r o m  l u n g ,  m a t e r n a l  t i s s u e ,  p l a c e n t a l  t i s s u e ,  a n d  f e t a l  p l a c e n t a l  
c a p i l l a r y  m o d e l s .
P iC O  =  i n h a l e d  c a r b o n  m o n o x i d e  p a r t i a l  p r e s s u r e ;  V c o ,m  =  m a t e r n a l  e n d o g e n o u s  c a r b o n  m o n o x i d e  p r o d u c t i o n ;  
V c o ,f =  f e t a l  e n d o g e n o u s  c a r b o n  m o n o x i d e  p r o d u c t i o n ;  V O 2 =  o x y g e n  c o n s u m p t i o n
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Table 3-15. Parameter Values for the Hill et al. (1977) Model
Parameter Definition Unit Value
Chemical parameters
DMC0 Lung membrane diffusing capacity mL C0/minute-Torr 5Ü, 6Ü
DLC0 Lung CO diffusing capacity mL C0/minute-Torr SÜ, 28
DP C0 Placental CO diffusing capacity mL CO/minute-Torr 1.5, 2.7
HbM Maternal blood Hb concentration g/mL 0.125
HbF Fetal blood Hb concentration g/mL 0.155
capM Maternal blood O2 capacity mL O2/mL 0.168
capF Fetal blood O2 capacity mL O2/mL 0.208
MM Haldane coefficient for maternal Hb unitless 22S
MF Haldane coefficient for fetal Hb unitless 181
Pb Atmospheric pressure Torr 760
PH0 H Partial pressure of water vapor (STP) Torr 47
(P02/02Hb)L Average ratio of partial pressure of O2 to O2Hb 
concentration in lung capillaries
Torr/% 1.029
(at PIC0=0)
(P02/0 2Hb)M Average ratio of partial pressure of O2 to O2Hb 
concentration in maternal placental capillaries
Torr/% 0.5609 
(at PIC0=0)
(P02/02Hb)F Average ratio of partial pressure of O2 to O2Hb 
concentration in fetal placental capillaries
Torr/% 0.4128 
(at PiCO=0)
PA 0 2 Partial pressure of O2 in alveolar air Torr 108
PA C02 Partial pressure of CO2 in alveolar air Torr 32
PV 0 2 Partial pressure of O2 in mixed venous blood in 
pulmonary artery
Torr 38
Pv C02 Partial pressure of CO2 in mixed venous blood in 
pulmonary artery
Torr 38
PF0 2 Partial pressure of O2 in umbilical artery Torr 20
Pf C02 Partial pressure of CO2 in umbilical artery Torr 48
PM0 2 Partial pressure of O2 in uterine artery Torr 95
PMC02 Partial pressure of CO2 in uterine artery Torr 32
P50,M Partial pressure of O2 at half O2 saturation in 
maternal blood
Torr 26.4
P5Ü,F Partial pressure of O2 at half O2 saturation in fetal 
blood
Torr 20.0
PHm pH of uterine artery blood M 7.4Ü
PHf pH of umbilical artery blood M 7.34
PHm pH of mixed venous blood M 7.37
PIC0 Partial pressure of inhaled CO Torr Input
VC0 ,M Maternal endogenous CO production rate mL/minute 0.0153
VC0 ,F Fetal endogenous CO production rate mL/minute 0.0006
V02 M Total maternal O2 consumption rate mL/minute 271
VO2F Fetal O2 consumption rate mL/minute 22
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Table 3-15. Parameter Values for the Hill et al. (1977) Model
Parameter Definition Unit Value
Compartment volumes
volM Maternal blood volume mL 5,000
volF  Fetal blood volume mL 400
Compartment flows
VA  Alveolar ventilation rate mL/minute 6,000
Qm Maternal placental blood flow mL/minute 350
Qf Fetal placental blood flow mL/minute 350
Ql Lung blood flow mL/minute 5,600
C O  =  c a r b o n  m o n o x i d e ;  H b  =  h e m o g l o b i n ;  S T P D  =  s t a n d a r d  t e m p e r a t u r e  a n d  p r e s s u r e ,  d r y  ( i . e . ,  a d j u s t e d  f o r  p a r t i a l  
p r e s s u r e  o f  w a t e r  v a p o r  i n  s a t u r a t e d  a i r  [ 4 7  T o r r  S T P ] ) .
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Bruce et al. (2008) Blood-Muscle Model
Bruce and Bruce (2003; Bruce et al. 2008) developed a multi-compartment model that simulates kinetics 
of carbon monoxide, blood COHb, and muscle COMb (Figure 3-10; Table 3-16). The model includes 
compartments for blood, muscle, and other non-vascular tissues. In blood, carbon monoxide exists as 
dissolved carbon monoxide in equilibrium with COHb. Binding of carbon monoxide and O2 to Hb is 
assumed to achieve instantaneous equilibrium of carbon monoxide with Hb, defined by the Haldane 
equation, with adjustment for cooperative binding of carbon monoxide and O2 to Hb and myoglobin. 
Simulation of arterial and venous blood includes a time delay to account for the time required to achieve 
mixing of arterial blood leaving the lung and mixed venous blood. The muscle compartment consists of 
two subcompartments, between which dissolved carbon monoxide exchanges by diffusion. 
Subcompartment 1 represents tissue that exchanges dissolved carbon monoxide with the arterial and 
venous vasculature (representing arterial-venous shunting). Subcompartment 2 represents tissue that 
exchanges with capillary blood. Dissolved carbon monoxide in muscle is in equilibrium with myoglobin, 
with the equilibrium defined by the Haldane equation adjusted for cooperative binding of O2. Carbon 
monoxide in the other tissue compartment is assumed to consist entirely of dissolved carbon monoxide.
Validation of the model. The Bruce et al. (2008) model was evaluated with data collected in 
experiments various experiments conducted in human volunteers (Benignus et al. 1994; Burge and 
Skinner 1995; Peterson and Stewart 1975; Tikuisis et al. 1987a). The evaluations are reported in Bruce 
and Bruce (2003, 2006) and Bruce et al. (2008). The model predicted observed arterial and venous blood 
COHb differences and kinetics during and following single or multiple brief exposures to carbon 
monoxide (Benignus et al. 1994). The model predicted continued uptake of carbon monoxide into muscle 
during the first 300 minutes following cessation of exposure, with subsequent return of muscle carbon 
monoxide to blood. (Bruce and Bruce 2006) Blood-muscle carbon monoxide exchange, in combination 
with elimination of carbon monoxide from blood to exhaled air, resulted in multi-phase blood elimination 
kinetics, with the early faster phase dominated by transfer of carbon monoxide from blood to muscle, and 
the later slower phase contributed by return of carbon monoxide from muscle to blood and elimination 
from blood to exhaled air. The multi-phase kinetics predicted form the model agreed with post-exposure 
elimination kinetics of carbon monoxide from blood observed in Benignus et al. (1994). The model also 
predicted blood COHb kinetics observed in 1- and 5-minute exposures observed in Tikuisis et al. (1987a).
Interroute extrapolation. T h e  H i l l  e t  a l.  ( 1 9 7 7 )  m o d e l s im u la te s  in h a la t io n  e x p o s u re s .
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
3. HEALTH EFFECTS
159
Figure 3-10. Structure of the Bruce et al. (2008) Model*
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* T h e  m o d e l  s i m u l a t e s  d i f f u s i v e  e x c h a n g e  o f  c a r b o n  m o n o x i d e  ( C O )  a n d  o x y g e n  ( O 2 )  b e t w e e n  a l v e o l a r  s p a c e  a n d  
c a p i l l a r i e s  a n d  t i s s u e  c a p i l l a r y  b l o o d  a n d  t i s s u e s .  C o m p e t i t i v e  c o o p e r a t i v e  b i n d i n g  o f  c a r b o n  m o n o x i d e  a n d  O 2 w i t h  
h e m o g l o b i n  ( H b )  o c c u r s  i n  b l o o d  a n d  t o  m y o g l o b i n  ( M b )  i n  m u s c l e .  N o  b i n d i n g  i s  a s s u m e d  i n  t h e  o t h e r  t i s s u e  
c o m p a r t m e n t s .  I n  m u s c l e ,  d i f f u s i v e  e x c h a n g e  i s  a s s u m e d  t o  o c c u r  b e t w e e n  b l o o d  a n d  b o t h  m u s c l e  
s u b c o m p a r t m e n t s ,  a s  w e l l  a s  b e t w e e n  m u s c l e  c o m p a r t m e n t s .
S ources : A d a p te d  from  B ruce  and B ruce  (2003); B ruce  et al. (2008 )
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Table 3-16. Parameter Values for the Bruce et al. (2008) Modela
Parameter Definition Unit Value
Chemical parameters
DLCO Lung CO diffusion capacity mL CO/minute-Torr S0
DmCO Muscle CO diffusion capacity mL CO/minute-Torr 1.75
DT0 2 Within tissue diffusion coefficient for O2 mL/minute-Torr 0.00060
Dj CO Within tissue diffusion coefficient for O2 mL/minute-Torr 0.00045
Hb Blood Hb concentration g/mL 0.14
HbF Fetal blood Hb concentration g/mL 0.155
MHb Haldane coefficient for Hb unitless 218
MMb Haldane coefficient for Mb unitless S6
n Hill equation exponent unitiless variablea
O2HbMax O2 capacity of Hb mL O2/g Hb 1.S81
Pb Barometric pressure Torr 760
2
O<P Partial pressure of O2 in arterial blood Torr 100
PMO2 Partial pressure of O2 in muscle Torr 20
P50Hb Partial pressure of at 50% Hb saturation Torr variablea
P cn o CT Partial pressure of at 50% Mb saturation Torr 2.S2
MRO2 B Whole body O2 consumption mL/minute/g 0.00S2
MRO2 M Muscle O2 consumption mL/minute/g 0.021-0.03
2
0S Solubility of O2 in plasma mL/Torr S.1410-5
SCO Solubility of CO in plasma mL/Torr 2.S510-5
VO2 Total body O2 consumption mL/minute 225
VCO Endogenous CO production ml/minute 0.007
Volumes
Vm Volume of muscle L 29.1
VM1F Volume of muscle subcompartment 1 L 0.4Vm
Vm 2F Volume of muscle subcompartment 1 L 0.6Vm
VOT Volume of other tissue L 9.6
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Table 3-16. Parameter Values for the Bruce et al. (2008) Modela
Parameter Definition Unit Value
Flows
Qc Cardiac output mL/minute 5,800
Qmí Blood flow fraction to muscles unitless 0.40
QOTf Blood flow fraction to other tissue unitless 0.25
Va Alveolar ventilation rate mL/minute 5,500
E s t i m a t e d  f r o m  H i l l  e q u a t i o n :
. . tPO-fP^T
O - H b  -  O - H b »  - ‘1 -  (PfVPso)’
V a l u e s  f o r  n  r a n g e d  f r o m  a p p r o x i m a t e l y  2 . 3 4  a t  C O H b = 0 %  t o  1 . 8  a t  C O H b = 1 0 0 % .  V a l u e s  f o r  P s o H b  r a n g e d  f r o m  
2 5  a t  C O H b = 0 %  t o  0  a t  C O H b = 1 0 0 %
C O  =  c a r b o n  m o n o x i d e ;  C O H b  =  c a r b o x y h e m o g l o b i n ;  H b  =  h e m o g l o b i n
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Model predictions match the CFK model when muscle diffusion is set to zero, and the model predicts 
lower blood COHb levels than the CFK model, when the muscle carbon monoxide diffusion is enabled. 
This difference reflects the blood-muscle kinetics and storage of carbon monoxide in muscle myoglobin 
that is not accounted for in the CFK model.
Risk assessm ent. Risk assessment applications of the Bruce et al. (2008) model were not identified 
in the available literature. However, the model has been applied to predicting the outcome of breathing 
100% O2 on blood COHb and muscle COMb kinetics (Bruce and Bruce 2006). The model predicted a 
decrease in blood and muscle elimination half-times. Of particular relevance to risk assessment is the 
prediction of continued uptake of carbon monoxide from blood to muscle that occurs for several hours 
after cessation of exposure, which contributes to slowing the elimination kinetics of carbon monoxide 
from the body.
Target tissues. The Bruce et al. (2008) model predicts blood COHb and muscle COMb levels and 
can also be used to predict blood and muscle carbon monoxide burden.
Species extrapolation. The Bruce et al. (2008) model has been applied only to predicting blood 
COHb and muscle COMb levels in humans. The model could be applied to other mammalian species 
providing that physiological and chemical-specific parameter values are available for species of interest.
Interroute extrapolation. The Bruce et al. (2008) model simulates inhalation exposures.
3.5 MECHANISMS OF ACTION
3.5.1 Pharmacokinetic Mechanisms
Pharmacokinetic mechanisms of carbon monoxide action are related to its binding to heme proteins. 
Kinetics and equilbria of binding to the major heme proteins that have the greatest influence on carbon 
monoxide pharmacokinetics (Hb and myoglobin) are discussed in the Section 3.4, Toxicokinetics.
Absorption. Inhaled carbon monoxide is rapidly and extensively absorbed into blood (Benignus et al. 
1994; Burge and Skinner 1995; Peterson and Stewart 1970, 1975; Tikuisis et al. 1987b). Inhaled carbon 
monoxide is transported to lung alveoli as result of convective forces in the respiratory tract and diffusion. 
At the alveolar gas-blood interface, carbon monoxide dissolves into pulmonary capillary plasma and, 
from plasma, diffuses into erythrocytes and other tissues. Binding of carbon monoxide by erythrocyte Hb
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(to form COHb) contributes to maintaining relatively low concentrations of dissolved carbon monoxide in 
erythrocyte cytosol and a partial pressure gradient to drive carbon monoxide transfer from alveolar air to 
blood. Diffusion of carbon monoxide into erythrocytes and binding of carbon monoxide to Hb is 
sufficiently rapid that near equilibrium is achieved between carbon monoxide partial pressures in alveolar 
air and alveolar end capillary (arterial) blood (Chakraborty et al. 2004). Continued uptake of carbon 
monoxide results from systemic elimination processes that lower mixed venous blood carbon monoxide 
concentrations returned to alveolar capillaries (Benignus et al. 1994).
Distribution. The distribution of absorbed carbon monoxide is determined, in large part, by its affinity 
for binding to heme. Binding of carbon monoxide to intracellular heme proteins contributes to 
maintaining gradients for carbon monoxide diffusion from plasma into erythrocytes and extravascular 
tissues. The dominant heme proteins that influence carbon monoxide distribution are erythrocyte Hb and 
muscle myoglobin. The distribution of carbon monoxide in the body is largely a reflection of the 
distribution of Hb and myoglobin, with the largest carbon monoxide burden found in blood, heart, 
skeletal muscle, and spleen (Vreman et al. 2005, 2006). Relatively large contributions of blood and 
skeletal muscle to total body carbon monoxide content is consistent with the contributions that these 
tissues make to total body Hb and muscle myoglobin (Bruce and Bruce 2003). In a typical adult, blood 
contains approximately 12 mmoles of Hb with a total binding capacity of approximately 48 mmole 
carbon monoxide when completely saturated, and muscle contains approximately 8 mmoles of myoglobin 
with a total binding capacity of 8 mmole carbon monoxide when completely saturated.
Metabolism. Metabolism of carbon monoxide consists of three major processes: (1) metabolic 
production of carbon monoxide from endogenous and exogenous precursors; (2) binding of carbon 
monoxide to heme proteins; and (3) oxidative metabolism of carbon monoxide to CO2.
Metabolic Production of Carbon Monoxide. Endogenous carbon monoxide is produced, primarily, from 
the enzymatic degradation of heme by the enzyme HO. Carbon monoxide is produced in all tissues that 
express HO; however, the major tissues contributing to carbon monoxide production are also major sites 
of heme metabolism, including liver, spleen, and reticuloendothelial system (Berk et al. 1974). Three 
isoforms of HO have been identified, of which, HO-1 is inducible, whereas, HO-2 and HO-3 are 
constitutive. In general, factors the induce HO-1 increase carbon monoxide production, whereas 
inhibition of HO activity or expression of HO decreases carbon monoxide production. Numerous stimuli 
have been shown to upregulate HO-1expression (Wu and Wang 2005): (1) those related to heme 
metabolism (e.g., heme and heme derivatives, endogenous carbon monoxide); (2) stimuli that produce or
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are associated with physiological or oxidative stress such as hyperoxia, heat shock factors, oxidized 
lipids, lipopolysaccharides, hydrogen peroxide, radiation (including ultraviolet light), endotoxin, heavy 
metals and arsenite, and various cytokines (e.g., interleukins, TNF-a); (3) substances that are mediators of 
vascular resistance (NO, angiotensin II); and (4) mitogens and other factors that regulate cell growth (e.g., 
growth factors, phorbol ester). Expression of the constitutive isoform, HO-2, is increased by estrogen, 
glucocorticoids, stimuli that inhibit HO, and stimuli that down regulate NO production (e.g., inhibition of 
NO synthase). In human cells (e.g., grown in culture), expression of HO-1 is down regulated in hypoxia, 
heat shock factors, and interferon-y. The response to the above factors is not uniform across species. For 
example, hypoxia and heat shock have been shown to induce HO in rodents, whereas the dominant effect 
in human tissues is downregulation (Nakayama et al. 2000; Shibahara et al. 2003; Wu and Wang 2005).
Carbon monoxide can be produced from oxidative metabolism of certain exogenous hydrocarbons (e.g., 
DCM), by isoform CYP2E1 of cytochrome P450 (Andersen et al. 1991); and from heme oxidase catalysis 
of products of auto-oxidation of phenols, photo-oxidation of organic compounds, and lipid peroxidation 
of cell membrane lipids (Rodgers et al. 1994).
Carbon Monoxide Binding to Heme Proteins. Carbon monoxide competes for O2 for binding to the iron 
site in heme. Kinetic constants and equilibrium constants for the binding of O2 and carbon monoxide to 
Hb and myoglobin are provided in Table 3-12.
Oxidative Metabolism of Carbon Monoxide. The mechanism of oxidative metabolism of carbon 
monoxide to CO2 is thought involve catalysis by cytrochrom c oxidase (Fenn 1970; Young and Caughey 
1986).
Excretion. Absorbed carbon monoxide is eliminated from the body by exhalation and oxidative 
metabolism. Oxidative metabolism of carbon monoxide has been estimated to be a relatively small 
fraction (<10%) of endogenous carbon monoxide production (Luomanmaki and Coburn 1969). Under 
most conditions, the dominant route of elimination of absorbed carbon monoxide is exhalation. The 
mechanism of elimination of carbon monoxide by exhalation is diffusion, with the driving forces at the 
alveolar interface being the partial pressure difference between carbon monoxide in alveolar air and in 
alveolar capillary blood. The latter is maintained at a relatively low level by binding of carbon monoxide 
to Hb. Diffusion is also the mechanism of release of carbon monoxide from intracellular stores to blood, 
with the driving forces influenced by binding of carbon monoxide to extravascular heme proteins (e.g., 
myoglobin) and blood Hb.
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Carbon monoxide exerts effects on cell metabolism through both hypoxic and non-hypoxic mechanisms. 
Both types of effects are thought to be largely (if not entirely) the result of the ability of carbon monoxide 
to bind to heme and alter function and/or metabolism of heme proteins. Carbon monoxide may also act 
through mechanisms unrelated to heme binding, although evidence for this is currently more contentious.
Hypoxic Mechanisms. Carbon monoxide produces tissue hypoxia by binding to and displacing O2 from 
Hb. The formation of COHb decreases the O2 carrying capacity of blood and impairs release of O2 from 
Hb for its utilization in tissues (see Section 3.4.3, Metabolism for further discussion of kinetics of binding 
of carbon monoxide and O2 to Hb). Through similar mechanisms, carbon monoxide decreases O2 storage 
in muscle cells by binding to and displacing O2 from myoglobin. The principle mechanisms underlying 
the hypoxic mechanism of carbon monoxide are: (1) higher affinity of carbon monoxide for Hb than O2, 
and (2) increased binding affinity for O2 from COHb. The overall affinity of Hb for carbon monoxide is 
approximately 230 times greater than that for O2 (Chakraborty et al. 2004). As a result, at a partial 
pressure of carbon monoxide that is approximately 230-fold lower than ambient O2 concentration 
(21%/230«900 ppm), O2 and carbon monoxide will bind to Hb in an equimolar ratio (i.e., COHb «50%). 
Binding of carbon monoxide and O2 to the four heme moieties of Hb is cooperative (Alcantara et al.
2007; Perrella and Di Cera 1999; Roughton 1970). The associative reaction rate (ka) becomes faster with 
successive additions of carbon monoxide or O2, increasing the affinity (Ka) of Hb for O2 and impairing 
the release of O2 from Hb for utilization in tissues. Overall, the affinity increase is 588-fold due to 
cooperative events as more carbon monoxide binds to hemoglobin; however, this is not a monotonic 
function with each ligation. Once the first hemoglobin chain binds a carbon monoxide molecule, the 
affinity increases 16.5-fold when the second carbon monoxide molecule binds, 4.6-fold at the third 
ligation step, and 7.7-fold in the fourth ligation step (Perrella and Di Cera 1999).
Although all tissues are vulnerable to carbon monoxide-induced hypoxic injury, those having the highest 
O2 demand are particularly vulnerable, including the brain and heart. Carbon monoxide-induced hypoxia 
triggers compensatory cardiovascular responses that include increased cardiac output (heart rate and 
stroke volume) and dilation of cardiac and cerebral vasculature. During exercise, cardiac work and O2 
consumption increase, and increase the vulnerability of the heart to carbon monoxide-induced hypoxic 
injury. In patients who have underlying coronary artery or myocardial disease, the increased O2 demand 
of exercise, in combination with decreased O2 carrying capacity of blood and impaired release of O2 from
3.5.2 Mechanisms of Toxicity
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Hb, can produce cardiac toxicity (e.g., myocardial ischemia, exertional angina, arrhythmia), at lower 
carbon monoxide exposure levels than experienced in healthy individuals (Adams et al. 1988; Allred et al. 
1989, 1991; Anderson et al. 1973; Kleinman et al. 1989, 1998; Leaf and Kleinman 1996b).
Brain hypoxia induced by carbon monoxide can result in various symptoms of impaired central nervous 
system function, including headache, dizziness, drowsiness, weakness, nausea, vomiting, confusion, 
disorientation, irritability, visual disturbances, convulsions, and coma (Dolan 1985; Ernst and Zibrak 
1998). Delayed development of neuropsychiatric and neurological impairment may occur within 1­
4 weeks of exposure, with symptoms including inappropriate euphoria, impaired judgment, poor 
concentration, memory loss, cognitive and personality changes, psychosis, and Parkinsonism (Choi 2002; 
Ernst and Zibrak 1998; Kao and Nanagas 2006; Klawans et al. 1982; Raub and Benignus 2002; Raub et 
al. 2000; Ringel and Klawans 1972; WHO 1999; Wolf et al. 2008).
Non-Hypoxic Mechanisms. Most of the non-hypoxic mechanisms of action of carbon monoxide have 
been attributed to binding of carbon monoxide to heme in proteins other than Hb. A list of heme proteins 
that have been shown to undergo functional modification in response to carbon monoxide is presented in 
Table 3-17. Notable targets of carbon monoxide include components of several important physiological 
regulatory systems, including: brain and muscle O2 storage and utilization (myoglobin, neuroglobin); 
nitric oxide NO cell signaling pathway (e.g., nitric oxide synthase [NOS], guanylyl cyclase [GC]); 
prostaglandin cell signaling pathway (cyclooxygenase, prostaglanding H synthase); energy metabolism 
and mitochondrial respiration (cytochrome c oxidase, cytochrome c, NADPH oxidase); steroid and drug 
metabolism (cytochrome P450 [CYP450]), cellular redox balance and reactive oxygen species (ROS) 
(catalase, peroxidases); and various transcription factors (e.g., neuronal PAS domain protein, NPAS2).
Endogenously produced carbon monoxide may participate in the physiological regulation of some, if not 
all, of these systems. This has potentially important implications for the understanding of carbon 
monoxide toxicology and dose-response relationships for the following reasons: (1) carbon monoxide 
modulation of physiological processes may underlie some aspects of the toxicity of exogenous carbon 
monoxide; (2) exogenous carbon monoxide may disrupt physiological regulation of those systems that are 
responsive to endogenous carbon monoxide (e.g., vascular resistance); and (3) exposures to exogenous 
carbon monoxide may affect carbon monoxide-mediated physiological responses at levels that approach 
those resulting from endogenous production. Whole-body endogenous carbon monoxide production rate 
has been estimated to be approximately 16.4 ^mol/hour (0.007 mL/minute, standard temperature, 
pressure, density [STPD]; Coburn 1970a). Local rates of production of carbon monoxide in tissues are
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Table 3-17. Heme Proteins Modulated by Carbon Monoxide
Name of protein
Effects or carbon monoxide or heme 
oxygenase up-regulation Reference
Catalase Inhibition Hu and Kincaid 1992
Cyclooxygenase Inhibition Alcaraz et al. 2003
Activation Lee et al. 2001
Cytochrome c Binding Bhuyan and Kumar 2002
Cytochrome P450 Inhibition Estabrook et al. 1980
Cytochrome c oxidase Inhibition Wohlrab and Ogunmola 1971
Guanylyl cyclase Activation Stone and Marletta 1994
Hemoglobin Inhibition Forster 1970
Neuroglobin Inhibition Burmester et al. 2000
Myoglobin Inhibition Coburn and Mayers 1971
Cytoglobin Inhibition Geuens et al. 2003; Sawai et al. 2003
NADPH oxidase Inhibition Taille et al. 2004
NO synthases Inhibition Thorup et al. 1999; Willis et al. 1995
Peroxidases Binding Carlsson et al. 2005
Prostaglandin H synthase Binding Lou et al. 2000
Tryptophan dioxygenase Inhibition Piantadosi 2002
NPAS2 Inhibition Dioum et al. 2002
S o u r c e :  W u  a n d  W a n g  2 0 0 5
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influenced by many tissue-specific factors, including those that regulate intracellular heme oxygenase 
activity (e.g. some areas of brain have relatively high HO-2 activities). A similar whole-body rate of 
delivery of carbon monoxide to the alveolar region of the lung would be achieved by inhaling air at a 
carbon monoxide concentration of approximately 1-2 ppm (i.e., assuming alveolar ventilation rate is 
approximately 4,000 mL/minute; 0.007 mL/minute/4,000 mL/minute = 1.75-10-6 mL CO/mL air, STPD 
= 1.75 ppm). Such levels are only modestly above national average ambient air carbon monoxide 
concentrations in the United States (approximately 0.5 ppm, see Chapter 6) and well within variability 
observed in measurements made with personnel air monitors (Chang et al. 2000). One implication of this 
is that, if a dose threshold for effects of exogenous carbon monoxide exists at all, it may lie near or below 
ambient air carbon monoxide concentrations. Although currently available toxicology and 
epidemiological studies provide evidence for increasing severity of adverse carbon monoxide effects in 
association with increasing levels of exposure, these studies do not provide strong evidence supporting or 
refuting a dose threshold for adverse effects.
Of the many physiological systems that may contribute to non-hypoxic mechanisms of carbon monoxide 
action, the following are thought to be particularly important and are the subject on ongoing intense 
research interests: modulation of cell signaling pathways and generation of ROS.
Carbon Monoxide Modulation of Cell Signaling. Cell signaling pathways that are thought to be 
modulated by carbon monoxide are depicted in Figure 3-11. These pathways contribute to the regulation 
of various physiological process, including inflammatory responses, apoptosis, cell proliferation, 
thrombosis (i.e., platelet aggregation), smooth muscle tone (including vasodilation and relaxation of 
extravascular smooth muscle) and synaptic neurotransmission in the central and peripheral nervous 
systems (e.g., glutamate). The nitric oxide radical (NO )^ plays an important signal transduction role in 
regulating smooth muscle relaxation, synaptic neurotransmission (e.g., glutamate), platelet function, and 
other physiological processes (Denninger and Marietta 1999). One of the major transduction pathways 
mediated by NO  ^is the NO^-cGMP pathway, in which NO  ^produced by the enzyme NOS binds to the 
heme moiety of soluble guanylate cyclase (sGC), which catalyzes conversion of guanosine triphosphate 
(GTP) to cyclic guanosine monophosphate (cGMP). The latter (cGMP) activates various downstream 
signaling cascades that regulate cell function (e.g., cGMP-dependent protein kinase, cGMP-regulated 
cation channels, and cGMP-regulated phosphodiesterase). Carbon monoxide binds to the heme moieties 
of both NOS and cGC; and in doing so, inhibits NOS activity and activates cGC activity (Stone and 
Marietta 1994; Thorup et al. 1999). The potency of carbon monoxide for activating sGC is approximately 
20-fold less than that of NO% as a result, in the presence of NO%
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Figure 3-11. Potential Signaling Pathways Modulated by Carbon Monoxide
M uscle Synaptic
Tone Transmission
c G M P  =  c y c l i c  g u a n o s i n e  m o n o p h o s p h a t e ;  C O  =  c a r b o n  m o n o x i d e ;  C O X  =  c y l c o o x y g e n a s e ;  C R F  =  c o r t i c o t r o p i n  
r e l e a s i n g  f a c t o r ;  C N S  =  c e n t r a l  n e r v o u s  s y s t e m ;  C Y P P 4 0  =  c y t r o c h o m e  P 4 5 0 ;  E R K  =  e x t r a c e l l u l a r  s i g n a l  r e g u l a t e d  
k i n a s e ;  2 0 - H E T E  =  2 0 - h y d r o x y e i c o s t e t r a e n o i c  a c i d ;  H S F  =  h e a t  s h o c k  f a c t o r ;  H S P  =  h e a t  s h o c k  p r o t e i n ;
I L  =  i n t e r l e u k i n ;  J N K  =  a  s t r e s s  a c t i v a t e  p r o t e i n  k i n a s e ;  M A P K  =  m i t o g e n  a c t i v a t e  p r o t e i n  k i n e a s e ;  M I P  =  m a c r o p h a g e  
i n f l a m m a t o r y  p r o t e i n ;  N A N C  =  n o n - n o r a d r e n e r g i c  n o n - c h o l i n e r g i c ;  N O ^  =  n i t r i c  o x i d e  r a d i c a l ;  N O S  =  n i t r o g e n  o x i d e  
s y n t h a s e ;  P D E  =  p h o s p h o d i e s t e r a s e ;  P G  =  p r o s t a g l a n d i n s ;  P K  =  p r o t e i n  k i n a s e ;  s G C  =  s o l u b l e  g u a n y l a t e  c y c l a s e ;  
T N F  =  t u m o r  n e c r o s i s  f a c t o r
A d a p te d  from  R y te r e t al. 2006; V o lti e t al. 2 008
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carbon monoxide may modulate sGC activity downward by displacing NO  ^from sGC (Stone and 
Marietta 1994). The NO^-cGMP signaling pathway has been implicated in the mechanism by which 
carbon monoxide produces relaxation of smooth muscle (Ny et al. 1996) and inhibition of platelet 
homotypic aggregation (Brune and Ullrich 1987). Carbon monoxide increases platelet-neutrophil 
interactions (heterotypic aggregation) through a free-radical mechanism (Thom et al. 2006).
Carbon monoxide modulates mitogen activated protein kinase (MAPK) signaling pathways, either 
through its interaction with sGC (Ryter et al. 2006) or through secondary effects on ROS generation (see 
below) MAPK pathways are important regulators of cytokine production and release in inflammatory 
responses, and in regulating apoptosis and proliferation.
Carbon monoxide exposure can perturb heme protein binding by nitric oxide, induce a variety of proteins 
including heme oxygenase (HO), superoxide dismutase, and nitric oxide synthase, alter mitochondrial 
function, and modify production of ATP and ROS (Brown and Piantadosi 1992; Davutoglu et al. 2006; 
Kim et al. 2007; Lee et al. 2006; Maulik et al. 1996; Nakao et al. 2008; Piantadosi et al.1997; Thom et al. 
1994, 1997, 2000; Zuckerbraun et al. 2003). Carbon monoxide increases production of ROS from 
mitochondria and also some non-mitochondrial sources, which can activate one or more protein kinases 
(e.g., p38 MAPK, c-Jun N-terminal kinase, ERK), signal transducers (e.g., peroxisome proliferator- 
activated receptor-y), and transcriptional regulators (e.g., nuclear factor-KB, AP-1), as well as guanylate 
cyclase, and lead to secondary events such as vasodilation and fibrinolysis (Arruda et al. 2004; Fujita et 
al. 2001; Mishra et al. 2006; Ryter and Otterbein 2004; Soares et al. 2004; Wijayanti et al. 2004).
Carbon monoxide also binds to the heme moieties and inhibits CYP450 and cycloxygenase (COX) and, 
thereby, can modify physiological processes regulated by products of these enzyme systems. Inhibition 
of CYP450 catalyzed production of eciosanoids (e.g., 20-hydroxyeicostetraenoic acid, [20-HETE]) and 
COX-mediated production of prostaglandins have been postulated as a potential mechanisms by which 
carbon monoxide may contribute to the regulation of vascular smooth muscle tone and vasodilation 
(Botros et al. 2002; Volti et al. 2008).
Carbon Monoxide Modulation of ROS Generation. Carbon monoxide may promote and/or modify ROS 
generation through several different mechanisms. Binding to the heme moiety and inhibition of 
mitochondrial cytochrome c oxidase disrupts mitochondrial respiration and promotes ROS generation 
(Alonso et al. 2003; D'Amico et al. 2006; Favory et al. 2006a; Iheagwara et al. 2007; Zuckerbraun et al.
2007). Carbon monoxide also appears to promote a more general disruption of the regulation of iron and
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ferrtin levels, at least in part through promotion of heme protein degradation (Cronje et al. 2004; Ghio et 
al. 2008; Iheagwara et al. 2007).
3.5.3 Animal-to-Human Extrapolations
Studies conducted in nonhuman primates, dogs, and various rodent species have demonstrated the major 
health effects of carbon monoxide that have been observed in humans, including COHb-related hypoxia, 
cardiovascular responses, and neurological effects (Benignus 1994; Benignus et al. 1990; EPA 1991,
2000; Raub and Benignus 2002). These studies also provide support for the concept of nonhypoxic 
modes of action of carbon monoxide that operate on a variety of physiological systems (e.g., Wu and 
Wang 2005; also, see Section 3.5.2 for discussion and relevant references). These systems include 
physiological regulatory systems that function in all mammalian species, such as brain and muscle 
oxygen storage and utilization; nitric oxide cell signaling pathway; prostaglandin cell signaling pathway; 
energy metabolism and mitochondrial respiration; steroid and drug metabolism; cellular redox balance 
and reactive oxygen species; and various transcription factors. Therefore, results from mechanistic 
studies conducted in typical laboratory animal models are likely to be directly relevant to understanding 
mechanisms of action of carbon monoxide in humans. Manifestations of these various modes of action 
may differ qualitatively and quantitatively across species. For example, rats exhibit pronounced 
hypothermia in response to exposures to carbon monoxide whereas at low levels of exposure (e.g., COHb 
<20%), this response is not evident in humans (Benignus 1994; Gordon 1990). Differences in dose- 
response relationships between humans and animal models can also be expected, in part, due to 
differences in physiological and chemical determinants of carbon monoxide uptake, elimination, and 
binding kinetics with major heme proteins (Benignus and Annau 1994; Longo and Hill 1977) as well as 
interspecies differences in physiological regulation of systems that are nonhypoxic targets of carbon 
monoxide.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial. The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a
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panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse. Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to 
the health of humans, aquatic animals, and wildlife. However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment. Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992). These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen. Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997). Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis. As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function. Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans and/or animals after exposure to 
carbon monoxide. Several cell signaling pathways that are thought to be modulated by endogenous 
carbon monoxide that could play a role in the regulation of activity of the hypothalamic-pituitary-adrenal 
(HPA) axis, including cGMP and NO  ^signaling (Mancuso et al. 1997; Snyder et al. 1998; Wu and Wang 
2005). Modulation of endogenous carbon monoxide levels and/or production has been shown to modify 
various HPA axis process including release of arginine vasopressin (AVP), gonadotropin, and 
corticotropin releasing hormone from the hypothalamus, release of adrenocorticotropic hormone (ACTH) 
from the pituitary, and response of the adrenal gland to ACTH (Wu and Wang 2005). The toxicological 
significance of these various actions of carbon monoxide has not been established.
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential
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effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.
Relevant animal and in vitro models are also discussed.
Children are not small adults. They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals. Children’s unique physiology and behavior can influence the 
extent of their exposure. Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993). Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993). Vulnerability often depends on developmental stage. There are 
critical periods of structural and functional development during both prenatal and postnatal life, and a 
particular structure or function will be most sensitive to disruption during its critical period(s). Damage 
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults. For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978). Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964). The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many 
xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996). Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification. There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948). 
Children and adults may differ in their capacity to repair damage from chemical insults. Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly 
relevant to cancer.
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Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical. For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993).
The fetus may be particularly vulnerable to maternal carbon monoxide exposure. Carbon monoxide in the 
maternal system distributes to fetal tissues. Measurements of steady-state fetal COHb concentrations in 
fetal and maternal blood of nonsmoking women have found fetal COHb concentrations to be 
approximately 10-15% higher than maternal blood (fetal/maternal ratio=1.1-1.15; Longo 1977). Binding 
affinity of fetal Hb is approximately twice that of maternal Hb (Di Cera et al. 1989). The higher binding 
affinity of fetal Hb as well as the relatively small diffusion gradients for carbon monoxide between 
maternal and fetal blood contribute to slower kinetics of COHb in fetal blood compared to maternal 
blood. As a result, with continuous exposure to a constant level of carbon monoxide in air, the kinetics of 
fetal blood COHb concentration would be expected to lag behind maternal kinetics and to reach a steady- 
state that is approximately 10-15% higher than maternal (Longo 1977). Similarly, following cessation of 
exposure, elimination kinetics of carbon monoxide from fetal blood would be expected to lag behind that 
of maternal blood (Hill et al. 1977).
Epidemiological studies have examined possible associations between exposure to ambient air carbon 
monoxide concentrations and various developmental outcomes, including pre-term birth, birth weight, 
congenital anomalies, and neonatal and infant death (see Section 3.2.6, Table 3-8). Results of these 
studies have been mixed and, collectively, do not provide strong evidence for developmental effects, 
including neonatal or infant mortality in association with exposures to ambient levels of carbon monoxide 
(<10 ppm). However, studies conducted in animals provide evidence of adverse developmental effects of 
gestational and early postnatal carbon monoxide in association with maternal exposure concentrations as 
low as 12-25 ppm. Observed effects have included decreased fetal weight, adverse central nervous 
system development, altered peripheral nervous system development, cardiac effects, altered sexual 
behavior, immunological effects, and hematological effects (see Table 3-9). In addition, some studies 
showed that developmental effects persisted beyond the postnatal period (Carratu et al. 1993, 2000a, 
2000b; De Salvia et al. 1995; Lopez et al. 2003, 2008; Stockard-Sullivan et al. 2003; Webber et al. 2003).
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Although no studies have directly compared the sensitivity of adults and children to the effects of carbon 
monoxide, several epidemiological studies have examined pulmonary function, asthma morbidity, and 
exacerbation of asthma symptoms in children (Chen et al. 1999; Fischer et al. 2002; Mortimer et al. 2008; 
Yu et al. 2000). Although results have been mixed, these studies provide some evidence for increased 
vulnerability of asthmatic children to carbon monoxide-associated respiratory effects (see Section 3.2.2, 
Respiratory Effects).
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989).
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment 
of the exposure of the U.S. population to environmental chemicals using biomonitoring. This report is 
available at http://www.cdc.gov/exposurereport/. The biomonitoring data for carbon monoxide from this 
report is discussed in Section 6.5. A biomarker of exposure is a xenobiotic substance or its metabolite(s) 
or the product of an interaction between a xenobiotic agent and some target molecule(s) or cell(s) that is 
measured within a compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure 
are generally the substance itself, substance-specific metabolites in readily obtainable body fluid(s), or 
excreta. However, several factors can confound the use and interpretation of biomarkers of exposure.
The body burden of a substance may be the result of exposures from more than one source. The 
substance being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels 
of phenol can result from exposure to several different aromatic compounds). Depending on the 
properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and route 
of exposure), the substance and all of its metabolites may have left the body by the time samples can be 
taken. It may be difficult to identify individuals exposed to hazardous substances that are commonly 
found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and selenium). 
Biomarkers of exposure to carbon monoxide are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
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cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity. Note that these markers are not often substance specific. They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused 
by carbon monoxide are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability 
to respond to the challenge of exposure to a specific xenobiotic substance. It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Carbon Monoxide
Measurement of blood COHb is the principal biomarker for identifying exposure to carbon monoxide. 
Nearly all carbon monoxide in the body exists as complexes with Hb and other heme proteins. 
Approximately 60-70% of the body burden exists as blood COHb (Vreman et al. 2006; Bruce and Bruce 
2003). Therefore, measurement of COHb provides a useful indicator of the elevated carbon monoxide 
body burden, although the utility for blood COHb measurements for large-scale screening for elevated 
exposures or poisoning is questionable (Heckerling et al. 1990). The relationship between COHb levels 
and exposure is more complex because of the numerous physiological factors that influence carbon 
monoxide uptake and elimination. The elimination half-time of absorbed carbon monoxide has been 
estimated to be approximately 300 minutes (Bruce and Bruce 2006; Peterson and Stewart 1970); 
therefore, a value for COHb measured at a given time following exposure will reflect both the exposure 
and elimination rate of carbon monoxide. Several pharmacokinetics models have been developed that can 
be used to predict blood COHb levels that would correspond to a given exposure concentration and 
duration, in a typical adult and in the fetus resulting from maternal exposures (see Section 3.4.5). These 
models can be used to reconstruct possible carbon monoxide exposure scenarios (e.g., concentrations, 
duration, and gap between measurement of COHb and cessation of exposure) that could result in a given 
measured COHb level.
3.8.2 Biomarkers Used to Characterize Effects Caused by Carbon Monoxide
Although blood COHb reflects current carbon monoxide body burden, measurement of blood COHb has 
not been shown to be a reliable predictor of severity of acute toxicity (Hampson and Hauff 2008).
Typical levels of COHb in nonsmokers are <2% (Adams et al. 1988; Allred et al. 1991; Anderson et al.
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1973; Hinderliter et al. 1989; Kleinman et al. 1989, 1998; Sheps et al. 1987, 1990). Levels of 10% or 
more can be observed immediately after smoking a cigarette (Kao and Nanagas 2006). In general, signs 
and symptoms of acute carbon monoxide poisoning can present at COHb levels ranging from 3 to 24% 
(Hampson and Hauff 2008; Kao and Nanagas 2006). Levels ranging from 2 to 6% have been shown to 
exacerbate underlying cardiovascular disease, including enhanced myocardial ischemia and increased 
cardiac arrhythmias (Adams et al. 1988; Allred et al. 1989, 1991; Anderson et al. 1973; Kleinman et al. 
1989, 1998; Leaf and Kleinman 1996b). More severe signs of carbon monoxide poisoning are poorly 
correlated with blood COHb, with loss of consciousness occurring at mean levels of 24.3% (range: 2-70) 
and fatality at mean levels of 32.1% (range: 3.0-60; Hampson and Hauff 2008). Exposures that result in 
COHb levels >50% are usually fatal (Kao and Nanagas 2006).
Diagnosis and characterization of carbon monoxide toxicity includes both the measurement of blood 
COHb and assessment of signs. In order of increasing severity, these include: (1) headache, nausea, 
dilation of cutaneous vasculature, vomiting, dizziness, blurred vision; (2) confusion, syncope, chest pain, 
dyspnea, weakness, tachycardia, tachynea rhabdomyolysis; and (3) palpitations, cardiac dysrhythmias, 
hypotension, myocardial ischemia, cardiac arrest, respiratory arrest, pulmonary edema, seizures, coma 
(Kao and Nanagas 2006). Neuropsychological testing and neuroimaging have been considered for 
evaluating central nervous system effects (Tomaszewski 2006).
Cardiac enzyme markers are associated with myocardial dysfunction and an elevated risk for long-term 
cardiac mortality following carbon monoxide poisoning; biochemical markers for brain injury such as 
neuron-specific enolase and S-100 beta protein have not been found to reliably correlate with severity of 
poisoning or clinical outcome (Brvar et al. 2004; Davutoglu et al. 2006; Kalay et al. 2007; Rasmussen et 
al. 2004; Satran et al. 2005).
3.9 INTERACTIONS WITH OTHER CHEMICALS
The effects of combined exposure of carbon monoxide with other chemicals (e.g., pollutants, drugs) were 
reviewed by the EPA (1991, 2000). In general, research has mainly focused on effects of combined 
chemical exposures on the cardiovascular, respiratory and central nervous systems. As discussed in 
Section 3.10 (Populations that Are Unusually Susceptible), in addition to interactions with other 
chemicals, exposure to carbon monoxide at a higher altitude may result in higher body burdens of carbon 
monoxide and, therefore, there may be higher vulnerability to carbon monoxide at higher altitudes than at
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lower altitudes (McGrath et al. 1993), in particular, for people who have not physiologically adapted to 
higher altitudes (Horvath et al. 1988; Hsia 2002).
Oxygen. The chemical interaction of highest toxicological and clinical significance is that between 
carbon monoxide and O2. Carbon monoxide and O2 compete for binding to heme (Chakraborty et al. 
2004; Gibson et al. 1986). Binding to and displacing O2 from heme proteins, including blood Hb and 
muscle myoglobin, has profound effects on the kinetics of distribution and elimination kinetics of both 
carbon monoxide and O2, and is also the principal mechanism underling the hypoxic effects of carbon 
monoxide (Bruce and Bruce 2006; Bruce et al. 2008; Vreman et al. 2005, 2006). Decreasing levels of O2 
in inspired air facilitates carbon monoxide binding to Hb and myoglobin and exacerbates carbon 
monoxide-induced hypoxia. This interaction can contribute to a higher vulnerability to carbon monoxide 
toxicity at lower O2 pressures that occur at higher altitudes (Horvath et al. 1988; Hsia 2002; McGrath et 
al. 1993). Increasing levels of O2 in inspired air facilitates displacement of carbon monoxide from Hb 
and myoglobin, increases the rate of carbon monoxide elimination from the body, and increases O2 
availability to tissues (Landaw 1973; Peterson and Stewart 1970; Weaver et al. 2000). These actions of 
O2 form the basis for the use of 100% O2 and hyperbaric O2 therapy in the treatment of carbon monoxide 
poisoning (Lavonas 2007; Tomaszewki 2006).
Cyanide. Carbon monoxide and cyanide poisonings can occur concomitantly in victims of smoke 
inhalation (Lundquist et al. 1989; Shusterman et al. 1996; Wetherell 1966). Experimental studies 
conducted in animal models provide evidence that carbon monoxide and cyanide can produce synergistic 
toxicity (Moore et al. 1987; Norris et al. 1986; Pitt et al. 1979).
Drugs Affecting the Central Nervous System. Due to effects of carbon monoxide on the central nervous 
system, it is anticipated that combined exposure to drugs with activity in the central nervous system, 
including therapeutic agents and drugs of abuse, could enhance the central nervous system toxicity of 
carbon monoxide (EPA 1991, 2000). However, the available data are not sufficient to determine if effects 
of combined exposures are additive or exhibit other types of interaction relationships (e.g., synergistic). 
Enhanced carbon monoxide-induced central nervous system toxicity has been reported to occur with 
concomitant exposures to alcohol, barbiturates, amphetamine, chlorpromazine, nicotine, diazepam, and 
morphine (EPA 1991).
Drugs Affecting the Cardiovascular System. In response to carbon monoxide-induced tissue hypoxia, 
alterations in hemodynamics and responsive compensatory mechanisms (e.g., vasodilation and increased
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cardiovascular output) occur, including increased coronary blood flow, decreased myocardial O2 
consumption, increased heart rate, and alterations in blood flow to various vascular beds (e.g., cerebral, 
limb muscular). Thus, drugs used to treat patients with coronary artery disease (e.g., beta-blockers, 
calcium-channel blockers, nitrates) potentially may affect susceptibility to carbon monoxide. This is of 
particular concern, as patients with cardiovascular disease are more susceptible to carbon monoxide- 
induced cardiovascular toxicity than are healthy individuals. However, little data evaluating potential 
interactions with therapeutic agents used to treat cardiovascular disease are available (EPA 1991, 2000).
Air Pollution. Numerous epidemiological studies have examined associations between exposure to 
carbon monoxide and other air pollutants (e.g., NO2, O3, particular matter, SO2). In general, these studies 
have found evidence for multiple air pollutant contributors to outcomes observed, including 
cardiovascular, respiratory, and mortality end points (see discussion of epidemiology in Section 3.2). The 
interactive aspects of these associations have not been fully explored or elucidated. However, evidence is 
provided from several studies of increased risks of adverse cardiovascular and respiratory outcomes in the 
context of ongoing cardiovascular disease (e.g., ischemic heart disease) and respiratory diseases (e.g., 
asthma). These studies suggest that it is both plausible and likely that interactions contribute to outcomes 
observed in populations that experience co-exposures to carbon monoxide, NO2, O3, particular matter, and 
SO2.
Tobacco Smoke. In addition to exposures to carbon monoxide, tobacco smoking results in exposures to a 
variety of agents that act directly on the heart to increase cardiac O2 demand (e.g., nicotine, Benowitz 
1997) and that contribute to respiratory and coronary vascular disease, both of which can render people 
more vulnerable to carbon monoxide toxicity (see Section 3.10, Populations that are Unusually 
Susceptible).
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to carbon monoxide than will most 
persons exposed to the same level of carbon monoxide in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke). 
These parameters result in reduced detoxification or excretion of carbon monoxide, or compromised 
function of organs affected by carbon monoxide. Populations who are at greater risk due to their 
unusually high exposure to carbon monoxide are discussed in Section 6.7, Populations with Potentially 
High Exposures.
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Cardiovascular Disease. Studies of the cardiovascular effects of inhalation exposures to carbon 
monoxide conducted in controlled human clinical studies, epidemiology studies, and various animal 
models (monkeys, dogs, rats, and rabbits) provide convincing evidence for adverse cardiovascular effects 
in association with carbon monoxide exposures that result in blood COHb levels of >2.4%, with effects 
occurring at the lowest levels in subjects who have compromised cardiovascular function (e.g., coronary 
artery disease). Therefore, exposure to carbon monoxide appears to exacerbate underlying cardiovascular 
disease, and people with cardiovascular disease that renders them vulnerable to myocardial ischemia (e.g., 
coronary artery disease) represent a population that would be unusually susceptible to carbon monoxide. 
Epidemiological studies of exposure to ambient concentrations of carbon monoxide and cardiovascular 
outcomes also provide supporting evidence for higher vulnerability of people with pre-existing heart 
conditions such as ischemic heart disease, people with a history of cardiac arrhythmia, and the elderly 
(Barnett et al. 2006; D’Ippoliti et al. 2003; Dockery et al. 2005; Hosseinpoor et al. 2005; Lanki et al.
2006; Lee et al. 2003b; Mann et al. 2002; Rich et al. 2005; Szyszkowicz 2007; von Klot et al. 2005).
Asthma and COPD. Several studies have examined possible associations between ambient air carbon 
monoxide concentrations and pulmonary function in subjects who had ongoing lung disease (e.g., asthma, 
chronic obstructive lung disease) and who might be more sensitive to agents that affect pulmonary 
function (Rabinovitch et al. 2004; Silkoff et al. 2005; Timonen et al. 2002), as well as asthma morbidity 
and asthma and exacerbation of symptoms (Park et al. 2005a; Rabinovitch et al. 2004; Schildcrout et al. 
2006; Silkoff et al. 2005; Slaughter et al. 2003; von Klot et al. 2002; Yu et al. 2000). Results of these 
studies have been mixed; however, collectively, these studies provide evidence for higher vulnerability of 
people who have ongoing respiratory disease, including asthma and chronic obstructive pulmonary 
disease. This subpopulation may also include a subpopulation of former tobacco smokers (Silkoff et al.
2005). As noted in Section 3.7, Children’s Susceptibility, the fetus may be particularly vulnerable to 
exposures that occur during pregnancy.
Anemia. Conditions that produce anemia (e.g., iron deficiency, hemolysis, hemorrhage, or reduced 
hematopoiesis) decrease the oxygen carrying capacity of blood. Hemolytic anemia increases heme 
metabolism and endogenous carbon monoxide production. These factors would be expected to render 
individuals more vulnerable to hypoxic effects of carbon monoxide.
Environmental and Behavioral Factors. In addition to ongoing diseases, other environmental and/or 
behavior factors may increase vulnerability to carbon monoxide toxicity. In general, factors that increase
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
3. HEALTH EFFECTS
181
alveolar ventilation and cardiac output, while maintaining alveolar ventilation perfusion matching (i.e., 
proportional increases in alveolar ventilation rate and cardiac output) tend to increase absorption of 
inhaled carbon monoxide. Factors that increase carbon monoxide absorption include moderate exercise, 
supine position, age (increased in infancy and childhood and declines in adults with age), altitude, 
increasing blood Hb concentration, and decreasing partial pressure of O2 in inhaled air or blood.
These factors could contribute to higher body burdens of carbon monoxide and, therefore, higher 
vulnerability to carbon monoxide at higher altitudes than at lower altitudes (McGrath et al. 1993), in 
particular, for people who have not physiologically adapted to higher altitudes (Horvath et al. 1988; Hsia 
2002). Exercise increases oxygen demand, absorption of carbon monoxide, and transfer of carbon 
monoxide from blood to muscle, and decreases elimination of carbon monoxide (Joumard et al. 1991; 
Richardson et al. 2002; Werner and Lindahl 1980); these factors may contribute to higher vulnerability 
during strenuous exercise.
3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section describes clinical practice and research concerning methods for reducing toxic effects of 
exposure to carbon monoxide. However, because some of the treatments discussed may be experimental 
and unproven, this section should not be used as a guide for treatment of exposures to carbon monoxide. 
When specific exposures have occurred, poison control centers and medical toxicologists should be 
consulted for medical advice. The following texts provide specific information about treatment following 
exposures to carbon monoxide:
Dart RC, ed. 2004. Medical toxicology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 
1208.
Lavonas EJ. 2007. Carbon monoxide poisoning. In: Haddad and Winchester's clinical management of 
poisoning and drug overdose. 4th ed. Philadelphia, PA: Saunders, 1297-1307
Tomaszewski C. 2006. Carbon monoxide. In: Goldfrank's toxicologic emergencies. New York, NY: 
McGraw-Hill, 1689-1704.
3.11.1 Reducing Peak Absorption Following Exposure
Human exposure to carbon monoxide occurs by the inhalation route. General recommendations for 
reducing absorption of carbon monoxide following acute high-level inhalation exposure have included 
immediate removal of the exposed individual from the contaminated area and administering 100%
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oxygen through a face mask that does not allow rebreathing of expired air or endotracheal tube for a 
minimum of 4 hours. For patients with life-threatening carbon monoxide exposure, hyperbaric oxygen 
(HBO) therapy has also been suggested, although this remains a controversial method for treatment (Dart 
2004; Lavonas 2007; Tomaszewski 2002; Weaver et al. 2000; Wolf et al. 2008). Hyperbaric oxygen 
treatment is optimal within 6 hours of exposure, as patients treated after 6 hours have displayed a higher 
percent of delayed sequelae (30 vs. 19%) and mortality (30 vs. 14%) (Tomaszewski 2006).
Studies conducted in animal models have provided evidence for a potential influence of isocapnia or 
hypercapnia (i.e., normal or elevated CO2 levels) in the effect of O2 therapy in promoting the reduction in 
carbon monoxide body burden. Studies utilizing laboratory animals (dogs and sheep) exposed to carbon 
monoxide have demonstrated that the carbon monoxide washout time can be significantly reduced if the 
subjects receive a mixture of oxygen and carbon dioxide gas designed to maintain normal PCO2 values 
(Fisher et al. 1999; Kreck et al. 2001). This outcome has been replicated in experimental trials using 
volunteers exposed to carbon monoxide concentrations producing COHb levels of 10-12%. As compared 
to the subjects treated with hyperoxia alone, those treated with hyperoxia and carbon dioxide that 
maintained isocapnia showed accelerated clearance of carbon monoxide (Rucker et al. 2002; Takeuchi et 
al. 2000). These studies identify a potential means to enhance the treatment of acute carbon monoxide 
poisoning.
3.11.2 Reducing Body Burden
Absorbed carbon monoxide binds to and displaces oxygen (O2) from blood Hb and other heme proteins 
(e.g., muscle myoglobin). Nearly all of carbon monoxide in the body exists as complexes with Hb or 
other heme proteins. Binding to heme proteins limits diffusion of carbon monoxide from tissues to blood, 
and elimination of carbon monoxide from blood to exhaled air. At ambient oxygen pressures of 
approximately 0.2 atmospheres, elimination of carbon monoxide occurs with a half-time of approximately 
100-300 minutes (Bruce and Bruce 2006; Peterson and Stewart 1970). However, the elimination rate can 
be increased substantially by administering 100% oxygen (Tomaszewski 2006; Weaver et al. 2000). As 
noted above, the general recommendation for reducing the body burden of carbon monoxide is 
administration of 100% oxygen through a face mask that does not allow rebreathing of expired air, at 
ambient pressure, and/or hyperbaric oxygen therapy. The longer time period required for the elimination 
of carbon monoxide in the fetus (Hill et al. 1977; Longo 1977) has prompted a concern about the 
premature cessation of oxygen therapy to a pregnant woman based upon her COHb level.
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Binding of carbon monoxide to Hb impairs transfer of oxygen to tissues and can produce tissue hypoxia. 
Tissues that have a high oxygen utilization rate, including brain and heart, are particularly vulnerable to 
hypoxia. Carbon monoxide-induced hypoxia is treated by administering 100% oxygen, which increases 
the dissolved concentration of oxygen in blood, facilitates displacement of carbon monoxide from Hb, 
and increases the rate of elimination of carbon monoxide from the body. Hyperbaric oxygen therapy may 
further reduce the risk of brain and heart injury from hypoxia. Intravenous fluids and inotropic agents 
may be administered to alleviate hypotension and myocardial depression (Lavonas 2007; Tomaszewski
2006).
3.12 ADEQUACY OF THE DATABASE
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of carbon monoxide is available. Where adequate information 
is not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of carbon monoxide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Carbon Monoxide
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
carbon monoxide] are summarized in Figure 3-12. The purpose of this figure is to illustrate the existing 
information concerning the health effects of carbon monoxide. Each dot in the figure indicates that one or 
more studies provide information associated with that particular effect. The dot does not necessarily 
imply anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”. A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
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Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments. Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. Human clinical studies of acute exposures have 
investigated cardiovascular, respiratory, and neurobehavioral end points. Human epidemiology studies 
have examined possible associations between ambient air carbon monoxide concentrations and various 
health end points, including mortality, cardiovascular, respiratory, blood biomarkers of coagulation and 
inflammation, and developmental (pre-term birth, birth weight, congenital anomalies, neonatal and infant 
mortality). Studies conducted in animals have included acute, intermediate, and chronic exposures that 
have largely focused on cardiovascular, respiratory, and reproductive (e.g., fetal mortality) end points. 
Bioassays of carcinogenicity of carbon monoxide have not been reported. Carbon monoxide has been 
assessed for genotoxicity in an in vivo mouse model of micronuclei formation and sister chromatid 
exchange.
3.12.2 Identification of Data Needs
Acute-Duration Exposure. Most information on effects of acute exposures to carbon monoxide 
derive from clinical case studies of carbon monoxide poisoning, in which blood COHb levels were >20%. 
Although these studies provide information on effects resulting from severe carbon monoxide-induced 
toxicity, they do not provide information on low dose-response relationships for carbon monoxide. 
Experimental clinical studies providing low dose-response information have focused on evaluating organ 
systems that are expected to be vulnerable to or contribute to hypoxia (e.g., brain, heart, respiratory tract). 
Effects of acute exposures to carbon monoxide on other organ systems have been studied far less 
thoroughly. Studies of low-dose carbon monoxide exposure in humans or animals have not identified 
NOAELs for sensitive organ systems and have not provided data that would enable low-dose response 
modeling (e.g., benchmark dose). Such studies would be beneficial for analyses in support of deriving 
MRLs.
Experimental clinical studies have examined cardiovascular effects in humans, including a major 
vulnerable subpopulation, people with ongoing heart disease; however, these studies have not identified 
NOAELs in cardiovascular disease patients (Adams et al. 1988; Allred et al. 1989, 1991; Anderson et al. 
1973; Kleinman et al. 1989, 1998; Leaf and Kleinman 1996b). Studies investigating the effects of acute- 
duration carbon monoxide exposure on hemodynamics have been conducted in several animal species, 
including monkeys, dogs, rats, and rabbits, under exposure conditions producing blood COHb levels 
ranging from 6.2 to 70% (EPA 1991, 2000). These studies have shown that brief exposure (from a few
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minutes to approximately 3 hours) to carbon monoxide at concentrations of 80-20,000 ppm produces 
alterations in hemodynamics that are consistent with COHb-induced hypoxia and responsive 
compensatory mechanisms (e.g., vasodilation and increased cardiovascular output), including increased 
coronary blood flow, decreased myocardial O2 consumption, increased heart rate, and alterations in blood 
flow to various vascular beds (e.g., cerebral, limb muscular).
A few clinical experimental studies have evaluated adverse respiratory effects of carbon monoxide 
exposure in relatively small numbers of healthy subjects (Chevalier et al. 1966; Fisher et al. 1969; Koike 
et al. 1991; Ren et al. 2001; Vesely et al. 2004). Results of these studies indicate that brief exposure to 
relatively higher levels (e.g., >500 ppm) of carbon monoxide may decrease ventilatory performance. No 
studies were identified that examined effects of carbon monoxide on respiratory function in patients with 
underlying respiratory diseases, who would be expected to have a higher sensitivity to hypoxic effects of 
carbon monoxide. Studies of dose-response relationships of respiratory function at low levels of carbon 
monoxide exposure (e.g., C0Hb<20%) in patients with respiratory disease (e.g., asthma) would be 
beneficial for quantifying vulnerability of this subpopulation to carbon monoxide toxicity.
Intermediate-Duration Exposure. Controlled experimental studies in humans of effects of 
intermediate-duration exposures to carbon monoxide were not identified. Intermediate-duration studies 
have examined cardiovascular and respiratory effects of exposure to carbon monoxide in various animal 
models, including monkeys, dogs, and rodents (EPA 2000). The observation of cardiomegaly in rats 
exposed chronically to carbon monoxide (S0rhaug et al. 2006) suggests that prolonged exposure to carbon 
monoxide may produce effects on the heart that might not be observed with acute exposures. Additional 
intermediate-duration exposure studies in animals that provide dose-response relationships for 
cardiovascular effects and other end points (e.g., respiratory, neurological) would be beneficial for 
analyses in support of deriving MRLs.
Chronic-Duration Exposure and Cancer. Epidemiological studies have examined health 
outcomes in the context of chronic exposures, or acute variations in exposure concentrations that occur 
during chronic exposures. Outcomes that have been assessed include mortality, including cancer 
mortality, cardiovascular effects, respiratory effects, effects on blood biomarkers of coagulation and 
inflammation, and developmental effects (pre-term birth, birth weight, congenital anomalies, neonatal and 
infant mortality). A chronic study conducted in rats found cardiomegaly, which may have represented 
long-term adaptive changes to carbon monoxide-induced hypoxia (S0rhaug et al. 2006). This finding 
suggests that prolonged exposure to carbon monoxide may produce effects on the heart that might not be
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evident from acute- or intermediate-duration studies. Additional chronic-duration exposure studies in 
animals would that provide dose-response relationships for cardiovascular effects and other end points 
(e.g., respiratory, neurological) would be beneficial for analyses in support of deriving MRLs.
Carbon monoxide has not been assessed for carcinogenicity using animal models. Cancer bioassays in 
animals would provide a more confident basis for establishing whether or not carbon monoxide has 
carcinogenic potential in humans.
Genotoxicity. In a bacterial replication assay with Escherichia coli, exposure to carbon monoxide- 
inhibited DNA synthesis (Cairns and Denhardt 1968). Gestational exposure of mice to carbon monoxide 
increased of micronuclei formation and sister chromatid exchange in dams (bone marrow) and fetuses 
(blood) (Kwak et al. 1986). Additional studies conducted on the mechanisms of genotoxicity in 
mammalian cells would provide a more confident basis for establishing whether or not carbon monoxide 
has carcinogenic potential in humans.
Reproductive Toxicity. Pregnancy outcomes, including fetal death in humans has been reported in 
cases of maternal carbon monoxide poisoning during pregnancy (Brown et al. 1992; Caravati et al. 1988; 
Cramer 1982; Elkharrat et al. 1991; Farrow et al. 1990; Greingor et al. 2001; Hollander et al. 1987; 
Margulies 1986; Norman and Halton 1990; Silverman and Montano 1997). Epidemiological studies have 
examined possible relationships between exposures to ambient air concentrations of carbon monoxide and 
fetal mortality (see Table 3-8). Few studies of reproductive effects in animals were identified, and these 
have been limited to assessments of effects of maternal exposure during pregnancy on fetal mortality 
(Astrup et al. 1972; Fechter and Annau 1977; Penney et al. 1983; Stupfel and Bouley 1970). The 
available data do not allow a confident determination of the relative sensitivity of reproductive systems to 
carbon monoxide. Greater confidence would be achieved from studies that examine more comprehensive 
end points of reproductive toxicity in females and males, in association with exposures prior to mating 
and pregnancy, and during pregnancy.
Developmental Toxicity. Epidemiological studies have examined developmental outcomes in the 
context of chronic exposures, or acute variations in exposure concentrations that occur during chronic 
exposures (see Table 3-8). Outcomes that have been assessed include pre-term birth, birth weight, 
congenital anomalies, neonatal and infant mortality. Studies conducted in animals provide evidence of 
adverse developmental effects of gestational and early postnatal carbon monoxide exposure, including 
decreased fetal weight, adverse central nervous system development, altered peripheral nervous system
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
3. HEALTH EFFECTS
188
development, cardiac effects, altered sexual behavior, immunological effects, and hematological effects. 
In addition, some studies showed that developmental effects persisted beyond the postnatal period (see 
Table 3-9). Two studies found functional impairments in the auditory system of rats in association with 
exposures to >12 ppm carbon monoxide during the neonatal periods or during gestation (Stockard- 
Sullivan et al. 2003; Webber et al. 2003). These values are the lowest LOAELs for external exposure that 
have been reported and, as a result, have a substantial impact on analyses conducted to derive MRLs. 
Additional studies to establish greater confidence in the dose-response relationship for 
neurodevelopmental effects on the auditory system would be beneficial for establishing MRLs for carbon 
monoxide based on this end point. Studies conducted to understand the mechanism for this effect would 
provide additional information about the relevance of these effects to humans exposed at similar levels.
Immunotoxicity. Epidemiological studies have examined effects on blood biomarkers of 
inflammation. Biomarkers examined have included been inflammation markers, CRP, SAA, and WBC; 
cell adhesion markers, E-selectin, vWF, ICAM-1 (Baccarelli et al. 2007; Liao et al. 2005; Pekkanen et al. 
2000; Rückerl et al. 2006, 2007; Steinvil et al. 2008). A study conducted in guinea pigs examined effects 
of carbon monoxide exposure on plaque forming cells in spleen (Snella and Rylander 1979). Effects of 
gestational exposure on the developing immune system have been studied in rats (Giustino et al. 1993, 
1994). Studies conducted in cell culture and in vivo models of sepsis have examined effects of 
endogenous and exogenous carbon monoxide on inflammatory responses and cytokine and signaling 
pathways involved in inflammation (Ryter et al. 2006). These studies suggest a potential for carbon 
monoxide to exert effects on the immune system. Additional studies to establish modes of action and 
dose-response relationships would be beneficial for determining the sensitivity of the immune system to 
carbon monoxide, relative to other targets of toxicity, and for establishing MRLs.
Neurotoxicity. Experimental clinical studies (Beningus et al. 1994), clinical case studies (Chambers 
et al. 2008; Dolan 1985; Ernst and Zibrak 1998; Hopkins et al. 2006; Kao and Nañagas 2006; Lo et al. 
2007; Parkinson et al. 2002; Raub and Benignus 2002), and studies conducted in animals (Beningus et al. 
1994; Chambers et al. 2008; Chen and Fechter 1999; Dolan 1985; Ernst and Zibrak 1998; Fechter et al. 
1988; Hopkins et al. 2006; Kao and Nañagas 2006; Lo et al. 2007; Parkinson et al. 2002; Raub and 
Benignus 2002; Young et al. 1987) have examined effects of acute carbon monoxide exposures on 
behavior cognitive function. Although these studies have provided strong evidence for impairments in 
association with exposures that result in blood COHb levels >20%, dose-response relationships for lower 
levels remain controversial (Benignus 1994; Benignus et al. 1990; Raub and Benignus 2002). Further 
research on dose-response relationships of neurobehavioral and neurosensory effects at low levels of
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carbon monoxide exposure (e.g., COHb<20%) utilizing double blind designs would be beneficial for 
analyses in support of deriving MRLs.
Epidemiological and Human Dosimetry Studies. Epidemiological studies have examined health 
outcomes in the context of chronic exposures, or acute variations in exposure concentrations that occur 
during chronic exposures (see Tables 3-3, 3-6, 3-7, and 3-8). Outcomes that have been assessed include 
mortality, including cancer mortality, cardiovascular effects, respiratory effects, blood biomarkers of 
coagulation and inflammation, and developmental effects (pre-term birth, birth weight, congenital 
anomalies, neonatal and infant mortality). Human dosimetry studies have examined relationships 
between carbon monoxide exposure levels and durations and blood COHb levels in resting subjects, 
during exercise, and at various altitudes (see Tables 3-4 and 3-5). Studies of elimination kinetics carbon 
monoxide in humans have explored effects of exercise, age, gender, and oxygen therapy on elimination 
half-time (Bruce and Bruce 2006; Joumard et al. 1991; Landaw 1973; Levasseur et al. 1996; Peterson and 
Stewart 1970; Shimazu et al. 2000; Weaver et al. 2000).
Biomarkers of Exposure and Effect.
Exposure. Measurement of blood COHb is the principal biomarker for identifying exposure to carbon 
monoxide. Several pharmacokinetics models have been developed that can be used to predict blood 
COHb levels that would correspond to a given exposure concentration and duration, in a typical adult and 
in the fetus resulting from maternal exposures. These models can be used to reconstruct possible carbon 
monoxide exposure scenarios (e.g., concentrations, duration, and gap between measurement of COHb and 
cessation of exposure) that could result in a given measured COHb level.
Effect. Although blood COHb reflects current carbon monoxide body burden, measurement of blood 
COHb has not been shown to be a reliable predictor of severity of acute toxicity (Hampson and Hauff
2008). Therefore, diagnoses and characterization of toxic effects of carbon monoxide relies on both the 
measurement of blood COHb and the assessment of signs and symptoms of carbon monoxide toxicity. 
Studies conducted to identify biomarkers of nonhypoxic mechanisms of carbon monoxide (those 
unrelated to blood COHb levels) would be beneficial for internal dosimetry in epidemiological and 
clinical experimental studies, for development of PBPK/PD models of nonhypoxic effects of carbon 
monoxide, and for improving diagnosis of carbon monoxide poisoning.
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Absorption, Distribution, Metabolism, and Excretion. Pharmacokinetics of carbon monoxide 
has been extensively studied in humans and in animal models, including non-human primates (see 
Section 3.4). Studies conducted in humans have provided information on absorption, metabolism, 
distribution, and elimination kinetics, as well as physiological factors (e.g., age, gender) and 
environmental factors (e.g., altitude, exercise) that affect carbon monoxide kinetics. These studies have 
provided the bases for pharmacokinetic models that simulate carbon monoxide absorption and elimination 
kinetics, and blood COHb and muscle COMb levels in humans (see Section 3.4.5). Several studies have 
provided estimates of rates of whole-body endogenous production of carbon monoxide in adult males and 
females, during and following pregnancy (Coburn et al. 1963; Delivoria-Papadopoulos et al. 1974; Longo 
1977; Mercke and Lundh 1976). However, measurement of local tissue production rates would also be 
valuable for studying mechanisms by which endogenously produced carbon monoxide modulates cellular 
metabolism and cell signaling pathways, as well as the relative contributions of exogenous carbon 
monoxide and endogenously produced carbon monoxide contribute to these processes.
Comparative Toxicokinetics. Major physiological and biochemical determinants of blood and 
skeletal muscle carbon monoxide kinetics that would be expected to contribute to interspecies differences 
in carbon monoxide toxicokinetics have been identified. This information provides a basis for 
extrapolating pharmacokinetics models across mammalian species, for which physiological (e.g., 
ventilation rates, blood Hb levels) and chemical-specific parameters are known (e.g., binding affinities 
and capacities of Hb and myoglobin, long carbon monoxide diffusion capacity). Models developed to 
simulate carbon monoxide kinetics in humans have been adapted for applications to animal models (e.g., 
rats; Benignus and Annau 1994) and to simulate maternal-fetal transfer of carbon monoxide during 
pregnancy in sheep (Longo and Hill 1977). Adaptation of these models to a wider range of species would 
be facilitated by studies that provide estimates of model parameters in these species (e.g., Haldane 
coefficient, binding coefficients of Hb and Mb, and the lung carbon monoxide diffusing capacity).
Methods for Reducing Toxic Effects. Efficacies of normobaric and hyperbaric oxygen therapy for 
hastening the elimination of carbon monoxide from the body and for treating carbon monoxide-induced 
hypoxia have been studied. Although hyperbaric oxygen therapy is considered to be a therapeutic option, 
its efficacy, over normobaric therapy, remains controversial (Wolf et al. 2008). Further research 
regarding benefits and limitations of hyperbaric oxygen therapy would improve the clinical management 
of treatment of carbon monoxide poisoning.
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Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs: 
Exposures of Children.
Mechanisms of Toxicity. Although hypoxic mechanisms of action of carbon monoxide are well 
established (i.e., those related to formation of COHb), a better understanding is needed of nonhypoxic 
mechanisms, their contribution to observed adverse health effects of carbon monoxide, and related dose- 
response relationships.
3.12.3 Ongoing Studies
Ongoing studies pertinent to information of health effects and/or mechanisms of action of carbon 
monoxide are listed in Table 3-18.
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Table 3-18. Ongoing Studies on the Health Effects of Carbon Monoxide
I n v e s t ig a t o r  A f f i l i a t io n R e s e a r c h  d e s c r ip t io n S p o n s o r
Abraham NG 
Bauer AJ 
Bauer PM
Choi AM
Durante W 
Fallon MB
Fowler AA 
Kibbe MR 
Lefer DJ 
Leffler CW 
Leffler CQ 
Lindahl PA
Machado RF 
Mapes JP
McCurry KR
Morse ED
Murase N
New York Medical 
College
University of Pittsburgh 
at Pittsburgh Office of 
Research
University of Pittsburgh 
at Pittsburgh Office of 
Research
Brigham and Women’s 
Hospital Research 
Administration
University of Missouri­
Columbia
University of Texas
Heme oxygenase regulation of 
eicosanoid biosynthesis
Protective mechanisms of carbon 
monoxide in intestinal inflammation
Role of caveolin-1 and eNOS in 
mediating the therapeutic effects of 
carbon monoxide in polycyclic 
aromatic hydrocarbons
Role of heme oxygenase in hyperoxic 
lung injury
Carbon monoxide and vascular cell 
function
Mediators of pulmonary 
vasodilatation in liver disease
National Institute of 
Diabetes and Digestive 
and Kidney Diseases
National Institute of 
Diabetes and Digestive 
and Kidney Diseases
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
Role of hypotoxia inducible factor-1 in 
inflammation
Virginia Commonwealth 
University
Northwestern University Nitric oxide eluting therapies for
vascular surgery
Yeshiva University Mechanism of myocardial reperfusion
injury in diabetes
University of Tennessee Carbon monoxide in newborn 
Health Science Center cerebral circulation
University of Tennessee Control of neonatal circulation 
Health Science Center
Texas A&M University 
System
Clinical Center
Rules-Based Medicine, 
Inc.
University of Pittsburgh 
at Pittsburgh Office of 
Research
University of Pittsburgh 
at Pittsburgh Office of 
Research
University of Pittsburgh 
at Pittsburgh Office of 
Research
Bioinorganic chemistry of carbon 
monoxide dehydrogenase
Effects of inhaled carbon monoxide 
on human lung inflammation
Biomarker profiles for carbon 
monoxide poisoning
Cytoprotective effect of carbon 
monoxide in lung ischemia/ 
reperfusion
Inhibitor of differentiation-1 mediates 
antifibrotic effects of carbon 
monoxide
Protective role of carbon monoxide in 
hepatic I/R injury
National Heart, Lung, 
and Blood Institute
National Institute of 
Diabetes and Digestive 
and Kidney Diseases
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
National Institute of 
General Medical 
Sciences
Not applicable
National Institute of 
Environmental Health 
Sciences
National Heart, Lung, 
and Blood Institute
National Heart, Lung, 
and Blood Institute
National Institute of 
Diabetes and Digestive 
and Kidney Diseases
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Table 3-18. Ongoing Studies on the Health Effects of Carbon Monoxide
Investigator Affiliation Research description Sponsor
O'Neill MS University of Michigan at Air pollution, inflammation, and 
Ann Arbor preterm birth: a mechanistic study in
Mexico City
National Institute of 
Environmental Health 
Sciences
Parfenova H University of Tennessee Heme oxygenase and cerebral 
Health Science Center vascular injury
National Institute of 
Neurological Disorders 
and Stroke
Raman CS University of Texas 
Health Science Center, 
Houston
Structural biology of gaseous 
messenger signaling
National Institute of 
General Medical 
Sciences
Roberts GP University of Wisconsin 
Madison
Sensing mechanisms for carbon 
monoxide and other small molecules
National Institute of 
General Medical 
Sciences
Tolbert PE Emory University Air pollution and birth defects in 
Atlanta, 1968-2002
National Institute of 
Environmental Health 
Sciences
Tulis DA North Carolina Central 
University
NO-independent cGMP regulation of 
vascular remodeling
National Heart, Lung, 
and Blood Institute
Vitali SH Children’s Hospital 
Boston
Hypoxic inflammation, pulmonary 
hypertension, and HO-1
National Heart, Lung, 
and Blood Institute
Williams MA Swedish Medical 
Center, First Hill
Ambient air pollution, preeclampsia, 
and preterm delivery
National Institute of 
Environmental Health 
Sciences
Xuan U University of Louisville Delayed cardioprotection induced by 
NO and carbon monoxide
National Heart, Lung, 
and Blood Institute
S o u r c e :  F E D R I P  2 0 0 9
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4 . C H E M IC A L  A N D  P H Y S IC A L  IN F O R M A T IO N
4.1 CHEM ICAL IDENTITY
The chemical identity of carbon monoxide is shown in Table 4-1.
4.2 P H YSIC A L AND CHEM ICAL P R O P ER TIES
Carbon monoxide is a highly poisonous, odorless, colorless, and tasteless gas. It is very flammable in air 
over a wide range of concentrations (George 2001) and burns in air with a bright blue flame (O’Neil et al. 
2006). It becomes a liquid at 81.62 K (-191.53 °C) and is insoluble in water above 70 °C (George 2001). 
The physical and chemical properties of carbon monoxide are shown in Table 4-2.
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Table 4-1. Chemical Identity of Carbon Monoxide
Characteristic Carbon monoxide3
Synonym(s) Carbon oxide, flue gas, monoxided
Registered trade name(s)
Chemical formula COb
Chemical structure O:C
Identification numbers:
CAS registry 630-08-0b
NIOSH RTECS FG350000
EPA hazardous waste No data
OHM/TADS No data
DOT/UN/NA/IMDG shipping 1016c; 9202d,e
HSDB 903
NCI No data
a A l l  i n f o r m a t i o n  o b t a i n e d  f r o m  H S D B  2 0 0 9 ,  e x c e p t  w h e r e  n o t e d .
b O ' N e i l  2 0 0 6
c C o m p r e s s e d
d N I O S H  2 0 0 5
e C r y o g e n i c  l i q u i d
C A S  =  C h e m i c a l  A b s t r a c t s  S e r v i c e ;  D O T / U N / N A / I M D G  =  D e p a r t m e n t  o f  T r a n s p o r t a t i o n / U n i t e d  N a t i o n s / N o r t h  
A m e r i c a / I n t e r n a t i o n a l  M a r i t i m e  D a n g e r o u s  G o o d s  C o d e ;  E P A  =  E n v i r o n m e n t a l  P r o t e c t i o n  A g e n c y ;
H S D B  =  H a z a r d o u s  S u b s t a n c e s  D a t a  B a n k ;  N C I  =  N a t i o n a l  C a n c e r  I n s t i t u t e ;  N I O S H  =  N a t i o n a l  I n s t i t u t e  f o r  
O c c u p a t i o n a l  S a f e t y  a n d  H e a l t h ;  O H M / T A D S  =  O i l  a n d  H a z a r d o u s  M a t e r i a l s / T e c h n i c a l  A s s i s t a n c e  D a t a  S y s t e m ;  
R T E C S  =  R e g i s t r y  o f  T o x i c  E f f e c t s  o f  C h e m i c a l  S u b s t a n c e s
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Table 4-2. Physical and Chemical Properties of Carbon Monoxide
Property Carbon monoxide3
Molecular weight 28.01
Color Colorless
Physical state Gas
Melting point -205 °C
Boiling point -191.5 °C
Density at 25°C 1.145 g/L at 25 °C and 1 atm3b
Odor
Odor threshold:
Odorless
Water No data
Air
Solubility:
No data
Water at 20 °C 2.3 mL/100 mL
Organic solvents 
Partition coefficients:
Appreciably soluble in ethyl acetate, 
chloroform, acetic acid; freely absorbed by a 
concentrated solution of cuprous chloride in 
hydrochloric acid or ammonium hydroxide; 
solubility in methanol and ethanol about 
7 times as great as in water; soluble in 
benzene
Log Kqw Not applicable
Log Koc Not applicable
Henry's law constant at 25 °C 57,978.5 atm/mol fraction 
(~1.04 atm-m3/mole)c
Autoignition temperature 605 °Cd
Flashpoint Flammable gasd
Flammability limits Upper limit 74.2%; lower limit 12.5%e
Conversion factors 1 ppm = 1.16 mg/m3 at 20 °C and 1 atmf
Explosive limits No data
a A l l  i n f o r m a t i o n  o b t a i n e d  f r o m  H S D B  2 0 0 9 ,  e x c e p t  w h e r e  n o t e d .
c Y a w s  e t  a l .  1 9 9 9
b L i d e  2 0 0 8
d I P C S  2 0 0 8
e G e o r g e  2 0 0 1
f V e r s c h u e r e n  2 0 0 1
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5 . P R O D U C T IO N , IM P O R T /E X P O R T , U S E , A N D  D IS P O S A L
5.1 PRODUCTION
Carbon monoxide is produced by the incomplete combustion of carbon in liquid, solid, and gaseous fuels 
(George 2001). Commercially, it is produced on an industrial scale by the partial oxidation of 
hydrocarbon gases from natural gas or by the gasification of coal and coke. Laboratory-scale production 
of carbon monoxide is accomplished by heating calcium carbonate with zinc dust (O’Neil et al. 2006). 
Carbon monoxide is also obtained from the dehydration of formic acid (Lewis 2007). The majority of 
carbon monoxide produced is used immediately downstream and at the plant site for chemical synthesis 
or steel manufacturing; consequently, quantitative production volumes are not available (George 2001).
Carbon monoxide is a co-product along with hydrogen in syn gas (synthetic gas) production, which are 
then separated and purified by pressure swing adsorption and/or cryogenic distillation.
Carbon monoxide is a major air pollutant (Lewis 2007). It is a byproduct of highway vehicle exhaust, of 
industrial processes and fuel combustion in boilers and incinerators, and of household appliances fueled 
with gas, oil, kerosene, or wood. The largest contribution comes from highway motor vehicles. Carbon 
monoxide exceeds all other atmospheric pollutants combined with the exception of CO2 (George 2001).
The major facility within the United States that manufactures or processes carbon monoxide (produced in 
commercial quantities exceeding 5,000 pounds or $10,000 in value annually) is Air Liquide America L.P. 
in Freeport, Texas (SRI 2008).
5.2 IM PORT/EXPORT
No data were located on the import and export of carbon monoxide.
5.3 U SE
Carbon monoxide is used by the chemical industry for the synthesis of many compounds such as acetic 
anhydride, polycabonates, acetic acid, polyketones, etc (George 2001). It finds application as a reducing 
agent in metallurgical operations, specifically the Mond process for the recovery of nickel, in the 
manufacture of metal carbonyls, and in organic synthesis, especially for the Fischer-Tropsch process for
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petroleum-related products and in the oxo reaction (O’Neil et al. 2006). Carbon monoxide is also used in 
the manufacture of zinc white pigments (Lewis 2007).
5.4. D ISPO SA L
EPA considers a waste to be hazardous if it exhibits any of the following characteristics: ignitability, 
corrosivity, reactivity, or toxicity as defined in 40 CFR 261.21-261.24. Under the Resource Conservation 
and Recovery Act (RCRA) (40 USC 6901 et seq.). EPA has specifically listed many chemical wastes as 
hazardous. Although carbon monoxide is not specifically listed as a hazardous waste under RCRA, EPA 
requires employers to treat waste as hazardous if it exhibits any of the characteristics discussed above 
(OSHA 2000).
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6. P O T E N T IA L  F O R  H U M A N  E X P O S U R E
6.1 OVERVIEW
Carbon monoxide has been identified in at least 12 of the 1,699 hazardous waste sites that have been 
proposed for inclusion on the EPA National Priorities List (NPL) (HazDat 2007). However, the number 
of sites evaluated for carbon monoxide is not known. The frequency of these sites can be seen in 
Figure 6-1.
Carbon monoxide is a colorless, odorless, and tasteless gas that is ubiquitous in the atmosphere (George 
2001). It arises from both natural and anthropogenic sources. It is produced as a primary pollutant during 
the incomplete combustion of fossil fuels and biomass, including wildfires and controlled burns. Carbon 
monoxide is also produced indirectly from the photochemical oxidation of methane and other VOCs in 
the atmosphere. Vegetation can emit carbon monoxide directly into the atmosphere as a metabolic 
byproduct and the photooxidation of organic matter in surface waters (lakes, streams, rivers, oceans) and 
soil surfaces also results in the formation of carbon monoxide. Volcanic activity is another natural source 
of carbon monoxide in the atmosphere. Carbon monoxide is also produced endogenously in humans 
during the normal catabolism of Hb. The amount of anthropogenic carbon monoxide emissions versus 
that from natural sources is difficult to quantify since both sources of carbon monoxide vary over time. 
The EPA estimated that 95% of all carbon monoxide emissions in 2002 arose as a result of human 
activity with biogenic emissions accounting for only 5% of the total emissions (EPA 2008). However, a 
recent analysis of the carbon monoxide budget over North America concluded that during the summer 
months, when natural sources of carbon monoxide precursors such as biogenic VOCs and forest fires are 
high, natural sources of carbon monoxide in the atmosphere are far greater than anthropogenic 
contributions (Miller et al. 2008). The vast majority of anthropogenic carbon monoxide emissions arise 
from gasoline-powered automobile usage (EPA 2000). Data from the EPA National Emissions Inventory 
(NEI) suggest that over 50% of the total point and non-point emissions of carbon monoxide are 
historically associated with on-road automobile use (EPA 2008).
The background levels of carbon monoxide have changed significantly in the past several decades. 
Concentrations have decreased appreciably due to reduced emissions from automobiles as a consequence 
of advancements in automotive design. The development of catalytic converters for passenger vehicles, 
beginning in the 1970s, resulted in a substantial decrease in carbon monoxide emissions, despite large 
increases in miles traveled (George 2001). In the early 1980s, automakers equipped vehicles with more 
sophisticated catalytic converters and added on-board computers and O2 sensors in order to help optimize
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the efficiency of the converter. The end result is that modern passenger automobiles emit about 90% less 
carbon monoxide over their lifetimes as compared to vehicles designed in previous decades (George 
2001).
The annual average outdoor carbon monoxide concentrations are roughly 0.12 ppmv in the Northern 
Hemisphere and about 0.04 ppmv in the Southern Hemisphere (EPA 2000). These levels are variable 
throughout the course of the year, with seasonal maximum levels occurring during late winter in both 
hemispheres when inversion conditions (in which air pollutants are trapped near the ground beneath a 
layer of warm air) are more frequent. Minimum levels are generally observed during late summer.
Carbon monoxide concentrations are reported to range from a minimum of about 0.03 ppmv during 
summer in the Southern Hemisphere to about 0.20 ppmv at high latitudes in the Northern Hemisphere 
during winter (EPA 2000). Urban locations with high automobile usage or a high volume of stationary 
emission sources, such as refineries or power plants, typically have greater atmospheric levels of carbon 
monoxide as compared to rural or remote sites. In metropolitan areas in the United States, as much as 
95% of all carbon monoxide emissions result from on-road vehicle exhaust (EPA 2008). The majority of 
these on-road emissions are derived from gasoline-powered vehicles since diesel vehicles emit less 
carbon monoxide. There is also a diurnal pattern of atmospheric carbon monoxide concentrations in 
urban areas, with the highest levels occurring during hours with heavy vehicular usage (rush hours) and 
the lowest levels occurring at times that correlate with lower commuting activity (Campbell et al. 1995; 
EPA 2000). Maximum carbon monoxide levels frequently exceed 5 ppmv at these locations during the 
high commute hours.
Carbon monoxide levels in indoor air are greatly dependent upon the presence of combustion-based 
appliances and whether occupants smoke tobacco products. Unvented kerosene and gas space heaters; 
leaking chimneys and furnaces; back-drafting from furnaces, gas water heaters, wood stoves, and 
fireplaces; gas stoves, generators, and other gasoline-powered equipment; automobile exhaust from 
attached garages; and tobacco smoke all contribute to indoor air levels of carbon monoxide (EPA 2009a). 
Average levels in homes without gas stoves vary from 0.5 to 5 ppmv. Levels near properly adjusted gas 
stoves are often 5-15 ppmv and those near poorly adjusted stoves may be >30 ppmv (EPA 2009a).
The primary degradation pathway of carbon monoxide in the environment occurs through its reaction 
with photochemically-produced hydroxyl radicals. (It should be noted that the production of hydroxyl 
radicals requires UV radiation that does not penetrate windows and therefore, photooxidation is likely 
negligible indoors.) In addition, soils and coastal waters may also act as a sink for carbon monoxide since
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various forms of microorganisms are capable of utilizing carbon monoxide as an energy source (Tolli et 
al. 2006).
Exposure of the general population to carbon monoxide occurs through inhalation of outdoor and indoor 
air. Populations living in urban areas with heavy vehicular traffic or stationary sources such as petroleum 
refineries, gas and coal burning power plants, petrochemical plants, and coke oven plants are more likely 
to be exposed to higher levels of carbon monoxide from ambient outdoor air. Employees in these 
refineries and plants and workers who are subject to high levels of vehicular exhaust (such as taxi cab 
drivers and toll booth workers) may be occupationally exposed to higher levels of carbon monoxide. 
Members of the public who smoke or work in smoke-filled environments such as restaurants, bars, and 
casinos where smoking is allowed are exposed to higher levels of carbon monoxide than members of the 
population who do not smoke and are not frequently exposed to second-hand tobacco smoke.
6.2 R E L E A S E S  TO THE ENVIRONMENT
Carbon monoxide releases are not required to be reported for inclusion in the Toxics Release Inventory 
(TRI) (EPA 2005).
6.2.1 Air
Title I of the Clean Air Act of 1970 establishes carbon monoxide as one of six criteria pollutants and sets 
national air quality standards for carbon monoxide and the other criteria pollutants (EPA 2000). Two 
databases developed by the EPA are particularly useful for monitoring carbon monoxide levels and 
emissions throughout the United States. EPA's National Emission Inventory (NEI) database contains 
detailed information about sources that emit criteria air pollutants and their precursors, and hazardous air 
pollutants for the 50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands. The Air 
Quality System (AQS) database is EPA's repository of criteria air pollutant monitoring data since the 
1970s. Table 6-1 supplies data for carbon monoxide emissions from 1970 to 2008 from the NEI database 
for 13 major emission categories. Detailed carbon monoxide emissions from these sources for individual 
years are available as zipped Microsoft Access database files that may be accessed directly from the EPA 
website; however, these data are subject to occasional revisions by EPA as emission estimates for a 
specific time period are amended. As indicated in Table 6-1, on-road vehicle use has historically 
accounted for the largest percentage of emissions in the United States as compared to the other emission 
sources; however, the quantity of carbon monoxide emitted from automobiles has been declining 
significantly over the past 4 decades due to the use of emission control devices and catalytic converters.
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Table 6-1. Carbon Monoxide Emissions (Thousands of Short Tons) from 1970 to
2008
Emissions by categorya3
Yearb 1 2 3 4 5 6 7 8 9 10 11 12 13 Total
1970 237 770 3,625 3,397 3,644 2,179 620 NA NA 7,059 163,231 11,371 7,909 204,042
1975 276 763 3,441 2,204 2,496 2,211 630 NA NA 3,230 153,555 14,329 5,263 188,398
1980 322 750 6,230 2,151 2,246 1,723 830 NA NA 2,300 143,827 16,685 8,344 185,408
1985 291 670 7,525 1,845 2,223 462 694 2 49 1,941 134,187 19,029 7,927 176,845
1990 363 879 4,269 1,183 2,640 333 537 5 76 1,079 110,255 21,447 11,122 154,188
1991 349 920 4,587 1,127 2,571 345 548 5 28 1,116 104,980 21,934 8,618 147,128
1992 350 955 4,849 1,112 2,496 371 544 5 17 1,138 99,705 22,419 6,934 140,895
1993 363 1,043 4,181 1,093 2,536 371 594 5 51 1,248 94,431 22,904 7,082 135,902
1994 370 1,041 4,108 1,171 2,475 338 600 5 24 1,225 89,156 23,389 9,656 133,558
1995 372 1,056 4,506 1,223 2,380 348 624 6 25 1,185 83,881 23,874 7,298 126,778
1996 408 1,188 2,741 1,053 1,599 354 561 1 70 2,904 78,606 24,358 15,016 128,859
1997 423 1,162 2,742 1,071 1,710 367 582 2 71 2,948 75,849 23,668 7,316 117,911
1998 451 1,151 2,727 1,081 1,702 366 590 2 72 3,121 73,244 23,689 7,184 115,380
1999 496 1,213 3,829 350 1,255 159 571 52 163 3,019 68,708 23,316 11,410 114,541
2000 484 1,219 3,081 361 1,295 161 592 51 169 1,849 68,061 24,178 12,964 114,465
2001 485 1,253 3,088 372 1,380 162 615 50 178 1,851 63,476 24,677 8,676 106,263
2002 657 1,267 3,550 284 987 357 490 2 118 1,594 60,596 22,662 18,493 111,057
2003 652 1,229 3,477 259 934 355 504 2 114 1,580 56,579 21,999 17,364 105,078
2004 647 1,190 3,404 233 882 353 519 2 111 1,567 52,562 21,336 16,235 99,041
2005 643 1,152 3,331 208 829 351 534 2 107 1,554 48,544 20,672 15,106 93,034
2006 661 1,173 3,343 227 869 352 522 2 110 1,564 45,318 19,793 13,981 87,915
2007 680 1,195 3,352 246 908 353 511 2 113 1,574 42,092 18,915 12,856 82,801
2008 699 1,216 3,369 265 947 355 500 2 115 1,584 38,866 18,036 11,731 77,685
a C a t e g o r i e s
1 .  F u e l  c o m b u s t i o n  e l e c t r i c  u t i l i t i e s
2 .  F u e l  c o m b u s t i o n  i n d u s t r i a l  u t i l i t i e s
3 .  F u e l  c o m b u s t i o n  o t h e r
4 .  C h e m i c a l  a l l i e d  m a n u f a c t u r i n g
5 .  M e t a l  p r o c e s s i n g
6 .  P e t r o l e u m  a n d  r e l a t e d  c a t e g o r i e s
7 .  O t h e r  i n d u s t r i a l  p r o c e s s e s
8 .  S o l v e n t  u t i l i z a t i o n
9 .  S t o r a g e  a n d  t r a n s p o r t
1 0 .  W a s t e  d i s p o s a l  a n d  r e c y c l i n g
1 1 .  H i g h w a y  v e h i c l e s
1 2 .  O f f - h i g h w a y
1 3 .  M i s c e l l a n e o u s
b E m i s s i o n  e s t i m a t e s  a r e  s u b j e c t  t o  u p d a t e s  f o r  s u b s e q u e n t  r e v i s e d  v e r s i o n s  o f  t h e  N a t i o n a l  E m i s s i o n s  I n v e n t o r y  D a t a b a s e  
( N E I )  d a t a b a s e .  T h e s e  n u m b e r s  m a y  b e  d i f f e r e n t  t h a n  v a l u e s  p u b l i s h e d  f o r  p r e v i o u s  v e r s i o n s  o f  t h e  d a t a  a n d  m a y  a l s o  b e  
d i f f e r e n t  t h a n  v a l u e s  f o r  s u b s e q u e n t  r e v i s i o n s  o f  t h e  d a t a  a s  g e n e r a t e d  b y  t h e  E n v i r o n m e n t a l  P r o t e c t i o n  A g e n c y .
N A  =  n o t  a v a i l a b l e
Source: EPA 2009h
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Indoor air levels of carbon monoxide are highly dependent upon the smoking habits, the types of 
appliances and heating units that are used in the home or building, and whether or not the home or 
building has an attached garage for automobiles. Carbon monoxide levels from the use of appliances will 
depend on several factors such as the type of fuel used, ventilation, appliance design, fuel consumption 
rate, use pattern, and operating condition (EPA 1991, 2000). As reported in the EPA Air Quality Criteria 
Reports (1991, 2000), carbon monoxide emissions from ranges, ovens, and pilot lights using natural gas 
were typically greater under yellow tipping flame conditions (characteristic of an improper air-fuel ratio) 
to blue tipping flame conditions (characteristic of properly adjusted stoves). The average emission rates 
(mass of carbon monoxide emitted per energy unit produced) for top burning ovens and broilers ranged 
from 11.9 to 87.7 ^g/kJ under blue flame conditions as opposed to 53.5-156.6 ^g/kJ for similar 
appliances operating under yellow tipping conditions. In separate tests using three different gas ranges 
deliberately adjusted to produce blue tipping or yellow tipping flames, the average emission rate ranged 
from 34.3 to 70.9 ^g/kJ under blue flame operation to 108.4-196.9 ^g/kJ under yellow flame conditions 
(EPA 1991, 2000).
Quantitative estimates have been made regarding emissions of carbon monoxide from wood-burning 
stoves and fireplaces under normal operating conditions (Houck et al. 2006). Carbon monoxide emission 
factor data were based on 277 tests on 70 fireplace models. The mean emission factor was 64.1 g carbon 
monoxide emitted per kg dry wood with a standard deviation of 40.7 g/kg dry wood (Houck et al. 2006). 
It has been reported that emission rates of carbon monoxide for well-tuned unvented gas appliances range 
from 0.15 to 3.2 g/hour, while rates for poorly tuned unvented ones range from 1.5 to 22 g/hour (Dutton 
et al. 2001).
Carbon monoxide was detected in air samples at each of the 12 current or former NPL hazardous waste 
sites where it was detected in some environmental media (HazDat 2007).
6.2.2 Water
Direct anthropogenic releases of carbon monoxide to water are not expected; however, natural processes 
occur that result in carbon monoxide formation in waters. The photodegradation of dissolved organic 
matter is primarily responsible for producing carbon monoxide in sunlit surface waters (Tolli et al. 2006).
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6.2.3 Soil
The formation of carbon monoxide in soils appears to occur by abiotic processes, such as thermal 
decomposition or photodecomposition of organic matter. In general, warm and moist conditions found in 
most soils favor carbon monoxide uptake, whereas hot and dry conditions as found in deserts and some 
savannas favor the release of carbon monoxide from soil to the atmosphere (EPA 2000).
Carbon monoxide was detected in a soil gas sample at one current or former NPL hazardous waste sites 
where it was detected in some environmental media (HazDat 2007).
6.3 ENVIRONM ENTAL FATE
6.3.1 Transport and Partitioning
Carbon monoxide is a gas that will partition to the atmosphere and is distributed globally by the advective 
action of the wind. Wind direction determines the horizontal transport of carbon monoxide and what 
impact emissions from one location will have upon another site (EPA 1991). Carbon monoxide levels 
may be high around local sources, and locations downwind from the source may also be elevated. The 
transport of carbon monoxide in urban locations is complex and can be influenced by the geometry of 
street canyons, topography around roadways, and presence of noise barriers, vegetation, and buildings, as 
well as local meteorological factors. A field study was designed to characterize the air quality and flow 
of pollutants near a highway with and without noise barriers (Baldauf et al. 2008). The site also contained 
an open field and a residential neighborhood with mature vegetation. Time-series carbon monoxide 
levels were collected in areas with no barriers, a noise barrier only, and a noise barrier and vegetation. 
Levels of carbon monoxide were reduced as much as 50% behind the noise barrier as compared to 
measurements taken near the road depending upon the directionality of the wind (Baldauf et al. 2008).
In most urban areas during the winter months, there is often enhanced stability in the atmospheric 
boundary layer, which attenuates the vertical mixing of emissions from the ground. This effectively traps 
carbon monoxide at street levels during these periods. Unreacted carbon monoxide in the troposphere is 
slowly transported to the mesosphere and stratosphere where it reacts with atomic oxygen generated by 
the photodissociation of O2 (Fabian et al. 1979; Pressman and Warneck 1970).
The surface waters of the world’s oceans are saturated with carbon monoxide with respect to the 
atmosphere and are therefore a net source of atmospheric carbon monoxide. Using a mean atmospheric
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carbon monoxide concentration over the ocean surface of 0.13 ppmv and a surface water concentration of 
6x 10-8 cm3 carbon monoxide per cm3 water, the total annual flux of carbon monoxide to the atmosphere 
from seawater was estimated at approximately 4.3x1013 g/year (43 Tg) (Liss and Slater 1974). Other 
reported estimates based on computed carbon monoxide concentrations in surface waters were reported to 
range from 13 to 165 Tg/year (Ohta 1997). Differences in microbial activity in surface water account for 
the variations in surface water levels and the flux into the atmosphere (Conrad and Seiler 1988).
6.3.2 Transformation and Degradation
6.3.2.1 Air
Carbon monoxide is generally stable under environmental conditions. Reactions with molecular oxygen 
(O2) or water vapor are very slow at ambient temperatures and pressure. Carbon monoxide reacts with 
ground-state triplet oxygen atoms, O(3P), produced by the atmospheric photodegradation of nitrogen 
dioxide and ozone, or atomic oxygen, formed by the photodissociation of molecular O2 in the 
stratosphere, to form CO2 (NRC 1977). However, the primary degradation pathway of carbon monoxide 
in the troposphere is through its reaction with photochemically-produced hydroxyl radicals. This results 
in the formation of CO2 and atomic hydrogen, which rapidly reacts with O2 to form peroxy radicals (EPA 
2000). The second-order rate constant for the gas-phase reaction of carbon monoxide with hydroxyl 
radicals at atmospheric pressure has been measured as 2.4x10-13 cm3/molecule-second (EPA 1991). This 
corresponds to an estimated tropospheric half-life of approximately 22-67 days, assuming a hydroxyl 
radical concentration of 5.0x105-1.5x106 hydroxyl radicals per cm3 air. No estimates of the half-life of 
carbon monoxide in indoor air were located. Hydroxyl radicals are formed photochemically by sunlight; 
therefore, their levels in indoor air will be negligible.
6.3.2.2 Water
Although oceans and other water bodies are considered a net source of carbon monoxide in the 
environment, evidence suggests that various microorganisms may degrade carbon monoxide in the water 
column (Conrad and Seiler 1988). Taxonomically diverse microorganisms isolated from surface waters 
collected off the New England coast readily oxidized carbon monoxide (Tolli et al. 2006). Microbial 
oxidation rate constants for carbon monoxide in coastal waters were reported to range from 0.01 to 
0.11 hours-1, corresponding to half-lives on the order of several hours (Tolli et al. 2006). These rates were 
reported to be approximately an order of magnitude greater than in oligotrophic environments, suggesting 
the presence of an active carbon monoxide oxidizing microbial community near shore.
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6.3.2.3 Sediment and Soil
Soils may act as a source or a sink for carbon monoxide depending on soil moisture, intensity of sunlight 
reaching the soil surface, and soil temperature (Conrad and Seiler 1985). In general, warm and moist 
conditions found in most soils favor uptake, whereas hot and dry conditions as found in deserts and some 
savannas favor the release of carbon monoxide (King 1999a). Global estimates of carbon monoxide 
consumption by soil microorganisms ranges from 15 to 640 Tg (1.5x1013-6.4x1014 g) per year (King 
1999a). Carbon monoxide oxidation to CO2 has been demonstrated for both aerobic and anaerobic 
microorganisms.
6.4 L E V E L S  MONITORED O R ESTIM ATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to carbon monoxide depends in part on the 
reliability of supporting analytical data from environmental samples and biological specimens. 
Concentrations of carbon monoxide in unpolluted atmospheres and in pristine surface waters are often so 
low as to be near the limits of current analytical methods. In reviewing data on carbon monoxide levels 
monitored or estimated in the environment, it should also be noted that the amount of chemical identified 
analytically is not necessarily equivalent to the amount that is bioavailable. The analytical methods 
available for monitoring carbon monoxide in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
The concentration of carbon monoxide in air can be represented using various concentration units. Air 
monitoring data for carbon monoxide is usually expressed or reported as ppmv or parts per billion by 
volume (ppbv). A concentration of 1 ppmv implies that for every million molecules of gas in the 
measured volume, one of them is a carbon monoxide molecule. In order to express these concentrations 
in mass units, the following conversion factors may be used: 1.00 ppmv=1.16 mg/m3 and 1.00 ppbv= 
1.16 ^g/m3 at 20 °C.
Annual average outdoor carbon monoxide concentrations are about 0.12 ppmv in the Northern 
Hemisphere and about 0.04 ppmv in the Southern Hemisphere (EPA 2000). In general, the concentration 
of carbon monoxide decreases with altitude in the Northern Hemisphere, but this vertical gradient may be 
reversed in the Southern Hemisphere due to the transport of carbon monoxide from the Northern to the 
Southern Hemisphere (EPA 1991). Annual 24-hour average carbon monoxide concentrations obtained at
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monitoring locations at rural sites in the United States are typically about 0.2 ppmv, compared with an 
annual 24-hour average of 1.2 ppmv across all monitoring sites (EPA 2000). Carbon monoxide levels 
(1- and 8-hour maximum levels) from various cities in the United States for 2008 are provided in 
Table 6-2. These data are derived from measurements submitted to the EPA AQS database, which 
collects data from EPA, state, local, and tribal air pollution control agencies. As indicated by the data 
presented in the table, only one measurement exceeded the EPA 8-hour carbon monoxide level of 9 ppm 
and no measurements exceeded the 1-hour average level of 35 ppm at the 365 different monitoring sites. 
Using this nationwide network of monitoring sites, EPA estimated that there has been a 76% decrease in 
the ambient levels of carbon monoxide in the United States from 1980 to 2007.
Urban areas with heavy vehicular traffic congestion tend to have high levels of carbon monoxide in 
ambient air. These levels follow a predictable diurnal pattern, which reaches maximum concentrations at 
times of heavy commuting and then decreases during periods of low vehicular traffic. The apex of these 
profiles corresponds to the morning and evening rush hour commutes when vehicle density is at its 
highest. For many locations, the morning peak yields higher carbon monoxide levels than the evening 
peak because the height of the mixed layer is much lower during the morning, thereby inhibiting vertical 
mixing that helps dissipate the carbon monoxide. In the late afternoon and into early evening, increased 
atmospheric turbulence resulting from solar activity raises the height of the mixed layer, resulting in 
generally lower carbon monoxide concentrations compared with those of the morning (EPA 2000). A 
study conducted by the Toronto (Canada) Public Health Department examined the level of carbon 
monoxide at four sites in Toronto as a function of traffic density (Campbell et al. 1995). The four areas of 
the study were categorized as low, medium, or high in terms of traffic density. Mean hourly carbon 
monoxide levels ranged from 0.63 ppmv at a low traffic density site (average daily vehicle count of
2.000 vehicles) to 1.54 ppmv at a site in which the vehicular count was about 45,000 per day (Campbell et 
al. 1995). Chen et al. (2008) measured carbon monoxide levels at 10 roadside pollution monitoring sites 
in the city of Leicester, England. A diurnal carbon monoxide concentration pattern was observed in this 
study; however, the carbon monoxide levels during the evening rush hour period generally exceeded the 
levels than the morning commute. Maximum carbon monoxide levels at these sites ranged from 0.8 to
3.1 ppmv during the morning commute, while maximum levels were 1.0-4.0 ppmv during the evening 
rush hour (Chen et al. 2008).
High levels of carbon monoxide inside vehicles and other transportation sources that use gasoline 
powered engines are frequently observed. Duci et al. (2003) studied the concentration of carbon 
monoxide in vehicles along heavy traffic routes in the Athens, Greece. The mean carbon monoxide
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
2,169 8.1 6.7 0 3.6 3.5 0 Fairbanks AK
2,176 6.1 6 0 4.1 3.8 0 Anchorage AK
1,988 5.1 4.5 0 2.5 2.3 0 Not provided AK
2,176 5.6 5.5 0 3.1 2.8 0 Anchorage AK
2,173 5.7 4.5 0 3.3 2.2 0 Fairbanks AK
2,173 8.3 8 0 4.8 4.7 0 Anchorage AK
7,500 19.6 15.9 0 10.7 8.1 1 Birmingham AL
7,563 8 6.1 0 2.3 2.2 0 Fairfield AL
8,012 3.4 3 0 2.4 2.3 0 Birmingham AL
8,750 6.8 2.5 0 1.8 1.5 0 North Little 
Rock
AR
5,049 1.5 1.4 0 1 1 0 Surprise AZ
4,584 0.7 0.7 0 0.5 0.5 0 Not provided AZ
7,947 3.1 3.1 0 2.5 2.4 0 Phoenix AZ
8,720 2.2 1.8 0 1.3 1 0 Tucson AZ
8,736 2.6 2.1 0 1.1 1.1 0 Tucson AZ
8,696 2.9 2.5 0 1.4 1.3 0 Tucson AZ
4,369 2.5 2.5 0 1.9 1.5 0 Tucson AZ
8,157 1.5 1.3 0 1 0.9 0 Tucson AZ
4,315 2 1.8 0 1.3 1.2 0 Tucson AZ
5,027 2.4 2.3 0 1.8 1.4 0 Tempe AZ
5,043 1.8 1.7 0 1.4 1.4 0 Chandler AZ
5,057 3.7 3.2 0 2.2 2 0 Phoenix AZ
8,654 3 3 0 2.7 2.4 0 Phoenix AZ
4,933 2 2 0 1.5 1.4 0 Scottsdale AZ
5,060 2.1 2 0 1.6 1.5 0 Glendale AZ
5,038 2.1 2 0 1.3 1.3 0 Phoenix AZ
5,012 1.7 1.7 0 1.4 1.3 0 Mesa AZ
8,575 4.7 4.5 0 3.1 3 0 Phoenix AZ
8,307 3.9 3.6 0 2.8 2.8 0 Phoenix AZ
8,397 3.6 3.5 0 2.6 2.2 0 Phoenix AZ
6,905 2.1 1.9 0 1.1 1 0 Lompoc CA
6,893 1.4 1.2 0 0.6 0.6 0 Goleta CA
6,097 1.6 1.3 0 0.7 0.6 0 Vandenberg 
Air Force Base
CA
6,177 3.3 3 0 2.1 1.9 0 San Jose CA
7,046 7.6 3.7 0 1.3 1.1 0 Davenport CA
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
6. POTENTIAL FOR HUMAN EXPOSURE
212
Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
6,230 2.7 2.5 0 1.9 1.7 0 Vallejo CA
6,251 0.9 0.9 0 0.7 0.6 0 Benicia CA
6,244 3.5 1.9 0 1.3 1.1 0 Santa Rosa CA
5,550 2.8 2.3 0 1.8 1.7 0 Modesto CA
6,035 1.9 1.9 0 1.2 1.2 0 Turlock CA
6,270 2.2 2.2 0 1.4 1.4 0 Livermore CA
6,227 2.9 2.4 0 1.6 1.4 0 Oakland CA
6,202 1.9 1.8 0 1.3 1.3 0 Fremont
(Centerville)
CA
6,175 2.1 2 0 1.5 1.5 0 Berkeley CA
5,576 3.1 3 0 2.4 2.1 0 Chico CA
6,240 1.5 1.5 0 1 1 0 Concord CA
6,274 1 0.9 0 0.8 0.8 0 Bethel Island CA
6,225 2.5 2.1 0 1.3 0.9 0 San Pablo CA
6,266 2.8 2.2 0 1.4 1.3 0 Pittsburg CA
5,430 2.6 2.6 0 1.8 1.7 0 Fresno CA
5,563 3.1 2.8 0 2.3 2.1 0 Fresno CA
5,519 1.6 1.5 0 1 1 0 Fresno CA
4,785 2.3 2.2 0 1.5 1.3 0 Clovis CA
5,768 1.9 1.9 0 1.6 1.4 0 Eureka CA
5,543 8.2 7 0 5.3 4.1 0 Calexico CA
5,262 7.3 6.8 0 3.2 3.1 0 Calexico CA
6,270 2.5 2.3 0 1.7 1.7 0 El Centro CA
4,139 3.5 2.7 0 2.2 2.1 0 Bakersfield CA
5,554 2.3 2.1 0 1.4 1.3 0 Azusa CA
5,552 2.7 2.3 0 1.8 1.7 0 West Los 
Angeles
CA
5,555 3 2.8 0 2.5 2 0 Burbank CA
5,560 2.9 2.8 0 2 1.9 0 Los Angeles CA
5,594 3.4 3.3 0 2.3 2.1 0 Reseda CA
5,579 5.8 5.7 0 4.3 4.1 0 Lynwood CA
5,281 2.9 2.5 0 1.9 1.8 0 Pico Rivera CA
5,557 2.6 2.6 0 1.7 1.7 0 Pomona CA
5,550 2.4 2.4 0 2 1.9 0 Pasadena CA
5,567 3.3 3 0 2.5 2.4 0 Long Beach CA
5,315 3.1 2.6 0 1.9 1.8 0 Los Angeles CA
5,495 1.6 1.5 0 0.9 0.8 0 Santa Clarita CA
5,538 2.2 1.7 0 0.9 0.8 0 Lancaster CA
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
6,208 1.7 1.7 0 1 1 0 San Rafael CA
7,224 4.5 3.9 0 3.4 3.3 0 Ukiah CA
3,282 1.5 1.4 0 1 0.9 0 Willits CA
7,177 2.2 1.6 0 0.9 0.8 0 Salinas CA
6,255 3.2 3.1 0 1.8 1.6 0 Napa CA
5,560 3.3 3 0 2.4 2.1 0 Anaheim CA
5,571 3 2.8 0 2 2 0 Costa Mesa CA
5,524 1.5 1.5 0 1.1 1 0 Mission Viejo CA
5,567 4.7 4.6 0 2.5 2.4 0 La Habra CA
5,605 4.7 4.5 0 1.9 1.9 0 Riverside CA
5,574 1 0.9 0 0.5 0.5 0 Palm Springs CA
5,546 2.7 2.5 0 1.9 1.7 0 Rubidoux
(West
Riverside)
CA
5,564 1.1 1.1 0 0.8 0.8 0 Lake Elsinore CA
6,390 2.3 2.3 0 1.8 1.8 0 North
Highlands
CA
7,292 2.9 2.7 0 2.5 1.8 0 Sacramento CA
8,036 3.1 3.1 0 2.8 2.4 0 Sacramento CA
4,812 2.7 2.5 0 1.8 1.7 0 Sacramento CA
5,519 1.4 1.3 0 1.2 1.1 0 Barstow CA
5,587 1.4 1.4 0 0.9 0.9 0 Victorville CA
5,491 2.1 1.9 0 1.4 1.2 0 Upland CA
1,388 1.3 1.1 0 0.8 0.8 0 Fontana CA
5,556 2.2 2.1 0 1.4 1.4 0 San
Bernardino
CA
6,212 2 2 0 1.5 1.5 0 Chula Vista CA
706 2.4 2.2 0 1.8 1.5 0 San Diego CA
6,006 4.6 4 0 2.8 2.5 0 Escondido CA
6,130 3.1 3.1 0 2.5 2.5 0 San Diego CA
5,119 4.3 3.9 0 2.7 2.5 0 Otay Mesa CA
6,247 2.1 1.9 0 1.5 1.4 0 San Francisco CA
5,546 2.6 2.5 0 1.6 1.6 0 Stockton CA
6,214 4.3 3.8 0 1.9 1.8 0 Redwood City CA
4,811 5.2 3.4 0 1.2 1.2 0 Santa Barbara CA
5,462 1.5 1.5 0 0.8 0.8 0 Santa Maria CA
6,182 3.5 2.5 0 1.7 0.9 0 Capitan CA
6,190 3.1 3.1 0 2.4 1.7 0 Welby CO
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
6,505 3.5 3.3 0 2.7 2.4 0 Longmont CO
6,507 3.4 3.2 0 2.3 2.2 0 Greeley CO
6,481 2.2 2.1 0 1.4 1.3 0 Grand Junction CO
6,487 5.1 4.6 0 3 2.2 0 Fort Collins CO
4,249 0.8 0.8 0 0.7 0.7 0 Not provided CO
6,420 4 3.5 0 2.6 2.3 0 Colorado
Springs
CO
6,203 7.1 7 0 3.1 2.3 0 Denver CO
6,488 4.8 4.5 0 2.4 1.9 0 Denver CO
6,499 6 5.9 0 3.7 3.1 0 Hartford CT
6,319 1.6 1.6 0 1.4 1.1 0 Westport CT
6,305 3.3 3.2 0 2.2 2 0 Bridgeport CT
6,491 1.2 1.1 0 0.9 0.9 0 Thomaston CT
6,511 1.8 1.6 0 1.3 1.2 0 East Hartford CT
3,314 2.2 2.1 0 1.9 1.6 0 New Haven CT
6,525 6 4 0 2.6 1.8 0 Washington DC
6,513 3 2.7 0 2.6 2.1 0 Washington DC
7,030 1.4 1 0 0.9 0.8 0 Not provided DE
7,171 2 2 0 1.3 1.1 0 Wilmington DE
6,500 2.1 2 0 1.6 1.6 0 Fort
Lauderdale
FL
6,513 1.6 1.5 0 1 0.9 0 Clearwater FL
6,499 2.4 2.1 0 1.6 1.5 0 Hollywood FL
6,269 8.7 6.2 0 3.3 2.8 0 Jacksonville FL
6,318 2.5 2.1 0 1.4 1.2 0 Jacksonville FL
6,250 2.3 2.2 0 1.1 1.1 0 Jacksonville FL
6,551 2.6 2.5 0 2 1.8 0 Tampa FL
6,511 1.2 1 0 0.5 0.4 0 Plant City FL
6,506 2.2 2 0 1.2 1.1 0 Miami FL
6,515 2.4 2 0 1.7 1.4 0 Not provided FL
6,329 3.9 3.9 0 2.4 2.1 0 Miami FL
6,550 2.8 2.6 0 2.1 1.6 0 Miami FL
6,449 1.1 1 0 1 1 0 Winter Park FL
2,167 1.5 1.4 0 1.1 1.1 0 Palm Beach FL
6,280 1.5 1.4 0 1.2 1.1 0 Pompano
Beach
FL
5,747 2.8 2.1 0 1.8 1.8 0 Decatur GA
6,435 0.5 0.5 0 0.5 0.5 0 Not provided GA
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
5,918 2.2 2.1 0 1.4 1.2 0 Atlanta GA
6,554 2.1 1.7 0 1 1 0 Honolulu HI
5,268 1.7 1.3 0 0.7 0.7 0 Ewa Beach HI
2,050 1.5 1.1 0 0.7 0.6 0 Cedar Rapids IA
5,017 1.6 1.5 0 1.3 1.2 0 Cedar Rapids IA
7,396 1.9 1.6 0 1 1 0 Des Moines IA
8,199 1.2 1.2 0 0.7 0.7 0 Davenport IA
4,609 4.1 3.6 0 1.6 1.5 0 Boise ID
7,797 2.9 2.7 0 2.3 2.2 0 East Saint 
Louis
IL
7,977 2.5 2.2 0 1.5 1.3 0 Springfield IL
7,965 5.6 3 0 1.9 1.7 0 Rockford IL
7,917 3.6 3.2 0 2.9 2.1 0 Peoria IL
7,960 2.5 2.5 0 2.3 2.2 0 Maywood IL
8,007 1.9 1.3 0 1.2 0.9 0 Northbrook IL
7,926 2.4 2.3 0 1.7 1.5 0 Cicero IL
7,783 2.3 2 0 1.8 1.5 0 Schiller Park IL
7,982 7.3 4.4 0 2 1.5 0 Chicago IL
6,380 1.9 1.7 0 1.2 1.2 0 Indianapolis
(Remainder)
IN
5,972 2 1.8 0 1.5 1.1 0 Evansville IN
6,538 9.1 7.1 0 3.3 3 0 East Chicago IN
3,984 0.8 0.8 0 0.7 0.7 0 Pittsboro IN
6,445 3.9 3.8 0 2.9 2.3 0 Fort Wayne IN
8,710 3.6 3.5 0 3.2 2.1 0 Indianapolis IN
6,520 2.8 2.7 0 2 1.2 0 Wichita KS
6,394 2.7 2.4 0 1.6 1.5 0 Wichita KS
6,389 2.2 2.2 0 1.8 1.4 0 Kansas City KS
7,113 6.9 3.4 0 2.8 2.2 0 Louisville KY
6,937 3.1 3.1 0 2.7 2.1 0 Louisville KY
7,723 2.9 2.5 0 1.9 1.8 0 Baton Rouge LA
5,769 0.9 0.7 0 0.4 0.4 0 Lynn MA
6,586 3.4 3.4 0 3 2.5 0 Springfield MA
6,835 3.7 3.2 0 2.6 2.1 0 Lowell MA
6,830 1.7 1.6 0 1.3 1 0 Boston MA
6,875 1.5 1.5 0 1.1 0.9 0 Boston MA
6,831 2.8 2.7 0 1.7 1.3 0 Worcester MA
6,022 2.6 2.4 0 1.6 1.5 0 Essex MD
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
6,407 0.4 0.4 0 0.3 0.3 0 Not provided MD
6,104 2.4 2.2 0 2.1 2 0 Baltimore MD
6,439 1.4 1 0 0.9 0.8 0 Beltsville MD
1,211 0.6 0.6 0 0.4 0.4 0 Presque Isle ME
5,816 1.6 1.4 0 1.3 1 0 Portland ME
6,351 0.4 0.4 0 0.4 0.3 0 Not provided ME
4,569 2 1.6 0 1.2 1.1 0 Allen Park MI
4,218 2 1.8 0 1.1 1 0 Grand Rapids MI
7,278 2 2 0 0.8 0.7 0 Minneapolis MN
7,262 0.5 0.5 0 0.3 0.3 0 Inver Grove 
Heights
MN
5,712 0.6 0.6 0 0.4 0.3 0 Rosemount MN
2,169 1.8 1.5 0 1.2 1.2 0 Fridley MN
7,022 3.2 3.1 0 2.4 2.4 0 St. Paul MN
6,975 1.8 1.7 0 1.2 1.2 0 St. Cloud MN
7,122 4.1 2.2 0 1.8 1.5 0 Duluth MN
6,533 1.1 1 0 0.7 0.7 0 Sunset Hills MO
6,536 1.9 1.8 0 1.2 1 0 Springfield MO
6,528 3.3 2.9 0 2.2 1.6 0 St. Louis MO
6,469 2.4 2.1 0 1.8 1.4 0 St. Louis MO
2,083 3.4 3.4 0 2.9 2.7 0 Missoula MT
2,104 2 1.9 0 0.7 0.7 0 Not provided MT
6,916 6.7 5.7 0 2.4 2.2 0 West
Yellowstone
MT
1,542 6.1 4.2 0 1.6 1.1 0 Not provided MT
7,130 4.8 3.7 0 2.3 2 0 Billings MT
7,244 7.7 3 0 1.8 1.5 0 Great Falls MT
5,578 7.2 3.4 0 2.4 1.9 0 Kalispell MT
2,819 1.5 1.5 0 1.3 1.1 0 Not provided NC
7,811 1.9 1.8 0 1.5 1.4 0 Charlotte NC
3,664 3.5 3.1 0 2.2 2.2 0 Raleigh NC
7,081 4 2.8 0 2.4 1.8 0 Raleigh NC
7,384 1.6 1.5 0 0.9 0.7 0 Rockwell NC
2,044 2.2 2.2 0 1.7 1.7 0 Fayetteville NC
7,927 2.3 2.1 0 1.9 1.6 0 Charlotte NC
1,985 1.9 1.9 0 1.6 1.5 0 Greensboro NC
6,531 2.7 2.5 0 2.3 1.9 0 Winston-Salem NC
2,754 1.9 1.9 0 1.5 1.2 0 Durham NC
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
7,930 6.5 1.7 0 1.2 0.7 0 Not provided ND
6,365 3.1 2.9 0 2.5 2 0 Omaha NE
7,252 6.5 4.5 0 1.8 1.8 0 Lincoln NE
6,464 9.4 6 0 4.4 3.5 0 Manchester NH
6,285 1.5 1.4 0 1.1 1.1 0 Fort Lee NJ
2,188 1.8 1.6 0 1.1 1 0 Elizabeth NJ
6,544 2.3 1.9 0 1.5 1.3 0 Morristown NJ
6,508 3.4 3.4 0 2 1.6 0 Freehold NJ
6,373 2.2 2.1 0 1.2 1.2 0 Camden NJ
6,522 1 0.9 0 0.7 0.6 0 Not provided NJ
6,498 2.1 2.1 0 1.7 1.5 0 Jersey City NJ
6,318 2 1.6 0 1.2 0.9 0 Perth Amboy NJ
6,484 2.2 2.2 0 1.8 1.6 0 Hackensack NJ
6,326 3.7 2.7 0 1.8 1.4 0 Burlington NJ
3,065 3.6 2.8 0 1.8 1.5 0 Albuquerque NM
6,140 2.6 2.2 0 1.7 1.1 0 Albuquerque NM
3,130 2.6 2.5 0 1.8 1.7 0 Albuquerque NM
5,792 6.5 3 0 2.4 2.3 0 Albuquerque NM
3,057 4.9 3.7 0 1.6 1.3 0 Albuquerque NM
806 2.4 2.4 0 1.9 1.8 0 South Valley NM
6,377 4.2 3.9 0 2.1 2 0 Sparks NV
6,463 2.2 1.9 0 1.5 1.5 0 Lemmon
Valley-Golden
Valley
NV
4,243 2.9 2.7 0 2.2 1.7 0 Carson City NV
5,033 3.5 2.9 0 2.3 2.1 0 Las Vegas NV
6,217 5.1 4.7 0 4.2 3.7 0 Las Vegas NV
6,275 4.1 3.9 0 3.1 2.8 0 Las Vegas NV
6,190 3.2 2.9 0 2.1 2.1 0 Las Vegas NV
6,271 4.2 3.6 0 2.5 2.4 0 Las Vegas NV
6,178 5.8 5.3 0 2.6 2.4 0 Stateline NV
6,476 2.1 2.1 0 1.5 1.5 0 Reno NV
6,515 1.8 1.7 0 1.3 1.3 0 Reno NV
6,400 3 2.9 0 2.3 2.2 0 Reno NV
6,512 1.8 1.7 0 0.8 0.8 0 Reno NV
6,466 1.8 1.8 0 1.2 0.9 0 Holtsville NY
7,922 3 2.7 0 1.8 1.8 0 Schenectady NY
7,445 8.6 2.3 0 1.7 1.6 0 New York NY
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
Number of 
measure­
ments
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Statea
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City
7,956 2 1.9 0 1.7 1.4 0 Syracuse NY
7,957 1.4 1.3 0 1.2 1 0 Niagara Falls NY
7,769 1.5 1.2 0 1 0.9 0 Albany NY
4,245 1.6 1.5 0 1.2 1.2 0 New York NY
7,429 1.3 1.2 0 1.1 1 0 Rochester NY
5,757 1.3 1 0 0.7 0.7 0 Tonawanda NY
7,452 1.6 1.6 0 1.1 1 0 Buffalo NY
7,962 2.3 2.1 0 1.8 1.7 0 New York NY
3,419 1.7 1.6 0 1.3 1.2 0 New York NY
6,967 4.8 4.8 0 2.1 1.5 0 Cleveland OH
7,023 7.8 6.3 0 3.3 2.4 0 Cleveland OH
6,948 2 1.5 0 0.9 0.8 0 Akron OH
7,003 1.7 1.6 0 1.3 1.1 0 Akron OH
6,158 2.9 2.9 0 2.6 2.5 0 Canton OH
8,739 2.3 2.3 0 1.6 1.5 0 Dayton OH
8,720 1.5 1.4 0 1.1 1 0 Dayton OH
7,259 2.6 2.6 0 2.6 2.3 0 Mentor OH
6,358 5.9 5.1 0 3.6 2.7 0 Cincinnati OH
7,183 2.7 2.3 0 1.6 1.4 0 Columbus OH
7,232 2 1.8 0 1.5 1.3 0 Cleveland OH
7,252 2 2 0 1.2 1.2 0 Cleveland OH
7,752 2.5 2.1 0 1.1 1.1 0 Oklahoma City OK
1,382 0.4 0.4 0 0.3 0.3 0 Cherry Tree OK
3,185 1.7 0.5 0 0.4 0.3 0 Park Hill OK
4,625 1.7 0.3 0 0.5 0.3 0 Not provided OK
2,278 1.7 1.6 0 1.4 1.3 0 Tulsa OK
7,991 2.1 1.9 0 1.3 1.2 0 Tulsa OK
5,933 2.7 2.6 0 2.3 2.2 0 Portland OR
6,541 2.7 2.7 0 1.8 1.6 0 Portland OR
6,437 3.4 3.4 0 2.6 2.2 0 Medford OR
6,530 2.2 2.1 0 1.7 1.6 0 Eugene OR
5,023 0.8 0.8 0 0.5 0.4 0 Not provided PA
7,048 1.9 1.8 0 1.6 1.5 0 Pittsburgh PA
7,243 2 2 0 1.3 1.2 0 York PA
7,211 1.4 1 0 0.8 0.5 0 Greensburg PA
6,517 1.6 1.6 0 1.3 1.1 0 Pittsburgh PA
6,523 2.3 2.1 0 1.7 1.4 0 Pittsburgh PA
7,054 2.6 2 0 1.6 1.3 0 Beaver Falls PA
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Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Number of 
measure­
ments
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City Statea
7,197 1.5 1.3 0 0.9 0.9 0 Not provided PA
7,206 1.4 1.2 0 0.8 0.7 0 Altoona PA
7,009 4.3 2.9 0 2 1.9 0 Bristol PA
7,215 1.7 1.4 0 1.2 1.1 0 Johnstown PA
7,174 1.4 1.4 0 1.1 1.1 0 Harrisburg PA
7,152 2.8 1.6 0 1 1 0 Erie PA
4,958 0.5 0.5 0 0.3 0.3 0 Not provided PA
7,212 1.8 1.4 0 1.2 1 0 Scranton PA
6,694 2.6 1.9 0 1.6 1.4 0 Lancaster PA
7,162 1.2 1.2 0 0.7 0.7 0 New Castle PA
7,200 2.6 2.4 0 1.9 1.5 0 Wilkes-Barre PA
7,306 1.1 1.1 0 0.8 0.8 0 Norristown PA
7,308 2.1 2 0 1.6 1.6 0 Freemansburg PA
6,160 3.7 2.7 0 1.7 1.3 0 Philadelphia PA
1,764 1.3 1.1 0 0.7 0.7 0 Philadelphia PA
7,094 1.3 1.2 0 1.2 1.1 0 Charleroi PA
3,795 4.2 2.8 0 2.3 2.3 0 Bayamon PR
5,854 3.8 3.7 0 2.4 2.3 0 San Juan PR
6,421 3.9 3.3 0 1.7 1.4 0 San Juan PR
6,420 1.5 1.4 0 1 0.9 0 East
Providence
RI
8,714 2.3 2 0 1.4 1.3 0 Greenville SC
8,561 0.9 0.8 0 0.5 0.5 0 Not provided SC
8,747 3.2 3.2 0 2.4 1.9 0 Nashville TN
6,248 1.7 1.5 0 1 1 0 Kingsport TN
8,514 3.2 2.5 0 1.5 1.4 0 Memphis TN
6,824 1.6 1.5 0 0.8 0.7 0 Brownsville TX
5,201 1.7 1.7 0 1.4 1.3 0 Dallas TX
7,170 7 6.1 0 4.9 3.2 0 El Paso TX
6,895 2.9 2.7 0 1.5 1.5 0 El Paso TX
7,198 5 4.8 0 3 1.8 0 El Paso TX
6,712 7.3 6 0 4.2 2.4 0 El Paso TX
7,202 6.7 6.6 0 4.8 3.9 0 El Paso TX
6,985 4.3 4 0 3 2.8 0 El Paso TX
7,040 3.5 3.4 0 1.7 1.7 0 Laredo TX
7,176 2.5 2.1 0 1.4 1.3 0 El Paso TX
6,875 2.9 2.7 0 1.7 1.5 0 Not provided TX
6,310 3.8 3.7 0 2.7 2.3 0 Houston TX
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
6. POTENTIAL FOR HUMAN EXPOSURE
220
Table 6-2. 1-Hour and 8 -Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
Number of 
measure­
ments
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Statea
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City
6,258 2.1 1.9 0 1.6 1.3 0 Houston TX
6,322 8.9 8.1 0 5.9 5.2 0 Houston TX
5,662 1.4 1.4 0 1 0.8 0 Houston TX
6,863 1.7 1.5 0 0.9 0.6 0 Deer Park TX
5,594 1.8 1.7 0 1 0.7 0 Nederland TX
7,105 0.8 0.3 0 0.3 0.3 0 Waco TX
7,080 1.7 1.7 0 1.1 1 0 Fort Worth TX
7,205 1.8 1.4 0 1 0.9 0 Arlington TX
7,241 0.7 0.6 0 0.4 0.4 0 Austin TX
6,942 3.2 2.9 0 1.4 1.3 0 Laredo TX
6,154 0.9 0.9 0 0.5 0.5 0 Not provided TX
6,309 2.5 2.4 0 1.9 1.4 0 San Antonio TX
7,199 7.8 4.7 0 2.7 2.6 0 San Antonio TX
7,235 3.2 2.9 0 1.6 1.6 0 Socorro TX
6,469 3 2.9 0 2.2 2.1 0 Not provided UT
6,297 4.1 3.6 0 2.4 2.3 0 Salt Lake City UT
5,776 27.9 24.2 0 8.8 6.4 0 Ogden UT
6,333 5 3.9 0 1.6 1.5 0 Provo UT
5,744 3.3 3.3 0 2 2 0 Ogden UT
2,125 3.7 3.3 0 1.8 1.8 0 West Valley UT
5,996 1.1 1 0 0.9 0.8 0 Annandale VA
6,479 1.3 1.2 0 1 0.8 0 Richmond VA
6,469 1.7 1.6 0 1.2 1.1 0 Not provided VA
7,175 1.4 1.4 0 1.2 1 0 Not provided VA
7,133 1.9 1.9 0 1.9 1.8 0 Franconia VA
6,489 2 2 0 1.5 1.4 0 Roanoke VA
7,097 2 2 0 1.5 1.5 0 Mclean VA
6,365 1.9 1.9 0 1.2 1.2 0 Alexandria VA
6,439 4.2 4.1 0 1.6 1.3 0 Hampton VA
6,487 4.7 4.5 0 2.2 1.9 0 Norfolk VA
6,218 3.1 2.7 0 2.1 1.8 0 Rutland VT
6,194 1.9 1.8 0 1.2 1.1 0 Burlington VT
7,232 3.4 3.1 0 2.3 1.9 0 Bellevue WA
5,468 0.3 0.3 0 0.3 0.3 0 Not provided WA
6,885 1.4 1.2 0 0.9 0.9 0 Seattle WA
7,140 4.3 4.1 0 2.4 2.4 0 Spokane WA
7,674 0.5 0.5 0 0.4 0.4 0 Not provided WI
6,541 3.9 3.5 0 2.3 2.2 0 Weirton WV
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
6. POTENTIAL FOR HUMAN EXPOSURE
221
Table 6-2. 1-Hour and 8-Hour Maximum Carbon Monoxide Levels at Monitoring
Stations Throughout the United States
Number of 
measure­
ments
1-Hour carbon monoxide level 8-Hour carbon monoxide level
Statea
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average
First
maximum
(ppmv)
Second
maximum
(ppmv)
Number
exceeding
average City
6,532 2.7 2.7 0 1.8 1.7 0 Weirton WV
6,449 4.5 4.3 0 2.9 2.3 0 Weirton WV
6,984 0.9 0.8 0 0.6 0.4 0 Not provided WY
6,361 0.9 0.9 0 0.7 0.7 0 Not provided WY
a P o s t  o f f i c e  s t a t e  a b b r e v i a t i o n s  a r e  u s e d .
S o u r c e :  E P A  2 0 0 9 i
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exposure level for trips greater than 30 minutes in duration were 21.4 ppmv for private car versus 10.4, 
9.6, 4, and 11.5 ppmv for bus, trolley, electric train, and pedestrians, respectively, during the winter 
season (Duci et al. 2003). Besides the mode of transportation, route travelled, monitoring period, and the 
season of year had significant influences on the measured carbon monoxide concentrations. In-vehicle 
carbon monoxide levels were monitored in a passenger vehicle driven along a heavily traveled route of a 
commercial/residential area of Beirut, Lebanon, under several ventilation modes (Abi Esper et al. 2007a). 
Trips were conducted during morning rush hours in spring and summer months. The highest mean 
carbon monoxide levels were observed within vehicles driven with the windows and vents closed 
(37.4 ppmv) and windows closed and air conditioning on recirculation ventilation settings (30.8 ppmv) 
(Abi Esper et al. 2007a). Opening a window or setting the air conditioning unit to fresh air intake 
generally resulted in a reduction of carbon monoxide levels within the vehicle.
Indoor air levels of carbon monoxide are greatly dependent upon the presence of indoor combustion 
sources such as wood burning stoves, fireplaces, gas space heaters, and gas stoves, as well as the 
operating condition and usage patterns of these appliances. Dutton et al. (2001) studied carbon monoxide 
levels in two residences located in Boulder, Colorado using unvented natural gas fireplaces. Time- 
averaged carbon monoxide levels ranged from 1.5 to 78 ppmv at one residence and 1.6-30 ppmv at the 
other residence while the fireplace operated uninterrupted; however, levels exceeding 100 ppm were 
observed at one of the residences on several occasions. Background carbon monoxide levels were 0­
7 ppmv in the homes when the fireplaces were not operating. Attached garages may also be a significant 
source of carbon monoxide to the indoor air of residences. The net increase of carbon monoxide levels in 
16 homes with attached garages ranged from <1 to 30 ppmv following the cold start of an automobile 
enclosed within the attached garage (Graham et al. 2004).
6.4.2 Water
The levels of carbon monoxide in the surface waters of the world’s oceans are supersaturated with respect 
to the partial pressure of carbon monoxide in the atmosphere and are subject to diurnal cycling. Levels 
have been reported to vary from 2x10-8 to 1.3x10-7 cm3 carbon monoxide per cm3 of water (20-130 nL/L) 
based on measurements in the Pacific Ocean and from 2x10-8 to 1x10-7 cm3 carbon monoxide per cm3 of 
water (20-100 nL/L) in the North Atlantic (Liss and Slater 1974). Carbon monoxide concentrations in 
seawater measured in the upwelling region of the equatorial Pacific Ocean were reported to range from 
42 to 173 nL/L on two consecutive sampling dates and reached a maximum value of 246 nL/L on 
subsequent sampling at a later date (Ohta 1997). These levels showed a marked diurnal variation with a
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maximum and minimum occurring early in the afternoon and morning, respectively. The concentrations 
in the water column decreased as a function of depth from the water surface to approximately 10 nL/L at 
a depth of 70 m. Tolli et al. (2006) reported a carbon monoxide level of 12 nanomoles/L at a coastal 
sampling location in Vineyard Sound, Massachusetts.
6.4.3 Sediment and Soil
In-situ soil-gas carbon monoxide levels were studied in a pine forest soil and cultivated soil as a function 
of depth from the surface (King 1999b). In the pine forest soil, the carbon monoxide concentrations 
remained elevated (250-320 ppbv) and greater than the atmospheric levels through the upper surface soil 
(O-horizon, 0-2 cm depth), but declined to values less than the atmospheric level in the lower depths of 
the soil (A-horizon 2-10 cm depth). In the cultivated soil, carbon monoxide levels decreased rapidly 
from approximately 250 ppbv in the upper 1 cm of the O-horizon to approximately 50 ppbv at a depth of
3 cm, which was roughly 5-fold less than ambient atmospheric levels.
6.4.4 Other Environmental Media
Carbon monoxide is released from tobacco smoke; however, the amount released is a function of the type 
of tobacco product (e.g., cigarette, cigar) and the degree to which tobacco is actively smoked. Moir et al. 
(2008) examined the emissions of carbon monoxide and other compounds under two smoking conditions 
from marijuana and tobacco cigarettes using a mechanical rotary smoking machine. The standard 
conditions employed a puff volume of 35 mL, puff duration of 2 seconds, and a puff interval of 
60 seconds. Conditions more consistent of marijuana smoking employed a puff volume of 70 mL, puff 
duration of 2 seconds, and a 30-second interval between puffs. These conditions were referred to as 
extreme conditions. Under standard conditions, the average±standard deviation emission of carbon 
monoxide in mainstream smoke (n=20) was 20.8±1.9 mg carbon monoxide per tobacco cigarette and 
13.4±1.6 mg carbon monoxide per marijuana cigarette. Under extreme smoking conditions, the levels 
were 41.5±4.0 mg carbon monoxide per tobacco cigarette and 35.3±2.9 mg carbon monoxide per 
marijuana cigarette. The carbon monoxide emissions in side stream smoke were 61.7±2.0 and 
54.0±3.7 mg carbon monoxide per tobacco cigarette and marijuana cigarette, respectively, using the 
standard conditions. Under extreme smoking conditions, the levels were 61.6±2.9 and 50.6±3.9 mg 
carbon monoxide per cigarette for normal tobacco and marijuana cigarettes, respectively.
Emissions from plants and biomass burning are reported to contribute approximately 1x1014 g/year to the 
global environment (Khalil and Rasmussen 1990). The direct emission of carbon monoxide from living
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plants increases as a function of solar irradiance. The source of the carbon monoxide likely occurs as a 
result of direct photooxidation of the plant material followed by transport to the stomata; however, the 
exact mechanism is not fully understood (Sanderson 2002).
6.5 G EN ER A L POPULATION AND O CCUPATIO N AL EXPO SU R E
The general population is exposed to carbon monoxide through the inhalation of indoor and outdoor air. 
Since carbon monoxide is ubiquitous in the environment, all humans are exposed to some level of carbon 
monoxide. The CDC estimated that during 2004-2006, an estimated average of 20,636 emergency room 
visits occurred for nonfatal, unintentional, non-fire-related carbon monoxide exposures annually (CDC
2008). Approximately 73% of these exposures occurred in residences, 13% occurred in workplace 
settings, and the rest were in other or unknown settings. The greatest number of incidences 
(8,538 incidences representing approximately 41% of the cases) occurred during the winter months of 
December through February. Nearly 70% of the incidences were diagnosed as carbon monoxide 
poisoning. Table 6-3 displays the estimated number of exposure cases categorized by age and gender.
Blood COHb levels were measured on a cross-sectional national probability sample of persons 
representative of the civilian population in the United States aged 3-74 years in the second National 
Health and Nutrition Examination Survey (NHANES II) conducted from February 1976 to February 1980 
(Radford and Drizd 1982). The statistical analysis of COHb levels in blood of the population based on 
smoking status and age is provided in Table 6-4. Four principle inhalation exposure routes were 
examined (outdoor air, indoor air, occupational exposure, and smoking). Of these four exposure routes, it 
was concluded that COHb levels in the population were most influenced by smoking status. Close 
examination of the data also indicated that COHb levels in the population tended to be greater during the 
winter months as opposed to the summer months, presumably due to the amount of time spent indoors 
where carbon monoxide levels are assumed to be higher than outdoor air.
Carbon monoxide exposure to European populations residing in five cities have been investigated through 
the EXPOLIS research project conducted from 1996 to 1998 and the results of this study have been 
summarized in several publications (Bruinen de Bruin et al. 2004a, 2004b; Hanninen et al. 2004). The 
geometric mean 48-hour exposure levels of nonsmoking subjects were 1.68, 0.82, 0.45, 2.17, and 
1.50 mg/m3 (1.45, 0.71, 0.39, 1.87, and 1.29 ppmv) in Athens, Basle, Helsinki, Milan, and Prague, 
respectively (Hanninen et al. 2004). Bruinen de Bruin et al. (2004a) used data for 50 office workers 
residing in Milan, Italy over a 1-year period to assess the contribution of local sources to exposure and
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Table 6-3. Average Annual Estimated Non Fatal Carbon Monoxide Exposure 
Cases in the United States Emergency Room Visits (2004-2006)
Age (years) Number of cases3 Percentage of the total
0-4 2,344 11.4
5-9 1,407 6.8
10-14 1,577 7.6
15-24 3,341 16.2
25-34 4,183 20.3
35-44 2,775 13.5
45-54 2,229 10.8
55-64 1,444 7.0
>65 1,328 6.4
Gender
Male 9,770 47.3
Female 10,866 52.7
a A g e  d a t a  w e r e  u n a v a i l a b l e  f o r  e i g h t  c a s e s .  
S o u r c e :  C D C  2 0 0 8
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microenvironment concentrations. This study examined the time that the subjects spent in 11 different 
microenvironments and three exposure influencing activities: gas cooking, smoking, and commuting.
The results of this study indicated that exposures from indoor environments contributed approximately 
82% of the total carbon monoxide exposures because this is where the study population spent over 90% 
of their time; however, approximately 16% of the total exposure to carbon monoxide occurred from 
commuting activities even though these activities only accounted for about 7.5% of the populations time.
Occupations such as toll both workers, gas station attendants, and taxi drivers are potentially exposed to 
high levels of carbon monoxide due to emissions from automobile exhaust. Carbon monoxide levels 
were monitored continuously during both morning (9 AM-12 PM) and afternoon (2-4 PM) hours at 
seven gas stations located in New York, New Jersey, and Connecticut (API 1994). Mean (arithmetic) 
concentrations of carbon monoxide at the pumping islands ranged from 1.15 to 5.44 ppmv with a 
maximum one-minute level of 144 ppmv observed at one station. Firefighters are potentially exposed to 
carbon monoxide levels near or exceeding recommended occupational exposure limits. A study 
conducted from 1986 to 1989 in northern California was performed to estimate the level of carbon 
monoxide that wildland firefighters are exposed to during various job tasks associated with that 
profession (Materna et al. 1992). Following a series of prescribed burns, the instantaneous fireline carbon 
monoxide levels ranged from 3 to 80 ppmv; however, firefighters that tended gasoline powered pumping 
engines were exposed to levels as high as 300 ppmv. The mean time-weighted average (TWA) exposure 
level obtained from 46 personal measurements was 14.4 ppmv, but one employee had a TWA exposure of 
38 ppmv and five firefighters had TWAs above 25 ppmv. Industrial or in-home use of methylene 
chloride paint strippers in poorly ventilated areas can lead to high levels of carbon monoxide in blood 
since carbon monoxide is a metabolic byproduct of methylene chloride.
6.6 EX P O SU R ES OF CHILDREN
This section focuses on exposures from conception to maturity at 18 years in humans. Differences from 
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults. A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume. A child’s diet often differs from that of adults.
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults. A child’s
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behavior and lifestyle also influence exposure. Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors. Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
As with adults, children are exposed to carbon monoxide through the inhalation of indoor and outdoor air. 
The NHANES II survey (see Table 6-4) includes COHb levels of children. Several activities may 
influence the levels of carbon monoxide that children or infants are exposed to. Time spent indoors 
versus outdoors, riding in automobiles, and exposure to second-hand tobacco smoke influence the total 
exposure that children receive to carbon monoxide. COHb levels in children were significantly greater 
when measured during the winter months of November-March as opposed to levels obtained in May- 
September. The average COHb level for all children in the NHANES study aged 3-11 years was 0.87% 
for samples collected during the winter months and 0.58% during the summer months. The location 
where the children in the population resided also influenced the COHb levels observed in the study. 
Children residing in central cities with populations over 1 million people tended to have the highest mean 
COHb levels (1.01% winter months and 0.77% summer months), while children living in rural areas had 
mean COHb levels of 0.79% in the winter months and 0.49% during the summer months (Radford and 
Drizd 1982).
Pregnant females who smoke potentially expose their unborn fetus to carbon monoxide, and the health 
consequences of this activity have been discussed in Chapter 3. Carbon monoxide crosses the placenta 
and can accumulate in the fetus to a greater extent than the mother.
6.7 POPULATIO NS WITH PO TEN TIA LLY HIGH EX P O SU R ES
Populations that are exposed to high levels of vehicular traffic are expected to have greater exposure to 
carbon monoxide as compared to individuals in low traffic density areas. As discussed in Section 6.5, 
certain occupations such as toll workers, gas station attendants, firefighters, and other professions exposed 
to combustion sources may have high levels of exposure.
Members of the general population that smoke are exposed to higher levels of carbon monoxide than 
nonsmoking members of the general population. Data from the NHANES II study indicates that mean 
COHb levels in the blood of smokers are approximately 4 times greater than levels for members of the 
nonsmoking population (Radford and Drizd 1982). More recent data support these conclusions. COHb 
levels were measured as part of pulmonary function testing in 100 subjects in one pulmonary laboratory
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Table 6-4. Carboxyhemoglobin Levels in the U.S. Population Based Upon
Smoking Status
Age
(years) N2a N3b
Mean
COHb
percent
Standard
deviation
Standard
error
50th
percentile
75th
percentile
90th
percentile
95th
percentile
All smoking status 
3-74 9,365 195,877 1.93 2.236 0.037 0.91 2.38 5.49 6.83
3-11 2,055 30,066 0.73 0.502 0.019 0.67 0.87 1.12 1.42
12-74 7,310 165,812 2.14 2.358 0.044 1.01 3.17 5.79 7.05
Never smoked
3-74 5,459 106,042 0.83 0.671 0.021 0.72 0.97 1.33 1.65
3-11 2,055 30,066 0.73 0.502 0.019 0.67 0.87 1.12 1.42
12-74 3,404 75,976 0.87 0.726 0.025 0.74 1.01 1.38 1.77
Ex-smokers
12-74 1,366 28,655 0.97 0.999 0.031 0.77 1.04 1.58 2.08
Current smokers
12-74 2,533 61.015 4.30 2.533 0.072 4.15 5.89 7.56 8.68
a N 2  =  u n w e i g h t e d  p o p u l a t i o n  s i z e .  
b N 3  =  p o p u l a t i o n  e s t i m a t e  i n  t h o u s a n d s .
S o u r c e :  R a d f o r d  a n d  D r i z d  1 9 8 2
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located in a Virginia hospital outpatient setting (Mahoney et al. 2007). COHb levels for the entire group 
averaged 1.9% with a range of 1-8%. The average COHb level for nonsmokers (n=85) was 1.6%, while 
the level for smokers (n=15) was 3.5%. COHb levels were measured for smokers versus nonsmokers at 
4 commercial establishments where cigarette smoking was not prohibited (Light et al. 2007). In addition, 
COHb levels were obtained in a control group of 50 college students and professors in a well-ventilated, 
nonsmoking environment. The average COHb concentration of 33 smokers from the commercial 
establishments was 5.04%, while the average value for the 27 nonsmokers was 2.49%. COHb levels 
ranged from 1 to 6% in the nonsmokers and from 1 to 14% in the smoking group. The COHb levels in 
the control group were 1%.
6.8 AD EQ U ACY OF THE D A TA BA SE
Section 104(i)(5)(A) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of carbon monoxide is available. Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of carbon monoxide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs
Physical and Chemical Properties. Information is available on the physical and chemical 
properties of carbon monoxide (George 2001; Lide 2008; O’Neil et al. 2006; Verschueren 2001). These 
data are captured in Chapter 4. No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA. The TRI, which contains this 
information for 2007, became available in February of 2009. This database is updated yearly and should
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
6. POTENTIAL FOR HUMAN EXPOSURE
230
provide a list of industrial production facilities and emissions. Adequate information on the production 
and use of carbon monoxide was located (George 2001); no information on the import/export of carbon 
monoxide was found but these volumes are assumed to be low. Since carbon monoxide is not required to 
be reported under the TRI, the production and emissions from U.S. industrial facilities is not reported to 
the EPA. The EPA continuously updates the NEI database, which contains detailed information about 
sources that emit carbon monoxide. No data needs are identified.
Environmental Fate. The environmental fate of carbon monoxide is well understood. When released 
to the atmosphere, carbon monoxide eventually reacts with photochemically produced hydroxyl radicals 
and is oxidized to CO2 (EPA 2000). Microorganisms have also been shown to oxidize carbon monoxide 
to CO2 (Tolli et al. 2006). Data on the half-life of carbon monoxide in indoor environments would be 
desirable.
Bioavailability from Environmental Media. Carbon monoxide is a gas and is not considered 
bioavailable from environmental media other than air. No data needs are identified.
Food Chain Bioaccumulation. Carbon monoxide is a gas and does not bioaccumulate in the food 
chain. No data needs are identified.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of carbon 
monoxide in contaminated media at hazardous waste sites are needed so that the information obtained on 
levels of carbon monoxide in the environment can be used in combination with the known body burden of 
carbon monoxide to assess the potential risk of adverse health effects in populations living in the vicinity 
of hazardous waste sites.
The EPA continuously monitors carbon monoxide levels throughout the United States. The EPA's NEI 
database contains detailed information about sources that emit criteria air pollutants including carbon 
monoxide for the 50 United States, Washington DC, Puerto Rico, and the U.S. Virgin Islands. The AQS 
database is EPA's repository of criteria air pollutant monitoring data since the 1970s. These databases are 
updated regularly.
Exposure Levels in Humans. All humans are exposed to carbon monoxide through the inhalation 
of ambient air. Indoor air levels of carbon monoxide are highly variable and depend upon the type, 
condition, and venting procedures of appliances. The NHANES II survey, conducted from February 1976
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to February 1980, provided an analysis of COHb levels in blood of the population based on smoking 
status, age, race, and other factors (Radford and Drizd 1982). These data are not current; therefore, a data 
need exists to update these data with new monitoring results.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are exposed to carbon monoxide by the same pathway as adults 
(inhalation of air). While the levels of COHb in children’s blood from the NHANES II study is 
comprehensive, these surveys are over 2 decades old. Therefore, a data need exists to update this study 
with new monitoring results.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data 
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for carbon monoxide were located. This substance is 
not currently one of the compounds for which a sub-registry has been established in the National 
Exposure Registry. The substance will be considered in the future when chemical selection is made for 
sub-registries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related to 
exposure to this substance.
6.8.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2009) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1. A study 
being conducted by Ohio State University (Ross Kauffman, principle investigator), seeks to study tobacco 
use in two Ohio prisons. One objective of this study is to examine the influence of an indoor tobacco ban 
on smoking behaviors among low-security prisoners. A second objective is to provide prison 
administrators with the information needed to develop successful policies by gathering information on 
prisoner attitudes toward tobacco control policies and cessation programs in correctional settings. The 
study is also intended to lay the groundwork for future studies of tobacco use in prison facilities.
It is anticipated that this study will address COHb levels in the prison facilities.
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7 . A N A L Y T IC A L  M E T H O D S
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring carbon monoxide, its metabolites, and other biomarkers of exposure and 
effect to carbon monoxide. The intent is not to provide an exhaustive list of analytical methods. Rather, 
the intention is to identify well-established methods that are used as the standard methods of analysis. 
Many of the analytical methods used for environmental samples are the methods approved by federal 
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health 
(NIOSH). Other methods presented in this chapter are those that are approved by groups such as the 
Association of Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits and/or to improve accuracy and precision.
7.1 B IO LO G ICAL M ATERIALS
Carbon monoxide forms a strong coordination bond with the iron atom complex of Hb forming COHb, 
which is a unique biomarker for carbon monoxide exposure for humans. COHb absorbs radiation in the 
blue wavelength region of the visible spectrum known as the Soret region (390-440 nm) and COHb 
levels in blood can be analyzed spectrophotometrically (Rodkey et al. 1979). Carbon monoxide­
oximeters are specialized medical instruments that are employed in clinical and hospital settings to 
rapidly determine COHb, O2Hb, and methemoglobin (MetHb) levels in blood by taking the difference 
between the light absorption at each of these Hb derivative’s and the total light absorption for all Hb 
derivatives that are present in the blood sample (Mahoney et al. 1993). This instrument is particularly 
useful for measuring high levels of COHb. Fetal Hb and bilirubin have the potential to interfere with 
spectrophotometric determination of COHb if present in sufficient quantities. Methylene blue cardiac dye 
and sulfhemoglobin can also adversely affect these measurements. In addition, some carbon monoxide­
oximeters have been shown to overestimate low concentrations of COHb as compared to gas 
chromatography (GC) methods (Mahoney et al. 1993).
GC with reduction gas detectors is a selective and sensitive method to measure the amount of carbon 
monoxide bound to Hb in the blood and is considered a highly reliable method for measuring exposure to 
carbon monoxide, especially at low levels. The addition of potassium ferricyanide to Hb-bound carbon 
monoxide oxidizes Hb to MetHb and releases carbon monoxide, which is injected in the gas 
chromatograph (Vreman et al. 1984). Carbon monoxide eluted from the GC column reacts with mercuric
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oxide (HgO) to form gaseous mercury vapor; the mercury released and measured spectrophotometrically 
at 254 nm is proportional to the amount of carbon monoxide gas released. The detection limits for this 
method were reported as 0.05 nL of carbon monoxide per microliter of blood, corresponding to a 
saturation of approximately 0.005% COHb in blood (Vreman et al. 1984).
Carbon monoxide levels in humans can be estimated by the analysis of exhaled breath using GC and 
electrochemical devices. In many measurement techniques, the subject performs an inhalation-breathhold 
maneuver and exhales through a mouthpiece into the instrument inlet. The alveolar air is retained for 
analysis, and the reading in ppm of carbon monoxide can be converted to COHb using a calibration curve 
(EPA 2000). A rapid and sensitive technique for the analysis of carbon monoxide in a single exhaled 
breath sample has been described (Fritsch et al. 2007). This analysis requires the subject to exhale into a 
mouthpiece that is attached to a Nafion® dryer and cooling trap to remove water, CO2, and other possible 
interfering species. Detection is by high resolution infrared cavity ring-down laser spectroscopy in a 
multipath absorption cell. Amperometric electrochemical sensors have also been used for the analysis of 
carbon monoxide in exhaled breath and ambient air (Vreman et al. 1994). These sensors typically consist 
of a series of electrodes (working, reference, and counter electrodes) immersed in an electrolyte solution. 
Carbon monoxide diffuses through a porous teflon membrane and is oxidized at the working electrode. 
The transfer of electrons that accompanies the redox reaction yields the output signal of the sensor. A 
reference electrode measures the potential of the electrolyte. The current flowing through the working 
electrode is compensated by the third electrode, a counterelectrode through which an equal and opposite 
current flows (Vreman et al. 1994).
The analytical methods used for the detection of carbon monoxide in biological samples are summarized 
in Table 7-1.
7.2 ENVIRONM ENTAL SA M PLES
Analytical methods for the detection of carbon monoxide in environmental samples have been thoroughly 
discussed in several review articles (EPA 1991, 2000; Novelli 1999). Table 7-2 provides a summary of 
many of these analytical methods that are commonly employed in environmental monitoring studies of 
carbon monoxide. Analytical methods used to measure carbon monoxide in environmental samples 
require the use of high purity standard reference gas in order to frequently calibrate the instrument and 
ensure consistent measurements between different laboratories.
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Table 7-1. Analytical Methods for Determining Carbon Monoxide in Biological
Samples
Sample
matrix Preparation method
Analytical
method
Sample Percent 
detection limit recovery Reference
Blood Collect sample and 
transfer to a 5 mL 
heparinized syringe and 
shake for 1 minute before 
analysis.
Spectro 
photometric 
determination 
using CO­
oximeters
<5% COHb Mahoney et al. 
1993
Blood Blood was placed into 
2 mL CO-free GC vial 
containing 100 g/L 
K3Fe(CN)6 in 0.1 mol/L 
potassium phosphate 
buffer, pH 6.0, containing 
10 g of saponin/L
GC with mercury 
reduction gas 
detector
0.005% COHb Mahoney et al. 
1993
Blood Obtain blood by heel stick 
(infant), or fingerstick 
(adult) and venipuncture. 
Mix with K3Fe(CN)6 
containing solution to 
liberate carbon monoxide 
to a headspace.
GC with mercury 
reduction gas 
detector
0.005% COHb Vreman et al. 
1984
Breath Breath samples were 
collected with a reverse 
syringe pump and 
analyzed within 
30 minutes or kept on ice 
until analysis within 
3 hours.
Electrochemical 
(EC) sensor or 
GC with mercury 
reduction gas 
detector
EC: 0.1 pL 
carbon
monoxide/L air
GC: 50% of the 
noise level of 
0.01 pL carbon 
monoxide/L air
Vreman et al. 
1994
C O H b  =  c a r b o x y h e m o g l o b i n ;  G C  =  g a s  c h r o m a t o g r a p h y ;  K 3F e ( C N )6 =  p o t a s s i u m  f e r r i c y a n i d e
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Table 7-2. Analytical Methods for Determining Carbon Monoxide in
Environmental Samples
Sample
matrix Preparation methoda
Analytical
method
Sample
detection
limitb
Percent
recovery Reference
Air
Air
Air
Air
Air
FTIR
Workplace
air
Atmospheric constituents 
are separated using two- 
column isothermic 
chromatography in a 
temperature-controlled 
oven, followed by analysis 
using FID, HgO/UV 
absorbance, or ECD.
Air samples are passed 
through reference and 
measurement optical 
cells. An optical filter is 
used to transmit only a 
small band width of 
infared radiation.
Air samples are 
introduced into 
commercial instruments 
over a wide spectral 
bandwidth or the use of 
optical filters can be 
employed to narrow the 
spectral wavelength.
Tune laser to 4.7 ^m and TDLS 
measure absorption by 
carbon monoxide gas.
Measure in fluorescence RF 
chambers operated at low 
pressure to avoid O2 
absorption.
Each sample is collected GC-DID
by drawing a known
volume of air into a five-
layer aluminized gas
sampling bag. A portion
of the gas sample is
introduced into a gas
sampling loop, injected
into a gas chromatograph,
and analyzed using a
discharge ionization
detector.
GC-FID 25-50 ppbv 
GC-HgO/UV GC-FID 
GC-ECD 10 ppb GC- 
ECD
1-2 ppb GC- 
HgO/UV
NDIR-GFC 22-70 ppbv
1 ppbv
NR Novelli 1999
NR Novelli 1999
NR Novelli 1999
<1 ppbv
5 ppbv
0.12 ppmv; 
(0.400 ppmv 
quantitative)
NR
NR
Novelli 1999
Novelli 1999
OSHA 1991 (Method 
210)
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Table 7-2. Analytical Methods for Determining Carbon Monoxide in
Environmental Samples
Sample
matrix Preparation methoda
Analytical
method
Sample
detection
limitb
Percent
recovery Reference
Sea water Water samples are 
siphoned into a glass 
stopcock and a portion of 
the water was replaced 
with carbon monoxide free 
synthetic air to create a 
headspace. The flask 
was shaken vigorously by 
hand for 1 minute and 
kept standing at room 
temperature for 5 minutes 
in the dark.
Soil gas Samples were collected 
using a 1-cm3 syringe 
fitted with a 50-mm-long 
26-gauge side port 
needle. A 1-cm3 sample 
was obtained (sampling 
time, about 60 seconds); 
the syringe was then 
raised, and its contents 
were rapidly analyzed in 
the field by using GC
GC-FID 6 nL of carbon 
monoxide/L of 
water
Ohta 1997
GC-HgO/UV <5 ppbv NR King 1999b
a H y d r o g e n  r i c h  c a r r i e r  g a s  i s  u s e d  t o  r e d u c e  c a r b o n  m o n o x i d e  t o  m e t h a n e  p r i o r  t o  a n a l y s i s  b y  F I D  a n d  N 2O  i s  a d d e d  
t o  a  n i t r o g e n  r i c h  c a r r i e r  g a s  f o r  a n a l y s i s  b y  E C D .  H e l i u m  g a s  i s  u s e d  a s  t h e  c a r r i e r  g a s  f o r  a n a l y s i s  b y  D I D .  
b M e a s u r e m e n t s  o f  a t m o s p h e r i c  c a r b o n  m o n o x i d e  l e v e l s  a r e  r e l a t i v e  t o  h i g h  p u r i t y  r e f e r e n c e  g a s  u s e d  t o  c a l i b r a t e  t h e  
i n s t r u m e n t s .
D I D  =  d i s c h a r g e  i o n i z a t i o n  d e t e c t o r ;  E C D  =  e l e c t r o n  c a p t u r e  d e t e c t o r ;  F I D  =  f l a m e  i o n i z a t i o n  d e t e c t o r ;  G C  =  g a s  
c h r o m a t o g r a p h y ;  F T I R  =  F o u r i e r  t r a n s f o r m  s p e c t r o s c o p y ;  G F C  =  g a s  f i l t e r  c o r r e l a t i o n ;  H g O  =  m e r c u r i c  o x i d e ;  
n o n d i s p e r s i v e  i n f r a r e d ;  R F  =  r e s o n a n c e  f l u o r e s c e n c e ;  N R  =  n o t  r e p o r t e d ;  T D L S  =  t u n a b l e  d i o d e  l a s e r  s p e c t r o s c o p y ;  
U V  =  u l t r a v i o l e t
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Most techniques used for the measurement of carbon monoxide in the environment employ spectroscopic 
methods or GC. Non-dispersive infrared (NDIR) spectroscopy and GC using flame ionization detection 
(FID) are the two most common methods used to analyze carbon monoxide in environmental samples. 
Commercial instruments are capable of detection limits in the ppb range. For analysis by NDIR 
spectroscopy, air is pumped into samples cells and the absorption is measured at a carbon monoxide 
vibrational band at 2,174 cm-1 (4.7 ^m). An optical filter is employed before the sample to remove light 
of other frequencies. Most NDIR spectrometers use gas filter correlation (GFC) methodology to improve 
sensitivity and reduce interferences by other gasses. In this method, the sample is simultaneously passed 
through both a reference cell containing a high concentration of carbon monoxide and a sample cell 
containing nitrogen gas. Gas species other than carbon monoxide will attenuate radiation equally in both 
cells; however, when carbon monoxide is present, the amount of light passing through the reference cell is 
unchanged, but that passing through the sample cell is absorbed at the characteristic carbon monoxide 
frequency. This difference in absorption between the light passing through the cells is linearly related to 
carbon monoxide concentrations in the air sample (EPA 2000).
In GC analysis of carbon monoxide, air samples are pumped through a silica gel or alumina pre-column 
followed by an analytical column composed of a molecular sieve. The pre-column captures CO2, non­
methane hydrocarbons, and water and the molecular sieve effectively separates carbon monoxide from 
hydrogen gas and methane. Since the sensitivity for carbon monoxide by FID is low, a hydrogen-rich 
carrier gas is used to reduce carbon monoxide to methane using heated nickel as a catalyst prior to FID 
analysis. Minimum detection limits of 0.05 ppmv or better have been achieved (Novelli 1999). With the 
development of the discharge ionization detector (DID) for use with GC analysis, it is possible to measure 
carbon monoxide concentrations directly at low levels in occupational settings (OSHA 1991). Helium is 
generally used as the sample carrier gas and as the ionized species. Helium passes through a chamber 
where a glow discharge is generated and high-energy photons are produced. The high-energy photons 
pass through an aperture to a second chamber and ionize the carbon monoxide in the sample stream. The 
resulting ions produce an electrical current, which is measured with a standard electrometer (OSHA 
1991). The greater the concentration of carbon monoxide in the sample, the more ions will be produced, 
resulting in a greater current. OSHA method 210 discusses the GC-DID analysis for carbon monoxide 
and reports a detection limit of 0.12 ppmv and quantification limit of 0.40 ppmv.
As discussed in Novelli (1999), electron capture detection (ECD) can also be used in conjunction with 
GC to measure atmospheric levels of carbon monoxide. Carbon monoxide does not elicit a strong 
response from the ECD because it does not easily capture electrons; however, the addition of N2O to a
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N2 carrier gas improves sensitivity. In addition, GC/mass spectrometry, GC with mercury reduction gas 
detection, Fourier transform infrared (FTIR) spectroscopy, tunable diode laser spectroscopy (TDLS), and 
resonance fluorescence spectroscopy have also been used to measure carbon monoxide levels in air 
(Novelli 1999).
Commercially available electrochemical carbon monoxide detectors for home use can be purchased at 
most hardware or home improvement stores. These detectors use electrodes that reside in an electrolyte 
solution such as dilute sulfuric acid. Carbon monoxide is oxidized at one electrode to CO2 and O2 is 
consumed at the other electrode (Vreman et al. 1994). Measurement of the current in the cell provides a 
measure of the concentration of carbon monoxide in the atmosphere. Metal oxide semiconductor 
detectors such as tin oxide sensors operate on the principle that the resistance of a tin oxide layer 
decreases as carbon monoxide adsorbs to the surface of the sensor and is oxidized to CO2 (Dobos and 
Zimmer 1985). When the conductance exceeds a preset threshold level, an 85 dB alarm is sounded (the 
same loudness as a smoke alarm). Biomimetic detectors use a gel-coated disc containing synthetic Hb 
that turns black when carbon monoxide is present at high levels. Reduction in the amount of transmitted 
light through the disc alerts the sensor to possible carbon monoxide contamination and sets off the alarm. 
Early carbon monoxide detectors were designed to provide an audible warning at relatively low levels of 
exposure and were often difficult to reset (Leikin 1996). Furthermore, the general public’s knowledge 
regarding the use and placement of these alarms in the residence was limited. Recent changes to the 
design and standards of these alarms have made them more user friendly to the general population and 
helped to eliminate low-level activations, which can be caused by a variety of common occurrences. The 
use and effectiveness of these home-based alarms, including guideline standards from Underwriters 
Laboratory, have been reviewed by Rhee and Leikin (2007).
Ohta (1997) discussed a GC-FID method for the detection of carbon monoxide in seawater. Water 
samples were collected in a glass stopcock and a portion of the water was replaced with carbon monoxide 
free synthetic air to create a headspace. The flask was shaken vigorously by hand for 1 minute and kept 
standing at room temperature for 5 minutes in the absence of sunlight in order to complete the 
equilibration between aqueous and gaseous phases. A small portion of air (1-2 mL) was injected into the 
GC for analysis. Carbon monoxide concentrations were corrected based on equilibrium constants of 
carbon monoxide between the aqueous and gaseous phases in the flask for headspace preparation. The 
concentrations were further corrected for water vapor contained in the headspace gas at concentrations of 
3.8-4.1% in volume at 26-27 °C. The detection limit was reported as 6 nanoliters of carbon monoxide 
per liter of water.
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7.3 AD EQ U ACY OF THE D A TA BA SE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of carbon monoxide is available. Where adequate information 
is not available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of 
research designed to determine the health effects (and techniques for developing methods to determine 
such health effects) of carbon monoxide.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs
Methods for Determining Biomarkers of Exposure and Effect.
Exposure. COHb is a unique biomarker of exposure for humans to carbon monoxide and accurate, 
sensitive methods exist for its measurement (Mahoney et al. 1993). GC methods are also available for 
measuring Hb-bound carbon monoxide (Vreman et al. 1984).
Effect. No specific biomarkers of effect for carbon monoxide were identified. Effects and symptoms of 
carbon monoxide poisoning are generally related to tissue hypoxia and are not specific for carbon 
monoxide exposure.
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Sensitive analytical methods are available for determining the levels of carbon monoxide in air 
samples. Thorough reviews on this subject are available from the EPA (1991, 2000) and Novelli (1999). 
Analytical methods are also available for the determination of carbon monoxide in water samples (Ohta 
1997).
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7.3.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2009) database provides additional information obtainable 
from a few ongoing studies that may fill in some of the data needs identified. Platypus Technologies LLC 
located in Madison, Wisconsin is developing a liquid crystal-based sensor for real-time detection of 
ozone, carbon monoxide, and CO2. Kestrel Labs Inc. located in Boulder, Colorado is developing a 
developing a new carbon monoxide-oximeter that can use laser light sources for accurate photo- 
plethysmographic measurements of COHb.
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8 . R E G U L A T IO N S , A D V IS O R IE S , A N D  G U ID E L IN E S
MRLs are substance specific estimates, which are intended to serve as screening levels, are used by 
ATSDR health assessors and other responders to identify contaminants and potential health effects that 
may be of concern at hazardous waste sites.
MRLs were not derived for carbon monoxide, as discussed in Section 2.3.
EPA (IRIS 2009) has not established an oral reference dose (RfD) or an inhalation reference 
concentration (RfC) for carbon monoxide.
The International Agency for Research on Cancer (IARC), the National Toxicology Program (NTP), and 
EPA have not classified carbon monoxide for human carcinogenicity (IARC 2009; IRIS 2009; NTP 
2005).
OSHA has required employers of workers who are occupationally exposed to carbon monoxide to 
institute engineering controls and work practices to reduce and maintain employee exposure at or below 
permissible exposure limits (PELs) (OSHA 2009). The employer must use engineering and work practice 
controls to reduce exposures to not exceed 55 mg/m3 (50 ppmv) for carbon monoxide at any time (OSHA
2009).
EPA has designated carbon monoxide as a hazardous air pollutant (HAP) under the Clean Air Act (CAA) 
(EPA 2009c). Additionally, under the National Ambient Air Quality Standards (NAAQS), EPA is 
required to set limits to protect public health, including the health of "sensitive" populations such as 
asthmatics, children, and the elderly. Carbon monoxide is required to not to exceed levels of 10 and 
40 mg/m3 (9 and 35 ppmv) for 8- and 1-hour averaging times, respectively, and not to be exceeded more 
than once per year (EPA 2009d).
The international and national regulations, advisories, and guidelines regarding carbon monoxide in air, 
water, and other media are summarized in Table 8-1.
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to Carbon
Monoxide
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC 
WHO
NATIONAL
Regulations and 
Guidelines:
a. Air
ACGIH
AIHA
EPA
Carcinogenicity classification
Air quality guidelines
TWA based on effects other than 
cancer or odor/annoyance using 
an averaging time of:
15 minutes
30 minutes
1 hour
8 hours
Drinking water quality guidelines
TLV (8-hour TWA)
TLV-basis (critical effect)
ERPG-1a
ERPG-2a
ERPG-3a
AEGL-1b
AEGL-2b 
10 minutes 
30 minutes 
60 minutes 
4 hours 
8 hours 
AEGL-3b 
10 minutes
30 minutes 
60 minutes
4 hours
8 hours 
Hazardous air pollutant
No data IARC 2GG9 
WHO 2GGG
1GG mg/m3 (87 ppm) 
6G mg/m3 (52 ppm) 
30 mg/m3 (26 ppm) 
1G mg/m3 (9 ppm) 
No data WHO 2006
29 mg/m3 (25 ppm) ACGIH 2008
Carboxyhemoglobinemia
229 mg/m3 (200 ppm) AIHA 2008
401 mg/m3 (350 ppm)
573 mg/m3 (500 ppm)
Not recommended due to EPA 2009b 
insufficient data
481 mg/m3 (42G ppm) 
172 mg/m3 (150 ppm) 
95 mg/m3 (83 ppm)
38 mg/m3 (33 ppm)
31 mg/m3 (27 ppm)
1,948 mg/m3 (1,700 ppm)
687 mg/m3 (600 ppm)
378 mg/m3 (330 ppm)
172 mg/m3 (150 ppm)
149 mg/m3 (130 ppm)
No EPA 2009c
42 USC 7412
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Table 8-1. Regulations, Advisories, and Guidelines Applicable to Carbon
Monoxide
Agency Description Information Reference
NATIONAL (cont.)
NIOSH
OSHA
b. Water 
EPA
c. Food 
FDA
d. Other 
ACGIH
EPA
National Ambient Air Quality 
Standards
8-hour averaging timec
1-hour averaging timec
REL (10-hour TWA)
Ceiling
IDLH
Target organs
PEL (8-hour TWA) for general 
industry
10 mg/m3 (9 ppm)
40 mg/m3 (35 ppm)
40 mg/m3 (35 ppm)
229 mg/m3 (200 ppm)
1,375 mg/m3 (1,200 ppm)
Cardiovascular system, 
lungs, blood, and central 
nervous system
55 mg/m (50 ppm)
Drinking water standards and health No 
advisories
National primary drinking water 
standards
No
National recommended water quality No 
criteria
EAFUSd
Carcinogenicity classification
Biological exposure indices (end of 
shift)
Carboxyhemoglobin in blood
Carbon monoxide in end-exhaled 
air
Carcinogenicity classification
RfC
RfD
Superfund, emergency planning, 
and community right-to-know
No
No
3.5% hemoglobin 
23 mg/m3 (20 ppm)
No
No
No
EPA 2009d
NIOSH 2005
OSHA 2009 
29 CFR 1910.1000, 
Table Z-1
EPA 2006a 
EPA 2003 
EPA 2006b
FDA 2008 
ACGIH 2008
IRIS 2009
***DRAFT FOR PUBLIC COMMENT***
8 .  R E G U L A T I O N S  A N D  A D V I S O R I E S
CARBON MONOXIDE 246
Table 8-1. Regulations, Advisories, and Guidelines Applicable to Carbon
Monoxide
Agency Description Information Reference
NATIONAL (cont.)
Designated CERCLA hazardous 
substance
No EPA 2009e 
40 CFR 302.4
Effective date of toxic chemical 
release reporting
No EPA 2009f 
40 CFR 372.65
NTP Carcinogenicity classification No NTP 2005
a E R P G - 1  i s  t h e  m a x i m u m  a i r b o r n e  c o n c e n t r a t i o n  b e l o w  w h i c h  n e a r l y  a l l  i n d i v i d u a l s  c o u l d  b e  e x p o s e d  f o r  u p  t o  1  h o u r  
w i t h o u t  e x p e r i e n c i n g  o t h e r  t h a n  m i l d ,  t r a n s i e n t  h e a l t h  e f f e c t s ;  E R P G - 2  i s  t h e  m a x i m u m  a i r b o r n e  c o n c e n t r a t i o n  b e l o w  
w h i c h  n e a r l y  a l l  i n d i v i d u a l s  c o u l d  b e  e x p o s e d  f o r  u p  t o  1  h o u r  w i t h o u t  e x p e r i e n c i n g  i r r e v e r s i b l e  o r  o t h e r  s e r i o u s  
a d v e r s e  e f f e c t s ;  a n d  E R P G - 3  i s  t h e  m a x i m u m  a i r b o r n e  c o n c e n t r a t i o n  b e l o w  w h i c h  n e a r l y  a l l  i n d i v i d u a l s  c o u l d  b e  
e x p o s e d  f o r  u p  t o  1  h o u r  w i t h o u t  l i f e - t h r e a t e n i n g  h e a l t h  e f f e c t s  ( A I H A  2 0 0 8 ) .
b A E G L - 1  i s  t h e  a i r b o r n e  c o n c e n t r a t i o n  o f  a  s u b s t a n c e  a b o v e  w h i c h  i t  i s  p r e d i c t e d  t h a t  t h e  g e n e r a l  p o p u l a t i o n ,  
i n c l u d i n g  s u s c e p t i b l e  i n d i v i d u a l s ,  c o u l d  e x p e r i e n c e  n o t a b l e  d i s c o m f o r t ,  i r r i t a t i o n ,  o r  c e r t a i n  a s y m p t o m a t i c  n o n s e n s o r y  
e f f e c t s ,  h o w e v e r ,  t h e  e f f e c t s  a r e  n o t  d i s a b l i n g  a n d  a r e  t r a n s i e n t  a n d  r e v e r s i b l e  u p o n  c e s s a t i o n  o f  e x p o s u r e ;  A E G L - 2  
i s  t h e  a i r b o r n e  c o n c e n t r a t i o n  o f  a  s u b s t a n c e  a b o v e  w h i c h  i t  i s  p r e d i c t e d  t h a t  t h e  g e n e r a l  p o p u l a t i o n ,  i n c l u d i n g  
s u s c e p t i b l e  i n d i v i d u a l s ,  c o u l d  e x p e r i e n c e  i r r e v e r s i b l e  o r  o t h e r  s e r i o u s ,  l o n g - l a s t i n g  a d v e r s e  h e a l t h  e f f e c t s  o r  a n  
i m p a i r e d  a b i l i t y  t o  e s c a p e ;  a n d  A E G L - 3  i s  t h e  a i r b o r n e  c o n c e n t r a t i o n  o f  a  s u b s t a n c e  a b o v e  w h i c h  i t  i s  p r e d i c t e d  t h a t  
t h e  g e n e r a l  p o p u l a t i o n ,  i n c l u d i n g  s u s c e p t i b l e  i n d i v i d u a l s ,  c o u l d  e x p e r i e n c e  l i f e - t h r e a t e n i n g  h e a l t h  e f f e c t s  o r  d e a t h  
( E P A  2 0 0 9 b ) .
c N o t  t o  b e  e x c e e d e d  m o r e  t h a n  o n c e  p e r  y e a r .
d T h e  E A F U S  l i s t  o f  s u b s t a n c e s  c o n t a i n s  i n g r e d i e n t s  a d d e d  d i r e c t l y  t o  f o o d  t h a t  F D A  h a s  e i t h e r  a p p r o v e d  a s  f o o d  
a d d i t i v e s  o r  l i s t e d  o r  a f f i r m e d  a s  G R A S .
A C G I H  =  A m e r i c a n  C o n f e r e n c e  o f  G o v e r n m e n t a l  I n d u s t r i a l  H y g i e n i s t s ;  A E G L  =  a c u t e  e x p o s u r e  g u i d e l i n e  l e v e l s ;
A I H A  =  A m e r i c a n  I n d u s t r i a l  H y g i e n e  A s s o c i a t i o n ;  C E R C L A  =  C o m p r e h e n s i v e  E n v i r o n m e n t a l  R e s p o n s e ,  
C o m p e n s a t i o n ,  a n d  L i a b i l i t y  A c t ;  C F R  =  C o d e  o f  F e d e r a l  R e g u l a t i o n s ;  E A F U S  =  E v e r y t h i n g  A d d e d  t o  F o o d  i n  t h e  
U n i t e d  S t a t e s ;  E P A  =  E n v i r o n m e n t a l  P r o t e c t i o n  A g e n c y ;  E R P G  =  e m e r g e n c y  r e s p o n s e  p l a n n i n g  g u i d e l i n e s ;
F D A  =  F o o d  a n d  D r u g  A d m i n i s t r a t i o n ;  G R A S  =  G e n e r a l l y  R e c o g n i z e d  A s  S a f e ;  iA r C  =  I n t e r n a t i o n a l  A g e n c y  f o r  
R e s e a r c h  o n  C a n c e r ;  I D L H  =  i m m e d i a t e l y  d a n g e r o u s  t o  l i f e  o r  h e a l t h ;  I R I S  =  I n t e g r a t e d  R i s k  I n f o r m a t i o n  S y s t e m ;  
N I O S H  =  N a t i o n a l  I n s t i t u t e  f o r  O c c u p a t i o n a l  S a f e t y  a n d  H e a l t h ;  N T P  =  N a t i o n a l  T o x i c o l o g y  P r o g r a m ;
O S H A  =  O c c u p a t i o n a l  S a f e t y  a n d  H e a l t h  A d m i n i s t r a t i o n ;  P E L  =  p e r m i s s i b l e  e x p o s u r e  l i m i t ;  R E L  =  r e c o m m e n d e d  
e x p o s u r e  l i m i t ;  R f C  =  i n h a l a t i o n  r e f e r e n c e  c o n c e n t r a t i o n ;  R f D  =  o r a l  r e f e r e n c e  d o s e ;  T L V  =  t h r e s h o l d  l i m i t  v a l u e s ;  
T W A  =  t i m e - w e i g h t e d  a v e r a g e ;  U S C  =  U n i t e d  S t a t e s  C o d e ;  W H O  =  W o r l d  H e a l t h  O r g a n i z a t i o n
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Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response. For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%. The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD.
Bioconcentration F actor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals). In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure. These may suggest 
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
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Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome. At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point 
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero 
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information. A health advisory is not a legally 
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from 
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from 
exposure to environmental agents such as chemicals.
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Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period.
Intermediate Exposure—Exposure to a chemical for a duration of 15-364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration^  (LClo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals.
Lethal Concentration^  (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying F actor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
Immunological Effects— F u n c t io n a l  c h a n g e s  in  th e  im m u n e  re s p o n s e .
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Mutagen—A substance that causes mutations. A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control. Effects may be produced at this dose, but they are not 
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system. There are two types of pharmacokinetic models: data-based 
and physiologically-based. A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose- 
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance.
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows. These models require a
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variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities. The models also utilize biochemical 
information, such as air/blood partition coefficients, and metabolic parameters. PBPK models are also 
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study. A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure. The qi* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually ^g/L for water, mg/kg/day for food, and 
^g/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime. 
The inhalation reference concentration is for continuous inhalation exposures and is appropriately 
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime. The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical. The RfDs are not applicable to 
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act. Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related 
endocrine system. The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past. Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may 
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek.
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from 
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest- 
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99­
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with 
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance. During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean-up or 
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1-14 days), intermediate (15-364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure. Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans. Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs. Exposure to a level 
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that
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are not expected to cause adverse health effects. Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances. ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process: Health Effects/MRL Workgroup reviews within the 
Division of Toxicology and Environmental Medicine, expert panel peer reviews, and agency-wide MRL 
Workgroup reviews, with participation from other federal agencies and comments from the public. They 
are subject to change as new information becomes available concomitant with updating the toxicological 
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.
For additional information regarding MRLs, please contact the Division of Toxicology and 
Environmental Medicine, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, 
Mailstop F-62, Atlanta, Georgia 30333.
MRLs were not derived for carbon monoxide, as discussed in Section 2.3.
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Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2 
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information. This summary is designed to present interpretive, weight- 
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect. Human 
data are presented first, then animal data. Both are organized by duration (acute, intermediate, chronic). 
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer 
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not 
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.
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MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water. 
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure.
MRL users should be familiar with the toxicologic information on which the number is based. Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance. Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects. If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans). In 
deriving an MRL, these individual uncertainty factors are multiplied together. The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 
in developing a substance-specific MRL are provided in the footnotes of the levels of significant exposure 
(LSE) tables.
Chapter 3 
Health Effects 
Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in 
conjunction with the text. All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure.
***DRAFT FOR PUBLIC COMMENT***
CARBON MONOXIDE
APPENDIX B
B-3
LEGEND
See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure. One of the first considerations when reviewing the toxicity of a substance
using these tables and figures should be the relevant and appropriate route of exposure. Typically 
when sufficient data exist, three LSE tables and two LSE figures are presented in the document. 
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes. Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15­
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure. 
In this example, an inhalation study of intermediate exposure duration is reported. For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer. 
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column. Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL.
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks. For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981).
(7) System. This column further defines the systemic effects. These systems include respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems. In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied. Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
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(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose. A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key 
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm. MRLs are not derived from 
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies. CELs are always considered serious effects. The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases.
(12) Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale "y" axis. Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based. The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived. The diamond 
symbol refers to a CEL for the test species-mouse. The number 38 corresponds to the entry in the 
LSE table.
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(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper- 
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*).
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure.
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Table 3-1. Levels of Significant Exposure to [Chemical x] -  Inhalation
Exposure
Key to frequency/
figure3 Species duration
LOAEL (effect)
NOAEL Less serious Serious (ppm)
System (ppm) (ppm) Reference
7 8 9 10
i i i i
Resp 3b 10 (hyperplasia)
INTERMEDIATE EXPOSURE
5
Systemic I
18 Rat
CHRONIC EXPOSURE 
Cancer
13 wk
5 d/wk
6 hr/d
3B
39
40
Rat
Rat
Mouse
1B mo 
5 d/wk 
7 hr/d
89-104 wk
5 d/wk
6 hr/d
79-103 wk
5 d/wk
6 hr/d
11
i
20
10
10
(CEL, multiple 
organs)
(CEL, lung tumors, 
nasal tumors)
Nitschke et al. 1981
Wong et al. 1982
NTP 1982
(CEL, lung tumors, NTP 1982 
hemangiosarcomas)
12 ^  a T h e  n u m b e r  c o r r e s p o n d s  t o  e n t r i e s  i n  F i g u r e  3 - 1 .
b U s e d  t o  d e r i v e  a n  i n t e r m e d i a t e  i n h a l a t i o n  M i n i m a l  R i s k  L e v e l  ( M R L )  o f  5 x 1 0 - 3  p p m ;  d o s e  a d j u s t e d  f o r  i n t e r m i t t e n t  e x p o s u r e  a n d  d i v i d e d  
b y  a n  u n c e r t a i n t y  f a c t o r  o f  1 0 0  ( 1 0  f o r  e x t r a p o l a t i o n  f r o m  a n i m a l  t o  h u m a n s ,  1 0  f o r  h u m a n  v a r i a b i l i t y ) .
6
3
4
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A P P E N D IX  C . A C R O N Y M S , A B B R E V IA T IO N S , A N D  S Y M B O L S
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLx 95% lower confidence limit on the BMDX
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CL ceiling limit value
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
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DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code 
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram 
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
Fj first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register
FSH follicle stimulating hormone
g gram
GC gas chromatography
gd gestational day
GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill
LDLo lethal dose, low
LDH lactic dehydrogenase
LH luteinizing hormone
LOAEL lowest-observed-adverse-effect level
LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans'-muconic acid
MAL maximum allowable level
mCi millicurie
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MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor
MFO mixed function oxidase
mg milligram
mL milliliter
mm millimeter
mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System
NLM National Library of Medicine
nm nanometer
nmol nanomole
NOAEL no-observed-adverse-effect level
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data Sys
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances
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OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
RfC reference concentration
RfD reference dose
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act
TWA time-weighted average
UF uncertainty factor
U.S. United States
USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization
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> greater than
> greater than or equal to
= equal to
< less than
< less than or equal to
% percent
a alpha
P beta
Y gamma
5 delta
^m micrometer
Mg, microgram
qi* cancer slope factor
- negative
+ positive
(+) weakly positive result
(-) weakly negative result
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APPENDIX D. INDEX
absorbed dose........................................................................................................................................176
adipose tissue..........................................................................................................................................10
adrenal gland.........................................................................................................................................172
adsorption..............................................................................................................................................199
aerobic..................................................................................................................................... 59, 88, 209
ambient air......................................... 10, 12, 13, 14, 16, 21, 26, 28, 29, 30, 31, 32, 33, 34, 35, 36, 44, 48,
65, 73, 80, 84, 85, 87, 89, 95, 96, 97, 107, 108, 109, 110, 111, 112, 
113, 127, 140, 143, 168, 174, 180, 185, 187, 210, 230, 234
anaerobic.............................................................................................................................................. 209
anemia......................................................................................................................................... 137, 180
biomarker.................................. 11, 12, 16, 17, 84, 85, 86, 87, 89, 175, 176, 185, 186, 188, 189, 233, 240
blood cell count.......................................................................................................................................17
breast milk............................................................................................................................................ 226
cancer............................................................................................................. 32, 127, 173, 186, 189, 244
carboxyhemoglobin (see COHb)...............................................................7, 149, 152, 153, 155, 161, 235
carcinogenic..........................................................................................................................................187
carcinogenicity.............................................................................................................  128, 185, 187, 243
cardiac arrhythmia...................................... 12, 13, 19, 27, 30, 48, 49, 50, 59, 65, 66, 72, 82, 83, 177, 180
cardiovascular...........................................  8, 11, 12, 13, 14, 20, 27, 29, 30, 32, 33, 48, 49, 50, 59, 65, 66,
81, 82, 90, 92, 165, 171, 177, 179, 180, 185, 186, 189
cardiovascular effects...........................................................  13, 20, 48, 49, 65, 82, 83, 180, 185, 186, 189
CFK model...............................................  11, 14, 15, 16, 20, 26, 30, 31, 66, 128, 145, 147, 148, 151, 162
clearance...............................................................................................................................................182
cognitive function................................................................................................................................. 188
COHb (see carboxyhemoglobin)....................... 7, 9, 10, 11, 12, 13, 14, 15, 16, 17, 20, 21, 25, 26, 27, 30,
34, 47, 48, 49, 50, 59, 65, 66, 73, 79, 82, 83, 84,
87, 88, 90, 91, 92, 93, 94, 95, 113, 125, 127, 128, 
130, 133, 134, 136, 137, 138, 140, 143, 145, 
147, 148, 149, 150, 151, 152, 153, 154, 155, 
158, 161, 162, 163, 165, 171, 174, 176, 177,
180, 182, 185, 186, 188, 189, 190, 191, 224, 
227, 228, 229, 231, 233, 234, 235, 240, 241
COMb..................................................................................................... 10, 134, 138, 142, 158, 162, 190
death............................................................................  12, 14, 19, 30, 32, 95, 96, 112, 113, 174, 187, 246
deoxyribonucleic acid (see DNA)..........................................................................................................128
dermal effects..........................................................................................................................................88
developmental effects......................................... 14, 20, 83, 89, 90, 96, 113, 125, 174, 186, 187, 189, 191
DNA (see deoxyribonucleic acid).................................................................................  128, 129, 176, 187
dopamine...............................................................................................................................................126
elimination half-time.......................................................................................  10, 143, 154, 162, 176, 189
elimination rate.................................................................................................................  143, 176, 182
endocrine................................................................................................................................. 88, 171, 172
endocrine effects.....................................................................................................................................88
endogenous production...................................................... 9, 10, 20, 27, 28, 133, 137, 142, 154, 166, 190
fetal tissue..............................................................................................................  10, 136, 154, 155, 174
fetus.................................................................... 12, 27, 136, 137, 154, 173, 174, 176, 180, 182, 189, 227
gastrointestinal effects............................................................................................................................ 83
general population.............................................................................................. 8, 204, 224, 227, 239, 246
genotoxic...............................................................................................................................................128
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genotoxicity..................................................................................................................................185, 187
growth retardation................................................................................................................................109
Haldane coefficient........................................................  136, 148, 149, 150, 151, 152, 153, 156, 160, 190
Haldane constant...........................................................................................  133, 134, 138, 139, 142, 147
half-life.........................................................................................................................  143, 175, 208, 230
hematological effects............................................................................  14, 16, 84, 96, 125, 127, 174, 188
hepatic effects.........................................................................................................................................88
Hepatic Effects........................................................................................................................................88
hydroxyl radical.....................................................................................................................203, 208, 230
hypoxic mechanisms............................................................... 9, 11, 17, 20, 21, 27, 28, 165, 166, 168, 191
immune system..................................................................................................... 14, 17, 20, 89, 127, 188
immunological..............................................................................................  14, 89, 90, 96, 125, 174, 188
immunological effects.........................................................................................  14, 89, 96, 125, 174, 188
Kow......................................................................................................................................................197
menstrual................................................................................................................................... 9, 107, 137
micronuclei........................................................................................................................... 128, 185, 187
musculoskeletal effects........................................................................................................................... 87
neonatal...............................................................................  14, 96, 97, 112, 174, 185, 186, 187, 189, 192
neurobehavioral................................................................................................................89, 172, 185, 188
neurodevelopmental.........................................................................................................................15, 188
neurological effects......................................................................................................................... 89, 171
nonhypoxic mechanisms.......................................................................................................... 21, 189, 191
norepinephrine......................................................................................................................................126
nuclear...................................................................................................................................................170
ocular effects...........................................................................................................................................88
odds ratio.......................................... 21, 35, 44, 45, 46, 73, 80, 81, 86, 107, 108, 109, 110, 111, 112, 113
pharmacodynamic................................................................................................................................. 144
pharmacokinetic............................................................................  144, 145, 146, 162, 173, 176, 189, 190
placenta................................................................................................................................................ 227
poisoning................................................................................  8, 11, 12, 15, 16, 21, 26, 27, 30, 31, 33, 87,
88, 89, 90, 91, 95, 138, 143, 176, 177, 178,
181, 182, 185, 187, 189, 190, 192, 224, 240
rate constant.................................................................................................................................. 139, 208
renal effects.............................................................................................................................................88
reproductive effects......................................................................................................................... 95, 187
respiratory effects....................................................................................  16, 33, 34, 35, 47, 175, 186, 189
retention........................................................................................................................................140, 142
solubility...............................................................................................................................................197
systemic effects.......................................................................................................................................33
toxicokinetic..................................................................................................................... 21, 11, 130, 190
weanling................................................................................................................................................125
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